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0.1 Abstract 
Cisplatin is an anti-cancer drug that acts by introducing toxic DNA interstrand 
crosslinks into proliferating cells, causing both cytostatic and cytotoxic effects. 
Although various models of the interstrand crosslink (ICL) response have been 
proposed, none of them are complete and much still remains unknown about how this 
process is coordinated. By understanding more about how cisplatin and ICLs cause 
cell death, we may be able to optimise the use of current drugs, or identify novel 
targets for new chemotherapeutic drugs. It is known that ubiquitination is important 
for the regulation of the ICL response and it is thus probable that some ubiquitin-
related proteins have previously unidentified roles in this process. 
This thesis describes the use of a robust high throughput siRNA screen to 
identify such novel ubiquitin-associated components of the response to cisplatin. 
Positive candidates were identified based on their ability to cause sensitivity to 
cisplatin and included both known and novel mediators of the ICL response. The 
siRNA screen formed an initial platform for further study of the roles of novel hits 
RNF113B, HOIP and ABIN1 in the DNA damage response.  
RNF113B was a previously uncharacterized E3 ligase. Studies described 
herein initially suggested that RNF113B might have a role in DNA repair after 
cisplatin treatment. However, final validation of a role for RNF113B in the ICL 
response was not forthcoming.  
HOIP is an E3 ubiquitin ligase that creates linear polyubiquitin chains as part 
of the linear ubiquitin assembly complex (LUBAC). LUBAC is required for innate 
and adaptive immunity, suppressing inflammation and the control of cell death 
through TNF and etoposide-induced signalling. HOIP was identified and validated as 
a top candidate of the siRNA screen. Within this thesis I show that cisplatin-induced 
caspase-3/7 activity is enhanced in HOIP-depleted cells, and corresponds with 
enhanced cisplatin-induced caspase-8 and -9 activities. Furthermore, HOIP depletion 
re-sensitises a cisplatin-resistant cancer line to cisplatin. Thus HOIP is an anti-
apoptotic protein in the response to cisplatin and may be a potential target for anti-
cancer therapeutics. 
ABIN1 is a polyubiquitin-binding protein involved in autoimmunity, 
inflammation and protecting cells from TNF-induced apoptosis. In this thesis I 
present data implying that ABIN1 also protects cells from cisplatin-induced cell death. 
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ABIN1-deficient cells, including ubiquitin-binding deficient Abin1D485N/D485N MEFs, 
are hypersensitive to interstrand crosslinkers. DNA damage checkpoint and repair 
responses are mostly intact in ABIN1-deficient cells, while cisplatin-induced 
apoptosis is vastly enhanced. Furthermore, GFP-ABIN1 forms ubiquitin-binding 
dependant macro-molecular structures in the cytosol that resemble previously 
described ‘speckles’ seen in caspase-8 mediated apoptotic signalling. As HOIP 
creates linear chains that ABIN1 can bind to, and both proteins protect cells from 
cisplatin-induced apoptosis, I also discuss whether ABIN1 and HOIP may act 
together in the same pathway. 
In conclusion, the siRNA screen identified several potential targets as novel 
regulators of the response to cisplatin. Further investigations revealed that HOIP and 
ABIN1 protect cells from cisplatin-induced apoptosis, emphasising the importance of 
ubiquitin signalling in cell death and the DNA damage response. 
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0.5 Abbreviations 
 
A adenine 
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Apaf apoptotic protease-activating factor 
AT ataxia telangiectasia 
ATM  ataxia telangiectasia mutated 
ATP  adenosine 5'-triphosphate 
ATR ATM and Rad3-related 
BAX BCL2-associated X 
BCA bicinchoninic acid 
Bcl-2 B-cell leukaemia/lymphoma 2 
BCL-XL B-cell lymphoma-extra large 
BER base excision repair 
Bid BH3-interacting-domain death agonist 
BIR break induced replication 
bp base pairs 
BRCA1/2 BReast CAncer 
BSA  bovine serum albumin 
C cytosine 
C-terminal  carboxy-terminal 
cdc cell division cycle 25 
CDK cyclin dependant kinase 
cFLIP cellular FLICE inhibitory protein 
CGE cell growth effect 
CHK1/2 checkpoint kinase 1/2 
CHX cycloheximide 
cIAP cellular IAP 
CPD cyclobutane pyrimidine dimer 
CPT camptothecin 
CSA clonogenic survival assay 
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CtIP CtBP-interacting protein 
CUL3 cullin-3 
CYLD cylindromatosis 
Da  dalton 
DDR DNA damage response 
dH2O distilled water 
DISC death-inducing signalling complex 
DLBCL diffuse large B-cell lymphoma 
DMEM Dulbecco’s Modified Eagle Medium 
DMSO dimethylsulphoxide 
DNA  deoxyribonucleic acid 
DNA-PK DNA-dependent protein kinase 
dNTP deoxynucleoside triphosphate 
DSB double strand break 
dsDNA double stranded DNA 
DSTT Division of Signal Transduction Therapy 
DTT  dithiotheitol 
DUB deubiquitinase 
EB ethidium bromide 
ECL  enhanced chemiluminescence 
EDTA  ethylenediamine tetraacetic acid 
EGFR epidermal growth factor receptor 
EGTA  ethyleneglycol bis (2-aminoethylether)-N'N'tetraacetic 
acid 
ERCC1 excision repair cross-complementation group 1 
ERK extracellular signal-regulated kinase 
FA Fanconi Anaemia 
FAAP20/24 Fanconi anemia-associated protein of 20 kDa 
FACC Fanconi Anaemia core complex 
FACS fluorescence activated cell sorting 
FADD Fas-associated death domain 
FAN1 FANCD2/FANCI-associated nuclease 1 
FANC[letter] FA complementation group [letter] 
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FasL Fas ligand 
FBS foetal bovine serum 
FRT Flp Recombination Target 
G guanine 
GAWS genome wide association studies 
gDNA genomic DNA 
GFP green fluorescent protein 
HECT homologous to E6-AP carboxyl terminus 
HEK human embryonic kidney 
HEPES N-[2-hydroxyethyl]piperazine-N’-[2- ethanesulphonic 
acid] 
HOIL haem-oxidized IRP2 ubiquitin ligase-1 
HOIP HOIL-1 interacting protein 
HR homologous recombination 
HRP horseradish peroxidase 
HU hydroxyurea 
IAP inhibitor of apoptosis protein 
IBR in‐between RING 
ICL interstrand crosslink 
IFN interferon 
IgG immunoglobulin G 
IKK inhibitor of nuclear factor kappa-B kinase 
IP immunoprecipitation 
IR ionising radiation 
ISG15 interferon-stimulated gene 15 
IκBα inhibitor of κB α 
JNK c-Jun N-terminal kinase 
LB lysogeny broth [1] 
LDS lithium dodecyl sulphate 
LUBAC linear ubiquitin assembly complex 
MAPK mitogen-activated protein kinase 
MDM2 mouse double minute 2 homolog 
MEF mouse embryonic fibroblast 
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MES 2-(N-morpholino)ethanesulfonic acid 
MKP1 mitogen-activated protein kinase dual-specificity 
phosphatase-1 
MMC mitomycin-C 
MMR mismatch repair 
MOPS 3-(N-morpholino) propanesulfonic acid 
MRC-PPU Medical Research Council Protein and Ubiquitylation 
Unit 
MRN Mre11-Rad50-Nbs1 
mRNA messenger RNA 
MS mass spectrometry 
N-terminal  amino-terminal 
NBS Nijmegen breakage syndrome 
NEAA non-essential amino acids 
NEDD8 neural precursor cell expressed, developmentally 
downregulated 8 
NEMO NF-κB essential modulator 
NER nucleotide excision repair 
NF-κB nuclear factor κB 
NHEJ non-homologous end joining 
NOD nucleotide-binding oligomerisation domain-containing 
protein 
nt nucleotide 
O6MeG O6-methyl-guanine 
PAGE  polyacrylamide gel electrophoresis 
PBS phosphate buffered saline 
PBS-T PBS-Tween 
PCD programmed cell death 
PCNA proliferating cell nuclear antigen 
PCR  polymerase chain reaction 
PEI polyethylenimine 
PFA paraformaldehyde 
PI propidium iodide 
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PI 3-kinase  phosphatidylinositol 3-kinase 
PIKK PI 3-kinase like kinase 
PNSF percentage normalised surviving fraction 
pol polymerase 
pRb retinoblastoma protein 
PRR post replication repair 
PUMA p53 upregulated modulator of apoptosis 
RA rheumatoid arthritis 
RBR RING‐in‐between‐RING 
RFC replication factor C 
RING really interesting new gene 
RIP receptor-interacting protein 
RIPA radioimmunoprecipitation assay 
RNA ribonucleic acid 
RNAi RNA interference 
RNF[number] RING-type zinc finger [number] 
ROS reactive oxygen species 
RPA replication protein A 
RPMI Roswell Park Memorial Institute 
SAPK stress-activated protein kinase 
SB signal to background 
SCE sister chromatid exchange 
SD standard deviation 
SDS  sodium dodecyl sulfate 
SEM standard error of the mean 
SF surviving fraction 
SHARPIN Shank-Associated RH Domain-Interacting Protein 
SIM SUMO-interacting motif 
siRNA small interfering RNA 
SLE systemic lupus erythematosus 
SLX1/4 synthetic lethal of unknown function 1/4 
Smac second mitochondrial activator of caspases 
SMC1 structural maintenance of chromosomes-1 
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SNM1A DNA cross-link repair 1A 
SSA single strand annealing 
SSB single strand break 
SSBR single-strand break repair 
SSC saline-sodium citrate 
SSc systemic sclerosis 
ssDNA single stranded DNA 
SUMO small Ub-like modifier 
SV40 simian virus 40 
T thymine 
TBE tris-borate-EDTA  
tBid truncated Bid 
TBS tris buffered saline 
TBS-T TBS-Tween 
TCR transcription-coupled repair 
TE Tris-EDTA 
TLR Toll-like receptor 
TLS translesion synthesis 
TNF tumour necrosis factor 
TNFR TNF receptor 
TNIP1 (TNFAIP3)-interacting protein 1 
TRADD TNFR-associated death domain protein 
TRAF TNFR-associated factor 
TRAIL TNF-related apoptosis-inducing ligand 
Tris  tris (hydroxymethyl) aminomethane 
Triton X-100  t-octylphenoxypolyethoxyethanol 
Tween polyethylene glycol sorbitan monolaurate 
U uracil 
UAF1 Usp1-associated factor 1 
UBA ubiquitin-associated domain 
UBAN ubiquitin binding in ABINs and NEMO 
UBD ubiquitin-binding domain 
UBL ubiquitin like 
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UBM ubiquitin-binding motif 
UBZ ubiquitin-binding zinc finger 
UEV ubiquitin-conjugating enzyme variant 
UIM ubiquitin-interacting motif 
USP1  ubiquitin-specific protease 1 
UV ultraviolet 
v/v  volume per volume 
w/v  weight per volume 
wt wild type 
XIAP X-linked IAP 
XP xeroderma pigmentosum 
XP[letter] XF complementation group [letter]  
β-ME β-mercaptoethanol 
γH2AX histone H2AX isoform γ 
 
  
 23 
1 Introduction 
 
1.1 The DNA damage response 
Genetic integrity is essential for life. DNA is under constant threat from both 
endogenous and exogenous sources of damage. Without a way of responding to this 
damage, cells would be at risk of acquiring mutations that lead to cellular dysfunction, 
disease or death. Thus organisms have evolved a complex signalling network to 
recognise and manage lesions, termed the DNA damage response (DDR). Different 
sources of DNA damage cause different DNA lesions, and these require specific 
modes of DNA repair. However, there is a general genome stability network that is 
activated in response to damage. This leads to checkpoint responses, cell cycle arrest, 
DNA repair and/or cell death if the damage is too great to be resolved.  
While all DNA damage can have serious consequences if left unrepaired, 
interstrand crosslinks (ICLs) are a particularly potent form of DNA injury. Indeed, 
ICL inducers such as cisplatin are often used as anti-cancer drugs due to their ability 
to introduce these toxic lesions into proliferating cells. This chapter shall introduce 
cisplatin-induced damage, what we know about how cells regulate the response to this 
threat and why we think the role of ubiquitination in the response to cisplatin is 
deserving of further study. 
 
The DDR and response to cisplatin are complex and thus employ many means 
of regulating and coordinating their multiple processes. These methods include 
controlling the transcription, translation, degradation, location and post-translational 
modifications (PTMs) of proteins involved. While the role of phosphorylation in 
regulating the DDR has long been recognised, in recent years an appreciation has 
been gained of the breadth and importance of ubiquitination in the ICL response. 
 
1.2 Ubiquitination 
Ubiquitination is the process of modifying proteins with another small, highly 
conserved protein called ubiquitin. Ubiquitination takes place through a catalytic 
cascade requiring three major classes of enzymes (Fig 1-1). Firstly, the E1 enzyme 
activates ubiquitin in an ATP-dependant manner and transfers it to the cysteine in the 
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active site of an E2, creating a thioester bond. An E3 ligating enzyme then transfers 
the ubiquitin to the target protein, creating an isopeptide bond between the C terminus 
of ubiquitin and a primary amino group on the substrate [2]. In humans there are two 
E1 activating enzymes, at least 40 E2 conjugating enzymes and more than 600 E3 
ligases [3–8], allowing for a large variety of specific ubiquitination events. 
Ubiquitination is a reversible reaction, with the removal of ubiquitin being catalysed 
by deubiquitinases (DUBs) [9].  
 
 
Figure 1-1 The ubiquitin cascade showing RING and HECT ligases (Yufeng 
Tong) 
 
1.2.1 E3 ubiquitin ligases 
E3 ubiquitin ligases can be further classified by their catalytic domains and 
method of action. Really interesting new gene (RING) and RING-like E3s, such as U-
box-containing ligases, catalyse the transfer of ubiquitin from the E2 to the target 
substrate by allosterically activating the charged E2 and priming the E2-ubiquitin 
thioester bond for transfer [10–13]. On the other hand, homologous with E6-
associated protein C-terminus (HECT)-type ligases play an active role in ubiquitin 
transfer by forming a thioester intermediate with ubiquitin on their active‐site cysteine 
before transferring it to the substrate [14, 15]. A third class of RING‐in‐between‐
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RING (RBR) E3 ligases with a ‘triad’ of catalytic domains consisting of a RING1, an 
in‐between RING (IBR), and a RING2 domain have also been identified [16, 17]. 
These act as RING-HECT hybrids [18–21] by first binding a ubiquitin-charged E2 in 
a manner similar to a RING ligase. They next form a ubiquitin thioester intermediate 
on a catalytic cysteine on their RING2 domain before transferring it to the substrate, 
like a HECT ligase. During ubiquitination substrate specificity is determined by the 
E3. In the case of RING ligases, the E2 determines the chain type (see Section 1.2.2), 
while in the case of HECT and RBRs the E3 performs this function. 
 
1.2.2 Ubiquitin modification and recognition 
Ubiquitin is primarily covalently linked to lysine residues. Single ubiquitin 
molecules can be conjugated to a single site within a target protein, known as 
monoubiquitination, and or to many sites in the same protein, know as multi 
monoubiquitination. However, ubiquitin itself contains seven lysine residues that can 
also be conjugated with ubiquitin, allowing for the creation of polyubiquitin chains. 
These target sites are K6, K11, K27, K29, K33, K48, and K63. Furthermore, the C 
terminus of one ubiquitin moiety can be bound to the initial methionine at the N 
terminus of another, forming an additional M1- or linear-linked polyubiquitin chain 
[22, 23]. Chains of mixed linkages are also possible [24], with mixed M1/K63 chains 
having recently been described [25]. 
Ubiquitination of a protein may affect its conformation and thus its 
functionality [26]. However, the modification of proteins with ubiquitin structures 
presents another method of signalling. Different ubiquitin linkages lead to different 
overall conformations of the chain. These different structures can be recognised by 
ubiquitin-binding domains (UBDs), which can specifically identify one or more type 
of polyubiquitin chain [27]. For example, the ubiquitin binding in ABINs and NEMO 
(UBAN) domain, binds both K63 and linear chains, although with a preference for 
linear polyubiquitin [28, 29]. Ubiquitin chains can thus signal for the recruitment of 
proteins to transduce a signal through a pathway, or even as instructions relating to 
the protein itself. K48 polyubiquitination is the best studied example of the latter, 
whereby recognition of K48-linked chains on a protein are recognised by the 
proteasomal subunit Rpn10/S5a, leading to its proteasomal degradation [30].  
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1.2.3 Ubiquitin-like (UBL) modifiers 
Ubiquitin-like (UBL) modifiers that are related to ubiquitin in sequence and 
conformation have also been discovered. These include small Ub-like modifier 
(SUMO), interferon-stimulated gene 15 (ISG15), autophagy 8 (ATG8) and neural 
precursor cell expressed, developmentally downregulated 8 (NEDD8). UBLs are 
conjugated to target proteins using a cascade of enzymes that is similar, although 
distinct, to the ubiquitin cascade [31]. SUMO2/3 and NEDD8 can also be 
amalgamated into chains [32, 33]. Likewise, UBLs can affect protein function by 
inducing a conformational change or through recognition of the modification by 
UBL-binding domains such as the SUMO-interacting motif (SIM) [34]. UBLs are 
involved in regulating processes throughout the cell, with SUMOylation particularly 
of note in the DDR [35, 36]. 
 
Thus the ubiquitination or deubiquitination of target proteins, with specific 
ubiquitin or UBL structures, at tightly regulated times and locations, affords a 
mechanism for the transduction of signals from stimuli to responses. This method of 
regulation is commonly employed in the DDR and the response to cisplatin.  
 
1.3 DNA damage, with a focus on interstrand crosslinkers 
DNA is under constant threat of damage from both endogenous and 
exogenous sources. Some examples of DNA damaging agents and the lesions they 
cause are shown in Table 1-1. Another type of DNA damage that is not indicated in 
this table is the covalent crosslinking of DNA, which is described in more detail in the 
following section. 
 
Table 1-1 Examples of DNA damaging agents and the lesions they cause 
Source Mode of action Lesion formed 
Endogenous sources   
Spontaneous chemical 
reactions 
Depurination of 
nucleotides 
Abasic sites 
 Deamination Interconversion between DNA 
By-products of 
aerobic metabolism 
Generation of reactive 
oxygen species (ROS) 
Oxidative base damage and DNA 
breaks 
Infection and 
inflammation 
Generation of ROS Oxidative base damage and DNA 
breaks 
Physiological 
processes 
Errors during replication Mismatch of DNA bases  
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 Replication fork collapse DNA breaks  
 Errors during meiosis DNA breaks  
 Errors during base repair DNA breaks  
Exogenous sources    
Ultraviolet (UV) light   Pyrimidine dimers and 
photoproducts 
Ionising radiation 
(IR) 
Generation of ROS Base damage, DNA breaks 
Cigarette smoke  Aromatic DNA adducts and 
oxidative damage 
Etoposide Inhibition of 
topoisomerase I 
DNA breaks 
Camptothecin (CPT) Inhibition of 
topoisomerase II 
DNA breaks 
 
1.3.1 DNA crosslinking agents 
DNA crosslinking agents are bifunctional compounds that are capable of 
covalently binding to two positions on DNA. Crosslinking agents can cause 
monoadducts and intrastrand, interstrand, interhelical and DNA-protein crosslinks. 
Intrastrand crosslinks involve compounds binding sites on the same strand, while with 
interstrand crosslinks (ICLs) two opposing strands of the DNA duplex are linked. 
Interhelical crosslinks bind two DNA duplexes, although these lesions have rarely 
been described [37]. ICLs are considered the most toxic of these lesions, as they 
prevent separation of the DNA and thus inhibit replication and transcription 
machinery from progressing through the genome. The genotoxic nature of ICL-
inducers make them potent forces of mutagenesis and genome instability, as 
evidenced by the genome instability phenotypes of Fanconi Anaemia patients who 
deficient in ICL repair [38]. 
ICLs can be created from endogenous sources [39]. Aldehydes, such as 
malondialdehyde, are metabolic by-products that are formed from dietary lipid and 
alcohol catalysis. Nitric oxide can also link guanine residues on opposite strands, and 
some types of abasic sites spontaneously developed within cells can also link adenine 
or guanine residues on opposite strands [40–42]. Due to the genotoxic nature of ICLs, 
many crosslinking agents are used in chemotherapy [37, 43], including the nitrogen 
mustards, psoralens, platinum compounds and mitomycin C (MMC). The latter two 
shall be discussed in more detail below. 
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1.3.2 Platinum-based crosslinking agents 
Platinum-based DNA damaging agents are used as anti-cancer drugs due to 
their ability to introduce crosslinks into proliferating cells [37]. The first of these 
agents to be discovered was cisplatin (Fig 1-2) [44], with second and third generation 
analogues such as carboplatin and oxaliplatin following soon after [45, 46]. Cisplatin 
has been effective in treating a multitude of cancers, notably testicular cancer, but also 
ovarian, cervical, head, neck and non-small cell lung cancers [47]. It is used alone or 
in combination as a first line therapy and as an adjuvant therapy after surgery or 
radiation therapy. However, despite its initial successes, cisplatin causes unwanted 
side effects, such as nephrotoxicity, neurotoxicity and ototoxicity. Carboplatin is used 
in the treatment of ovarian and non-small cell lung cancer but has side effects such as 
myelosuppression, while oxaliplatin is used in combination treatment for colorectal 
cancer [47]. In addition to the side effects caused by platinum based reagents, 
resistance to cisplatin is a major problem, reducing its efficacy. Although it is not 
exactly clear how this occurs, two major reasons have been postulated – that of 
decreased access of cisplatin to DNA, and that of increased repair or tolerance of 
cisplatin-induced damage. 
 
 
Figure 1-2 Structure of cisplatin (Noll et al, 2006 [48]) 
 
1.3.2.1 Cisplatin-induced DNA damage 
Once in a cell, cisplatin is aquated – that is, its chloride ions are removed and 
replaced with water molecules [49]. The positively charged platinum molecule can 
then react with nucleophillic molecules such as DNA, RNA and proteins. The most 
common target for activated cisplatin is DNA, with cisplatin forming covalent bonds 
with the N7 atoms of the imidazole rings of purine bases. This reaction can lead to the 
formation of a monoadduct between cisplatin and DNA. However, in most cases a 
second reaction takes places leading to the formation of crosslinks. The lesions 
created are mostly 1,2-d(GpG) intrastrand crosslinks, although a small proportion of 
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d(GpC)d(GpC) interstrand crosslinks are also formed [48]. While this represents a 
small percentage of the DNA lesions caused by cisplatin, ICLs are considered to be 
the most dangerous to cisplatin-treated cells. Cisplatin-DNA interstrand crosslinks 
cause significant distortion of the DNA structure, causing extrusion of the cytosines, 
bending of the helix toward the minor groove by 20–40, and unwinding of the DNA 
by to 80º [50–53]. 
 
1.3.3 Mitomycin C (MMC) 
MMC (Fig 1-3) is another anti-cancer agent capable of introducing 
interstrand-crosslinks. It is used in the treatment of bladder, cervical, stomach, 
pancreatic and metastasised breast cancer among others [37]. MMC is required to be 
activated by the reduction of its quinone ring, forming a quinone methide. This 
compound can form monoadducts, mostly at 5'CpG sites, or further react with the 
same site to create a crosslink within the minor groove of DNA [48]. MMC reduction 
also leads to the production of ROS that can further damage DNA [43]. Similar to 
cisplatin, MMC can thus multiple forms of DNA damage, with ICLs contributing 
about 10% of the lesions. Although MMC interstrand crosslinks lead to some 
widening of the minor groove, they cause no bending of the helix and thus cause 
minimal disruption to the conformation of DNA [54, 55]. 
 
 
Figure 1-3 Structure of MMC (Noll et al, 2006 [48]) 
 
Like all DNA damage, recognition of ICLs leads to a general DDR, which 
may include repair of the lesion using a specialised repair process (see Section 1.5). 
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1.4 Initial stages of the DDR 
 
1.4.1 Initiation of the DDR 
In response to DNA damage such as crosslinks, cells can initiate checkpoints 
responses, repair damage or undergo cell death. However these processes need to be 
coordinated for efficient protection of genomic integrity. Thus the DDR is regulated 
by overall mediators such as Ataxia telangiectasia mutated (ATM) and ataxia 
telangiectasia and Rad-3-related (ATR). These kinases are involved in the DDR from 
the recognition of damage stage through to the transduction of checkpoint and repair 
signalling. 
ATM is activated by double-stranded breaks (DSBs) [56], while ATR is 
activated by multiple types of damage, including DSBs and stalled replication forks 
[57, 58]. ATM and ATR are members of the phosphatidylinositol 3-kinase-like 
kinases (PIKK) family and are activated by autophosphorylation [59]. They regulate 
the DDR by phosphorylating downstream mediators of DDR processes such as the 
histone H2AX isoform γ (γH2AX) which leads to the accumulation of repair 
complexes and the formation of DNA damage foci [60]. Furthermore, both ATM and 
ATR regulate cell cycle progression and cell death in response to genotoxic stress by 
phosphorylating targets such as CHK1/2 (see below) and p53 (see Section 1.6.1). 
 
1.4.2 DNA damage checkpoints 
The cell cycle is a complex, tightly regulated process consisting of alternating 
phases of growth (G1 and G2), DNA synthesis (S) and cell division, known as mitosis 
(M). To ensure cells do not progress through the cell cycle until ready, cell cycle 
checkpoints have evolved. If DNA damage is recognised, checkpoints can cause cell 
cycle retardation or arrest to allow cells time to repair the lesions, or induce apoptosis 
to maintain the fidelity of the genome [61]. When DNA damage checkpoints are 
defective, cells can continue replication and propagation of deficient DNA, causing 
the transformation of healthy cells to cancerous tissue. DNA damage can inhibit 
progression through the cycle at the point of entry from G1 to S phases (G1/S), within 
the S phase (intra-S) and the transition from G2 to M phases (G2/M) [62, 63]. Many of 
the sensing and regulating proteins involved play similar roles across each of these 
pathways.  
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During the G1/S DNA damage checkpoint ATM and ATR phosphorylate and 
activate the checkpoint kinase signal transducers CHK1 and CHK2 [64]. Activated 
CHK1 and CHK2 phosphorylate the phosphatase Cdc25-A, leading to its deactivation 
[65]. This prevents the dephosphorylation and activation of CDK2/cyclin E, which is 
required to initiate DNA replication through phosphorylation of retinoblastoma 
protein (pRb) and Cdc45. Cell cycle arrest is maintained through a second pathway in 
which ATM and ATR phosphorylate p53 [66]. This inhibits p53’s polyubiquitination 
by MDM2 and subsequent proteosomal degradation. Accumulation of p53 leads to 
increased transcription of its target genes, such as p21, which also binds to and 
inhibits CDK2. 
During S phase, the ATM/ATR–Chk2/Chk1–Cdc25A–CDK2 pathway also 
prevents Cdc45 from stimulating replication of DNA [67]. Similar to the G1 
checkpoint, a second pathway also maintains cell cycle arrest and encourages DNA 
repair, this time through the phosphorylation of NBS1 by ATM and CHK2, leading to 
MRN-mediated propagation of the DDR, for example through the phosphorylation of 
structural maintenance of chromosomes-1 (SMC1) [68]. ATM and ATR-mediated 
checkpoint signalling might also slow progression of and help stabilise replication 
forks in S-phase, encouraging DNA repair and preventing the formation of lethal 
DSBs. 
 
1.5 DNA repair 
The mechanisms employed to repair DNA depend on the type of lesion 
involved [62]. Damage to DNA bases can be repaired by direct reversal, mismatch 
repair (MMR), base excision repair (BER) and nucleotide excision repair (NER). 
Singe stranded breaks (SSBs) are repaired through single-strand break repair (SSBR). 
DSBs can be repaired through nonhomologous end joining (NHEJ), generally 
believed to be an error- prone, ligation-based mechanism, or homologous 
recombination (HR).  
As ICLs covalently link both strands of DNA their resolution is particularly 
complicated [48]. The creation of multiple intermediate structures means the ICL 
response requires the regulation and coordination of multiple repair pathways. 
Various models of ICL repair have been proposed but none of them are complete and 
much still remains unknown about how this response is regulated. This is partly 
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because specific responses to ICLs are difficult to study in vivo, due to the fact that 
most ICL-inducers predominantly cause other types of DNA defects [39]. However 
the use of methods such as cell free systems have helped advance our knowledge of 
the response to ICLs [69].  
 
1.5.1 Overview of ICL repair 
In general, ICLs are repaired by excising the lesion from first one strand of 
DNA and then the other to prevent multiple DSBs. During replication [39], the DNA 
is incised on either side of the ICL on one strand. This leads to formation of a DSB 
and “unhooking” of the ICL from this strand. Translesion synthesis (TLS) machinery 
can then synthesise DNA across the gap and initiation of replication and repair of the 
DSB on the other strand can now take place via homologous recombination (HR). 
The strand thus synthesised can be used as a template for repairing the final gap in the 
last strand using conventional DNA synthesis. Outside S/G2 phase, a similar process 
repairs ICLs by first unhooking the lesion from one strand, although this its thought to 
occur via nucleotide excision repair (NER). TLS then fills in the gap and NER can 
remove the lesion from the other strand [39]. However, in eukaryotes ICL repair 
generally occurs during S phase, as detailed below. 
 
1.5.2 The Fanconi Anaemia pathway 
Fanconi Anaemia (FA) is a genomic instability syndrome characterised by 
bone marrow failure, congenital abnormalities, early onset of cancer and sensitivity to 
interstrand crosslinkers [38]. There are at least sixteen FA complementation groups 
that correspond to known genes. Genetic and biochemical studies of this disease 
discovered that most of the FA genes are involved in a ubiquitin signalling cascade 
that is important in sensing ICL and DNA damage in S phase, and is called the FA 
pathway. 
During replication it is believed that the first stage of ICL repair is recognition 
of one or two stalled replication forks by the FA pathway [70]. FANCM, along with 
FAAP24 and MHF, bind ssDNA at a stalled fork (Fig 1-4) [71, 72]. FANCM uses its 
translocase activity to remodel the DNA, allowing damage recognition and activation 
of the DDR through ATR [73–75]. FANCM also recruits the remaining members of 
the FA Core Complex (FACC); FANCA, FANCB, FANCC, FANCE, FANCF, 
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FANCG and FANCL. Recruitment of the FACC is enhanced by binding to FAAP20, 
which recognises RNF8-UBC13-mediated polyubiquitination of histone H2A at sites 
of damage [76].  
In conjunction with UBE2T the FACC then uses its catalytic subunit FANCL, 
a RING type E3 ligase, to monoubiquitinate FANCD2 and FANCI [77–80]. 
Monoubiquitinated FANCD2/I accumulates on chromatin at the site of DNA lesions 
where it recruits and co-localises with downstream repair factors such as FAN1 [81–
84]. Similarly, recruitment of TLS polymerases like REV1L and pol ζ [85, 86], and 
HR machinery components [87] to sites of ICL damage is also mediated by 
FANCD2/I monoubiquitination. The deubiquitination of FANCD2 by USP1 and its 
partner UAF1 is later required to dissolve the complex and complete ICL repair [88–
91] 
  
 
Figure 1-4 Activation of the FA pathway (Clauson et al, 2013 [39]) 
 
1.5.3 ICL repair 
After recognition of an ICL by the FA pathway, repair is initiated (Fig 1-5a). 
First the ICL is unhooked from one strand, achieved by incisions 5′ and 3′ of the 
lesion (Fig 1-5b). The endonuclease FANCQ/XPF-ERCC1 has been proposed to 
make the 3′ incision [74, 92]. It is not clear which enzyme cleaves DNA 5′ of the ICL. 
Candidates include the endonuclease FAN1, the endonuclease SLX1 that is recruited 
by FANCP/SLX4 [93, 94], and the exonuclease SNM1A [95]. These incisions lead to 
the formation of a DSB on one strand (Fig 1-5c). However, TLS machinery can then 
synthesise DNA across the gap on the other strand, as below, to create an intact strand 
for DSB repair.  
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TLS is not a DNA repair pathway, but a means of tolerating DNA damage. 
TLS is therefore considered an error-prone pathway, but contributes to overall 
genomic stability by preventing replication fork collapse due to damage [96]. By 
placing a nucleotide opposite DNA damage, TLS polymerases allow for the extension 
of DNA around a lesion and the continuation of replication or repair [97]. Candidate 
polymerases for bypassing ICLs include REV1L and pol ζ [69, 85, 86, 98]. It is 
suggested that REV1L places the first base opposite the ICL, while pol ζ is proposed 
to complete extension of the leading strand (Fig 1-5c).  
This provides an intact sister chromatid which can be used as a template for 
initiating HR-mediated repair to correct the DSB. Resection of the 5′ ends of the DSB 
is regulated by an MRN-CtIP-BRCA1 complex (Fig 1-5d) [99, 100]. RPA binds to 
the resulting 3′ ssDNA overhangs. With the aid BRCA2/FANCD1 RPA is displaced 
by Rad51 to create a nucleoprotein filament [101, 102]. Rad51 promotes strand 
invasion [103] of the homologous sequence by one of the 3′ overhangs (Fig 1-5e). 
This creates a “D-loop” structure allowing for DNA synthesis to extend the annealed 
3′ end [100]. To complete DSB repair the structure is resolved.  
The final unhooked ICL may be removed by NER, creating a fully replicated 
and repaired DNA sequence. Thus, ubiquitin-dependant protein-protein interactions 
are essential for both ICL repair and signalling to checkpoint and cell survival 
responses.  
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Figure 1-5 Model of ICL repair (modified from Clauson et al, 2013 [39]) 
 
1.6 Damage-induced apoptosis 
If DNA repair fails, or too much damage is present, cells can undergo 
programmed cell death (PCD) to maintain genetic integrity within the organism and 
prevent cancer. The major form of DNA damage-induced PCD is apoptosis. DNA 
damage can induce cell death through both the intrinsic and extrinsic apoptotic 
pathways, as well as through recently discovered internal death signalling complexes 
such as the ripoptosome. It does so through multiple signalling mediators, such as p53 
and the stress activated MAPKs. 
 
 
 
a)
b)
c)
e)
d)
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1.6.1 Activation of apoptosis by the intrinsic pathway 
The intrinsic, or mitochondrial, pathway of apoptosis is regulated by the B-cell 
leukaemia/lymphoma 2 (Bcl-2) protein family that consists of pro- and anti-apoptotic 
members [104]. Pro-apoptotic Bcl-2 proteins permeabilise the mitochondria outer 
membrane, leading to the release of pro-death molecules such as cytochrome c. Anti-
apoptotic Bcl-2 members bind to and sequester the pro-apoptotic proteins to prevent 
cell death. Once released into the cytosol, cytochrome c binds to apoptotic protease-
activating factor (Apaf)-1, procaspase-9, procaspase-3 and X-linked inhibitor of 
apoptosis protein (XIAP) to form the apoptosome [105–107]. Within the apoptosome 
procaspase-9 is cleaved and activated, feeding into the caspase cascade [108]. 
Apoptosis is negatively regulated by the E3 ligase inhibitor of apoptosis 
proteins (IAPs). XIAP regulates the intrinsic pathway by directly binding to caspase-9 
and downstream caspases, thus inhibiting them [109]. Conversely, activation of the 
apoptosome is aided by the release of second mitochondrial activator of caspases 
(Smac, also known as Diablo), and Omi/HtrA2, which negatively regulate the IAPs 
[110, 111]. 
On induction of DNA damage the intrinsic apoptotic pathway is regulated by 
the tumour suppressor p53 [112]. P53 is constitutively targeted for proteosomal 
degradation, but in response to DNA damage and ATM and ATR activation p53 is 
stabilised, activated and translocates to the nucleus. In response to cisplatin p53 
upregulates the expression of pro-apoptotic Bcl-2 members such as BAX, NOXA and 
PUMA, and can bind and directly inhibit anti-apoptotic Bcl-xL [113, 114]. However, 
p53 can also have anti-apoptotic effects by upregulating DNA repair proteins. 
 
1.6.2 Activation of apoptosis by the extrinsic pathway 
The extrinsic, or death receptor, pathway of apoptotic activation is mediated 
by the binding of death ligands, such as tumour necrosis factor (TNF), Fas ligand 
(FasL) and TNF-related apoptosis-inducing ligand (TRAIL), to their cognate death 
receptors [115]. Ligands binding causes multimerisation of the receptor and 
recruitment of signalling complexes to the cytoplasmic membrane.  
At Fas and TRAIL receptors the complex formed is known as the death-
inducing signalling complex (DISC). The DISC includes the death receptors, Fas-
associated death domain (FADD), procaspase-8 and procaspase-10. The proximity of 
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procaspase-8 molecules allows for their auto-activation and activation of the caspase 
cascade [116–118]. DISC-mediated activation of apoptosis is also regulated through 
polyubiquitination of caspase-8 by CUL3 [119]. Ubiquitination of caspase-8 promotes 
its own recruitment to the DISC and subsequent activation, as well as the recruitment 
of p62. A p62-caspase-8-ubiquitin containing complex then translocates and 
aggregates in the cytosol. These complexes can be visualised as ‘speckles’ in the cell 
and promote apoptosis. This effect is attenuated by the deubiquitination of capase-8 
by A20. 
TNF treatment leads to the formation of two opposing signalling complexes 
[120–122]. Complex I causes the activation of NF-κB and MAPK signalling, cell 
propagation and inflammation, while complex II upregulates apoptosis and 
necroptosis. Complex I contains TNF receptor (TNFR), receptor-interacting protein 
(RIP), TNFR-associated death domain protein (TRADD), TNFR-associated factor 
(TRAF)-1/2 and other molecules. It can activate the nuclear factor (NF)-κB signalling 
pathway by recruiting the IKK complex, and can activate c-Jun N-terminal kinase 
(JNK) through a TRAF-2 dependent mechanism. Complex I can also translocate to 
the cytosol where, now known as Complex II or the traddosome, it recruits and 
activates procaspase-8 and -10.  
The extrinsic pathway can be regulated by cellular FLICE inhibitory protein 
(cFLIP), an inhibitor of apoptosis that binds to death receptor complexes [123]. There 
are three isoforms of cFLIP that implement separate pro- and anti-apoptotic functions 
by binding to caspase-8 to inhibit or activate it. cFLIP can regulate and in turn be 
regulated by signalling of stress-related proteins such as the MAPK family. 
In addition the extrinsic apoptotic pathway is negatively regulated by cellular 
IAP 1 and 2 (cIAP1 and cIAP2) [124]. One method of achieving this is through their 
binding to death receptor induced complexes and polyubiquitination of RIP1 with 
K11 and K63 chains. This ubiquitination of RIP1 is required for recruitment of 
activators of the NF-κB pathway leading to pro-survival signalling. Removal of cIAP-
mediated RIP1 ubiquitination by cylindromatosis (CYLD) causes it to dissociate from 
TNF-induced complex I and instead bind FADD and capase-8, thus promoting 
apoptosis. 
The extrinsic pathway is activated in response to DNA damage by the 
upregulation of expression of death ligands such as FasL by mediators such as p53 
and the mitogen-activated protein kinases (MAPKs). Stress-activated protein kinase 
 38 
(SAPK)/c-Jun N-terminal kinase (JNK) is usually downregulated by 
dephosphorylation by MKP1, however in response to inhibition of transcription by 
genotoxic stress MKP1 levels are reduced. This allows for sustained activation of 
JNK and p38, resulting in an increase in c-Jun level and AP-1 activity [125]. AP-1 is 
a transcription factor whose increased activation causes increased Fas-L expression 
and extrinsic pathway-mediated apoptosis.  
Furthermore, signalling through the extrinsic pathway is upregulated after 
cisplatin treatment by p53-mediated degradation of FLIP [126, 127]. 
 
1.6.3 The ripoptosome 
The ripoptosome is a cell death signalling complex that is formed in response 
to treatment with etoposide [128–131]. The ripoptosome acts as a switch between 
DNA damage-induced apoptosis and necroptosis. To date the core components of the 
ripoptosome have been recognised as RIP1, caspase-8 and FADD, making it similar 
in structure to TNF-induced complex II. Ripoptosome factors are constitutively 
targeted for degradation by the IAPs [130], preventing its formation. In response to 
genotoxic stress however, the IAPs are downregulated and spontaneous formation of 
the ripoptosome can occur. This leads to caspase-8 activation and the caspase cascade. 
Ripoptosome formation and activation are further regulated by the presence of 
different cFLIP isoforms. While cFLIPL inhibits its formation entirely, cFLIPS 
promotes formation of the complex but inhibition of caspase-8 activity, leading to 
necroptosis [128, 129]. Although no role has yet been shown for the ripoptosome in 
regulating cell death after cisplatin-induced damage, it is conceivable that it could act 
in a similar way in this situation. 
 
1.6.4 The caspase cascade 
Apoptotic activation pathways converge through the activation of the caspase 
cascade [132]. The caspase family is a group of cysteine-aspartate proteases 
consisting of proenzymes that exist in an initial inactive state and are activated by the 
cleavage of their regulatory domain [133]. Caspases themselves cleave their 
substrates after the last aspartate residue of a DEXD signalling sequence [134]. 
Upstream initiator caspases such as caspases-8, -9 and -10 activate downstream 
effector caspases like caspases-3, -6 and -7. The effector caspases then go on to 
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deactivate DNA repair enzymes, disassemble the cytoskeleton, activate DNA 
cleavage enzymes and effectively dismantle the cell [132, 135].  
Upon activation of the caspase cascade crosstalk is possible between apoptotic 
pathways. This is regulated by the Bcl-2 proteins. BH3-interacting-domain death 
agonist (Bid), is cleaved by caspase-8 to truncated Bid (tBid) which translocates to 
the mitochondria to inhibit anti-apoptotic and activate pro-apoptotic Bcl-2 members 
[136].  
 
1.6.5 NF-κB signalling and DNA-damage induced apoptosis  
DNA damage-induced apoptosis can be further regulated by NF-κB. This 
transcription factor acts as a dimer to upregulate both pro- and anti-apoptotic genes, 
although it is most commonly considered a pro-survival regulator. NF-κB is normally 
inhibited by the IκB proteins, which bind to it and sequester it in the cytoplasm [137]. 
The IκB proteins can in turn be inhibited by the IκB kinase (IKK) complex, which 
phosphorylates them, signalling for their ubiquitination and proteasomal degradation. 
The IKK consists of NEMO/IKKγ with IKKα and/or IKKβ and is activated by signal 
transduction pathways such as those mediated by TNF-induced Complex I, and thus 
acts as an antagonist of TNF-induced Complex II-mediated apoptosis. 
Furthermore, NF-κB can be activated in response to DSBs through 
intracellular signalling. On recognition of a DSB NEMO localises to the nucleus in a 
SUMO-dependant manner, where it binds to and is phosphorylated by ATM [138, 
139]. NEMO and ATM then translocate to the cytosol in a ubiquitin-dependant 
manner where they bind IKK and stimulate it to phosphorylate IκBα. Subsequent 
degradation of IκBα releases NF-κB, allowing it to upregulate expression of anti-
apoptotic proteins such as Bcl-xL, c-IAP2, TRAF1 and 2 and MKP1 [140].  
 
1.6.6 Understanding cell death in the context of damage 
As indicated above, cisplatin-induced genotoxic stress leads to both pro-
survival and pro-death signals. Indeed many of the individual factors that regulate the 
DDR can be considered both pro- and anti-apoptotic, depending on the cellular 
situation. It is the balance of these signals, presumably based on the extent of damage 
and otherwise competency and signalling background of the cell, that determine 
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whether a cell will survive damage to its DNA. However we are far from 
understanding how exactly this balance is tipped in one direction. 
 
1.7 Objectives 
Cisplatin is an anti-cancer drug that acts by introducing toxic interstrand 
crosslinks into the DNA of proliferating cells. However, cisplatin can cause unwanted 
side effects, and resistance to this drug can be inherent or acquired, which limits its 
efficacy. There is much still unknown about the response to cisplatin and how the 
DNA damage it causes results in cell death. However, it is acknowledged that 
ubiquitination is important for the regulation of the ICL response. It is thus probable 
that further ubiquitin-related proteins have previously unidentified roles in this 
process. The detection and characterisation of these components would be a powerful 
way to increase our understanding of how cells respond to cisplatin. This might help 
to optimise the current chemotherapeutic use of this agent, or even aid in the search 
for new anti-cancer drugs.  
The aim of this thesis is to present the identification of such novel regulators 
through the use of a high throughput siRNA screen, and subsequent characterisation 
of their roles in the response to cisplatin. 
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2 Materials and Methods 
 
2.1 Materials 
 
2.1.1 Cell lines 
The U2OS cell line is a human osteosarcoma cell line. It was established in 
1964 from the bone tissue of a 15 year old female with osteosarcoma. Cells are 
adherent and have functional p53 and pRb [141]. U2OS were obtained from the 
American Type Culture Collection. 
The A2780 cell line was established from ovarian tumour tissue from an 
untreated patient. A cisplatin-resistant A2780 cell line (A2780 CisR) was previously 
created in vitro by continuously growing cisplatin-sensitive (A2780 CisS) cells in 
increasing concentrations of cisplatin [142]. A2780 cells are adherent. The paired 
A2780 CisS  and CisR lines were a kind gift from Dr. Gillian Smith (University of 
Dundee, Dundee, UK). 
Flp-In T-Rex cells were obtained from Life Technologies (Paisley, UK) and 
are described in further detail below. 
Abin1D485N/D485N primary mouse embryonic fibroblasts (MEFs) isolated from 
Abin1D485N/D485N mice [28] were a kind gift from Prof. Sir Philip Cohen (University of 
Dundee, Dundee, UK) . Corresponding wild type and heterozygous primary MEFs 
were isolated from their littermates. Abin1-/- and Abin1+/+ MEFs [143] were a kind 
gift from Averil Ma (UCSF School of Medicine, California, USA). MEF cells are 
adherent. 
The DT40 cell line is derived from a chicken B cell bursal lymphoma. The 
lymphoma was induced in vivo in a chicken (Gallus Gallus) using avian leukosis 
virus (ALV) in the 1980s [144]. DT40 cells are still capable of gene conversion and 
have a high frequency of targeted to random DNA integration. As a result they are 
particularly easy to genetically manipulate in cell culture and are often used for 
creating knock out cell lines in the study of DNA repair pathways. DT40 cells are 
suspension cells. 
Transformation-competent DH5α Escherichia coli cells were obtained from 
Life Technologies (Paisley, UK). 
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2.1.2 Chemicals and reagents 
The PBS, trypsin, chicken serum, FBS, penicillin/streptomycin, L-glutamine, 
sodium acetate and non-essential amino acids (NEAA), DMEM, McCoy’s 5A 
medium, RPMI 1640 + GlutaMAX-I medium, RPMI medium, OptiMEM, 
Lipofectamine RNAiMAX used in cell culture were purchased from Life 
Technologies (Paisley, UK). Trypan blue was also from Life Technologies. β-
Mercaptoethanol was bought from Calbiochem (Merck-Millipore, Darmstadt, 
Germany). The 20x NuPAGE MOPs, 20x NuPAGE MES, 20x NuPAGE Tris-Acetate 
Buffer, 20x NuPAGE Transfer Buffer and NuPAGE gels used for Western Blotting 
were obtained from Life Technologies (Paisley, UK). ReddyMix PCR Master Mix, 
Solaris qPCR Master Mix, and Solaris Human qPCR Gene Expression Assays for 
RNF113B and ACTB were ordered from Thermo Scientific (Leicestershire, UK). 
Ponceau S was bought from Sigma (Gillingham, UK). Coomassie Protein Assay 
Reagent, ECL Plus Western Blotting Reagent, anti-sheep and anti-rabbit secondary 
antibodies for Western Blotting and immunofluorescence were also bought from 
Pierce/Thermo Scientific. The anti-mouse secondary antibody came from Bio-Rad 
(Hertfordshire, UK). The ECL Western Blotting Detection Reagents and Hyperfilm 
ECL X-ray films were from Amersham/GE Healthcare (Buckinghamshire, UK). The 
Aplus X-ray films were ordered from Konica Minolta (Essex, UK). The Re-Blot Plus 
Mild Solution was obtained from Merck-Millipore (Darmstadt, Germany). MyFi 
DNA Polymerase was purchased from Bioline (London, UK). PrimeSTAR DNA 
polymerase was bought from TaKaRa (Saint-Germain-en-Laye, France). DMSO, 
Cisplatin, Mitomycin C, etoposide and hydroxyurea were acquired from Sigma 
(Gillingham, UK). Quantilum Recombinant Luciferase was from bought Promega 
(Southampton, UK). D-Luciferin free acid was obtained from Synchem 
(Felsberg/Altenburg, Germany). Gel Loading Dye (6x), Quick-Load 100 bp and 1kbp 
DNA ladders, BamHI restriction enzyme were purchased from NEB (Herts, UK). 10x 
TBE, 10x TBS, LB media and LB-Amp agar plates were received from the Media 
Kitchen, College of Life Sciences (Dundee, UK). Milk was from Marvel. SYBR Safe 
DNA Gel Stain was bought from Life Technologies (Paisley, UK). All chemicals that 
constituted buffer components were purchased from Sigma (Gillingham, UK). 
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2.1.3 Kits 
The NucleoBond Xtra Midi Plus kit was purchased from Macherey-Nagel 
(Duren, Germany). The QIAprep Spin Miniprep, Puregene DNA Purification, RNeasy 
Mini, and QIAquick Gel Extraction kits were bought from Qiagen (Manchester, UK). 
The First Strand cDNA Synthesis and BCA Protein Assay kits were obtained from 
Pierce (Thermo Scientific).  
 
2.1.4 Consumables 
Gene Pulser Cuvette electroporation vials were obtained from Bio-Rad 
(Hertfordshire, UK). 5 ml round bottomed FACS tubes were bought from BD 
Biosciences (Oxford, UK). Sterile 96, 24 and 6 well plates, T75 and T25 flasks and 
pipettes were obtained from Greiner Bio-One (Stonehouse, UK). Non-sterile pipettes 
were also purchased from Greiner Bio-One (Stonehouse, UK). Sterile pipette tips 
were acquired from StarLabs (Milton Keynes, UK), while non-sterile pipette tips were 
obtained from Anachem (Bedfordshire, UK). 50 ml and 15 ml Falcon tubes were 
purchased from Fisher Scientific (Loughborough, UK). 1.5 ml “eppendorf” tubes 
were obtained from Axygen (Lanarkshire, UK). 
 
2.1.5 Instruments 
A Multipette plus pipette was acquired from eppendorf (Stevenage, UK). The 
ZM400 printer was purchased from Zebra Technologies (Illinois, USA).  The Xpp-
721 dispensing robot used in the screen was purchased from fluidX (Cheshire, UK). 
The PP-96L-M liquid handling robot was acquired from Apricot Designs (California, 
USA). The EnVision Xcite Multilabel Reader was bought from and serviced by 
PerkinElmer (Massachusetts, USA). The CFX96 Real-Time System was obtained 
from Bio-Rad (Hertfordshire, UK). The Airstream ClassII hood, the Laminar Flow 
Cabinet, and the Celculture CO2 incubator were purchased from Esco (Wiltshire, UK). 
The SUBAqua18 water bath was obtained from Grant (Cambridgeshire, UK). The 
Allegra X-12R centrifuge was purchased from Beckman Coulter (High Wycombe, 
UK) and the Heraeus Fresco 17 centrifuge for 1.5 ml tubes was from Thermo 
Scientific. VERSAmax microplate reader was acquired from Molecular Devices 
(California, USA). The Ultrospec 2100 pro and NanoVue Plus were purchased from 
Amersham/GE Healthcare (Buckinghamshire, UK). The SRX-101A film processor 
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was acquired from Konica Minolta (Essex, UK). The Perfection V700 photo scanner 
was bought from Epson (Hertfordshire, UK). The Mini-Sub Cell GT tank, Sub-Cell 
model 192 tank and DNAEngine Peltier thermal cycler were purchased from Bio-Rad 
(Hertfordshire, UK). The Safe Imager was acquired from Invitrogen/ Life 
Technologies (Paisley, UK). The GeneFlash was obtained from Syngene (Cambridge, 
UK).  
 
2.1.6 Software 
Microsoft Office, including Word, Excel and Powerpoint, was obtained from 
Microsoft (California, USA) Photoshop CS4, Illustrator CS4 and Acrobat Pro were 
from Adobe (Berkshire, UK). ImageJ was received rom the National Institutes of 
Health (NIH, USA). Prism 6 was ordered from GraphPad (California, USA). R was 
gratefully downloaded from The R-Project (St Andrew’s University CRAN, UK) and 
RStudio was received from RStudio (Massachusetts, USA). MacVector was obtained 
from MacVector, Inc (North Carolina, USA). CFX Manager Software was purchased 
from Bio-Rad (Hertfordshire, UK). ZebraDesigner v2 was acquired from Zebra 
Technologies (Illinois, USA). The EPSON Scan 3.81EN used for scanning blots and 
gels came from Epson (Hertfordshire, UK). SoftWoRx Image Analysis Software was 
obtained from Applied Precision/GE Healthcare (Buckinghamshire, UK). SoftMax 
Pro was acquired from Molecular Devices (California, USA). 
 
2.1.7 Buffer compositions 
 
Bacterial growth  
Lysogeny buffer /Luria 
Bertani (LB) 
1% (w/v) tryptone peptone, 0.5% (w/v) yeast extract, 86 
mM NaCl. 
LB plates LB with 2% (w/v) bacto-agar 
  
Luciferase assay  
2x Lysis/luciferase buffer 50 mM Tris/Phosphate pH 7.8, 16 mM MgCl2, 2 mM 
DTT, 2% (v/v) Triton-X-100, 30% (v/v) Glycerol, 1% 
(w/v) BSA, 0.25 mM D-Luciferin free acid, 8 µM 
Na4O7P2, 500 ng/ml Quantilum Recombinant Luciferase 
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Lysis  
Mammalian lysis buffer 40 mM HEPES pH7.4, 120 mM NaCl, 1% (v/v) Triton, 1 
mM EDTA 
RIPA buffer 1% (v/v) NP40, 0.1% (w/v) SDS, 0.5% deoxycholate 
  
Western Blotting  
MES running buffer 50 mM MES, 50 mM Tris Base, 0.1% SDS, 1 mM EDTA, 
pH 7.3  
MOPS running buffer 50 mM MOPS, 50 mM Tris Base, 0.1% SDS, 1 mM 
EDTA, pH 7.7  
Tris-acetate running buffer 50 mM Tricine, 50 mM Tris Base, 0.1% SDS, pH 8.24  
Transfer buffer 5% (v/v) NuPAGE 20X transfer buffer, 20% methanol 
(v/v) where NuPAGE 20X transfer buffer consists of: 25 
mM Bicine, 25 mM Bis-Tris (free base), 1 mM EDTA, 
pH 7.2  
TBS 50 mM Tris-Cl, pH 7.5 
TBS-T TBS with 0.1% (v/v) Tween-20 
  
DNA gels  
TE 10 mM Tris-Cl pH8, 1 mM EDTA 
TBE 89 mM Tris, 89 mM Boric acid, 2 mM EDTA. 
  
Southern Blotting  
20x SSC 3 M NaCl, 300 mM Na3Citrate.2H2O, pH7 with HCl 
Depurination buffer 0.25 M HCl 
Denaturation buffer 0.5 M NaOH, 1.5 M NaCl 
Neutralisation buffer 0.5 M Tris pH7.5, 1.5 M NaCl 
Low stringency 2x SSC, 0.1% (w/v) SDS 
Medium stringency 1x SSC, 0.1% (w/v) SDS 
High stringency 0.1x SSC, 0.1% (w/v) SDS 
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2.1.8 Plasmids 
Plasmids used in this thesis were constructed by Nikki Wood and Mel 
Wightman (Cloning Team, DSTT, University of Dundee). The correct sequences of 
all constructs were verified by the DNA Sequencing Service (University of Dundee) 
by full sequencing of both strands.  
 
Table 2-1 Plasmids and their uses 
Plasmid name DSTT catalogue 
number 
Function 
pBS-∆Rnf113-Bsr  Creation of ∆Rnf113 DT40 cell 
line, blasticidin resistance 
pBS-∆Rnf113-puro  Creation of ∆Rnf113 DT40 cell 
line, puromycin resistance 
pcDNA5 FRT/TO GFP 
Abin1 siRNA resistant 
DU25039 Expression of siRNA resistant 
GFP-ABIN1  
pcDNA5-FRT/TO-GFP 
ABIN1 
DU32934 Expression of GFP-ABIN1 
pcDNA5-FRT/TO-GFP 
ABIN1 D472N 
DU21792 Expression of GFP-
ABIN1[D472N] 
pcDNA5-FRT/TO-GFP 
RNF113B 
DU21830 Expression of GFP-ABIN1 
pcDNA5-FRT/TO-GFP-
Abin1 delta aa462-593 
DU23575 Expression of GFP-
ABIN1[∆UBAN] 
 
2.1.9 Oligonucleotides  
The primers in Table 2-2 were designed using the MacVector programme and 
purchased from the Oligonucleotide Synthesis Service at the University of Dundee.  
 
Table 2-2 Primers used in this thesis 
Primer name Oligo sequence (5′-3′) Function 
113PF1 CTGAGCAGCAGCGATGATGATGATCCG
TCGAAG 
Southern blotting 
113PF2 CGTACAAATCAACAAGGTCGGCGGTA
AGGAC 
Southern blotting  
113PR1 CTAGCAAAGCACTCTGTTTTGTATGGA
GCCG 
Southern blotting  
113PR2 GTTAACCAGACCAGAACAAGAGCAGA
GGCAG 
Southern blotting 
113SBF3 GCATCTGGGTGTCACTGATGTCAGTAA
CACG 
Southern blotting 
113SBR3 CTCTACAGCATGAGAGAAGGCAGGAC
GTTG 
Southern blotting 
113PCRF1 CTATGAGGTGAGCAGTGATG PCR genotyping 
113PCRR1 GGGAAGCATGGATATAGCAG PCR genotyping 
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113PCRF2 CTAATGAGTCCAGTGTCTGG PCR genotyping 
113PCRR2 GTCTGGAAAGCACAAAGGAG PCR genotyping 
113PCRR4 GCCTGCTAATGTGAAGAAGC PCR genotyping 
113PCRR5 GAGCTCTCTGTTTTCCATGCAGATCAA
GCG 
PCR genotyping 
113PCRR6 CATTCGTTGGATCTGTCACC PCR genotyping 
BSRPCRF1 CTTAACTCCACACAGGCATAG PCR genotyping 
BSRPCRF2 GCCATCTAGTGATGATGAGGCTACTGC
TGAC 
PCR genotyping 
BSRPCRF3 GTCTTGGTCCGGATCTTTGTGAAGGAA
CC 
PCR genotyping 
PUROPCRF1 TTCCATGACCGAGTACAAGC PCR genotyping 
PUROPCRF2 CTCGACATCGGCAAGGTGTG PCR genotyping 
PUROPCRF3 GGGTCACCGAGCTGCAAGAACTCTTC PCR genotyping 
 
The primers and probes in Table 2-3 were purchased from Dharmacon 
(Thermo Fisher Scientific, Leicestershire, UK) and used for qRT-PCR of RNF113B 
and β-Actin mRNA. 
 
Table 2-3 Primer and probes used in qRT-PCR 
mRNA Oligo type Oligo sequence (5′-3′) 
RNF113B Forward primer CCAAAGAACTGATGGCGAAAC 
 Reverse primer TACTCAACAGGCTGCTTC 
 Probe TATGTACACTGGGGAGA 
β-Actin Forward primer TGGAGAAAATCTGGCACCAC 
 Reverse primer GGTCTCAAACATGATCTGG 
 Probe ACCGCGAGAAGATGACC 
 
2.1.10 siRNA 
SiUBE2T, siFAN1 and siATR were purchased from MWG-Biotech (Eurofins, 
Ebersberg, Germany). All other siRNAs were purchased from Dharmacon (Thermo 
Fisher Scientific, Leicestershire, UK). This included all smart pools and individual 
siRNA used in the screen. The sequences of siRNAs used (apart from those used in 
the screen and which are available on request) are shown in Table 2-4. 
 
Table 2-4 Sequences of siRNAs used 
Target 
protein 
Oligo name in thesis Sequence(s) 
Non-targeting siNT pool containing: 
UGGUUUACAUGUCGACUAA 
UGGUUUACAUGUUGUGUGA 
UGGUUUACAUGUUUUCUGA 
UGGUUUACAUGUUUUCCUA 
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REV1L siREV1L  pool containing: 
GAAGUUAAUUGAUGGGUUU 
CAUAUCAGCUGUACACCAA 
GUGGAGACUUGCAGUAUAU 
CAUCAGAGCUGUAUAAUGC 
RNF113A siRNF113A  pool containing: 
GACAAGAUCUAUCGGGGAA 
GGGUGGUGCUUCCGACUUG 
GCGAAAGAAUUGAUUGCUA 
UUACUUAGGUUUCCCAUAA 
RNF113B siRNF113B-05 (later 
siRNF113B) 
CGACCAAGCAGACCAGGUA 
siRNF113B-06 CCAAAGAACUGAUGGCGAA 
siRNF113B-07 GAGGGUCGCUACUGUAUCU 
siRNF113B-08 GGAAUCCACAGCUACCUGA 
HOIP 
 
siHOIP-05 GCCGAGAUGUGCUGCGAUU 
siHOIP-06 GGCGUGGUGUCAAGUUUAA 
siHOIP-07 (later siHOIP) CCUAGAACCUGAUCUUGCA 
siHOIP-08 GCAGAAUACUCAUCCAAGA 
ABIN1 siABIN1-05 GAAUACACCUGGCGUCUAC 
siABIN1-06 GAGCAGCGCACCUCCAUUC 
siABIN1-07 AAUCAGAGCUCCCAAGUGA 
siABIN1-08 (later 
siABIN1) 
CAAGAGAAGCCCUCAGACA 
ATR siATR GGGAGCCUGUUGAGACAAGAU 
FAN1 siFAN1 GUAAGGCUCUUUCAACGUA 
UBE2T siUBE2T CCUGCGAGCUCAAAUAUUA 
 
2.1.11 Antibodies 
The source, catalogue number and function of primary antibodies used in this 
thesis are shown below. 
 
Table 2-5 Primary Antibodies used in this thesis 
Protein Source Catalogue number Function 
ABIN1 (human) DSTT S010C Western blotting 
ABIN1 (mouse) DSTT S345C Western blotting 
β-Actin  Cell signalling #4967C Western blotting 
ATR Santa Cruz Biotech sc-1887 Western blotting 
Cleaved caspase-3 Cell signalling #9661S Western blotting 
FAN1 DSTT S420C Western blotting 
FANCD2 DSTT S099D Western blotting 
GFP DSTT S268B Western blotting 
γH2AX Bethyl A300-081A Immunofluorescence 
HOIP DSTT S174D Western blotting 
pChk1 (S345) Cell signalling #2341S Western blotting 
pChk2 (Thr68) Cell signalling #2661S Western blotting 
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pSMC1 Bethyl A303-821A Western blotting 
RNF113B (mouse) Abcam ab68253 Western blotting 
RNF113B (rabbit) Abcam ab85467 Western blotting 
RNF113B DSTT S264D Western blotting 
UBE2T DSTT S820C Western blotting 
Ubiquitin Merck-Millipore 04-263 (Clone 
FK2) 
Immunofluorescence 
 
2.2 Methods 
 
2.2.1 Cell culture  
All cell culture work was undertaken in aseptic conditions, in an Airstream 
ClassII hood. This included all maintenance of cell lines and experimental work. All 
equipment and materials were sterilised before use. All cells were maintained in a 
Celculture CO2 incubator at 37°C with 5% CO2. Medium and trypsin were always 
pre-warmed to 37ºC in a SUBAqua18 water bath before being applied to cells. 
 
2.2.1.1 Media for maintenance of cell lines  
For maintenance of stock cell lines, human cells were grown in the media 
shown in Table 2-4. For maintenance of stocks, media for human cell lines was 
supplemented with 100 units/ml penicillin, 100 µg/ml streptomycin and 10% (v/v) 
foetal bovine serum (FBS) as well as the supplements indicated in Table 2-6. Media 
for A2780 and FlpIn cells was sterile filtered and all media were stored at 4ºC for up 
to month. For some experiments the stock medium was unsuitable and this is 
indicated in the relevant method section. 
 
Table 2-6 Media for cell lines derived from humans 
Cell line Medium Supplements Selection Typical 
dilution 
factor 
A2780 CisS RPMI- 1640 2 mM L-glutamine - 10 
A2780 CisR RPMI- 1640 2 mM L-glutamine 1 µM cisplatin 3 
HEK293 DMEM 2 mM L-glutamine - 20 
Flp-In T-REx 
293 (pre-
transfection) 
DMEM 2 mM L-glutamine 200 µg/ml 
zeocin, 15 
µg/ml 
blasticidin 
20 
Flp-In T-REx 
293 (post- 
DMEM 2 mM L-glutamine 15 µg/ml 
blasticidin, 100 
20 
 50 
pcDNA5/FRT/T
O transfection) 
µg/ml 
hygromycin 
Flp-In T-REx 
U2OS (pre-
transfection) 
McCoy’s 5A - 200 µg/ml 
zeocin, 15 
µg/ml 
blasticidin 
10 
Flp-In T-REx 
U2OS (post- 
pcDNA5/FRT/T
O transfection) 
McCoy’s 5A - 15 µg/ml 
blasticidin, 100 
µg/ml 
hygromycin 
10 
U2OS McCoy’s 5A - - 10 
 
For maintenance of mouse embryonic fibroblast (MEF) lines, cells were 
grown in DMEM supplemented with 100 units/ml penicillin, 100 µg/ml streptomycin, 
2 mM L-glutamine, 1 mM sodium pyruvate, 1% (v/v) non-essential amino acids 
(NEAA) and 10% (v/v) foetal bovine serum (FBS). Medium for MEFs was sterile 
filtered and stored at 4ºC for up to month. 
DT40 chicken cells were maintained in RPMI 1640 + GlutaMAX-I medium 
supplemented with 7% (v/v) heat inactivated FBS, 3% (v/v) heat inactivated chicken 
serum, 100 units/ml penicillin, 100 µg/ml streptomycin and 50 µM β-
mercaptoethanol. Medium for DT40 cells was sterile filtered and stored at 4ºC for up 
to one month.  
 
2.2.1.2 Maintenance of cell lines 
Adherent cells (all mammalian lines) were passaged by first washing the cells 
in 5 – 10 ml PBS. The PBS was removed and 1 - 2 ml 0.5% EDTA trypsin was added 
to the cells. Cells were incubated at 37 ºC for less than 5 min and the trypsin was then 
neutralised in pre-warmed medium. Cells were pipetted up and down to remove 
clumps and an appropriate volume was transferred to a fresh flask containing the 
relevant media. MEFs were typically diluted by a factor of 20, and human-derived 
cell lines as per Table 2-6. Mammalian cell stocks were usually maintained in T75 
flasks and were expanded as required.  
Suspension cells (DT40 chicken cells) were passaged by a simple dilution, of 
usually three to five fold, in fresh media. Once a week cells were transferred to a 15 
ml tube, pelleted by spinning at 233 x g for 5 min on an Allegra X-12R centrifuge and 
resuspended in fresh medium before being transferred to a fresh flask. Stocks of 
DT40s were typically maintained in T25s and expanded as required.  
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When required for an experiment mammalian cells were washed and 
trypsinised as above, before being pelleted by spinning at 233 x g for 5 min on an 
Allegra X-12R centrifuge. Cells were resuspended in an appropriate volume of the 
relevant media, counted if necessary, diluted in medium and seeded in dishes as 
required. DT40s were prepared in the same way with the exclusion of the PBS wash 
and trypsin steps. 
 
2.2.1.3 Cell counting 
Cells were counted using a Neubauer-style haemocytometer. Cells were 
trypsinised (if required), pelleted and resuspended in 2 – 10 ml of media depending on 
the pellet size. A small volume of cells, typically 10 µl, was combined with the same 
volume of trypan blue in a 1.5 ml tube. 10 µl of cells/trypan blue solution was added 
to one side of the haemocytometer chamber and drawn across its grid by capillary 
action. The number of cells in the four large squares, each of 1 mm2 area, was counted 
using by eye using a microscope. The mean number of cells per square was calculated. 
As the volume above one of these squares is 100 nl, the number of cells per millilitre 
of sample was calculated by multiplying the number of cells per square by 10,000.  
 
2.2.1.4 Cryopreservation of cells 
Mammalian and DT40 cells were cryopreserved for long-term storage of cell 
lines. Mammalian cells were first washed in PBS, trypsinised and the trypsin 
neutralised in medium. Both mammalian and DT40 cells were then pelleted by 
spinning at 233 x g for 5 min on a Allegra X-12R centrifuge. Cells were resuspended 
in 1 ml of the appropriate freezing solution as in Table 2-7. Freezing solution was 
stored at 4ºC for up to one month. After resuspension cells were transferred to a 
cryogenic vial and vials were wrapped in many layers of tissue. DT40 cells were 
placed on dry ice to slowly freeze and once frozen were stored at -80ºC. Mammalian 
cells were placed in a polystyrene box and allowed to freeze slowly at -80ºC. They 
were stored at -80ºC for up to one month or in liquid nitrogen for longer periods of 
time. Once frozen cells were transported on dry ice to prevent accidental thawing. 
When cell lines were required they were thawed rapidly at 37ºC, transferred to pre-
warmed medium and pelleted by spinning at 233 x g. Cells were resuspended in fresh 
medium and transferred to a T25 flask. They were then maintained or expanded as 
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required for one to two weeks to allow the cells to recover from freezing before being 
used in experiments. 
 
Table 2-7 Components of freezing media for cells.  
Percentages represent v/v. 
Cell type DMSO FBS Chicken serum (%) Medium 
DT40 10% 67% 23% - 
A2780 10% 50% - 40% RPMI 
MEF 10% 90% - - 
Stable Flp-In 293  10% 50% - 40% DMEM 
Stable Flp-In U2OS 10% 50% - 40% McCoy’s 
 
2.2.2 Creation of DT40 knock out cells 
DT40 chicken cells were used to create the Rnf113-/- cell line using 
homologous recombination. Details of the gene targeting process are presented in 
Chapter 4. 
 
2.2.2.1 Transfection of DT40 cells with DNA 
The plasmid for transfection (38 µg) was precipitated in ethanol and 
resuspended in 50 µl of sterile dH2O. The DNA and a Gene Pulser Cuvette 
electroporation vial for each plasmid were pre-cooled on ice. The DT40 cells for 
transfection were counted and 25 x 106 cells for each construct were placed in a 50 ml 
tube. Cells were pelleted by centrifugation at 233 x g for 5 min and resuspended in 
800 µl of medium.  The DNA was added to the cells and mixed by gently votexing. 
The cell/DNA mixture was transferred to the electroporation vial and incubated on ice 
for 20 min. The vial was placed in a GenePulser Xcell Electroporation System 
chamber and a voltage of 700 V with a resistance of ∞ was applied to the cells. The 
vial was immediately transferred to ice and the cells were allowed to recover for 5 
min. The cells were added to 50 ml of medium in a T75 flask and mixed well. Cells 
were incubated overnight.  
 
2.2.2.2 Selection of positive DT40 clones after transfection 
The following day a two-fold concentration of selection media was produced 
and 50 ml was combined with the transfected cells. Cells transfected with construct 
pBS-∆Rnf113-bsr to create Rnf113-/+ cells were selected with 20 µg/ml blasticidin. 
Cells transfected with construct pBS-∆Rnf113-puro to create Rnf113-/- cells were 
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selected with 0.5 µg/ml puromycin. The cell/selection mixture was poured into a 
sterile reservoir and an eight-channel multi-pipette was used to seed 200 µl of cells 
per well of five 96 well plates. The cells were incubated for 7 – 10 days until clones 
were visible. Media from wells that contained only one clone was pipetted up and 
down to dislodge the cells, and then transferred to a fresh well of a 24 well plate. Each 
well was given a number and this was considered the clone number for future 
reference. An additional 500 µl of media was added to each well and the clones were 
incubated for 2 – 3 days. As the cells expanded additional media was added as 
required. When the cells were confluent a replica plate of the clones was created. 
Media was added to the well in a one to one dilution of the media already present, and 
half of the final volume was added to a fresh, pre-labelled well in a new 24 well plate. 
Both plates were incubated for 1 – 2 days or until the cells were again confluent. 
Clones in the original master plate were then frozen. The growth media was carefully 
removed and replaced with DT40 freezing media. The plate was wrapped in 
protective tissue and placed on dry ice until the cells and media were frozen. The 
plate was then stored at -80ºC until required. Meanwhile, the clones of the replica 
plate were genotyped to identify positive clones (see Sections 2.1.16). When positive 
clones had been classified the master plate was thawed and the chosen clones were 
expanded and refrozen as required. 
 
2.2.3 Creation of stable over-expressing cell lines 
Stable cell lines capable of the over-expression of specific protein were 
created using the Flp-In system. This system enables the integration of a gene of 
interest into a Flp Recombination Target (FRT) site present in the FlpIn cells using 
Flp recombinase-mediated DNA recombination [145]. Before transfection the FRT 
site is maintained under selection by zeocin and becomes disrupted after introduction 
of the gene of interest. The Flp recombinase is expressed from the pOG44 plasmid 
under the control of the human CMV promoter. This plasmid is cotransfected with the 
pcDNA5/FRT/TO plasmid, which contains the gene of interest and a hygromycin 
resistance cassette under the control of the human CMV promoter. Blasticidin selects 
for the pcDNA6/TR plasmid present in the Flp-In cells, which allows your gene of 
interest to be expressed in a tetracyclin-inducible manner.  
 54 
Low passage tetracyclin-inducible Flp-In T-REx 293 or U2OS cells were 
seeded in 15 cm dishes and allowed to adhere overnight. When cells reached 75% 
confluency they were transfected with as follows. A cotransfection mix was prepared 
for each plasmid containing a 9 µg of pcDNA/FRT/TO (with the protein of interest) 
to 1 µg pOG44 (the Flp-recombinase expression vector), and a final concentration of 
30 µg/ml polyethylenimine (PEI) in 1 ml serum-free media. A negative control 
transfection mix containing only PEI and media was also prepared. The transfection 
mix was immediately vortexed and incubated at room temperature for 20 min. 
Meanwhile the media on the cells was replaced with serum-free media. The 
transfection mix was added dropwise to the cells and cells were incubated at 37ºC for 
4 hr before the addition of FBS to a final concentration of 2% (v/v). After 72 hr, with 
cell passaging as required, the media was replaced with selection media containing 
100 µg/ml hygromycin and blasticidin (15 µg/ml). Flp-In T-REx 293 cells were then 
incubated for up to two weeks, and Flp-In T-REx U2OS for up to a month, changing 
the medium every 2-3 days. Clones that survived selection were considered to be 
positive for the pcDNA/FRT/TO plasmid. All clones for each plasmid were combined, 
expanded and frozen at low passage numbers. To check for expression of the protein, 
expression was induced with tetracyclin, cells were lysed and the protein extracts 
were analysed via Western Blotting and the appropriate antibodies. Typically 
expression induction was optimised with a range of tetracyclin concentrations (1 – 
1000 ng/ml) and/or induction times (8 – 24 hr). 
 
2.2.4 Immortalisation of MEFs 
Primary MEF lines have limited ability to grow in culture and were thus 
unsuitable for many of the assays used in this thesis. To circumvent this problem 
MEFs were immortalised using SV40 transformation or serial passage (spontaneous 
immortalisation).  
Throughout this thesis the term ‘corresponding wild type MEFs’ refers to a 
wild type cell line that was immortalised at the same time and using the same 
procedure as the MEF line in question. In the case of Abin1D485N/D485N MEFs it also 
designates a primary or immortalised wild type line that came from a littermate of the 
original Abin1D485N/D485N embryo used to create the primary line. 
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2.2.4.1 Immortalisation by SV40 transformation 
Transformation with the Simian virus 40 (SV40) can be used to immortalise 
MEFs. The large tumour (T) antigen, coded for by the SV40 A gene, binds to and 
disrupts the activities of p53, and Rb family proteins(reviewed in [146]). Inhibiting 
these tumour suppressors allows the cells to overcome senescence. 
The SV40 retrovirus was prepared by Dennis Castor. He transfected the pSC-
B-SV40 PolyA plasmid into HEK293T cells using FuGENE transfection reagent. 
Cells were incubated for 48 hr to allow them to produce the retrovirus with the SV40 
plasmid. Medium was collected from the cells, filtered and stored in 15 ml tubes at -
20ºC until required.  
Abin1 MEFs were seeded in 10 cm dishes and allowed to adhere overnight. 
They were transfected by replacing the growth medium with the SV40 viral 
supernatant and the addition of 8 µg/ml polybrene. Cells were incubated for 3 hr and 
the viral medium was replaced with fresh MEF medium. The infection was repeated 
24 hr later, uncluding the replacement with fresh media. After 24 hr cells were split 
and the media was then changed every day for up to a week, after which time the cells 
began to proliferate again. Viral waste was disposed of separately to normal 
CategoryI cell culture waste. Wild type Abin1, Abin1wt/D485N and Abin1D485N/D485N 
Clone 3 MEFs immortalised by SV40 transformation were labelled Clone 3A. 
 
2.2.4.2 Immortalisation by serial passage 
Using the serial passage method, freshly isolated primary MEFs were 
passaged until they stopped proliferating. The media was then changed every two or 
three days for up to six weeks until the MEFs overcame senescence and began to 
proliferate again. Wild type Abin1, Abin1wt/D485N and Abin1D485N/D485N Clone 3 MEFs 
immortalised by serial passage were labelled Clone 3B.  
 
2.2.4.3 Identification and cryopreservation of immortalised cells 
In general cells were considered to be immortalised when they began to 
proliferate rapidly, however cellular morphology was also used to identify 
immortalised cells. Primary or arrested MEFs had large, spherical shapes with much 
cytoplasmic, while immortalised cells were generally more extended with larger 
nuclei to cytoplasm ratios. Immortalised cells were frozen immediately with low 
passage numbers.  
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2.2.5 RNA interference 
RNA interference (RNAi) was used to knock down proteins in human-derived 
cell lines.  Cells were transiently transfected with small interfering RNA (siRNA) 
using a forward or reverse transfection method as indicated in the appropriate method 
section. Typically reverse transfections were used for experiments involving 96 well 
plates or cell lines requiring tetracycline induction, while forward transfections were 
used for experiments involving lysates, microscopy and flow cytommetry. 
Unless otherwise indicated the final siRNA concentration against any target 
protein was 10 nM.  
 
2.2.5.1 Reverse siRNA transfection 
The lipid-based transfection reagent Lipofectamine RNAiMAX is not 
compatible with antibiotics, and so all medium used for reverse transfection was 
antibiotic-free. If the cells were to be used in luminescence-based experiments, such 
as for luciferase or caspase assays, the medium was also phenol red-free. The day 
before transfection sufficient U2OS cells were placed in antibiotic-free medium. On 
the day of transfection 10 µl of siRNA buffer (Mock transfection) or 10 µl of working 
concentration siRNA against each protein was added to the required number of wells 
of a 96 well assay plate. Lipofectamine RNAiMAX was diluted by a factor of 100 
into phenol-red free OptiMEM medium and incubated for 5 min at room temperature. 
10 µl of the lipofectamine solution was added to each well and the plate was shaken at 
800 rpm for 1 min. The siRNA and lipofectamine solution were allowed to combine 
by incubation at room temperature for 40 min. Meanwhile the U2OS cells were 
trypsinised and counted as usual. Cells were diluted to 62,500 cells/ml in antibiotic-
free medium and 80 µl of cells were dispensed into each well of the plate. The cells 
were incubated for 6 -8 hr before tetracycline addition if required, and/or for 16 – 20 
hr before drug treatment. Blank wells were included in each plate which contained 10 
µl siRNA buffer, 10 µl lipofectamine solution and 80 µl antibiotic-free medium. For 
10 cm dishes the same protocol was followed but the volumes were up-scaled and the 
siRNA and lipofectamine solution were combined and mixed in a tube before being 
added to the dish.  
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2.2.5.2 Forward siRNA transfection 
The day before transfection U2OS cells were seeded in 10 or 15 cm dishes and 
allowed to adhere overnight so they would be 25% confluent on the day of 
transfection. SiRNA and INTERFERin transfection reagent were diluted in Opti-
MEM and vortexed gently for 10 sec. This transfection mix was designed to give a 
final concentration of 10 nM siRNA and 0.35% (v/v) INTERFERin. A separate 
transfection mix containing only INTERFERin diluted in Opti-MEM was created to 
act as a Mock transfection mix. The transfection mixes were incubated at room 
temperature for 10 min. Meanwhile the medium on the cells was replaced. The 
transfection mix was then added dropwise to the appropriate plates – 500 µl of mix 
per 10 ml of medium, and the plate was swirled gently to mix. The cells were 
incubated for 36 – 48 hr before treatment. 
 
2.2.6 Treatment of cells with genotoxins 
 
2.2.6.1 Drug preparation 
Cisplatin was resuspended in DMSO for the siRNA screen, and DMF for all 
other experiments. This gave a stock concentration of 33.33 mM cisplatin which was 
aliquoted and stored at -80ºC for up to one year. MMC was resuspended in dH20 to a 
concentration of 1.5 mM, aliquoted and stored at -80ºC for up to one year. Etoposide 
was resuspended in DMSO to a stock concentration of 100 mM, aliquoted and stored 
at -20ºC. Hydroxyurea was resuspended in dH20 to a stock concentration of 500 mM 
and used immediately. If necessary the above drugs were diluted to working 
concentrations in appropriate media and used immediately. Cyclohexamide (CHX) 
was resuspended in dH20 to a concentration of 10 mg/ml and stored at 4ºC. Pan-
caspase, csapase-8 and caspase-9 inhibitors were resuspended in DMSO to a stock 
concentration of 10 mM and stored at -20ºC.  
 
2.2.6.2 Vehicle treatments 
Where test cells were treated with a drug, “0 µM” or “0 hr” etc. refers to the 
negative control vehicle treatment for each cell line. Cells were treated with the same 
volume of appropriate vehicle (DMSO or DMF) as the highest volume of drug, and/or 
for the same amount of time as the longest timepoint used in the experiment. 
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2.2.6.3 Treatment with ionising radiation 
Plates were taken in a sterile protective container to a 137Caesium γ-ionising 
irradiator. The machine was programmed for the required amount of time, dishes 
were placed inside the canister and the canister in the radiation chamber. As the 137Cs 
source of radiation degrades each year the exposure time required for the same 
radiation dose varied over time, however in 2013 this machine delivered a dose of 2 
Gy/min. The cells were irradiated, removed from the canister and returned to the 
protective container. As soon as all cells had been treated they were returned to the 
tissue culture suite incubated at 37ºC as required. Mock treated or “0 Gy” cells were 
taken to the irradiator with other cells but did not receive any dose. 
 
2.2.7 Cell lysis of eukaryotic cells 
To analyse protein and signalling changes within cells, they were first lysed 
using protocols optimised for each cell type. 
 
2.2.7.1 Harvesting whole cell lysates from human-derived cell lines 
U2OS and FlpIn U2OS cells required for whole cell lysates protein extraction 
were grown on 15 cm dishes. HEK293 and A2780 cells were grown on 10 cm dishes. 
When required they were placed on ice and washed in PBS. Depending on the cells’ 
confluency 200 – 400 µl of U2OS lysis buffer was applied to the plate. The U2OS 
lysis buffer consisted of mammalian lysis buffer supplemented with Cømplete 
Protease Inhibitor Cocktail, or Halt Protease and Phosphatase Inhibitor Cocktail if 
phosphorylated proteins were to be analysed. Cells were then scraped from the dish 
and collected on ice in a 1.5 ml tube, which was vortexed. The lysed cells were then 
centrifuged for 30 min at 17000 x g at 4ºC and the supernatant was transferred to a 
fresh tube. Samples were maintained on ice while the protein concentration of the 
lysate was determined using a Bradford assay.  
 
2.2.7.2 Harvesting whole cell lysates from MEFs 
MEFs required for whole cell lysates protein extraction were grown on 15 cm 
dishes. When required they were washed in PBS, trypsinised, washing in PBS and 
transferred to a 15 ml tube on ice. Cells were centrifuged at 233 x g for 5 min at 4ºC 
and the supernatant was discarded. The cell pellet was resuspended in 800 µl of ice 
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cold PBS and transferred to a 1.5 ml tube on ice. The cells were centrifuged for 30 sec 
at 900 x g and 4ºC. The tube was turned within the centrifuge and the spin repeated 
until all cells were collected in a pellet – typically about 10 times. The supernatant 
was carefully aspirated on ice and cells were resuspended in 200 – 400 µl of MEF 
lysis buffer depending on the pellet size. The MEF lysis buffer consisted of a 
radioimmunoprecipitation assay (RIPA) buffer supplemented with Cømplete Protease 
Inhibitor Cocktail, or Halt Protease and Phosphatase Inhibitor Cocktail if 
phosphorylated proteins were to be analysed. Cells were then vortexted and passed 
through a syringe with 19G needle at least 8 times on ice. The lysed cells were then 
centrifuged for 30 min at 17000 x g at 4ºC and the supernatant was transferred to a 
fresh tube. Samples were maintained on ice while the protein concentration of the 
lysate was determined using a BCA assay.  
 
2.2.7.3 Harvesting whole cell lysates from DT40s 
DT40s required for whole cell lysate protein extraction were grown in T75 
flasks. When required they were decanted into a tube of appropriate size and 
centrifuged at 223 x g for 5 min. The supernatant was discarded and the cell pellet 
was resuspended in 800 µl of ice cold PBS and transferred to a 1.5 ml tube. The cells 
were next centrifuged for 5 min at 900 x g and at 4ºC. The supernatant was carefully 
aspirated and cells were resuspended in 200 µl of RIPA buffer supplemented with 
Cømplete Protease Inhibitor Cocktail on ice. Cells were then vortexted and passed 
through a syringe with 19G needle at least 8 times on ice. The lysed cells were 
centrifuged for 20 min at 17000 x g at 4ºC and the supernatant was transferred to a 
fresh tube. Samples were maintained on ice while the protein concentration of the 
lysate was determined using a BCA assay.  
 
2.2.7.4 Preparation of protein samples from lysates 
After cell lysis and the appropriate protein concentration assay were 
performed, samples were equilised to an appropriate concentration. This was typically 
1 µg/µl and achieved by diluting the protein sample in dH2O, NuPAGE LDS Sample 
Buffer and NuPAGE Sample Reducing Agent. Lysates were then boiled for 10 min at 
100ºC. Samples were analysed immediately by SDS-PAGE and Western Blot, and 
then snap frozen in liquid nitrogen and stored at -80ºC 
 
 60 
2.2.8 Protein quantification 
2.2.8.1 Bradford assay 
The Bradford assay was used to determine the concentration of proteins 
obtained from cells lysed in mammalian lysis buffer.  
Protein lysate samples were diluted by a suitable amount in dH2O, typically by 
a factor of 10, in a final volume of 100 µl. A blank sample consisting of the same 
dilution of lysis buffer in water was also created. 20 µl of the diluted sample was 
added to 1 ml of Coomassie Protein Assay Reagent in a disposable cuvette in 
duplicate. The sample was vortexed and the absorbency of each sample at 595 nm 
was analysed on an Ultrospec 2100 pro spectrophotometer. These values were 
compared to a prepared standard curve to calculate the concentrations of the diluted 
lysate samples. 
 
2.2.8.2 BCA assay 
The bicinchoninic acid (BCA) assay was used to determine the concentration 
of proteins obtained from cells lysed in RIPA buffer.  
The Compatibility Reagent was reconstituted by first preparing Working 
Reconsitution Buffer (500 µl Reconstitution Buffer in 500 µl ultrapure water). This 
was added to the Compatibility Reagent which was vortexed at high speed for 30 s. 
Protein standards were created by serial dilution of the BSA solution provided with 
the kit to give concentrations of 125, 250, 500, 750, 1000, 1500 and 2000 µg/ml. 
Compatibility Reagent and protein standards were stored at -20ºC and reused. Protein 
lysate samples were diluted by a suitable amount in dH2O, typically by a factor of 4, 
in a final volume of 20 µl.  In duplicate, 5 µl of diluted sample was added to a well of 
a 96 well plate, along with 5 µl of the Compatibility Reagent. Duplicate ‘blank’ wells 
containing 5 µl of diluted lysis buffer and 5 µl of Compatibility Reagent were also 
included. The plate was protected from light and incubated for 15 min at 37ºC. The 
Working Reagent was prepared by mixing 50 parts Reagent A with 1 part Reagent B 
and 200 µl was added per well. The plate was again incubated, for 30 min at 37ºC. 
The plate was cooled at room temperature for 10 min and the absorbency of each well 
then read at 562 nm on a VERSAmax microplate reader. The data was analysed using 
SoftMax Pro. The absorbency values of the blank wells were subtracted from all 
standard and sample wells. The average absorbency values of the protein standards of 
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known concentration were then used to create a standard curve against which the 
concentrations of the diluted lysate samples could be read. 
 
2.2.9 Analysis of cellular proteins by PAGE and Western Blotting 
2.2.9.1 Protein separation by gel electrophoresis 
Proteins were separated using the NuPAGE Electrophoresis System as per the 
manufacturer’s instructions. Briefly, gels were washed and placed in the XCell 
SureLock Mini-Cell. The inner chamber thus created was filled with NuPAGE 
running buffer diluted in water and allowed to overflow. Samples were loaded into 
the wells of the gel, with typically 10 – 20 mg of protein being loaded. SeeBlue Plus2 
Prestained protein ladder was loaded to the left of the protein samples as an indicator 
of size. Current was applied until the protein of interest was expected to be roughly in 
the centre of the gel. Proteins of less than 20 kDa were separated on 4 – 12% Bis-Tris 
gels, and run with MES buffer at a voltage of 200 V. Proteins with molecular weight 
between 20 – 120 kDa were separated on 4 – 12% Bis-Tris gels, and using MOPS 
buffer at a voltage of 180 V. Proteins greater than 120 kDa were separated on 3 – 8% 
Tris-Acetate gels with Tris-Acetate SDS running buffer at 80 V for 30 min and then 
160 V for 2 hr. To prevent over heating, the tanks of gels that needed to be run for 
more than 1 hr were placed in a bucket of ice to prevent overheating. 
 
2.2.9.2 Western Blotting 
Gels were transferred to nitrocellulose membrane using the NuPAGE system 
using the manufacturer’s instructions. Briefly, nitrocellulose membrane and Whatman 
blotting paper were first cut to an appropriate size. The membrane, along with transfer 
sponges, was pre-soaked in NuPAGE Transfer buffer. Gels were released from their 
casing and placed in a sandwich consisting of two pieces of pre-wetted Whatman 
paper, the gel, membrane and two more pieces of pre-wetted Whatman paper. This 
sandwich was transferred to the XCell II Blot module cassette to create a second 
sandwich with the pre-soaked sponges. The entire XCell II Blot module was 
assembled with transfer buffer being poured into the cassette and water filling the 
outer cavity. Proteins were transferred to membranes at 30 V for 2 hr at room 
temperature. 
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The membrane was removed from the module and incubated with Ponceau S 
for a few minutes to check that proteins transferred correctly. Blots were washed with 
Tris-Buffered saline (TBS) with 0.1% (v/v) Tween-20 (TBS-T) until the Ponceau was 
removed, and then incubated for at least 1 hr in appropriate blocking solution with 
gentle mixing. The blocking solution used, either 5% milk or BSA in TBS-T, are 
shown in Table 2-8. Membranes were probed with primary antibodies diluted in the 
appropriate blocking solution for 1 hr at room temperature, or overnight at 4ºC, as per 
Table 2-8. Blots were washed with TBS-T three times for 15 min. membranes were 
incubated with the appropriate secondary antibody conjugated to horseradish 
peroxidase (HRP) for 30 min at room temperature. Excess secondary antibody was 
removed by washing three times for 10 min with TBS-T. Blots probed with antibodies 
against cleaved caspase-3, pChk1, pChk2 or pSMC1 were incubated with ECL Plus 
Western Blotting Reagent for 5 min. These blots were transferred to an X-ray cassette 
and exposed to Hyperfilm ECL X-ray films while protected from light.  All other 
blots were incubated with ECL Western Blotting Detection Reagents in a 1:1 ratio for 
1 min. Membranes were transferred to an X-ray cassette and exposed to Aplus X-ray 
films while protected from light. Films were developed on an SRX-101A processor. 
Approximate size markings were copied from the membrane to the film for future 
reference. 
 
Table 2-8 Primary antibodies used for Western Blotting 
Protein Concentration 
or dilution 
Blocking 
solution 
Incubation time Host species 
ABIN1 (human) 1 µg/ml Milk 1 hr Sheep 
ABIN1 (mouse) 1 µg/ml Milk 1 hr Sheep 
β-Actin 5000 Milk 1 hr Rabbit 
ATR 1 µg/ml Milk o/n Goat 
Cleaved caspase-3 1000 Milk o/n Rabbit 
FAN1 1 µg/ml  Milk 1 hr Sheep 
FANCD2 1 µg/ml  Milk o/n Rabbit 
GFP 1 µg/ml Milk 1 hr Sheep 
HOIP 1 µg/ml Milk 1hr Sheep 
pChk1 (S345) 1000 BSA o/n Rabbit 
pChk2 (Thr68) 1000 BSA o/n Rabbit 
pSMC1 1 µg/ml Milk o/n Rabbit  
RNF113B (all) 1 µg/ml Milk o/n See results 
UBE2T 1 µg/ml Milk 1 hr Sheep 
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Occasionally antibodies were stripped from blots using Re-Blot Plus Mild 
Solution diluted by a factor of 10. Membranes were incubated for 10 min, washed in 
TBS-T three times for 5 min and then blocked and reprobed as required. 
 
2.2.9.3 Analysis and presentation of Western Blots 
Developed films of Western Blots were scanned used a Perfection V700 photo 
scanner and images were saved as tiff files. Images were cropped, converted to 
grayscale and had their ‘levels’ auto-adjusted in Photoshop. Images of bands were 
then copied to Illustrator and annotated for presentation.  
ImageJ was used to quantify the intensity of bands using non-manipulated tiff 
format images. Files were opened in ImageJ and a rectangle selection box to fit the 
largest band was created. A background value was obtained by measuring the Mean 
Grey Value of the blot away from the bands, and the Mean Grey Value of each band 
was then analysed. These values represent the intensity of the area within the 
selection box. The mean grey values were copied to Excel and the value for each band 
was subtracted from the background value. Quantified intensities could then be 
expressed as ratios or fold increase after treatment as required. 
 
2.2.10 Clonogenic survival assays (CSAs) with DT40 cells 
Clonogenic survival assays (CSAs) are a sensitive method to determining the 
effect of a treatment on cell viability. They are based on the ability of individual cells 
to multiply into colonies that are allowed to grow large enough to be counted by eye. 
Cells that are hypersensitive to drugs are less able to develop into colonies than 
resistant lines after drug treatment. Modified protocols were used for CSAs with 
DT40 (suspension) cells and mammalian (adherent) cells. 
 
2.2.10.1 Medium for CSAs with DT40s 
A viscous medium was required to prevent the DT40 suspension colonies 
from diffusing through out the well and allow them to grow large enough to count. 
This methylcellulose media was produced by dissolving 11.9 g DMEM and 2.44 g 
sodium bicarbonate gradually in autoclaved dH20, to a volume of 500 ml. This was 
filtered. Next, 10 g methylcellulose was dissolved in 400 ml pre-heated autoclaved 
dH20. This was allowed to cool and then gradually combined with the DMEM 
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mixture. The mixture was stirred at 4ºC overnight, after which it was supplemented 
with 7% (v/v) FBS, 3% (v/v) chicken serum, 100 units/ml penicillin, 100 µg/ml 
streptomycin and 50 µM β-mercaptoethanol. The media was again stirred at 4ºC 
overnight and thereafter stored at 4ºC for up to one month. 
 
2.2.10.2 Overall methodology for CSAs with DT40s 
The exact protocol followed for CSAs with DT40 cells depended on the 
treatment in question. However, in general the density of each cell line was first 
calculated and an appropriate number of cells were placed in a 15 ml tube. Cells were 
centrifuged at 233 x g for 5 min and resuspended in 10 ml medium. Cells were then 
treated with genotoxic agent as detailed below. To ensure that single colonies were 
obtained cells were seeded at multiple densities. Cells were serially diluted to give 
final densities of 10000, 1000 and 100 cells/well in  prewarmed methylcellulose 
medium in duplicate wells of a 6 well plate. The plate was swirled gently to ensure 
even distribution of cells. Cells were incubated for 7 – 10 days after which time the 
colonies were counted by eye using a light box. Wells with between 20 and 100 
clones were used for quantification. Values from wells that had been seeded with 
fewer cells were normalised to values from wells with higher seeding densities by 
multiplying with 10 or 100 as appropriate. Viability values for each cell line and 
treatment concentration were then calculated by expressing the average number of 
colonies for that concentration as a percentage of the average vehicle treatment for 
that cell line. 
 
2.2.10.3 Cisplatin treatment for CSAs with DT40s 
Cells were counted and 2 x 106 cells of each cell line required were pelleted 
and resuspended in 10 ml medium. To each well of a 24 well plate 1 ml of cells was 
added so as to give one well per treatment concentration. Two-fold working 
concentrations of cisplatin were created and 1 ml was added to the appropriate well to 
give final treatment concentrations of 0, 1, 2, 4 and 6 µM cisplatin. Cells were 
incubated for 1 hr at 37ºC. Treated cells from each line were then serially diluted and 
seeded in duplicate in 6 well plates before incubation.  
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2.2.10.4 MMC treatment for CSAs with DT40s 
Cells were counted and 2 x 106 cells of each cell line required were pelleted 
and resuspended in 10 ml medium. To each well of a 24 well plate 1 ml of cells were 
added so as to give one well per treatment concentration. Two-fold working 
concentrations of MMC were created and 1 ml was added to the appropriate well to 
give final treatment concentrations of 0, 30, 60, 90 ng/ml MMC. Cells were incubated 
for 1 hr at 37ºC. Treated cells from each line were then serially diluted and seeded in 
duplicate in 6 well plates before incubation.  
 
2.2.10.5 Chronic HU treatment for CSAs with DT40s 
Cells were counted and 1 x 106 cells of each cell line required were pelleted 
and resuspended in 10 ml medium. Cells from each line were serially diluted and 100 
µl of each of the dilutions were seeded in a 6 well plate as in Section 1.2.11.2. 
Working concentrations of HU were created and added to the wells to give final 
concentrations of 0, 25, 50, 75 and 100 µM HU. The plates were again swirled gently 
to mix the cells and drug. 
 
2.2.10.6 IR treatment for CSAs with DT40s 
Cells were counted and 1 x 106 cells of each cell line required were pelleted 
and resuspended in 10 ml medium. Cells were then distributed into a 15 ml tube for 
each IR dose (2 x 105 cells/tube) and treated with 0, 2, 4 or 6 Gy. Treated cells from 
each line were then serially diluted and seeded in duplicate in 6 well plates before 
incubation. 
 
2.2.11 Clonogenic survival assays (CSAs) with mammalian cells 
CSAs with mammalian cells involved seeding the cells and allowing them to 
adhere overnight before treating them. Drugs were removed 24 hr later cells were 
allowed to recover before the media was removed as cells were stained and counted 
as below. 
 
2.2.11.1 CSAs with human-derived cell lines 
U2OS or HEK293 cells were seeded at a density of 1 x 106 cells/dish in 10 cm 
dishes, with one dish per siRNA required. Cells were allowed to adhere overnight. 
 66 
HEK293 cells were mock transfected or forward transfected with 12.5 nM siABIN1, 
12.5 nM siHOIP or 12.5 nM siFAN1.  U2OS cells were mock transfected or forward 
transfected with 10 nM siRNF113B, 10 nM siFAN1 or 10 nM siATR. Cells were 
incubated for 48 hr after which time they were washed, trypinised, neutralised and 
pelleted. Cells were resuspended in 5 – 10 ml of media depending on the pellet size, 
counted and diluted to give a final density of 500, 2000, 4000 or 8000 cells per 10 cm 
dish. Cells were seeded in duplicate dishes for each siRNA/density/treatment 
combination. Cells were distributed evenly across the dishes and allowed to adhere 
overnight. After seeding remaining cells were pelleted and lysed, and protein samples 
were obtained and analysed for knock down. Cells seeded for the assay were treated 
with a dose range of IR (0 – 2 Gy) or a range of working concentrations giving final 
concentrations of 0 – 30 nM MMC or 0 – 3.3 µM cisplatin. Cells were incubated for 
10 – 14 days until colonies were visible.  
 
2.2.11.2 CSAs with MEFs 
Each MEF cell line was washed, trypinised, neutralised and pelleted. Cells 
were resuspended in 5 – 10 ml of media depending on the pellet size, counted and 
diluted to give a final density of 1000 cells per 10 cm dish. Cells were seeded in 
triplicate dishes for each drug treatment. Cells were distributed evenly across the 
dishes and allowed to adhere overnight. A range of working concentrations of drugs 
were produced to give final treatment concentrations of 0 – 600 nM cisplatin, 0 – 240 
nM MMC or 0 – 500 nM etoposide. Cells were treated with these drugs or a dose 
range of IR (0 – 6 Gy). After 24 hr the media was replaced on cells that had been 
treated with cisplatin, MMC or etoposide, to allow the cells to recover. The cells were 
incubated for 7 – 10 days until colonies were visible.  
 
2.2.11.3 Staining of CSA plates with mammalian cells 
After incubation the media was decanted from each dish and plates were dried 
overnight. Cellular nuclei were stained with 3 – 5 ml of a solution of Giemsa diluted 
by a factor of 4 in methanol. After a few minutes the stain was poured off and 
background staining was removed by washing the dishes with dH2O. The dishes were 
allowed to dry for a few hours before the colonies were counted by eye using a light 
box. Viability values for each cell line and treatment concentration were then 
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calculated by expressing the average number of colonies for that concentration as a 
percentage of the average vehicle treatment value for that cell line/siRNA. 
 
2.2.12 Metabolic activity/proliferation assays  
The CellTiter 96 AQueous Non-Radioactive Cell Proliferation Assay, or MTS 
assay, was used to identify differences in proliferation between cell lines after drug 
treatment. The reagents for this assay contain an MTS tetrazolium compound that is 
reduced to coloured formazan by dehydrogenases produced by living cells. The 
amount of formazan per well, which can be quantified by measuring the absorbancy 
of the well, is thus proportional to the amount of metabolic activity undergone by 
cells in each well, and hence to the number of proliferating cells per well.  
 
2.2.12.1 MEF growth curves 
MEFs were seeded at a density of 2000 cells/well in triplicate in multiple 96 
well plates in 100 µl final volume. Complete MTS reagents (see below) were 
immediately added after seeding and then every subsequent 24 hr until the growth 
curve plateaued.  
 
2.2.12.2 Viability assay with MEFs 
MEFs were seeded at a density of 2000 cells/well in 96 well plates in 100 µl 
final volume in triplicate for each treatment concentration. Cells were allowed to 
adhere for 16-20 hr before being treated with cisplatin, MMC, etoposide, HU or IR. 
Working concentrations of cisplatin, MMC, etoposide and HU were created fresh and 
20 µl was added to each well as appropriate to give a range of cisplatin (0 – 10 µM), 
MMC (0 – 5 µM), etoposide (0 – 5 µM) and HU (0 – 100 µM) concentrations. 
Otherwise cells were treated with a γ-irradiator to give a dose range of 0 – 8 Gy. Cells 
were incubated for 72 hr.  
 
2.2.12.3 Viability assay with FlpIn cells 
FlpIn U2OS cells expressing GFP-ABIN1, or GFP-ABIN1 that is resistant to 
siABIN1 (GFP-ABIN1R), were reverse transfected and seeded at a density of 5000 
cells/well in 96 well plates, in antibiotic-free media, in triplicate for each treatment 
concentration. After 6 - 8 hr, 5 µl of freshly prepared working concentration 
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tetracycline was added to give a final concentration of 10 ng/ml for GFP-ABIN1 cells 
and 100 ng/ml for GFP-ABIN1R cells. Cells were incubated overnight before being 
treated with 20 µl of freshly prepared working solutions of cisplatin to give a range of 
0 - 10 µM. Cells were incubated for 72 hr.  
 
2.2.12.4 Viability assay with A2780 cells 
A2780 cells were seeded at a density of 5000 cells/well in 96 well plates, in 
triplicate for each treatment concentration, in 100 µl final volume. Cells were allowed 
to adhere for 16-20 hr. Working concentrations of cisplatin were created fresh and 20 
µl was added to each well as appropriate to give a final range of 0 – 10 µM cisplatin. 
Cells were incubated for 72 hr.  
 
2.2.12.5 MTS assay 
The MTS Solution and PMS Solution were thawed and combined. The 
complete reagent were stored -20ºC. After the required incubation of cells 20 µl/well 
of complete MTS reagent was added to each well. Plates were incubated at 37˚C for 3 
hr before the absorbency at 490 nm of each well was read on a VERSAmax 
microplate reader. The average absorbency of each cell line or transfected line after 
treatment was then calculated and expressed as a percentage of the average 
absorbency of the vehicle treatment, giving percentage viability values. 
 
2.2.13 Caspase activity Assays 
Caspase-Glo 3/7, 8 and 9 Assays were used with U2OS, MEF and FlpIn cells 
to detect increases in the activity levels of these caspases. The reaction mixes for 
these assays contain a lysis buffer and luminogenic substrates with specific cleavage 
sites for active caspase-3/7, -8 or -9 as appropriate. Once cleaved the product 
luminesces and can be quantified using a luminometer. The amount of luminescence 
per well is therefore proportional to the total activity of that caspase in that well.  
The phenol-red present in the media used for maintaining stock cells interferes 
with the luminescence read-out for the assays. Thus all media used in these assay was 
phenol-red free. U2OS and FlpIn U2OS cells also required a reverse transfection step, 
and so the media used in this assay for these cells was also antibiotic-free media.  
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2.2.13.1 Preparation of U2OS cells for caspase activity assays 
U2OS cells were reverse transfected and seeded in white 96 wells plates to 
give 5000 cells/well in 100 µl final volume, in triplicate for each treatment. For every 
caspase assay plate a duplicate clear 96 well plate was prepared for a simultaneous 
MTS assay. Cells were allowed to adhere for 16-20 hr. Working concentrations of 
cisplatin were created fresh in the appropriate media and 20 µl was added to each well 
as appropriate to give a final concentration of 0, 5 or 10 µM cisplatin. Cells were 
incubated for 24 or 48 hr.  
 
2.2.13.2 Preparation of MEFs for caspase activity assays 
MEFs were seeded at a density of 1000 cells/well in white 96 wells plates in 
100 µl final volume, in triplicate for each treatment condition. Duplicate clear 96 well 
plates were also prepared for simultaneous MTS assays to obtain viability data. Cells 
were allowed to adhere for 16-20 hr. Working concentrations of cisplatin were created 
fresh in the appropriate media and 20 µl was added to each well as appropriate to give 
a final concentration of 0, 2 or 5 µM cisplatin. Cells were incubated for 24 or 48 hr.  
 
2.2.13.3 Measurement of caspase activity 
Caspase-Glo 3/7, 8 or 9 Substrates were reconstituted in Caspase-Glo 3, 8 or 9 
Buffer and MG132 was added to Caspase-Glo 8 and 9 reagents. Reconstituted 
reagents were stored for up to one week at 4ºC. 60 µl/well of complete Caspase-Glo 
3/7, 8 or 9 Assay Reagents were added to the white plate, while 20 µl complete MTS 
reagent was added to the duplicate clear plate. Both plates were incubated at 37˚C for 
3 hr. The luminescence of each well of the white plates was read on an EnVision 
Xcite Multilabel Reader with the Wallac EnVision Manager. The absorbency at 490 
nm of each well of the clear plates was read on a VERSAmax microplate reader. 
Viability data was obtained from the MTS assay as described in Section 1.2.15.5.  
The average luminescence values for the Caspase-Glo assay were calculated from the 
triplicate well and were normalised to the viability data. Fold increases in caspase-3/7, 
8 and 9 activity levels before and after cisplatin treatment for each transfection were 
then calculated. 
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2.2.14 Preparation and analysis of DNA 
2.2.14.1 Primer preparation 
Primers for PCR were designed using MacVector and created by the 
Oligonucleotide Synthesis Service, University of Dundee. Primers were resuspended 
in 200 µl Tris-EDTA (TE) buffer and mixed for 1 hr at 800 rpm at room temperature. 
The DNA concentration in ng/µl was measured and converted to molarity using the 
molecular weight (Mr) of the primer. Primers were then diluted to 100 µM with TE 
buffer and stored at -20ºC. When required the stock primers were diluted with water 
to give working solutions of 10 µM. 
 
2.2.14.2 Amplification and extraction of plasmids from bacterial cells 
Bacterial cells were transformed with DNA to amplify plasmids for 
transfection of eukaryotic cells. All stages of the transformation of bacterial cells took 
place under asceptic conditions using a Bunsen burner and sterile equipment such as 
tips, tubes and spreaders. All medium and plates were pre-warmed to 37C. DH5α 
Escherichia coli cells were defrosted on ice. An appropriate volume of DNA was 
added to the cells in a 1.5 ml tube and mixed gently. Bacteria and DNA were 
incubated on ice for 20 mins before being heat-shocked at 42C for 1 min. Cells were 
incubated for 2 min on ice before 400 µl of lysogeny broth (LB) medium was added. 
Transformed cells were allowed to recover for 1 hr at 37C while being shaken at 800 
rpm. E. coli were then pipetted onto a plate containing LB agar with 50 µg/ml 
ampicillin at different densities to ensure single colonies were obtained. Cells were 
spread evenly across the agar and the plates were incubated at 37°C overnight. The 
next morning a single colony was picked using a pipette tip and transferred to 1 ml 
LB medium with 50 µg/ml ampicillin (LB-Amp) medium to create a ‘starter culture’. 
Cells were incubated for 6 – 8 hr at 37C shaking at 220 rpm. After incubation, 100 µl 
of the starter culture was added to 100 ml of LB-Amp and incubated at 37C shaking 
at 220 rpm overnight. This culture was decanted into appropriate tubes and 
centrifuged for 15 min at 3273 x g at 4C. The supernatant was discarded. From here 
the NucleoBond Xtra Midi Plus kit was used as per the manufacturer’s instructions to 
lyse cells and extract the plasmid. 
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2.2.14.3 Extraction of genomic DNA from DT40 cells 
Cells were genotyped to identify positive Rnf113-/+ and ΔRnf113 clones. 
Genomic DNA (gDNA) first needed to be isolated from all clones. This was achieved 
using buffers from the Puregene DNA Purification Kit. Approximately 1 ml of cells 
were transferred to a 1.5 ml tube and centrifuged at 17000 xg for 10 sec. Most of the 
supernatant was discarded and cells were resuspended in the remaining liquid by 
vigorous vortexing. Cells were then lysed by the addition of 300 µl of Cell Lysis 
Solution and an overnight incubation at room temperature. Next, protein was removed. 
Protein Precipitation Solution (100 µl) was added, the lysate was vortexed vigorously 
for 20 sec and the solution was incubated on ice for 2 min before being centrifuged at 
16,000 g for 7 min at 4ºC. The supernatant was transferred to fresh tubes containing 
500 µl of 100% isopropanol to precipitate the DNA. Samples were inverted 50 times 
and centrifuged at 16,000 g for 20 min at 4°C. The supernatant was discarded and the 
DNA dried briefly before being washed with 300 µl of 70% ethanol. Again, the tubes 
were inverted several times, centrifuged at 16,000 g for 10 min at 4°C and the 
supernatant was discarded. The DNA was air-dried and rehydrated with 50 µl of DNA 
Hydration Solution and an overnight incubation with shaking at 800 rpm. The 
concentration of gDNA was then determined. DT40 gDNA was stored at 4ºC for up 
to a month and was used for Southern Blotting or PCR genotyping. 
 
2.2.14.4 Determining DNA and RNA concentration 
DNA and RNA content were quantified using a NanoVue Plus. The sensor 
was cleaned and blanked twice with 2 µl of the solution the DNA or RNA was 
dissolved in. The platform was cleaned and 2 µl of the sample was placed on the 
sensor. The absorbency at 260 nm of the sample was read. As it is known that a DNA 
solution with a concentration of 50 ng/µl has an absorbency of 1, the DNA 
concentration of the sample was calculated by multiplying its absorbency by 50. 
Similarly, an RNA solution with a concentration of 40 ng/µl also has an absorbency 
of 1 and the RNA concentration was calculated by multiplying its absorbency by 40. 
The procedure was repeated to acquire duplicate concentration values for each sample 
and the average was taken as the DNA or RNA concentration of the sample in ng/µl. 
The A260/A280 ratio was used as a measure of purity for each DNA sample and was 
required to be about 1.8 for the sample to be considered of good quality. 
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2.2.14.5 DNA precipitation 
To precipitate DNA the sample concentration was first obtained. An 
appropriate amount of DNA, for example 30 µg for DT40 transfections, was diluted 
in a total volume of 250 µl DNA elution buffer. Three times this volume of 100% 
ethanol and 10% of this volume of 3 M sodium acetate were added. The sample was 
incubated at room temperature for 20 min before being centrifuged for 30 min at 
17,000 x g and 4°C. The supernatant was discarded. The DNA was washed with 500 
µl of 70% ethanol and a 10 min spin at 17,000 x g and 4°C. The supernatant was 
again discarded and the pellet was air-dried. The DNA was dissolved in 50 µl of 
sterile dH2O by shaking for 1 hr at 65ºC. Precipitated DNA was stored at 4ºC until 
required. 
 
2.2.14.6 Separating and analysing DNA 
Agarose gels were used to separate DNA fragments. Gels of 0.8 – 1.2% 
agarose were used to separate DNA; the larger the fragment sizes to be separated the 
lower the agarose content. The required amount of agarose was placed in a conical 
flask with the required amount of Tris-Borate-EDTA (TBE) buffer. SYBR Safe DNA 
Gel Stain was diluted 10000 fold in the TBE and the flask was swirled gently to mix 
the contents. The mixture was heated in a microwave and mixed every few seconds 
until the agarose had fully dissolved in the TBE buffer. The mixture was allowed to 
cool until it was safe to touch and then poured into a mould with an 8 or 15 well comb. 
The gel was protected from light while it was allowed to set for at least 30 min. The 
comb was carefully removed from the gel and the gel was placed in a Mini-Sub Cell 
GT tank and covered with TBE. Gel Loading Dye (6x) was added to the DNA 
samples and they were loaded into the gel wells. Quick-Load 100 bp or 1kbp DMA 
ladders were loaded alongside the samples as an approximate guide for DNA size. 
The apparatus was fully assembled and a current of 90 V was applied for 30 min or 
until the DNA bands should have separated. The gel was protected from light while 
being run. The apparatus was disassembled and the gel was removed from the mould.  
If DNA bands were to be excised from the gel the DNA was visualised using a 
Safe Imager and bands were removed with a scalpel. If an image of the gel was 
required it was placed in a GeneFlash UV imager and a photograph was printer using 
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a Seikosha VP-1200 printer. Images were scanned using a Perfection V700 photo 
scanner and cropped in Photoshop as required. 
If more detailed analysis of DNA samples was required, for example for 
genotyping, an agarose gel was used in conjunction with Southern Blotting.  
 
2.2.15 Southern Blotting 
A Southern Blot was used in the process of genotyping Rnf113-/+and Rnf113-/- 
DT40 clones. 
 
2.2.15.1 Preparation and separation of gDNA for Southern Blot 
Genomic DNA was isolated from DT40 cells and 30 µl of this was digested 
with 1.5 x103 units/ml BamHI restriction enzyme overnight at 37ºC in a final volume 
of 40 µl. A large 0.8% agarose gel with 26 lanes was prepared without any DNA dye. 
Loading dye was added to each sample (8 µl of 6x loading dye) and about 30 µl of 
each digested sample was loaded into the wells of the gel in a Sub-Cell model 192 
tank. A 1 kbp ladder was run in the same gel for estimation of DNA fragment sizes. 
The tank was assembled and the gel was run overnight at 30 V or until the DNA dye 
had travelled 10 cm down the gel. The gel was removed from the mould and 
incubated with a solution of 0.5 µg/ml ethidium bromide (EB) in TBE for 20 min. 
The gel was photographed to ensure the digest had worked. It was then incubated with 
depurination buffer for 20 min, denaturation buffer for 1 – 2 hr, neutralization buffer 
for 30 min and 20x saline-sodium citrate (SSC) buffer for 30 min with the gel being 
rinsed with dH2O between incubation.  
 
2.2.15.2 Southern Blot transfer 
After the final incubation the Southern Blot transfer apparatus was set up. This 
consisted of a sandwich of the pre-soaked Whatman paper, the gel, a pre-cut, pre-
soaked positively charged nylon membrane and 4 pieces of pre-cut Whatman paper 
on top of a glass plate. The edges of the bottom layers of Whatman paper draped over 
the side of the glass plate into a container of 20x SSC buffer, which acted as the 
transfer buffer. The sandwich was continuously kept moist with transfer buffer. A 
large pile of tissues was placed evenly on top of the sandwich to carry the transfer 
buffer up through the sandwich by capillary action and transfer the DNA from the gel 
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to the membrane with it. To prevent evaporation of the transfer buffer parafilm was 
stretched from the edges of the gel to the edges of the container with the buffer. The 
apparatus was left to soak and transfer overnight.  
 
2.2.15.3 Creation of Southern Blot probe 
Meanwhile the DNA probe was created and purified. Using DNA from wild 
type DT40 cells as a template a probe was created using PCR.  Primers 113SBF3 and 
113SBR3 (see Table 2-2 for sequences) were used at 200 nM along with the template, 
PrimeSTAR DNA polymerase, buffer and dNTPs in a final concentration of 50 µl. 
The template DNA was expanded using an initial separation of 95ºC for 5 min, an 
expansion cycle of 95ºC for 30 sec, 56ºC for 30 sec and 72ºC for 1 min sec, which 
was repeated 30 times, and a final expansion of 72ºC for 10 min. The PCR product 
was run on a 1.2% agarose gel and the band was cut from the gel. The probe was 
purified using the QIAquick Gel Extraction Kit as per the manufacturer’s instructions. 
The purified probe was analysed on a second 1.2% agarose gel and stored at -20ºC 
until it was required for labelling. During the optimisation stages further probes were 
created using primer combinations 113PF1/R113PR1, 113PF1/R113PR2, 
113PF2/R113PR1 and 113PF2/R113PR2 in the same manner. 
 
2.2.15.4 Radiolabelling and applying the probe 
The next morning the DNA probe was labelled with 32P-αCTP using the 
NEBlot kit as per the manufacturer’s instructions. Briefly, 25 ng of the probe was 
diluted in RNase-free dH2O, boiled at 100ºC for 5 min and buried on ice for 5 min. 
The 10x Buffer, dNTPs (excluding dCTP), 32P-αCTP and Klenow polymerase were 
added in a room prepared for radioactivity using appropriate safety procedure. The 
mixture was incubated at 37ºC for 1 hr 30 min.  
Meanwhile, well positions were indicated on the transferred membrane and 
the DNA was crosslinked to the membrane with 120 mJ/cm2 of ultraviolet (UV) light. 
The blot was incubated for 1 hr with pre-heated RapidHyb hybridization buffer at 
65ºC while rolling. The probe-labelling reaction was stopped with the addition of 19 
mM EDTA (final concentration). The mixutre was transferred to a pre-cleared GE G-
50 column and centrifuged for 2 min at 735 x g to remove unbound laballed 
nucleotides. The collected probe was boiled for 5 min. The probe was added to fresh 
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hybridisation buffer and this replaced the buffer incubating with the blot. The 
membrane and probe were hybridised for 2 hr at 65ºC. 
 
2.2.15.5 Washing and exposing the Southern Blot 
The blot was washed four times in 2x SSC for 10 min, twice in 0.2x SSC for 
10 min, twice in low stringency wash buffer for 5 min, twice in medium stringency 
wash buffer for 15 min, and twice in high stringency wash buffer for 10 mins each. 
After each wash the radiation levels of the membrane were checked. Washes were 
stopped when the radioactivity of the area of the membrane above the wells was near 
background radiation levels. The membrane was wrapped in cling film and placed in 
a X-ray film cassette. The blot was exposed to Hyperfilm ECL X-ray film overnight 
at -80ºC while protected from light. Films were developed on a SRX-101A processor 
and the well positions and blot outline were copied to the film. Using the photograph 
previously taken of the gel, the ladder positions indicating DNA sizes were also 
indicated on the film.  
If required the membrane was stripped. Boiling 0.1% (w/v) SDS was poured 
over the membrane and it was brought back to the boil in a microwave. The 
membrane was cooled to room temperature while shaking and rinsed in 2x SSC. This 
was repeated until the radioactivity of entire membrane returned to background levels. 
The blot was then rehybridised as required. 
 
2.2.16 PCR genotyping 
To identify positive Rnf113-/+and Rnf113-/- DT40 clones a PCR genotyping 
method was employed (strategy explained in detail in Chapter 4). gDNA was first 
isolated from each clone as above. PCR for wild type and blasticidin resistance (BSR) 
cassette genotyping used ReddyMix PCR Master Mix. PCR for puromycin 
genotyping used MyFi Polymerase. Primers for wild type genotyping were used at a 
concentration of 200 nM, and for BSR and puromycin cassettes at a concentration of 
500 nM. A master mix of polymerase and associated buffers, forward primer, reverse 
primer and dH2O was created. The mix was aliquoted into small PCR tubes (24 µl per 
tube). Genomic DNA from each clone was added to each tube, typically 1 µg. 
Samples were assembled and maintained on ice until they could be run on a 
DNAEngine Peltier thermal cycler. The PCR protocols carried out to look at the 
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following bands are indicated in the tables below. PCR products were analysed on 
0.9% agarose gels and photographed to identify positive clones. 
 
Table 2-9 PCR conditions for wild type bands 
Genotyping band Exon 8 Exon 6/7 (control) 
Forward primer 113PCRF1 113PCRF2 
Reverse primer 113PCRR1 113PCRR2 
Initial separation 95°C for 2 min 95°C for 2 min 
Expansion cycle  
x 40 
95°C for 25 sec 
56°C for 35 sec 
72°C for 45 sec 
95°C for 25 sec 
56°C for 35 sec 
72°C for 45 sec 
Final extension 72°C for 5 min 72°C for 5 min 
 
Table 2-10 PCR conditions for BSR cassette bands 
Genotyping band BSR 1 BSR 2 BSR 3 
Forward primer BSRPCRF1 BSRPCRF2 BSRPCRF3 
Reverse primer 113PCRR4 113PCRR5 113PCRR5 
Initial separation 95°C for 2 min 95°C for 2 min 95°C for 2 min 
Expansion cycle  
x 35 
95°C for 25 sec 
56°C for 35 sec 
72°C for 3 min 
95°C for 25 sec 
56°C for 35 sec 
72°C for 3 min 
95°C for 25 sec 
63°C for 35 sec 
72°C for 3 min 12 sec 
Final extension 72°C for 5 min  72°C for 5 min  72°C for 5 min 
 
Table 2-11 PCR conditions for puromycin bands 
Genotyping band Puromycin 1 Puromycin 2 Puromycin 3 
Forward primer PUROPCRF1 PUROPCRF2 PUROPCRF3 
Reverse primer 113PCRR4 113PCRR4 113PCRR5 
Initial separation 95°C for 1 min 95°C for 1 min 95°C for 1 min 
Expansion cycle  
x 35 
95°C for 15 sec 
59°C for 15 sec 
72°C for 3 min  
95°C for 15 sec 
58°C for 15 sec 
72°C for 3 min  
95°C for 15 sec 
65°C for 15 sec 
72°C for 3 min  
 
2.2.17 QRT-PCR 
Quantitative real time polymerase chain reaction (qRT-PCR) was used to 
analyse the mRNA levels of RNF113B and β-actin in U2OS cells. U2OS cells were 
reverse transfected with 10 nM non-targeting siRNA with 1 x 105 cells/well of a 6 
well dish. Cells were incubated for 48 hr before cells were lysed and mRNA was 
isolated using the RNeasy Mini Kit as per the manufacturer’s instructions. The 
mRNA concentration was obtained using a NanoVue Plus. Samples were treated with 
DNase to remove gDNA. cDNA was created from the mRNA via reverse 
transcription using the First Strand cDNA Sythesis Kit  as per the manufacture’s 
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instructions. mRNA was stored at -80ºC and cDNA was stored at -20ºC. qRT-PCR 
was performed on a CFX96 Real-Time System using Solaris qPCR Master Mix, 
primers designed to amplify β-actin and RNF113B mRNA, and probes designed to 
specifically bind to the resulting products. The primer and probe sequences are 
described in Table 2-3 while a schematic of the regions they bind to is shown in 
Chapter 4. Serial dilutions of the cDNA were created and run to obtain standard 
curves for each cDNA/primer/probe mix. These were used to calculate the optimum 
cDNA concentration range for analysis. Samples for analysis were run in duplicate for 
both β-actin and RNF113B primer/probe mixes. The machine was programmed and 
data were collected and analysed using CFX Manager Software. 
 
2.2.18 Immunofluorescence and Microscopy 
Cells were seeded at an appropriate density on sterile 13 mm diameter glass 
coverslips in 6 well plates (three coverslips per well). Cells were allowed to adhere 
before siRNA transfection, induction with tetracyclin and/or treatment with cisplatin 
as required. Cells were then washed in ice cold PBS twice before being incubated 
with fixing solution (PBS + 2% paraformaldehyde (PFA)) for 10 min at room 
temperature. The PFA was removed and cells were washed several times with PBS. 
Samples were then stored for up to two weeks or further processed immediately. Cells 
were next incubated in permeabilisation solution (PBS + 0.2% Triton X-100) for 10 
min at room temperature before being washed several times with PBS. Cells that did 
not require additional staining, such as GFP-expressing cells, were immediately 
mounted and DAPI-stained as below. Samples that required further staining were first 
blocked in blocking solution (3% IgG–free BSA in PBS-T (PBS with 0.2% Tween-
20)) for 1 hr at room temperature with gentle shaking. Cells were then incubated with 
1 µg/ml primary antibody in blocking solution, also for 1 hr at room temperature with 
gentle shaking. Samples were extensively washed in PBS-T before the appropriate 
secondary antibody conjugated to AlexaFluor (2 µg/ml in blocking solution) was 
added. Samples were protected from light and incubated for 45 min at room 
temperature with gentle shaking. Cells were extensively washed in PBS-T, while still 
protected from light. The coverslips were then mounted on glass slides. A drop of 
Vectashield hard set mounting medium, which contains DAPI to stain nuclei, was 
applied to each coverslip. A larger coverslip was placed on top to protect the fixed 
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cells, and samples were incubated for 5 min at room temperature while protected from 
light. Slides were stored at 4ºC until they were analysed on a DeltaVision Core 
microscope with a 60x lens. Images were taken using an Olympus 1x71 camera and 
the Resolve3D package. Images were deconvolved using SoftWoRx Image Analysis 
Software. Where appropriate foci were counted by eye on the microscope. 
 
2.2.19 siRNA screen 
The overall workflow for the siRNA screen involved a reverse siRNA 
transfection of U2OS cells, cisplatin or MMC treatment, incubation and a luciferase-
based viability assay.  
 
2.2.19.1 siRNA transfection for screen 
The reverse transfection for the siRNA screen was based on the same protocol 
as described in Section 1.2.5.1 with some modifications to allow for the high-
throughput nature of the screen. U2OS cells were prepared and maintained in 
antibiotic-free, phenol-free medium as described. Barcode labels were printed using 
ZebraDesigner software and a ZM400 printer, and fixed to white 96 well plates. 
siRNA was stamped from custom-made ‘ubiquitinome’ library plates (described in 
Chapter 3) to the assay plates using a fluidX Xpp-721 dispensing robot in a Laminar 
Flow Cabinet. siRNA against REV1L was used as a positive control, non-targeting 
siRNA (ON-TARGETplus Non-targeting pool, siNT) was used as a negative control 
and mock transfected (non-transfected) cells with no siRNA were used as a cell 
growth control. The final siRNA concentration was 10 nM. The Lipofectamine 
RNAiMAX solution was prepared and added to the wells in an Airstream ClassII 
hood. The plates were mixed and incubated for 40 min as usual. U2OS cells were 
washed, trypsinised, centrifuged and counted. They were seeded at a density of 5000 
cells/well in a final volume of 100 µl and incubated for 16 to 20 hrs. During the 
primary screen the Lipofectamine solution and cells were dispensed using an Apricot 
Designs PP-96L-M liquid handling robot. During the secondary and tertiary screens 
they were dispensed using a Multipette plus pipette.  
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2.2.19.2 Drug treatment for screen 
During the primary screen cells were vehicle treated or treated with a single 
concentration of cisplatin (3.25 µM for the first replicate and 3 µM for the second 
replicate). During the secondary and tertiary screens they were treated with a range of 
cisplatin (0 – 6 µM) or MMC (0 – 1 µM) concentrations. Cells were treated by 
creating six-fold working concentrations of the drugs fresh and then adding 20 µl to 
each well as appropriate using a Multipette plus pipette. During the secondary and 
tertiary screens antibiotics were also added to the working solutions to give final 
concentrations of 100 units/ml penicillin and 100 µg/ml streptomycin. At all stages of 
the screen cells were incubated for 72 hr after treatment to enable the cells to go 
through multiple replication cycles. 
 
2.2.19.3 Luciferase-based viability assay for screen 
A luciferase-based assay was used to determine cell viability. In this assay 
ATP from lysed cells is used in a reaction that produces a luminescent byproduct. 
Thus the luminescense per well is proportional to the number of cells in the well. A 
combined 2x lysis buffer/luciferase assay buffer containing Quantilum Recombinant 
Luciferase and D-Luciferin free acid was prepared and filtered. This was used fresh or 
stored at -20ºC and thawed once. The buffer was added to the cells in a one to one 
ratio (120 µl of buffer) using a fluidX Xpp-721 dispensing robot. Cells were mixed 
for 10 min at 900 rpm. The luminescence values of each well of the plate were 
obtained using an EnVision Xcite Multilabel Reader with the Wallac EnVision 
Manager. 
 
2.2.20 Antibody production 
Antibodies raised against RNF113B were created in collaboration with the 
PPAD and DSTT divisions of the University of Dundee. Full length HsRNF113B 
fused to a 6xHis tag was expressed in bacteria by the PPAD and used as an antigen 
for injecting into sheep at Scottish National Blood Transfusion Service (Penicuik, 
U.K.). Prior to injection His-RNF113B was emulsified in Freund’s adjuvant. As 
standard protocol, one pre-immune bleed was taken on the same day as the first 
injection of antigen. Thee more injections, one every 28 days, were administered and 
blood was taken seven days after the second and third of these injections. Typically 
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750 ml of blood is taken per bleed, which yields 250-350 ml of serum. Each bleed 
was allowed to clot overnight at 4ºC and, following centrifugation for 60 min at 1500 
x g at 4ºC, the sheep antiserum was decanted though glass wool and stored at -20ºC. 
The antibodies were affinity-purified by the DSTT antibody production team co-
ordinated by James Hastie and Hilary McLauchlan (University of Dundee). The 
serum was heated for 20 min at 56ºC followed by filtration though a 0.45 µM filter. 
The anti-serum was diluted 1:1 in 50 mM Tris/HCl pH 7.5 with 2% Triton X-100  and 
anti-His antibodies were first depleted. Flow-though fractions were affinity purified 
against RNF113B. The antibody was eluted with 50 mM glycine pH 2.5 into 
eppendorfs containing 200 mM Tris pH 8 to adjust the pH to 7 – 7.5. Antibodies were 
then dialyzed overnight into PBS. 
 
2.2.21 Data analysis and statistics 
Quantitative raw data was initially analysed in Microsoft Excel. Raw values 
were copied from the appropriate software, such as ImageJ, SoftMax Pro or Wallac 
EnVision Manager, into Excel. Blank values were subtracted as appropriate and 
average, fold increase or percentage viability values were calculated as indicated in 
the appropriate experimental section.  
During the screen data obtained from luciferase assays were analysed by Amit 
Garg (Ron Hay group, University of Dundee) as described in the results sections. For 
all other experiments data was transferred from Excel to GraphPad Prism for 
statistical analysis and graphical presentation. Statistical significance was determined 
as described in the figure legends, with * indicating p < 0.5, ** p< 0.01 and *** p< 
0.001. All graphs show the mean ± the Standard Error of the Mean (SEM). 
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3 Identification of novel ubiquitin-related 
components of the damage response to cisplatin 
through an siRNA screen 
 
3.1 Introduction 
 
Previously, genome-wide and biased screens, such as kinome based screens, 
have been undertaken to identify novel components of the ICL response [147]. Indeed, 
novel proteins that have a role in ICL repair, for example FAN1 and FANCI, have 
already been discovered with this method [82, 148]. An siRNA screen that focused on 
identifying DUBs involved in the checkpoint response to etoposide recognised 
USP150 as a mediator of the DNA damage response [149]. However, no RNA 
interference (RNAi) screen has yet been presented that focuses purely on ubiquitin 
and ubiquitin-like (UBL) related proteins after cisplatin treatment. A screen that is 
biased for different types of ubiquitin-related proteins might identify components of 
the ICL response that have been overlooked in previous genome-wide or kinome 
based screens. 
This hypothesis was the driving force behind a robust high throughput siRNA 
screen undertaken to identify novel ubiquitin-related components of the DNA damage 
response, and specifically sensitizers to cisplatin. Ubiquitin-related proteins were 
targeted for knock down using an siRNA “ubiquitinome” library, treated with ICL-
inducers and assessed for viability. U2OS cells, derived from human osteosarcoma 
tissue, were used in the screen as cisplatin is used in the treatment of osteosarcoma 
and U2OS cells have effective p53 and DNA damage responses.  
 
3.2 Results 
3.2.1 Design of an siRNA screen to identify novel ubiquitin-related 
components of the ICL response to cisplatin 
To identify potential novel ubiquitin related proteins in the cellular response to 
ICL inducers, a robust high throughput siRNA screen was undertaken in cells treated 
with cisplatin. For the primary screen a specialised ‘ubiquitinome’ siRNA library was 
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designed in collaboration with Adel Ibrahim and Amit Garg of the Ron Hay/siRNA 
group in the University of Dundee. The library was formed of 96 well plates, each 
well of which contained pooled siRNA made of four oligomers against an individual 
protein. The target siRNA (siTarget) consisted of siRNA against 1067 known and 
predicted ubiquitin and ubiquitin-like (UBL) related enzymes, including ubiquitin, 
SUMO and NEDD8 E3 ligases, E2 conjugating enzymes, ubiquitin binding proteins 
and deubiquitinases (DUBs). Each plate also contained non-targeting siRNA (siNT) 
as a negative control and wells with siRNA buffer only to act as a mock transfection 
or cellular growth control. siRNA against REV1L was included as a positive control 
as REV1L is a polymerase known to be involved in translesion synthesis in the ICL 
response [69, 85, 86, 150, 151]. 
The overall workflow of the primary screen is shown in Fig 3-1. U2OS cells 
were reverse transfected with siRNA from the ubiquitinome library plates on 
duplicate 96 well plates for 16 – 20 hr. One plate was then vehicle treated while the 
other was treated with a single dose of cisplatin. A luciferase-based viability assay 
was performed 72 hr later to determine the effect of siRNA transfection and cisplatin 
treatment on cell viability. 
Data obtained from luciferase assays were analysed by Amit Garg. Cell 
growth effect (CGE) values were calculated for individual siRNAs by expressing the 
luminescence measurements of their wells as a percentage of vehicle-treated siNT 
luminescence. The surviving fraction (SF) value for each siRNA was defined as the 
difference of log2 luminescence values between vehicle treated and drug treated cells. 
In the primary screen percentage normalised SF (PNSF) values were also calculated 
by normalising siTarget SF values to siREV1L (100%) and siNT (0%) SF values. The 
signal to background (SB) ratios, or ratios of luminescence values between positive 
and negative controls, were calculated for each plate. Finally, Z′ values were 
calculated to ascertain the statistical significance of differences between positive and 
negative control populations. They were used as quality control for each plate and 
also as a measure of the overall screen performance. The average Z′ factor for the 
entire screen was 0.58, indicating excellent performance. Z′ values were determined 
for each plate using the standard deviation (SD) for controls in the following formula: 
 
 Z′  =  1   –        3SD of negative control + 3SD of positive control 
        |mean of negative control – mean of positive  control| 
siNT
siTarget
siREV1L
siNT
siTarget
siREV1L
16 - 20 hr
- cisplatin
+ cisplatin
siRNA transfection Cisplatin treatment
72 hr
Viability assay
Mock-transfected
Mock-transfected
Figure 3-1 Workow of the primary siRNA screen 
U2OS cells were reverse mock-transfected or transfected with siNT, siREV1L or pooled 
siTargets at a density of 5000 cells/well on two replicate 96 well plates. After 16 to 20 hr 
one plate was vehicle-treated while the other was treated with 3.25 μM (rst replicate) 
or 3 μM (second replicate) cisplatin. Cell viability was determined via luciferase assay 72 
hr later. Cell Growth Eect (CGE), Surviving Fraction (SF), and Percentage Normalised SF 
(PNSF) values were determined. 
 84 
3.2.2 The primary screen identified 112 target siRNAs which sensitise 
cells to cisplatin  
Optimisation for the primary screen was performed by Arno Alpi and Adel 
Ibrahim. To determine the concentration of cisplatin that gave the optimum difference 
in viability between cells transfected with siNT and siREV1L, cells were treated with 
a range (0 – 8 µM) of cisplatin concentrations. Treatments of 3 to 4 µM cisplatin were 
chosen for future experiments. This range represented the greatest difference in 
viability between siNT and siREV1L-transfected controls while also ensuring 
minimal lethality (>60% cell viability) in siNT-transfected cells (Fig 3-2A). 
The primary screen was performed by Adel Ibrahim. Two independent 
primary screen replicates were carried out by treating transfected cells with 3.25 µM 
(first replicate) or 3 µM (second replicate) cisplatin. Z′ values were determined for 
each plate and all were above 0.5, indicating a robust assay and allowing further 
analysis of the data (see Appendix 1 for quality control values for the primary screen). 
Initially only the CGE and SF values were calculated. However, there was significant 
variation in the CGE and SF values for both siNT and siREV1L-transfected cells 
between the plates within each replicate. SF values from the plates of the first 
replicate are shown in Fig 3-2B as a representation of this variation. To circumvent 
the difficulty of comparing target values from different plates, PNSF values were also 
calculated. There was also significant variation in the CGE and SF values for the 
control cells between the two screen replicates. Consequently, data from the first and 
second replicates were analysed separately and different thresholds were applied to 
identify positive candidates.  
Firstly, siRNAs that resulted in less than 50% CGE (replicate 1) and less than 
60% CGE (replicate 2) in untreated cells were considered cytotoxic and excluded 
from further analysis. Next, cut off thresholds were decided based on the SF and 
PNSF values of positive control siREV1L-transfected cells. In the first replicate 
siTargets that resulted in less than -1.47 SF (Fig 3-3A, threshold value indicated by 
dotted red line) and greater than 86% PNSF (Fig 3-3B) were considered to show 
statistically significant reductions in cell viability. In the second replicate target 
siRNAs that caused less than -0.77 SF and greater than 81% PNSF were considered 
sensitizers to cisplatin. Due to the large volume of data created during the primary 
screen, only summary date from the first replicate is shown overleaf. However the  
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Figure 3-2 Optimisation of the primary siRNA screen 
A) U2OS cells were mock-transfected or transfected with siNT or siREV1L at a density of 5000 
cells/well in a 96 well plate. Cells were treated with a range (0 – 8 µM) of cisplatin concentra-
tions, the cell viability was determined via luciferase assay 72 hr later and SF values were 
calculated. B) U2OS cells were reverse mock-transfected or transfected with siNT, siREV1L or 
pooled siTargets at a density of 5000 cells/well on two replicate 96 well plates. After 16 to 20 
hr one plate was vehicle-treated while the other was treated with 3.25 μM (rst replicate) or 
3 μM (second replicate) cisplatin. The cell viability was determined via luciferase assay after 
72 hr. CGE, SF and PNSF values were calculated and the experiment was repeated twice. SF 
values from the control plates of the rst replicate are shown.
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Figure 3-3 The primary screen identied 112 target siRNAs that sensitise cells to 
cisplatin 
U2OS cells were reverse mock-transfected or transfected with siNT, siREV1L or pooled 
siTargets at a density of 5000 cells/well on two replicate 96 well plates. After 16 to 20 hr 
one plate was vehicle-treated while the other was treated with 3.25 μM (rst replicate) or 
3 μM (second replicate) cisplatin. The cell viability was determined via luciferase assay 
after 72 hr. CGE, SF and PNSF values were calculated and the experiment was repeated 
twice. Data is shown from the rst replicate only. A) Scatterplot showing SF values of the 
control and siTarget-transfected cells. B) Scatterplot showing PNSF values of the control 
siTarget-transfected cells. Dotted red lines indicate the cut o points of SF and PNSF 
values for identifying positive hits.
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CGE, SF and PNSF values for all targets from the ubiquitinome library in the primary 
screen are presented in Appendix 2 of this thesis, and detailed information and 
analysis on siRNF113B, siRNF31/HOIP, and siTNIP1/ABIN1 are presented in the 
appropriate chapter. Target siRNAs that passed the criteria in either replicate were 
considered positive candidates overall. This led to the identification of 112 positive 
hits that caused hypersensitive to cisplatin in the primary stage of the screen.  
 
3.2.3 The secondary screen identified 21 target siRNAs which induce 
dose dependent sensitivity to cisplatin 
To eliminate false positives, the 112 hits that passed the primary screen stage 
were further investigated in the secondary stage of the screen. Cisplatin causes dose 
dependent cytotoxicity, and dose dependency may vary between hits. Thus it was 
decided to verify positive candidates by examining the response of transfected cells to 
a range of cisplatin concentrations. Of necessity the plate layout was changed to allow 
for treatment with different cisplatin concentrations on one plate (workflow shown in 
Fig 3-4A). However, this also accorded a technical advantage as it reduced the 
problem of variation between treated and untreated plates previously observed in the 
primary screen.  
During the optimisation phase for the secondary screen the optimum cisplatin 
concentration range was determined. A spectrum of 0 – 6 µM cisplatin was chosen as 
there was a large difference in viability between the positive siREV1L-transfected 
cells and negative siNT-transfected cells at these concentrations (Fig 3-4B). 
U2OS cells were transfected as for the primary screen but treated with this 
range of cisplatin concentrations. After 72 hr a luciferase assay was performed and SF 
and CGE values were calculated and reproduced in graphical form. Representative 
graphs from a single plate are shown in Fig 3-5A, while the CGE and SF graphs for 
all targets in the secondary screen are presented in Appendix 3. SiTargets that caused 
dose dependant sensitivity to cisplatin were recognised based on their effect on the SF 
and CGE graphs for each replicate. If the siTarget slopes were similar to or greater 
than the slopes of the siREV1L-transfected cells for that plate the siRNA was deemed 
to have a ‘high’ effect on the sensitivity of cells to cisplatin, and given an effect score 
of ‘2’. Conversely, if the effect of siTarget transfection on the SF and CGE slopes was 
more similar to the effect of siNT-transfection for that plate, the siRNA was rejected  
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Figure 3-4 Workow and optimisation of the secondary screen
A) U2OS cells were reverse mock-transfected or transfected with siNT, siREV1L or pooled 
siTargets at a density of 5000 cells/well in 96 well plates. After 16 to 20 hr cells were treated 
with a range of cisplatin concentrations. The cell viability was determined via luciferase 
assay after 72 hr. CGE and SF values were calculated. The secondary screen was repeated 
three times. B) As A) except that U2OS cells were reverse mock-transfected or transfected 
with siNT or siREV1L only, and cells were treated with a range (0 – 6 µM) of cisplatin concen-
trations. 
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Figure 3-5 The secondary assessed target siRNAs for induction of dose 
dependent sensitivity to cisplatin
U2OS cells were reverse mock-transfected or transfected with siNT, siREV1L 
or pooled siTargets at a density of 5000 cells/well in 96 well plates. Cells 
were treated with a range of concentrations of cisplatin (0 – 6 μM) for 72 hr 
before a luciferase assay was performed. CGE and SF values were calculated. 
The secondary screen was repeated three times. A) Representative SF and 
CGE graphs from one plate of one replicate. B) Average maximum SF values 
from siTargets of the secondary screen.
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and given a score of ‘0’. Likewise, if the effect of the siTarget on the SF and CGE 
slopes of cells gave an intermediate effect compared to the positive and negative 
controls it was given a ‘low’ rating and score of ‘1’. These ratings were also used as 
an indication of the goodness of fit of the individual points to the slope. Thus a ‘low’ 
rating was also assigned when an siTarget slope was similar to the positive control 
overall, but individual values fluctuated with increased cisplatin concentration. The 
secondary screen was repeated three times and the scores from three replicates were 
combined. Hits were ranked in order of their total scores with a maximum possible 
score of 6 (Table 3-1). To further grade hits and compare them to the positive and 
negative controls, the average maximum SF values for each siTarget were also plotted 
(Fig 3-5B). In this manner several hits were eliminated from the screen as they 
showed no significant reproducible and/or dose dependent sensitivity to cisplatin. 
However, this process did confirm 21 target siRNAs that induced dose dependent 
sensitivity to cisplatin and therefore had a high likelihood of being true hits.  
 
Table 3-1 Effect rating and scores for candidates with cisplatin treatment 
  Replicate rating Replicate score   
 Target 
Gene  Rep1 Rep2 Rep3 Rep1 Rep2 Rep3 
Total 
score 
FBXW11 High High High 2 2 2 6 
RNF31 High High High 2 2 2 6 
TNIP1 High High High 2 2 2 6 
KCTD3 Low High High 1 2 2 5 
KRTAP5-9 High Low High 2 1 2 5 
RFPL2 Low High High 1 2 2 5 
RNF113B Low High High 1 2 2 5 
USP54 Low High High 1 2 2 5 
VHL High Low High 2 1 2 5 
BIRC2 Low High Low 1 2 1 4 
LGALS3BP Low Low High 1 1 2 4 
LOC51035 High Low Low 2 1 1 4 
LOC646463 Low High Low 1 2 1 4 
RNF150 Low High Low 1 2 1 4 
REV1L Low High Low 1 2 1 4 
USP50 Low High Low 1 2 1 4 
USP37 Low High Low 1 2 1 4 
UBE2W High High Reject 2 2 0 4 
UBE2N Reject High High 0 2 2 4 
TRIM8 High High Reject 2 2 0 4 
UBE2D2 Reject High High 0 2 2 4 
AMFR High Reject Low 2 0 1 3 
ASB18 Low Low Low 1 1 1 3 
CBLC Low Low Low 1 1 1 3 
DCUN1D3 Reject Low High 0 1 2 3 
FBXW10 Low Low Low 1 1 1 3 
HKR3 Low Low Low 1 1 1 3 
KCNA4 High Reject Low 2 0 1 3 
KCND1 Reject High Low 0 2 1 3 
KCND3 Low Low Low 1 1 1 3 
LOC51136 High Reject Low 2 0 1 3 
MAP3K7IP2 High Low Reject 2 1 0 3 
MLLT6 Low Low Low 1 1 1 3 
RABGEF1 Low High Reject 1 2 0 3 
TNIP3 Reject High Low 0 2 1 3 
TRIM71 Low High Reject 1 2 0 3 
USP42 Reject High Low 0 2 1 3 
USP33 Reject High Low 0 2 1 3 
UBE2T Low High Reject 1 2 0 3 
BCL6B Low Reject Low 1 0 1 2 
C20ORF18 Reject Low Low 0 1 1 2 
DTX3 Low Reject Low 1 0 1 2 
FBXO2 Low Low Reject 1 1 0 2 
HERC2 Reject Low Low 0 1 1 2 
HERC5 Reject Low Low 0 1 1 2 
JARID1C Low Low Reject 1 1 0 2 
JARID1D Low Low Reject 1 1 0 2 
KCNB2 Low Reject Low 1 0 1 2 
KCNC1 Reject Low Low 0 1 1 2 
LOC340359 Low Low Reject 1 1 0 2 
LOC643596 Low Reject Low 1 0 1 2 
LOC643904 High Reject Reject 2 0 0 2 
MARCH-III Low Low Reject 1 1 0 2 
OTUB1 High Reject Reject 2 0 0 2 
PHF12 Low Low Reject 1 1 0 2 
PHF21A Reject Low Low 0 1 1 2 
PHF21B Low Reject Low 1 0 1 2 
RBM10 High Reject Reject 2 0 0 2 
STAMBPL1 Low Reject Low 1 0 1 2 
TRIM49 Low Low Reject 1 1 0 2 
ZBTB38 Low Low Reject 1 1 0 2 
ZNF297B Low Low Reject 1 1 0 2 
ZSWIM2 Reject High Reject 0 2 0 2 
CUEDC1 Reject Low Reject 0 1 0 1 
DCUN1D1 Reject Low Reject 0 1 0 1 
KCNS1 Reject Low Reject 0 1 0 1 
LOC652557 Reject Low Reject 0 1 0 1 
PARC Low Reject Reject 1 0 0 1 
M96 Low Reject Reject 1 0 0 1 
NSFL1C Low Reject Reject 1 0 0 1 
NSMCE1 Low Reject Reject 1 0 0 1 
NUP153 Low Reject Reject 1 0 0 1 
NYREN18 Low Reject Reject 1 0 0 1 
SENP6 Low Reject Reject 1 0 0 1 
RNF168 Low Reject Reject 1 0 0 1 
UBE2M Reject Reject Low 0 0 1 1 
USP43 Reject Low Reject 0 1 0 1 
USP10 Reject Reject Low 0 0 1 1 
ARIH1 Reject Reject Reject 0 0 0 0 
ASB16 Reject Reject Reject 0 0 0 0 
BARD1 Reject Reject Reject 0 0 0 0 
BRCA1 Reject Reject Reject 0 0 0 0 
CHFR Reject Reject Reject 0 0 0 0 
FLJ25555 Reject Reject Reject 0 0 0 0 
HOZFP Reject Reject Reject 0 0 0 0 
KCTD1 Reject Reject Reject 0 0 0 0 
KCTD2 Reject Reject Reject 0 0 0 0 
MDM2 Reject Reject Reject 0 0 0 0 
MGC5306 Reject Reject Reject 0 0 0 0 
MLL4 Reject Reject Reject 0 0 0 0 
PARK2 Reject Reject Reject 0 0 0 0 
PCGF5 Reject Reject Reject 0 0 0 0 
PROSAPIP2 Reject Reject Reject 0 0 0 0 
RFC1 Reject Reject Reject 0 0 0 0 
RHOBTB1 Reject Reject Reject 0 0 0 0 
RHOBTB3 Reject Reject Reject 0 0 0 0 
RNF20 Reject Reject Reject 0 0 0 0 
RNF34 Reject Reject Reject 0 0 0 0 
RWDD3 Reject Reject Reject 0 0 0 0 
SAE1 Reject Reject Reject 0 0 0 0 
SENP3 Reject Reject Reject 0 0 0 0 
SQSTM1 Reject Reject Reject 0 0 0 0 
STAM2 Reject Reject Reject 0 0 0 0 
STAMBP Reject Reject Reject 0 0 0 0 
TRIM36 Reject Reject Reject 0 0 0 0 
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MNAT1 Reject Reject Reject 0 0 0 0 
MSL2L1 Reject Reject Reject 0 0 0 0 
MYO6 Reject Reject Reject 0 0 0 0 
NEIL3 Reject Reject Reject 0 0 0 0 
NEURL Reject Reject Reject 0 0 0 0 
NFX1 Reject Reject Reject 0 0 0 0 
NPL4 Reject Reject Reject 0 0 0 0 
 
3.2.4 The 21 siTargets from the secondary screen also enhance 
sensitivity to MMC 
To confirm whether the top 21 hits identified in the secondary screen are 
sensitive to ICL inducers in general, or specifically sensitive to cisplatin, the 
secondary screen was repeated with MMC treatment with these candidates. 
Initially, the optimum range of MMC concentration was assessed. U2OS cells 
were transfected with siNT or siREV1L, treated with a range of MMC concentrations 
and a luciferase assay was used to analyse viability after 72 hr. siNT- and siREV1L-
transfected cells showed the greatest differences in viability at a range of 0 – 1 µM 
MMC (Fig 3-6A). Thus this range was chosen for confirmation of the top hits of the 
secondary screen.  
U2OS cells were again transfected with siNT, siREV1L or siRNA against the 
top 21 hits of the secondary screen. Cells were treated with 0 – 1 µM MMC and 
incubated for 72 hr. A luciferase assay was performed and data were analysed as in 
the secondary screen with cisplatin. Representative graphs from a single plate are 
shown in Fig 3-6B, while the CGE and SF graphs for all targets treated with MMC 
are presented in Appendix 4. The SF and CGE slopes of siTargets were again 
compared, rated and scored against the SF and CGE slopes of the control siRNAs. 
This stage of the screen was also repeated three times and hits were again ranked in 
order of their total scores (Table 3-2). To a greater or lesser extent, all 21 siTargets 
that caused hypersensitivity to cisplatin also enhanced sensitivity to MMC. Thus no 
further proteins were eliminated at this stage. 
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Figure 3-6 Verication of top hits from the secondary screen with 
MMC treatment
A) U2OS cells were reverse mock-transfected or transfected with siNT 
or siREV1L at a density of 5000 cells/well in 96 well plates. Cells were 
treated with a range of concentrations of cisplatin (0 – 6 μM) for 72 hr 
before a luciferase assay was performed.  CGE and SF values were 
calculated. The experiment was repeated three times. B) As A) except 
that cells were treated with 0 – 1 µM MMC and siTargets were 
included. Representative SF and CGE graphs from one plate of one 
replicate are shown. 
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Table 3-2 Effect rating and scores for candidates with MMC treatment 
  Replicate rating Replicate score   
Target gene Rep1 Rep2 Rep3 Rep1 Rep2 Rep3 Total score 
BIRC2 High High High 2 2 2 6 
REV1L High High High 2 2 2 6 
RFPL2 High High High 2 2 2 6 
RNF31 High High High 2 2 2 6 
TNIP1 High High High 2 2 2 6 
UBE2D2 High High High 2 2 2 6 
USP37 High High High 2 2 2 6 
VHL High High High 2 2 2 6 
FBXW11 High High Low 2 2 1 5 
KRTAP5-9 High High Low 2 2 1 5 
LOC646463 High High Low 2 2 1 5 
UBE2N High High Low 2 2 1 5 
UBE2W High High Low 2 2 1 5 
USP50 High Low High 2 1 2 5 
USP54 High High Low 2 2 1 5 
RNF150 High Low Low 2 1 1 4 
LOC51035 Low Low Low 1 1 1 3 
RNF113B Low Low Low 1 1 1 3 
TRIM8 Low Low Low 1 1 1 3 
LGALS3BP Low Low Reject 1 1 0 2 
KCTD3 Low Reject Low 1 0 1 2 
 
3.2.5 Eight target proteins passed the deconvolution stage 
In the primary and secondary screen cells were transfected with pooled siRNA 
consisting of four oligomers against each target. To eliminate siRNAs with off target 
effects, the oligomers of the pool were assessed to determine whether they could 
individually induce sensitivity to cisplatin. This tertiary stage of an siRNA screen is 
known as deconvolution.  
U2OS cells were mock transfected or transfected with siNT, pooled siREV1L, 
or four individual siRNAs against each target. As in the secondary stage of the screen, 
cells were treated with a range of cisplatin concentrations and a luciferase assay was 
performed. The effect of each oligomer on cellular viability after cisplatin treatment 
was analysed by comparing the slopes of target SF graphs only with the slopes of 
control SF graphs for that plate. This effect was again rated and scored as for the 
secondary screen. Representative SF graphs from a single plate are shown in Fig 3-7, 
while the SF graphs for all individual oligomers used during deconvolution are 
presented in Appendix 5. Two oligomers against BIRC2 (siBIRC2-13 and -14), also 
known as cIAP1, induce dose-dependant sensitivity to cisplatin, while two others 
(siBIRC2-12 and -15) do not. The deconvolution stage of the screen was also repeated 
three times. Individual oligomers were analysed over the course of three replicates. If  
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Figure 3-7 The deconvolution stage assessed individual siRNA oligo-
mers for induction of cisplatin sensitivity
U2OS cells were reverse mock-transfected or transfected with siNT, siREV1L 
or four individual siTarget oligomers from the previous pools at a density of 
5000 cells/well in 96 well plates. Cells were treated with a range of concen-
trations of cisplatin (0 – 6 μM) for 72 hr before a luciferase assay was 
performed. The secondary screen was repeated three times. Representative 
SF and CGE graphs from one plate of one replicate are shown. 
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oligomers displayed ‘high’ or ‘low’ effects in at least two out of the three replicates 
they were considered positive oligomers (Table 3-3). The greater the number of 
individual oligomers that can induce the same phenotype as the siRNA pool, the 
higher the probability that these siRNAs are on-target. Therefore, to validate target 
siRNAs at this stage of the screen, at least two of their four oligomers had to 
individually enhance sensitivity to cisplatin. Eight target proteins were identified for 
which two or more oligomers induced sensitivity to cisplatin. These proteins; REV1L, 
RNF31/HOIP, TNIP1/ABIN1, BIRC2/cIAP1, UBE2D2, BIRC2, USP33, USP37 and 
USP42, were therefore considered positive hits of the overall siRNA screen.  
 
Table 3-3 Effect rating for candidates of the deconvolution stage 
Target gene siRNA label Rep1 Rep2 Rep3 Oligo result Positive oligos 
REV1L 
OS00872-05 High High High Positive 
4 
OS00872-06 Low Low High Positive 
OS00872-07 High High High Positive 
OS00872-08 High High High Positive 
RNF31 
OS00454-05 High High High Positive 
3 
OS00454-06 Reject Reject High Negative 
OS00454-07 High High High Positive 
OS00454-08 High High High Positive 
BIRC2 
OS00226-12 Reject Reject Reject Negative 
2 
OS00226-13 Low Low Low Positive 
OS00226-14 High High High Positive 
OS00226-15 Reject Reject Reject Negative 
TNIP1 
OS00917-05 High High High Positive 
2 
OS00917-06 Reject Reject Reject Negative 
OS00917-07 Reject Reject Reject Negative 
OS00917-08 High High High Positive 
UBE2D2 
OS00055-06 Reject Reject Reject Negative 
2 
OS00055-07 Reject High High Positive 
OS00055-08 Low Low High Positive 
OS00055-09 Reject Reject Low Negative 
USP33 
OS00981-05 Reject Low Low Positive 
2 
OS00981-06 Low Low Low Positive 
OS00981-07 Reject Reject Reject Negative 
OS00981-08 Reject Reject Reject Negative 
USP37 
OS00985-06 Reject Reject Reject Negative 
2 
OS00985-07 Reject Reject Reject Negative 
OS00985-08 High High High Positive 
OS00985-09 Low Low Low Positive 
USP42 
OS00991-05 Reject Reject Reject Negative 
2 
OS00991-06 Low Low Low Positive 
OS00991-07 Low Low High Positive 
OS00991-08 Reject Reject Reject Negative 
RNF113B 
OS00406-05 High High High Positive 
1 OS00406-06 Reject Reject Reject Negative 
OS00406-07 Reject Reject Reject Negative 
 96 
OS00406-08 Reject Reject Reject Negative 
RNF150 
OS00426-07 High High Low Positive 
1 
OS00426-08 Reject Reject Reject Negative 
OS00426-09 Reject Reject Reject Negative 
OS00426-10 Reject Reject Reject Negative 
USP50 
OS01000-05 High High High Positive 
1 
OS01000-06 Reject Reject Reject Negative 
OS01000-07 Reject Reject Reject Negative 
OS01000-08 Reject Reject Reject Negative 
USP54 
OS01003-05 Reject Reject Reject Negative 
1 
OS01003-06 Reject Reject Low Negative 
OS01003-07 Reject Reject Reject Negative 
OS01003-08 High High High Positive 
TRIM8 
OS00556-05 High High High Positive 
1 
OS00556-06 Reject Reject Reject Negative 
OS00556-07 Reject Reject Reject Negative 
OS00556-08 Reject Reject Reject Negative 
UBE2W 
OS00082-07 Low Reject Reject Negative 
1 
OS00082-08 High High High Positive 
OS00082-09 Reject Reject Reject Negative 
OS00082-10 Reject Reject Reject Negative 
UBE2N 
OS00071-06 Reject Low Reject Negative 
1 
OS00071-07 High High High Positive 
OS00071-08 Reject Reject Reject Negative 
OS00071-09 Reject Low Reject Negative 
 
3.3 Discussion 
To identify novel ubiquitin and UBL-related components of the ICL response, 
a robust high throughput screen using an siRNA ubiquitinome library and ICL-
inducing agents was employed. During the primary stage 1067 siRNAs against 
ubiquitin and UBL proteins were screened, and 112 potential candidates were 
identified which induced sensitivity to cisplatin. In the secondary stage many of these 
hits were validated by the introduction of a range of cisplatin and MMC 
concentrations, with 21 siTargets enhancing dose dependent sensitivity to cisplatin 
and MMC. Thus it is probable that these hits are involved in a common ICL response 
rather than a specific response to cisplatin- or MMC-induced damage. Furthermore, 
this gave an initial indication that these hits might be involved downstream of the 
factors that specifically recognise lesions caused by cisplatin or MMC. Final 
verification of the top candidates came from the deconvolution stage of the screen in 
which eight target proteins were identified for which two or more oligomers induced 
hypersensitivity to cisplatin.  
Only one oligomer against RNF113B caused sensitivity to cisplatin. However, 
there are two isoforms of RNF113 in human cells, RNF113A and RNF113B. One 
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isoform may be able to compensate when the level of the other has been reduced. It 
was hypothesised that the oligomer that induced hypersensitivity to cisplatin may 
have targeted both isoforms, while the other three only targeted one.  It was possible 
that siRNF113B was still an on target hit, and thus RNF113B was included in the top 
hits considered for further investigation.  
Proteins from across the range of ubiquitin related protein classes were 
identified in the screen, including three E3s, an E2, three DUBs and two ubiquitin 
binding proteins (Table 3-4). Furthermore, the top positive candidates included both 
known and novel regulators of the DDR.  
 
Table 3-4 Top targets identified in the siRNA ubiquitinome screen 
Screen 
nomenclature 
Protein aliases Ubiquitin 
class 
Known functions 
BIRC2 cIAP1;, API1; HIAP2; 
MIHB; RNF48 
E3 Inhibitor of apoptosis, NF-κB 
signalling after DNA damage 
[124] 
REV1L  Binding TLS polymerase in the ICL 
response [69, 85, 86, 150, 151] 
RNF113B RNF161; ZNF183L1; 
bA10G5.1 
E3 (Recently) ICL repair factor [152] 
RNF31 HOIP; ZIBRA E3 Immunity, inflammation, NF-κB 
signalling, (recently) cell death in 
response to etoposide [153, 154] 
TNIP1 ABIN1; VAN; NAF1; 
nip40-1 
Binding Immunity, inflammation, TNF-
induced apoptosis [155] 
UBE2D2 UBC4; PUBC1; UBC4/5; 
UBCH5B; E2(17)KB2 
E2 p53 degradation [156]  
USP33 VDU1 DUB Cell migration, receptor recycling, 
centromere localization, vesicle 
trafficking [157–159] 
USP37 KIAA1594 DUB Cell cycle regulation [160–162] 
USP42 tcag7.880 DUB Regulates p53 function [163] 
 
REV1L, which is already known to be involved in ICL repair [69, 85, 86, 150, 
151], was used as the positive control throughout the screen. However it was also 
included in the original target library as a hidden control, and identified as a positive 
hit. The ability of this screen to identify a known ubiquitin-related ICL response 
protein inspires confidence in the design and criteria applied throughout the screen. It 
also increased confidence in the other top candidates that were identified.  
Conversely, not all known ubiquitin related components of the ICL pathway 
targeted in the siRNA library were considered hits in our screen. For example, 
FANCL was eliminated at the primary stage as it did not reach our threshold SF and 
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PNSF values. However, this is similar to other screens carried out using cisplatin that 
also failed to identify FA proteins [147]. This could be for several reasons. There may 
be differences in the knocking down efficiency of target siRNA or, as reducing 
mRNA levels does not necessarily remove all protein from a cell, perhaps residual 
protein levels were sufficient to allow the cell to recover from the damage induced by 
cisplatin. Also, as only one concentration of cisplatin was used in the primary screen 
subtler effects on cell viability may have been missed that might have been enhanced 
at a higher drug concentration. Thus, based on the strict criteria applied, and as in the 
case of some known mediators of the ICL response, some novel regulators of the 
response to cisplatin may have been rejected. However, it was believed that a 
restrictive standard should be applied to hits to reduce the likelihood of identifying 
false positives. This approach has subsequently been proven justified by the 
identification and validation of at least two novel targets. 
However, it should be further noted that RNAi is frequently associated with 
disadvantages such as potential non-specific targeting of mRNA [164]. Thus, while 
the identification of known components of the ICL response increased confidence in 
novel hits found, further validation of individual candidates is required before they 
can be considered true components of the ICL response. 
Nevertheless, the siRNA screen was a valuable tool to identify several 
potential targets as novel regulators of the response to cisplatin. This work formed the 
basis of further study into the roles of RNF113B, RNF31/HOIP and TNIP1/ABIN1 in 
the ICL response, as described in the following chapters. 
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4 RNF113B and the DNA damage response 
 
4.1 Introduction 
Interstrand crosslinks (ICLs) are a particularly potent form of DNA damage 
that involve covalent linking of complementary strands of the DNA duplex. Although 
various models of ICL repair have been proposed, none of them are complete and 
much still remains unknown about how this response is regulated. It is however 
known that ubiquitination is important for its regulation and that finding new 
ubiquitin-related components could help further our understanding of how these toxic 
lesions are repaired. This chapter describes the identification of RNF113B as a 
potential component of the ICL response, and attempts to characterise this role. 
 
4.1.1 A role was predicted for CeRNF113 in the Fanconi Anaemia 
pathway 
At the time the screen was completed, RNF113B was an uncharacterised 
protein in humans. Yet RNF113B is highly conserved within vertebrates and there are 
also putative homologues in organisms such as Caenorhabditis elegans, 
Saccharomyces cerevisiae, and Schizosaccharomyces pombe. A schematic alignment 
of the human (Hs), chicken (Gg) and worm (Ce) versions of RNF113 proteins is 
shown in Fig 4-0. 
In C. elegans, RNF113 was shown to bind to FCD-2, the homologue of 
HsFANCD2 [165, 166]. In worms the equivalent of HsFANCL has not been yet been 
identified. Based on the predicted presence of a RING finger domain in RNF113 it 
was suggested that it could be the E3 ligase that ubiquitinates FCD-2 [167]. Recently, 
it has been shown that CeRNF113 is not needed for FANCD2 foci formation, but is 
required for ICL resolution [152].  
In yeast, the homologue cwc24p is involved in RNA splicing. The splicing of 
primary transcripts is required during the regulation of gene expression, and this is 
performed by the spliceosome complex. Cwc24p is necessary for stabilising the 
interaction of more than one spliceosome component with the complex as a whole in 
both S. cerevisiae, and S. pombe [168–171]. In C. elegans RNF113 has also been 
implicated in pre-mRNA splicing necessary for development [172]. 
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Figure 4-0 Schematic of domain structures of Homo sapien (Hs) RNF113B in 
alignment with HsRNF113A, Gallus gallus (chicken, Gg) RNF113 and 
Caenorhabditis elegans (Ce) RNF113. 
 
4.1.2 There is no known role for RNF113B in humans 
In some mammals, including humans, there are two isoforms of the RNF113 
protein – RNF113A and RNF113B (Fig 4-0). These isoforms were produced by 
duplication of the RNF113A gene [173] and the proteins expressed are thus very 
similar. Based on the predicted presence of a RING finger domain in these proteins it 
was anticipated that they could act as ubiquitin E3 ligases. In humans, RNF113A has 
been identified as a binding partner of TRF2 [174], a component of the telomere 
nucleoprotein complex and a regulator of telomere length. More recently, using a 
yeast two-hybrid approach, and corresponding with its role in S. cerevisiae and C. 
elegans, HsRNF113A has been shown to associate with components of the 
spliceosome [175]. However, no studies on the function of RNF113A or B have yet 
been presented, and neither protein has been predicted to be involved in the DDR in 
humans. Therefore, upon identification of RNF113B in the siRNA screen, it was 
further investigated as a potential mediator of the ICL response. 
 
4.2 Results 
4.2.1 RNF113B was identified as a positive candidate in an siRNA 
screen 
A high-throughput siRNA screen was undertaken to identify novel ubiquitin-
related components of the interstrand crosslink response. Cells were transfected with 
siRNA, treated with cisplatin or MMC, and a luciferase-based assay was used to 
HsRNF113A
Zinc finger
HsRNF113B
GgRNF113
CeRNF113
RING finger
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identify wells with reduced viability. Throughout the screen, mock transfections and 
non-targeting siRNA (siNT) were used as negative controls, and siRNA against 
REV1L was used as a positive control. As RNF113B was predicted to be an E3 ligase, 
siRNF113B was included in the primary screen library. Data relevant to RNF113B is 
reproduced below. 
 
4.2.1.1 The primary screen identified siRNF113B as a sensitizer for cisplatin 
The primary screen was performed by Adel Ibrahim. During the primary 
screen, positive siTargets were identified based on their Cell Growth Effect (CGE), 
Surviving Fraction (SF) and Percentage Normalised SF (PNSF) values. Data from the 
first and second replicates were analysed separately and different thresholds decided 
on. The cut off values, along with siRNF113B values, are shown in Table 4-1 Along 
with 111 other siRNAs, siRNF113B fulfilled the criteria in at least one of the 
replicates, and was considered a positive candidate for reducing cell viability in 
response to cisplatin.  
 
Table 4-1 siRNF113B values from the primary screen 
 Replicate 
 1 2 
Value Cut off siRNF113B cells Cut off siRNF113B cells 
CGE > 50% 66.38% > 60% 73.19% 
SF < -1.47 -1.62 < -0.77 -0.45 
PNSF > 86% 117.22% > 81% 3.2% 
 
4.2.1.2 siRNF113B caused dose dependent sensitivity to cisplatin in the 
secondary screen 
To eliminate false positives, hits that passed the primary screen stage – 
including siRNF113B – were further investigated in the secondary stage of the screen. 
In the secondary screen siTargets that caused dose dependant sensitivity to cisplatin 
were recognised based on their SF and CGE graphs for each replicate. In the first 
replicate, the SF and CGE slopes of siRNF113B-transfected cells increased compared 
to siNT-transfected cells, giving siRNF113B a ‘low’ effect score (Fig 4-1A and B). In 
the second replicate the SF and CGE slopes of siRNF113B graphs broadly resembled 
the slopes of REV1L graphs (Fig 4-1C and D). In the third replicate the effect of 
siRNF113B transfection on the SF and CGE slopes was even greater than the effect of  
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Figure 4-1 siRNF113B caused dose dependent sensitivity to cisplatin in the 
secondary screen
U2OS cells were reverse transfected with pooled siNT, siREV1L and siRNF113B at 
5000 cells/well of a 96 well plate. Cells were treated with a range of concentrations 
of cisplatin (0 – 6 μM) for 72 hr before a luciferase assay was performed. Cell Growth 
Eect (CGE) and Surviving Fraction (SF) values were determined.
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siREV1L transfection (Fig 4-1E and F). In replicates two and three siRNF113B was 
therefore assigned effect scores of ‘high’, conferring on it an overall score of 5. Thus 
the dose dependant sensitivity to cisplatin induced by siRNF113B placed it within the 
top 9 of 21 siTargets that passed the secondary stage of the screen. 
 
4.2.1.3 siRNF113B also causes dose dependent sensitivity to MMC 
To increase confidence that the positive hits of the seconardy screen cause 
sensitivity to ICL inducers in general, the secondary screen was repeated with MMC 
treatment. In the first replicate the SF slope of siRNF113B-transfected cells was 
decreased to a similar level as siREV1L-transfected cells (Fig 4-2A), giving it a ‘high’ 
effect rating. In the second replicate siRNF113B transfection resulted in decreased SF 
compared to siNT transfection, although not to the same extent as siREV1L cells, 
thereby giving it a ‘low’ effect rating. The decrease in SF slope of siRNF113B cells in 
the third replicate was even more pronounced than in siREV1L-transfected cells, 
again giving it a high rating of 2 points. These ratings were confirmed by the effect of 
siRNF113B transfection on the CGE graphs, as these slopes were similar to the 
siREV1L-transfected cells in all three replicates. With a total effect score of 5, 
siRNF113B induced dose dependant sensitivity to MMC in U2OS cells in the 
secondary screen.  
 
As siRNF113B transfection caused dose-dependant sensitivity to both 
cisplatin and MMC, it was considered a positive candidate in the secondary screen. 
 
4.2.1.4 One siRNF113B oligomer individually induces sensitivity to cisplatin 
To eliminate siRNAs with off-target effects, the oligomers of the original 
siRNA pools were assessed to determine whether they could individually induce 
sensitivity to cisplatin. The data was analysed separately for each biological replicate, 
however for clearer graphical presentation Fig 4-3A to D shows the combined SF 
graphs for three replicates. Transfection with siRNF113B-05 caused decreased SF 
with increased cisplatin concentration in a manner similar to siREV1L transfection. 
However, transfection with siRNF113B-06, -07 and -08 did not decrease cells’ 
viability in response to cisplatin when compared to siNT transfection (Fig 4-3B, C 
and D). When analysed on a replicate-by-replicate basis, individual oligomers that 
resulted in an SF slope greater than or equal to that of REV1L were considered ‘high’  
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Figure 4-2 siRNF113B also causes dose dependent sensitivity to MMC
U2OS cells were reverse transfected with pooled siNT, siREV1L and siRNF113B at 5000 
cells/well of a 96 well plate. Cells were treated with a range of concentrations of MMC (0 
– 1 μM) for 72 hr before a luciferase assay was performed. Cell Growth Eect (CGE) and 
Surviving Fraction (SF) values were determined.
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Figure 4-3 One siRNF113B oligomer individually induces sensitivity to cisplatin
A) - D) U2OS cells were reverse transfected with pooled siNT, siREV1L and four individual 
siRNF113B oligomers at a density of 5000 cells/well of a 96 well plate. Cells were treated with 
a range of concentrations of cisplatin (0 – 6 μM) for 72 hr before a luciferase assay was 
performed. Surviving Fraction (SF) values were determined. The experiment was repeated 
three times and error bars represent SEM. E) Individual siRNF113B oligomers were aligned 
with RNF113A and RNF113B mRNA.
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hits. Oligomers whose resulting slopes were less than that of siREV1L’s were rejected. 
In all three replicates siRNF113B-05 was classed as a ‘high’ hit and was considered 
positive overall (Table 4-2). siRNF113B-06, -07 and -08 were rejected in all 
replicates and classified as negative candidates overall. Generally for candidates to be 
considered true hits in the deconvolution stage of the screen, at least two of their 
oligomers had to be classed as positive. However, it was noted that there are two 
isoforms of RNF113 in human cells (A and B) and it is possible that one isoform may 
be able to compensate when the other has been depleted. The oligomer that did induce 
cisplatin sensitivity may have targeted both isoforms, while the other three only 
targeted one. Indeed an alignment of siRNF113B oligomers against RNF113A and 
RNF113B mRNA shows similar siRNA target sites in both mRNAs (Fig 4-3E). 
Hence it was considered worthwhile to further validate and investigate RNF113B as a 
potential regulator of the ICL response. Unless otherwise indicated, siRNF113B 
oligomer 05 was used for all future experiments.  
 
Table 4-2 Summary of the results for siRNF113B deconvolution 
 
  Replicate 
 siRNA 1 2 3 Overall 
siRNF113B-05 High High High Positive 
siRNF113B-06 Reject Reject Reject Negative 
siRNF113B-07 Reject Reject Reject Negative 
siRNF113B-08 Reject Reject Reject Negative 
 
4.2.2 Confirmation of MMC sensitivity in siRNF113B-transfected 
cells 
U2OS cells transfected with one siRNA oligomer against RNF113B showed 
hypersensitivity to cisplatin and MMC in the siRNA screen using a luciferase-based 
viability assay. To confirm this result, and validate RNF113B as a regulator of the 
ICL response, clonogenic survival assays (CSAs) were employed. siRNA against 
FAN1 is known to sensitise cells to ICL inducers [83], and so was used as a positive 
control.  
U2OS cells were mock transfected or forward transfected with siRNF113B or 
siFAN1 before being trypsinised and reseeded. Cells were treated with a range of 
MMC concentrations for 24 hr and then allowed to recover until colonies were visible. 
Viability values were calculated by expressing the average number of colonies for 
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each treatment as a percentage of the average vehicle treatment value for that cell line. 
As expected, siFAN1-transfected cells show dose dependant sensitivity to MMC 
compared to mock-transfected cells (Fig 4-4A). The viability of siRNF113B-
transfected cells is also further reduced after MMC treatment compared to mock-
transfected cells. The use of an independent, sensitive method thus confirmed that 
siRNF113B transfection causes mild sensitivity cells to MMC. 
 
4.2.3 GFP-RNF113B localises to the nucleus 
RNF113B was a previously uncharacterised protein in mammals, and as a 
result there were no commercial tools, such as antibodies, available for studying it. 
Many studies to investigate its potential role in the ICL response, for example by 
determining its subcellular localisation or confirming the efficiency of siRNF113B 
transfection, were not immediately possible. To solve this problem a cell line was 
designed to express a GFP tagged version of RNF113B. 
 
4.2.3.1 Creation of a GFP-RNF11B-expressing cell line 
This cell line, in which GFP-RNF113B was over-expressed in a tetracyclin-
inducible manner, was developed using the Flp-In T-REx 293 system as described in 
the Methods chapter. Six separate GFP-RNF113B plates were created and assessed 
for GFP expression after 8 hr tetracycline induction. All six cell lines expressed a 
GFP-tagged protein of the expected size for a GFP-RNF113B fusion protein (65 kDa, 
Fig A). However, expression was highest in Plate 3, and so cells from this plate were 
used in future experiments.  
Next, this cell line was used in an attempt to confirm whether siRNF113B 
transfection corresponded to reduced RNF113B levels. Expression of GFP-RNF113B 
was induced in Flp-In 293 cells with tetracycline, and cells were then mock 
transfected or transfected with siRNF113B. Low levels of GFP-RNF113B were 
expressed without tetracycline, although its expression was greatly increased after 
tetracyclcine treatment (Fig 4-5B). However, GFP-RNF113B levels were not 
decreased after siRNF113B transfection, either before or after tetracycline induction. 
  
0 10 20 30
1
10
100
MMC (nM)
%
 V
ia
bi
lit
y
Mock
siFAN1
siRNF113B
Figure 4-4 Conrmation of MMC sensitivity in siRNF113B-transfected cells
U2OS cells were seeded in 10 cm dishes and mock transfected or forward trans-
fected with siRNF113B or siFAN1. Cells were incubated for 48 hr, trypsinised and 
reseeded in duplicate dishes for each treatment condition. Cells were allowed to 
adhere overnight before treatment with a range (0 – 30 nM) of MMC concentrations 
for 24 hr. Cells were allowed to recover for 10 – 14 days until colonies were visible. 
Plates were stained and the clones were counted. Viability values were calculated by 
expressing the average number of colonies for each treatment as a percentage of 
the average vehicle treatment value for that cell line. The experiment was repeated 
at least four times and error bars represent SEM. Linear regression on log10 trans-
formed data was used to determine the statistical signicance of dierences 
between slopes.
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Figure 4-5 GFP-RNF113B cell line expresses GFP fusion protein at the expected 
weight
A) Flp-In 293 cells designed to express GFP-RNF113B were treated with 1 µg/ml of tetra-
cycline for 8 hr. Cells were lysed and analysed via Western Blotting with the indicated 
antibodies. B) GFP-RNF113B Flp-In 293 cells (plate 3) were treated with 1 µg/ml of tetra-
cycline for 8 hr and then forward mock transfected or transfected with siRNF113B for 
48hr. Cells were lysed and analysed via Western Blotting with the indicated antibodies.
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4.2.3.2 GFP-RNF113B localises to the nucleus  
To gain an indication as to where RNF113B may act in the cisplatin-induced 
ICL response, it was decided to study its subcellular localisation using microscopy 
with the GFP-RNF113B cell line. A previously created Flp-In 293 cell line that stably 
expressed GFP-only was used as a control line. GFP expression was induced by 
treatment with tetracycline, and cells were fixed and analysed with a filter for GFP 
fluorescence. GFP is localised throughout the cell in GFP-only expressing cells (Fig 
4-6, upper panel). Conversely, GFP-RNF113B is found predominantly in the nucleus 
(lower panel). 
 
4.2.4 Investigation into the DNA damage response in siRNF113B-
transfected cells 
At the time the screen was completed, no evidence supporting a role for 
RNF113B in the DNA damage response had been presented. However, siRNF113B-
transfection sensitises U2OS cells to cisplatin and MMC. To determine why this is, 
and where RNF113B might act after treatment with these drugs, investigations were 
performed into the DNA damage response in siRNF113B-transfected cells. These 
included studying IR sensitivity, DNA repair markers and damage-induced apoptosis.  
 
4.2.4.1 siRNF113B-transfection does not cause sensitivity to IR  
Although many of the recognition and repair stages of the DNA damage 
response can depend on the type of DNA lesion involved, some downstream cellular 
responses are similar or shared. By determining whether siRNF113B-transfected cells 
are sensitive to other types of DNA damage it may be possible to estimate whether 
RNF113B acts in a specific ICL response mechanism or a more general DDR 
pathway. Therefore, siRNF113B-transfected cells were assessed for sensitivity to 
ionising radiation (IR) using a CSA. Deficiencies in ATR sensitise cells to IR [176, 
177] and so siATR was used as a positive control.  
U2OS cells were mock transfected or forward transfected with siRNF113B or 
siATR before being trypsinised and reseeded. Cells were treated with a range of IR 
doses and allowed to recover until colonies were visible. Viability values were 
calculated by expressing the average number of colonies for each treatment as a 
percentage of the average vehicle treatment value for that cell line. As expected,  
GFP-only
GFP-RNF113B
GFP DAPI Merge
Figure 4-6 GFP-RNF113B localises to the nucleus. Its localisation is not 
aected by cisplatin treatment 
GFP-only and GFP-RNF113B-expressing Flp-In 293 cells were seeded on cover-
slips, and treated with 1 µg/ml of tetracycline for 8 hr. Cells were treated with 3 
µM cisplatin for 3 hr and allowed to recover overnight. Cells were xed, stained 
and analysed by microscopy. White scale bars represent 30 µm.
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siATR-transfected cells show dose dependant sensitivity to IR compared to mock-
transfected cells (Fig 4-7A). However the viability of siRNF113B-transfected cells is 
not reduced compared to mock-transfected cells after IR treatment. To ensure that the 
siRNA transfection was effective, protein levels were assessed in remaining cells after 
the reseeding process of the CSA. Without an RNF113B antibody it was not possible 
to assess its levels after transfection. However, siATR-transfected cells displayed 
reduced ATR levels (Fig 4-7B), indicating that the siRNA transfection procedure was 
efficient. Thus siRNF113B-transfection does not sensitise U2OS cells to IR, and 
RNF113B may act in a specific response to ICL inducers.  
 
4.2.4.2 FANCD2 ubiquitination is normal in siRNF113B-transfected cells 
After DNA damage, cell cycle checkpoints are activated, leading to cell cycle 
arrest. This allows the cells to repair the damaged DNA or, if the damage is too great, 
cells can undergo apoptosis. The hypersensitivity to ICL inducers seen in cells after 
siRNF113B transfection could therefore be caused by defective checkpoint responses, 
prolonged cell cycle arrest, delayed DNA repair or cells actively undergoing 
programmed cell death in response to ICL induction. The situation of GFP-RNF113B 
in the nucleus presented the possibility that RNF113B could act a DNA repair protein. 
It was hypothesised that its depletion could lead to defects in the upstream DNA 
damage response.  
After induction of an ICL, damage is recognised by the Fanconi Anaemia core 
complex (FACC) [178]. Together with UBE2T [78, 79], the FACC monoubiquitinates 
FANCD2 and FANCI, which consequently co-localise with and recruit downstream 
repair factors. The ubiquitination of FANCD2 can therefore be used as a marker for 
the effective initiation of the ICL response, and siUBE2T can be used as positive 
control.  
To identify whether siRNF113B-depleted cells displayed deficiencies in 
FANCD2 ubiquitination, mock-, siRNF113B- or siUBE2T-transfected U2OS cells 
were vehicle treated or treated with MMC. Cells were lysed and the 
monoubiquitinated and non-ubiquitinated forms of FANCD2 were separated using 
SDS-PAGE. The resulting bands were probed by Western Blot with a specific 
antibody against FANCD2, and their intensity was quantified. The ratio of 
ubiquitinated FANCD2 to non-ubiquitinated FANCD2 was determined for each 
sample. After MMC treatment FANCD2 ubiquitination is increased in mock- 
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Figure 4-7 siRNF113B-transfection does not cause sensitivity to IR cells
U2OS cells were seeded in 10 cm dishes and mock transfected or forward transfected 
with siRNF113B or siFAN1. Cells were incubated for 48 hr and trypsinised. A) Cells 
were reseeded in duplicate dishes for each treatment condition. Cells were allowed 
to adhere overnight before treatment with a range of IR doses (0 – 2 Gy). Cells were 
incubated for 10 – 14 days until colonies were visible. Plates were stained and the 
clones were counted. Viability values were calculated by expressing the average 
number of colonies for each treatment as a percentage of the average vehicle treat-
ment value for that cell line. B) Remaining cells not used in the CSA were lysed and 
the protein extracts were analysed by Western Blotting with the indicated antibod-
ies. The experiment was repeated six times. Error bars in A) represent SEM. while B) 
shows a representative image.
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transfected cells (Fig 4-8A). Conversely, in cells in which UBE2T has been depleted 
there is very little ubiquitinated FANCD2 present even after MMC treatment. In 
siRNF113B-transfected cells FANCD2 ubiquitination is also increased after MMC 
treatment. In fact, the ratio of ubiquitinated to non-ubiquitinated FANCD2 (Ub-
FANCD2/FANCD2) is similar in mock-transfected and siRNF113B-transfected cells 
after MMC treatment (Fig 4-8B). The reverse is true of siUBE2T-transfected cells, in 
which there is a highly significant defect in this ratio. Thus, cisplatin-induced 
FANCD2 ubiquitination is normal in siRNF113B-transfected cells, and the ICL 
response appears to be activated as usual. 
 
4.2.4.3 Cisplatin-induced apoptosis is not increased in siRNF113B-transfected 
cells 
Initial DNA damage responses are functioning in siRNF113B-transfected cells. 
A further reason for the hypersensitivity of these cells to ICL inducers could be 
increased cell death after DNA damage. Other candidates identified in the siRNA 
screen - such as cIAP1, HOIP and ABIN1, act as anti-apoptotic proteins. To 
determine whether RNF113B plays a similar role in protecting cells against cisplatin-
induced apoptosis, siRNF113B-transfected cells were assessed for increases in 
apoptotic markers. During the apoptotic response effector caspases such as caspases-3 
and -7 are activated [179]. These function as proteases to activate downstream targets 
and ulttimately dismantle the cell. The activation of effector caspases can therefore be 
used as markers for the initation of apoptosis. To determine whether siRNF113B 
transfection leads to increased cisplatin-induced cell death, cell based caspase-3/7 
activity assays were employed. HOIP has a protective effect against cisplatin-induced 
apoptosis, and caspase-3/7 activity is increased after cisplatin treatment in siHOIP-
transfected U2OS cells (see Chapter 5 and [180]). siHOIP was therefore used as a 
positive control in this experiment. 
Initially, basal levels of caspase-3/7 activity were assessed in transfected cells 
to determine whether siRNF113B alone could increase apoptosis. U2OS cells were 
transfected with non-targeting siRNA (siNT), siRNF113B or siHOIP and allowed to 
proliferate for 24 or 48 hr.  A Caspase-Glo 3/7 Assay was performed and fold 
increase values of luminescence over mock-transfected cells were calculated for each 
transfected line. siRNF113B-transfected cells displayed a moderate but highly 
significant increase in basal caspase-3/7 activity over mock transfected cells after 24  
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Figure 4-8 MMC-induced FANCD2 ubiquitination is normal in 
siRNF113B-transfected cells 
U2OS cells were mock transfected or transfected with siRNF113B or siUBE2T. 
After 48 hr cells were vehicle treated or treated with 0.9 µM MMC overnight. 
Cells were lysed and protein extracts were analysed by Western Blotting with 
the indicated antibodies. The experiment was repeated three times. A) A 
representative image is shown. B) FANCD2 band intensities were quantied 
and the ratio of ubiquitinated FANCD2 to non-ubiquitinated FANCD2 (Ub-
FANCD2/FANCD2) was determined for each sample. Error bars indicate SEM. 
Multiple comparison tests were used to assess signicance and ** indicates a 
p values of <0.01.
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Figure 4-9 Cisplatin-induced apoptosis is not increased in siRNF113B-
transfected cells
U2OS cells were reverse transfected with non-targeting siRNA (siNT), siRNF113B 
or siHOIP at a density of 5000 cells/well in 96 well plates for 20 hr. A) Cells were 
allowed to grow for 48 hr before Caspase Glo 3/7 reagents were added to the 
plate and luminescence was read after 3 hr. The fold increase in activity over the 
mock-transfected vehicle treated wells was calculated for each treatment.  B) As 
above except that cells were treated with 5 µM cisplatin and incubated for 0, 24 
or 48 hr and the fold increase in activity over the vehicle treated wells for each 
siRNA was calculated for each treatment. The experiment was repeated ve 
times and error bars represent SEM. Unpaired t tests were used to calculate 
signicance with p values of less than 0.05 considered statistically signicant 
and  * indicating signicant dierences. 
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hr of growth (p 0.005) (Fig 4-9A). After 48 hr of growth the increase in caspase-3/7 
activity in siRNF113B-transfected cells was decreased, although this was not 
statistically significant.  
Next, cisplatin-induced apoptosis was analysed in siRNF113B-transected cells. 
U2OS cells were transfected as above, treated with vehicle or 5 µM cisplatin and 
incubated for 24 or 48 hr. A Caspase Glo 3/7 assay, without corresponding MTS 
assay was performed. The fold increase in activity over the vehicle treated wells for 
each siRNA was calculated for each treatment. siHOIP-transfected cells display very 
highly significantly increased caspase-3/7 activity after 24 hr cisplatin treatment (p 
<0.001) (Fig 4-9B), and significantly increased levels after 48 hr of cisplatin 
treatment (p 0.036). Cells transfected with siRNF113B cells do not show significantly 
increased caspase-3/7 activity after cisplatin treatment. Thus apoptosis is not 
increased in siRNF113B cells and RNF113B is not likely to act in an anti-apoptotic 
manner in U2OS cells.  
 
4.2.5 Characterisation of anti-RNF113B antibodies 
At the time of these studies there was no published work on the function of 
RNF113B in mammals and consequently there was also a lack of reliable tools 
available for studying it. To confirm that the phenotype of hypersensitivity to ICL 
inducers seen in siRNF113B-transfected cells corresponded to reduced RNF113B 
protein levels it was essential to obtain an antibody that specifically recognised 
RNF113B in U2OS cells.  
 
4.2.5.1 Commercial anti-RNF113B antibodies bind protein non-specifically 
At the time of research, there were only two commercial anti-RNF113B 
antibodies available, neither of which had been used in peer-reviewed research. To 
assess the specificity of these antibodies against RNF113B, U2OS cells were mock 
transfected or transfected with siRNF113B, lysed and probed with the antibodies via 
Western blotting. The Abcam mouse antibody bound to more than one protein, with 
the predominant band estimated to be roughly 60 kDa in molecular weight (Fig 4-
10A). RNF113B is predicted to have a molecular weight of 36 kDa but this antibody 
did not recognise any protein of this size. Futhermore, none of these bands were 
reduced after siRNF113B transfection. Similarly, the Abcam rabbit antibody also  
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Figure 4-10 Characterisation of commercial anti-RNF113B antibodies
U2OS cells were forward mock transfected or transfected with siRNF113B in 
duplicate for 48 hr. Cells were lysed and probed with anti-(α)RNF113B antibodies 
created in A) mouse and B) rabbit by Abcam. The predicted molecular weight of 
RNF113B is 36 kDa.
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predominantly recognised a protein of less than 64 kDa (Fig 4-10B). However, on an 
over-exposed blot a second band of less than 39 kDa was visible. While this protein 
conforms to the predicted weight of RNF113B, it did not disappear with siRNF113B 
transfection. Thus it was not clear whether this band corresponded to RNF113B or a 
non-specific protein. 
 
4.2.5.2 An in-house anti-RNF113B antibody recognises recombinant RNF113B 
To further study RNF113B and confirm its knock down after siRNF113B 
transfection, an in-house antibody was developed. In collaboration with the Protein 
Production team in the MRC-PPU, a purified recombinant form of 6xHis tagged 
RNF113B was created and an antibody against His-RNF113B was raised in sheep.  
To initially detect whether this antibody was capable of recognising RNF113B, 
recombinant RNF113B with a Dac tag [181] was spotted on a nitrocellulose 
membrane and probed as per a Western Blot protocol. The anti-RNF113B antibody 
bound to both natured and denatured RNF113B in a concentration-dependant manner 
(Fig 4-11A). 
 
4.2.5.3 An in-house anti-RNF113B antibody recognises over-expressed RNF113B 
Next, to determine whether this antibody could recognise over-expressed 
RNF113B in cell lysates, GFP-RNF113B expression was induced with tetracycline in 
Flp-In 293 cells. Cells were lysed and probed with the antibody via Western Blot. As 
the GFP tag has a molecular weight of about 27 kDa, GFP-RNF113B would be 
expected to run at about 63 kDa. Indeed, the predominant band detected by this 
antibody was present just below the 64 kDa marker (Fig 4-11B). This band also 
increased in intensity with increased tetracycline induction, similar to the increased 
protein levels identified with an antibody against GFP. Cumulatively, this suggests 
than the sheep anti-RNF113B is capable of binding over-expressed GFP-RNF113B. 
 
4.2.5.4 An in-house anti-RNF113B antibody recognises a band of the predicted 
molecular weight for endogenous RNF113B 
To assess whether this antibody can recognise endogenous in a specific 
manner, U2OS cells were mock-transfected or transfected with siRNF113B, lysed and 
analysed by Western Blotting. The antibody in question bound to a protein of about 
39 kDa, a similar size to the predicted weight for RNF113B (Fig 4-11C). However,  
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Figure 4-11 In-house anti-RNF113B antibody binds RNF113B
A) Unaected or denatured recombinant Dac-RNF113B was diluted and spotted on nitrocel-
lulose membrane to give the indicated weights. The membrane was probed with an 
anti-(α)RNF113B antibody created in sheep. B) GFP-RNF113B expressing Flp-In 293 cells were 
treated with 1 µg/ml of tetracycline for the indicated times. Cells were lysed and probed with 
the indicated antibodies. C) U2OS cells were forward mock transfected or transfected with 
siRNF113B for 48 hr. Cells were lysed and probed with the indicated antibodies. The predicted 
molecular weights of RNF113B and GFP-RNF113B are 36 and 63 kDa respectively.
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analogous to the protein recognised by the commercial antibody, this band did not 
decrease after transfection with siRNF113B. 
 
4.2.5.5 Anti-RNF113B antibody recognises recombinant RNF113A and 
RNF113B 
There are two isoforms of RNF113 in human cells – RNF113A and RNF113B, 
and it is possible this antibody recognises both. In this case the antibody would still 
recognise endogenous RNF113A present in the cell, even if RNF113B levels had 
been reduced by siRNA transfection. To determine whether the anti-RNF113B 
antibody can also bind RNF113A, recombinant Dac-tagged RNF113A and RNF113B 
were diluted, separated by SDS-PAGE and probed by Western Blot. The RNF113B 
antibody bound Dac-RNF113A in a concentration-dependant manner, but bound 
RNF113B with a slightly highly affinity (Fig 4-12A). 
 
4.2.5.6 Anti-RNF113B recognises a band which does not disappear after 
siRNF113A/B transfection 
To assess whether the endogenous protein identified after siRNF113B 
transfection was RNF113A, U2OS cells were mock transfected or transfected with 
pooled siRNF113A, pooled siRNF113B or a combination of siRNF113A with 
siRNF113B. Cells were lysed and probed with the in-house anti-RNF113B antibody. 
Regardless of which siRNA cells were transfected with, the band at 36 kDa was still 
recognised by the anti-RNF113B antibody and was not reduced (Fig 4-12B). 
 
4.2.6 RNF113B mRNA is not detected in U2OS cells 
Cells transfected with siRNF113B are sensitive to ICL inducers. However, 
using an anti-RNF113B antibody it was not possible to verify that this sensitivity 
corresponded to the reduction of RNF113B protein levels. An alternative approach 
was required to confirm that it is the knock down of RNF113B, and not an off-target 
effect of the siRNA, that causes this sensitivity. Hence it was decided to assess 
RNF113B’s mRNA levels in U2OS cells using quantitative real time PCR (qRT-PCR). 
U2OS cells were reverse transfected with non-targeting siRNA (siNT) in 
duplicate for 48 hrs. mRNA was isolated and cDNA was created. qRT-PCR was 
performed using primers designed to amplify β-ACTIN and RNF113B mRNA, and  
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Figure 4-12 Further characterisation of an in-house anti-RNF113B antibody
A) Recombinant Dac-RNF113A and Dac-RNF113B were serially diluted  and loaded onto 
a gel to give nal weights of 3.33 µg, 1.67 µg, 33.3 ng, 16.7 ng, 3.33 ng, 1.67 ng and 0.33 
ng. Protein was separated by SDS-PAGE and probed by Western blotting with the α
RNF113B antibody created in sheep. B) U2OS cells were forward mock transfected or 
transfected with pooled siRNF113A, pooled siRNF113B or a combination of siRNF113A 
with siRNF113B, for 48 hr. Cells were lysed and probed with the indicated antibodies. The 
predicted molecular weights of RNF113B, Dac-RNF113B and Dac-RNF113A are 36, 65 and 
65 kDa respectively.
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probes designed to specifically bind to the resulting products (schematic in Fig 4-
13A). After multiple attempts to optimise the primers and PCR conditions for 
RNF113B mRNA, no mRNA signal was detected (Fig 4-13B). However, using the 
same mRNA preparations, β-ACTIN mRNA levels increased with increased cycle 
number, indicating that the sample mRNA had not been degraded after cell harvesting. 
The apparent lack of RNF113B mRNA present in U2OS cells could be 
because no RNF113B is expressed, or be an artefact caused by problems with the 
qRT-PCR procedure. To determine whether other researchers had detected RNF113B 
mRNA, the Expressed Sequence Tag (EST) database was consulted. U2OS cells are 
derived from an osteosarcoma cell line and no ESTs were recorded for RNF113B in 
bone cells (Fig 4-13C). 
 
4.2.7 Creation of RNF113-/- DT40 cells  
Despite siRNF113B-transfected cells showing increased sensitivity to ICL 
inducers, it was not possible confirm a reduction in either RNF113B protein or 
mRNA levels in U2OS cells after transfection. To eliminate the possibility that the 
phenotypes seen were due to off-target effects of the siRNA, and to avoid confusion 
with potential redundancy between the two RNF113 isoforms in human cells, a 
genetic approach was taken. DT40 chicken cell lines were created in which the 
RNF113 gene was disrupted. DT40 cells were chosen as there is only one isoform of 
RNF113 in chickens and a knock out DT40 chicken cell line would circumvent the 
potential problem of redundancy between the human RNF113A and RNF113B 
isoforms. GgRNF113 shows about 40% protein sequence homology with 
HsRNF113B and it was hypothesised that their functions may therefore also be 
conserved. DT40 cells are also particularly easy to genetically manipulate and are 
regularly used in the study of the DNA damage response. 
 
4.2.7.1 RNF113-/- cell lines were created using homologous recombination 
Exons 8 to 10 of the GgRNF113 gene were replaced with drug resistance 
cassettes under the control of the β-actin promoter. As these exons correspond to 
RNF113’s RING finger domain these cell lines are assumed to be RNF113 functional  
knock outs and labeled RNF113-/-. Cells were created by targeting the RNF113 alleles 
in a sequential manner via homologous recombination. A schematic of this strategy is  
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Figure 4-13 RNF113B mRNA is not detected in U2OS cells
A) Schematic showing where qRT-PCR primers and probes for RNF113B mRNA bind. 
B) U2OS cells were reverse transfected with non-targeting siRNA (siNT) in duplicate for 
48 hrs. mRNA was isolated and cDNA was created. qRT-PCR was performed using primers 
designed to amplify β-actin and RNF113B mRNA, and probes designed to specically 
bind to the resulting products. C) Numbers of EST transcripts found in relevant cell lines, 
from the EST database (www.ncbi.nlm.nih.gov/UniGene/ESTProleViewer)
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Figure 4-14 Schematic of the homologous recombination-based method of mutating 
RNF113
Exons 8 to 10, corresponding to the RING domain, of the GgRNF113 gene were replaced with drug 
resistance cassettes to create RNF113-/- DT40 cells. The rst allele was targeted with a blasticidin 
resistance cassette and the second with a puromycin resistance cassette. The location of primers 
used in PCR genotyping and their expected product size are indicated. 
 126 
shown in Fig 4-14. Firstly the pBS-∆RNF113-bsr construct was used to target one 
allele and create RNF113-/+ cells with a blasticidin resistance cassette. A second 
transfection with a pBS-∆RNF113-puro construct targeted the second allele and 
created RNF113-/- cells with a puromycin resistance cassette. Positive ∆RNF113 
clones were identified based on resistance to the relevant drug and their genotype.  
 
4.2.7.2 ∆RNF113 cell lines could not be genotyped by Southern Blotting 
Initially a Southern Blot (SB) method was employed to genotype ∆RNF113 
cells. After potential clones were recognised by their ability to grow under blasticidin 
or puromycin selection, they were expanded and their gDNA isolated. gDNA was 
then digested using a BamHI restriction enzyme (Fig 4-15A). There is one BamHI 
site located just within the RNF113 gene, and another downstream of it. The drug 
resistance cassettes included two additional BamHI target sequences, thereby 
introducing supplementary BamHI sites into the ∆RNF113 genome. This should lead 
to different patterns of cleaved DNA in wild type and ∆RNF113 cells. Using a cDNA 
probe complementary to the non-modified section of RNF113, the resulting fragments 
of different sizes should be visible on a SB and used to distinguish between these cells. 
However, an initial protocol using modified Church and Gilbert buffer as a 
hybridisation buffer displayed no binding of the probe to DNA (Fig 4-15B). Using a 
commericial hyrbidisation buffer (RapidHyb) instead led to non-specific binding of 
the probe to the blot (Fig 4-15C). Other techniques that were applied to optimise the 
Southern Blot strategy included creating five different probes to bind at different sites, 
producing fresh buffers, adjusting the wash times and buffers, and altering the 
incubation times for membrane blocking, probe creation, probe hybridisation and blot 
exposure. Despite this comprehensive programme, no improvement to the Southern 
Blot outcome was achieved. 
 
4.2.7.3 ∆RNF113 cell lines were genotyped using long range PCR 
Due to the difficulty screening DT40 cell lines using the Southern Blot 
approach it was decided to employ a long range PCR screening method similar to that 
used in DT40 cells by others [182]. This involved assessing the cell lines for 3 
diagnostic criteria, as illustrated in Fig. Firstly, heterozygous RNF113-/+ cells were 
identified by the presence of the blasticidin resistance cassette in the correct position 
in the genome. This was achieved using one primer inside the drug resistance cassette  
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Figure 4-15 ∆RNF113 cell lines could not be genotyped by Southern 
Blotting
A) Potenital ∆RNF113 clones were lysed and their gDNA was subjected to 
BamHI cleavage. Digested gDNA was separated by gel electrophoresis. B) 
Digested gDNA was transferred to nylon membrane and probed with a 
cDNA fragment targeted to the RNF113 gene using modied Church and 
Gilbert buer. C) As B) except that RapidHyb buer was used. 
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and one primer outside the region to be replaced. Out of 48 clones screened, 34 
RNF113-/+ cell lines were distinguished.  
After a repeat transfection to target the second allele using two different 
RNF113-/+ clones, RNF113-/- cells were identified by the presence of the puromycin 
resistance cassette. Primers were designed for this purpose in the same way as for 
blasticidin recognition. From 230 potential clones, only three RNF113-/- cell lines 
tested positive. Finally, primers targeting exon 8 were used to confirm the absence of 
this wild type region in the three knock out lines. Primers crossing the exon 6/7 
boundary, which should be present in all cells, were used as a loading control for 
genomic DNA.  
Fig 4-16 shows the final genotyping confirmation for positive clones 
identified based on this process. All clones were created from the wild type clone 18 
background (Fig 4-16A). RNF113-/- clone 101 was produced from the RNF113-/+ 
clone 26 line, while RNF113-/- clones 219 and 220 were based on the RNF113-/+ clone 
27 line. There was a problem with the blasticidin band for RNF113-/+ clone 26 (Fig 4-
16A), possibly due to a low level of gDNA sample. Therefore to verify the genotypes 
for these cell lines, fresh gDNA samples were obtained from this family and the final 
PCR confirmation was repeated (Fig 4-16B).  
 
4.2.8 RNF113-/- DT40 cells are not sensitive to genotoxins 
To determine whether RNF113 plays a role in the DNA damage response in 
DT40 cells, RNF113-/- cells were assessed for sensitivity to genotoxins using a CSA 
method modified for suspension cells. ∆UBE2T DT40 cells are sensitive to multiple 
genotoxins [78, 79, 183] and were therefore used as positive controls. 
 
4.2.8.1 RNF113-/- DT40 cells are not sensitive to cisplatin or MMC 
First, to assess whether RNF113 is involved in ICL repair, RNF113-/- cells and 
their corresponding heterozygous RNF113-/+ and wild type control cells were treated 
with cisplatin or MMC and allowed to recover for up to 10 days. Colonies were 
counted and percentage viability values for each cell line and treatment concentration 
were calculated. ∆UBE2T cells display vastly decreased viability after cisplatin and 
MMC treatment compared to wild type cells. However, although RNF113-/- clone 101 
shows a mild sensitivity to MMC it is not sensitive to cisplatin (Fig 4-17A and C). To  
RNF113
Exon 8
Blasticidin resistance
Puromycin resistance
Exons 6/7
wt (
18) 
-/+ (
26)
-/+ (
27)
-/- (
101
)
-/- (
219
)
-/- (
220
)
Exon 8
Blasticidin resistance
Puromycin resistance
Exons 6/7
RNF113
wt (
18) 
-/+ (
26)
-/- (
101
)
A)
B)
Figure 4-16 ∆RNF113 cell lines were genotyped using long range 
PCR
Wild type, RNF113-/+ and RNF113-/- clones were lysed and their gDNA 
was subjected to long range PCR using primers designed to amplify 
sequences from the indicated exons or casettes. PCR products were 
analysed by gel electrophoresis. The red cross in A) indicates a missing 
band, presumably due to experimental error.
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Figure 4-17 RNF113-/- cells are not sensitive to cisplatin or MMC
Wild type (clone 18), RNF113-/+ (clones 26 and 27), RNF113-/- (clones 101, 219 and 
220) and ∆UBE2T (clone 24) DT40 cells were treated with a range of A) and B) cispla-
tin (0 – 6 µM) or C) and D) MMC (0 – 90 nM) concentrations for 1hr. Cells were 
seeded in duplicate in viscous media and allowed to recover for 10 days. Colonies 
were counted and percentage viability values for each cell line and treatment 
concentration were calculated. The experiment was repeated three times and 
error bars represent SEM.
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further confirm whether RNF113-deficient DT40 cells are sensitive to ICL inducers, 
two more RNF113-/- clones were subjected to CSAs with cisplatin and MMC. Neither 
RNF113-/- clone 219 nor clone 220 showed decreased viability after cisplatin or MMC 
treatment compared to wild type cells (Fig 4-17B and D).  
 
4.2.8.2 RNF113-/- DT40 cells are not sensitive to IR or HU 
To determine whether RNF113 plays a role in other DNA damage response 
pathways, RNF113-/- cells and corresponding control cells were treated with IR and 
allowed to recover, or were subjected to chronic HU treatment. Colonies were 
counted and percentage viability values for each cell line and treatment concentration 
were calculated. In agreement with the literature, ∆UBE2T cells display mild 
sensitivity to IR and vastly decreased viability after HU treatment, compared to wild 
type cells. However none of the three RNF113-/- clones showed defects in 
proliferation after IR (Fig 4-18A) or HU treatment (Fig 4-18B). 
 
Thus RNF113-defective DT40 cells are not sensitive to cisplatin, MMC, IR or 
HU. 
 
4.3 Discussion 
RNF113B was identified as a positive candidate of the siRNA screen to 
discover novel regulators of the ICL response. RNF113 was already predicted to have 
a role in the Fanconi Anaemia pathway in C. elegans [167]. Data that was personally 
communicated to Dr Alpi at the time and later published [152], substantiated the 
premise that RNF113 is a DNA repair protein. Thus RNF113B was further 
investigated as a potential regulator of the ICL response.  
As RNF113B had not been previously characterised in human cells, neither 
commercial nor peer-validated tools were available. To study RNF113B, instruments 
such as RNF113B-expressing cell lines, antibodies and knock out cell lines, had to be 
created and optimised. 
Analysis of a GFP-RNF113B-expressing cell line revealed that RNF113B 
localises to the nucleus. This position of RNF113B conforms to a hypothesised role in 
the DDR. However, Cwc24p, the S. cerevisiae equivalent of HsRNF113 proteins, and 
RNF113A have ben implicated in mRNA splicing [168, 175]. If RNF113B and  
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Figure 4-18 RNF113-/- cells are not sensitive to IR or HU
Wild type (clone 18), RNF113-/- (clones 101, 219 and 220) and ∆Ube2t (clone 24) 
DT40 cells were treated with a range of A) IR doses (0 – 6 Gy) or B) HU concentra-
tions (0 – 100 µM). Cells were seeded in duplicate in viscous media and grown for 
10 days. Colonies were counted and percentage viability values for each cell line 
and treatment concentration were calculated. The experiment was repeated at 
least three times and error bars represent SEM.
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RNF113A share similar or redundant functions, the localisation of RNF113B to the 
nucleus could be because it has a role in RNA splicing, rather than in the DDR.  
 
Out of four siRNF113B oligomers, only one induced sensitivity to cisplatin 
and MMC using an ATP-based assay and using an independent CSA technique it was 
further verified that this siRNF113B oligomer causes sensitivity to MMC. There are 
two isoforms of RNF113 in human cells (A and B), which may have redundant 
functions. It was hypothesised that the oligomer that induced sensitivity might target 
both isoforms, while the other three only targeted one. Indeed an alignment of 
siRNF113B oligomers against RNF113A and RNF113B mRNA shows similar siRNA 
target sites in both mRNAs.  
Thus it was necessary to determine whether sensitivity to ICL inducers 
corresponded with reductions in RNF113B levels or function. Multiple approaches 
were employed to achieve this, including assessing RNF113B protein and mRNA 
levels and creation of a GgRNF113-/- chicken cell line. 
To determine whether siRNF113B transfection reduces RNF113B mRNA 
levels, qRT-PCR was used. No RNF113B mRNA was detected in U2OS cells that 
were transfected with non-targeting siRNA. However, no positive control for 
RNF113B mRNA was included in this experiment and thus it is possible that the 
primers and/or PCR conditions were not sufficiently optimised to detect it. The GFP-
RNF113B Flp-In 293 cell line could be used as a control, as RNF113B mRNA would 
certainly be present in these cells after tetracycline-induced expression of this protein. 
As an alterative approach for assessing the efficiency of siRNF113B 
transfection, Western Blotting was used to analyse RNF113B protein levels after 
transfection. First, commercial antibodies against RNF113B were assessed and found 
to predominantly bind a protein(s) of larger molecular weight than was expected for 
RNF113B. It is possible that RNF113B is constitutively found in a complex within 
the cell, however the sample lysates analysed were denatured and it would be 
expected that complexes have been destroyed. Similarly, a specially created in-house 
antibody against RNF113B does not recognise these proteins, suggesting that they are 
non-specific interactors of the commercial antibodies. The in-house antibody 
recognises recombinant and over-expressed RNF113B in a concentration dependant 
manner, and indeed binds a protein of RNF113B’s expected size in cell lysates. 
However, levels of this protein are not reduced after transfection with siRNF113B-05, 
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or pooled siRNA against RNF113B and/or RNF113A. It is possible that the antibody 
also non-specifically binds another protein of the same molecular weight, thus 
obscuring the effect of reduced RNF113B levels after siRNA transfection. However, 
when GFP-RNF113B-expressing cells were siRNF113B-transfected an anti-GFP 
antibody detected no reduction in GFP-RNF113B levels either. Thus, RNF113B 
protein levels are not reduced after siRNF113B-05 transfection. This implies that 
siRNF113B does not actually knock down RNF113B and that the sensitivity to ICL 
inducers caused by its transfection is due to an off-target effect.  
Given that siRNF113B is a non-specific siRNA other observations into 
RNF113B’s role in the ICL response presented in this chapter, such as investigations 
into cisplatin-induced apoptosis, are redundant. 
 
Meanwhile, to further attempt to correlate cisplatin sensitivity with defects in 
RNF113, and to avoid potential issues of redundancy between the two human 
isoforms, GgRNF113-/- DT40 cell lines were created and tested for sensitivity to 
genotoxins. 
One RNF113-/- clone (101) was sensitive to MMC but not cisplatin. While 
cisplatin and MMC both introduce ICLs, these ICLs are believed to distort the DNA 
to different extents. It is therefore possible that some proteins could be involved in the 
recognition of MMC- but not cisplatin-induced damage. However, two additional 
RNF113-/- clones (219 and 220) did not show sensitivity to either MMC or cisplatin. 
Therefore, the sensitivity of clone 101 to MMC is likely due to an experimental 
artefact or secondary mutation, and RNF113-/- DT40 cells are not sensitive to ICL 
inducers. In addition, none of the RNF113-/- clones were sensitive to IR or HU, 
indicating that these mutants are not sensitive to genotoxins in general. 
Yet, it should be noted that the RNF113-/- cells are only predicted to be 
RNF113 functional knock outs as they omit its RING finger domain. The resulting 
premature ending of this gene might be expected to lead to the degradation of the 
entire protein. However it is not known whether a truncated fragment of the RNF113 
protein missing the RING domain is expressed. If this were to occur, the N-terminal 
portion of RNF113 may be sufficient for it to fulfil a non-ubiquitination dependant 
role in the genotoxic response in DT40 cells. Furthermore, DT40 cells are a 
lymphoblastoid cell line derived from chickens and do not express p53 [184, 185]. If 
RNF113 were to act within a p53-mediated response to ICLs, this pathway would not 
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be activated in DT40s and the absence of ubiquitin-ligating RNF113 would not be 
detrimental to the cells’ viability. Thus p53- or non-ligase function-dependant roles of 
RNF113 within the ICL response in chickens cannot be ruled out using this cell line.  
The conclusion that RNF113 is not required for the ICL response does not 
align with previous work by Lee et al [152]. This group showed that hatching rates 
are decreased when C. elegans are transfected with siRNF113 and treated with an ICL 
inducer. Using immunofluorescence with an antibody against RNF113, they showed 
that RNF113 levels are decreased after siRNF113-transfection. The authors also 
checked that expression of hlp-2 (a protein co-transfected with CeRNF113) is not 
affected by siRNF113-transfection. However, it is possible that this siRNF113 
additionally targets another known or novel DNA repair protein. No rescue 
experiments, such as the over-expression of a version of RNF113 that cannot be 
knocked down, were conducted to eliminate this scenario. Thus it is possible that the 
sensitivity to ICL induction seen in C. elegans was also due to off-target effects of 
siRNF113. 
Even allowing that RNF113 plays a role in ICL repair in C. elegans, this 
protein may play a different role in different organisms. The sensitivity to cisplatin 
seen in U2OS cells after siRNF113B transfection is likely due to an off-target effect, 
and hypersensitivity to ICL inducers was not reproduced in RNF113-deficient DT40 
cells. Thus the investigations detailed here offer no evidence that RNF113B is 
involved in the ICL response in humans or chickens. Yet, while these studies do not 
increase our knowledge of the DDR for now, the tools that have been created may 
prove invaluable in future research, should further information on RNF113B’s 
function come to light. 
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5 HOIP protects cells from cisplatin-induced 
apoptosis 
 
5.1 Introduction 
 
Interstrand crosslinkers such as cisplatin are often used as anti-cancer drugs 
due to their ability to introduce these toxic lesions into proliferating cells. However, 
cancer cells are capable of acquiring resistance mechanisms to prevent cell death. By 
understanding more about how cisplatin and ICLs cause destruction of cells, we may 
be able to optimise the use of current drugs, or identify novel targets for new 
chemotherapeutic drugs. This chapter describes the discovery that HOIL-1 interacting 
protein (HOIP), also known as RNF31, protects cells from cisplatin-induced apoptosis, 
and the implications this may have for platinum-based chemotherapy.  
 
5.1.1 HOIP regulates signalling pathways by creating linear ubiquitin 
chains 
HOIP is an E3 ubiquitin ligase, and the essential catalytic subunit of the linear 
ubiquitin assembly complex (LUBAC). LUBAC is the only ligase known to create 
linear polyubiquitin chains, also known as M1-linked chains [22]. HOIP is a member 
of the RING-in-between-RING ligase family, which work as RING/HECT hybrid E3 
ligases [18–21]. HOIL-1 and SHARPIN are also constituents of LUBAC [186–188], 
although it is not clear whether HOIP works in conjunction with both components 
simultaneously. HOIP is necessary for LUBAC activity, as HOIL-1/SHARPIN 
complexes alone are incapable of forming linear chains, although these interactors are 
needed to enhance HOIP’s activity to a functional level [20, 21]. 
LUBAC is required for innate and adaptive immunity, suppressing 
inflammation and the control of cell death. It is involved in receptor mediated 
signalling through TNF, IL-1β, CD40 ligand, Toll-like receptors (TLRs), nucleotide-
binding oligomerisation domain-containing protein 2 (NOD2), RIG1 and interferon 
(IFN) (reviewed in [154]), but its role is best understood in TNF signalling (schematic 
in Fig 5-0).  
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TNF treatment leads to the formation of two opposing signalling complexes 
that result in either (mostly proliferative) gene activation or cell death. Complex I 
activates NF-κB and MAPK signalling, cell propagation and inflammation, while 
complex II upregulates apoptosis and necroptosis. LUBAC is involved in both 
progressing canonical NF-κB signalling, and protecting cells from apoptotic and 
necroptotic cell death after TNF exposure [186, 188–190]. In the former case the 
modification of RIP1 and NEMO with linear chains leads to the recruitment of 
NEMO to complex I [191], activation of the IKK complex and subsequent release of 
NF-κB (Fig 5-0, number 1). The latter effect may be achieved by stabilising complex 
I to prevent the formation of complex II, the ubiquitination of RIP1, and/or through 
the upregulated expression of anti-apoptotic proteins caused by NF-κB activation 
(represented by arrow numbers 2, 3 and 4 in Fig 5-0 respectively). SHARPIN and 
HOIL-1 may have different contributions to LUBAC activity in this role as 
SHARPIN-deficient mice have higher levels of TNF-induced apoptosis than HOIL-1-
deficient-mice [186]. SHARPIN mice also display chronic proliferative dermatitis 
(cpdm) [186, 188, 192], an inflammatory disease associated here with increased TNF-
induced cell death, while HOIL-1 mice do not. Thus it is possible that HOIL-1 and 
SHARPIN interact with or regulate HOIP separately in response to different stimuli.  
Despite intensive interest in LUBAC and linear chains in recent years, no role 
has yet been suggested for HOIP in response to cisplatin. As a known E3 ligase, 
HOIP was included as a target in a high-throughput siRNA screen undertaken to 
identify novel ubiquitin-related components of this response. 
 
A) 
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B) 
 
Figure 5-0 HOIP schematics. A) Linear structures of LUBAC components; 
HOIP, HOIL1 and SHARPIN. B) Simplified schematic of HOIP-dependant TNF 
signalling (described in text). 
 
5.2 Results 
5.2.1 HOIP was identified as a positive candidate in the siRNA screen 
To identify novel ubiquitin-related components of the ICL response, cells 
were transfected with siRNA from a ubiquitinome library, treated with cisplatin or 
MMC, and a luciferase-based assay was used to identify wells with reduced viability. 
siRNAs were considered positive candidates only if they caused reduced cell viability 
after treatment with an ICL inducer.  
 
5.2.1.1 The primary screen identified siHOIP as a sensitiser for cisplatin 
The primary screen was performed by Adel Ibrahim. As described in Chapter 
3, during the primary screen positive siTargets were identified based on their Cell 
Growth Effect (CGE), Surviving Fraction (SF) and Percentage Normalised SF 
(PNSF) values. Data from the first and second replicates were analysed separately and 
different thresholds decided on. The cut off values, along with siHOIP values are 
shown in Table 5-1. Along with 111 other siRNAs, siHOIP fulfilled the criteria in at 
least one of the replicates, and was considered a positive candidate for reducing cell 
viability in response to cisplatin.  
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Table 5-1 siHOIP values from the primary screen. 
 Replicate 
 1 2 
Value Cut off siHOIP cells Cut off siHOIP cells 
CGE > 50% 66.39% > 60% 94.93% 
SF < -1.47 -1.3 < -0.77 -1.41 
PNSF > 86% 114.34% > 81% 181.17% 
 
5.2.1.2 siHOIP caused dose dependent sensitivity to cisplatin in the secondary 
screen 
To eliminate false positives, hits that passed the primary screen stage – 
including HOIP – were further investigated in the secondary stage of the screen. In 
the secondary screen siTargets that caused dose dependant sensitivity to cisplatin 
were recognised based on their SF and CGE graphs for each replicate. In the first 
replicate, the SF and CGE slopes of siHOIP-transfected cells were similar to the 
slopes of the siREV1L-transfected positive control cells (Fig 5-1A and B). In the 
second and third replicates siHOIP transfection decreased the SF slopes of cells to an 
even greater extent than siREV1L transfection (Fig 5-1C, D, E and F). In each of 
these replicates the effect of siHOIP on cells’ viability was considered ‘high’ and 
given a score of 2 points, resulting in the optimal overall score of 6. Thus the dose 
dependant sensitivity to cisplatin induced by siHOIP placed it within the top three of 
21 siTargets that passed the secondary stage of the screen. 
 
5.2.1.3 siHOIP also causes dose dependent sensitivity to MMC 
To increase confidence that the positive hits of the secondary screen cause 
sensitivity to ICL inducers in general, the secondary screen was repeated with MMC 
treatment. 
In each replicate, the effect of siHOIP-transfection on the SF slope was even 
greater than the slope of positive control, siREV1L (Fig 5-2A, C and E). Likewise, in 
the second replicate siHOIP caused decreased CGE with increasing MMC 
concentration in a manner similar to siREV1L’s decreased CGE levels (Fig 5-2D). 
This effect was further enhanced in the first and third replicates, where siHOIP’s CGE 
slopes were even greater siREV1L’s CGE slopes (Fig 5-2B and F), compared to the 
siNT control. Both of these measures of viability thus indicated that siHOIP induces 
dose dependant sensitivity to MMC in U2OS cells. siHOIP was thereby given a ‘high’  
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Figure 5-1 siHOIP caused dose dependent sensitivity to cisplatin in the 
secondary screen
U2OS cells were reverse transfected with pooled siNT, siREV1L and siHOIP at 5000 
cells/well of a 96 well plate. Cells were treated with a range of concentrations of 
cisplatin (0 – 6 μM) for 72 hr before a luciferase assay was performed. The experie-
ment was repeated three times and Surviving Fraction (SF) (A, C and E) and Cell 
Growth Eect (CGE) (B, D and F) values are presented for each replicate.
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Figure 5-2 siHOIP also causes dose dependent sensitivity to MMC
U2OS cells were reverse transfected with pooled siNT, siREV1L and siHOIP at 5000 
cells/well of a 96 well plate. Cells were treated with a range of concentrations of MMC (0 
– 1 μM) for 72 hr before a luciferase assay was performed. The experiement was 
repeated three times and Surviving Fraction (SF) (A, C and E) and Cell Growth Eect 
(CGE) (B, D and F) values are presented for each replicate.
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siRNA effect score of 2 points for each replicate, again giving it the optimal overall 
score of 6, and placing it in the top eight candidates at this stage of the screen. 
 
5.2.1.4 Three siHOIP oligomers individually induce sensitivity to cisplatin 
To eliminate siRNAs with off target effects, the oligomers of the original 
siRNA pools were assessed to determine whether they could individually induce 
sensitivity to cisplatin. The data was analysed separately for each biological replicate, 
however for clearer graphical presentation Fig 5-3A to D shows the combined SF 
graphs for three replicates. Transfection with siHOIP-05, -07 and -08 caused 
decreased SF with increased cisplatin concentration in a manner similar to or greater 
than siREV1L transfection (Fig 5-3A, C and D). However, transfection with siHOIP-
06 did not decrease cells’ viability in response to cisplatin to the same extent as 
siREV1L transfection (Fig 5-3B). Alignments of each of the four siHOIPs with HOIP 
mRNA are shown in Fig 5-3E. In all three replicates siHOIP-05, -07 and -08 were 
classed as ‘high’ hits and were considered positive overall (Table 5-2). siHOIP-06 
was only considered ‘high’ in replicate 3, and was thus rejected as a negative 
oligomer. As three out of four siHOIP oligomers recreated the dose-dependant 
sensitivity to cisplatin seen with pooled siHOIP, it was verified as a positive candidate. 
In fact, along with siREV1L, siHOIP was the only candidate of the screen for which 
more than two individual oligomers induced the same phenotype as the pool. This 
marked it out as the top novel candidate after the deconvolution stage of the screen. 
 
Table 5-2Summary of the results for siHOIP deconvolution 
 
  Replicate   
 siRNA 1 2 3 Overall 
siHOIP-05 High High High Positive 
siHOIP-06 Reject Reject High Negative 
siHOIP-07 High High High Positive 
siHOIP-08 High High High Positive 
 
5.2.2 Cisplatin-induced apoptosis is increased in HOIP-deficient cells 
HOIP was identified as a top candidate in the siRNA screen to identify novel 
regulators of the cellular response to cisplatin. HOIP was validated as a true mediator 
of the response to cisplatin by Craig MacKay, a postdoc in the Alpi lab. As shown in 
Appendix 6 and [180], Craig showed that defects in HOIP levels or ligase activity  
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Figure 5-3 Three siHOIP oligomers individually induce sensitivity to cisplatin
U2OS cells were reverse transfected with pooled siNT, siREV1L and four individual siHOIPs 
(A, B, C and D) at 5000 cells/well of a 96 well plate. Cells were treated with a range of 
concentrations of cisplatin (0 – 6 μM) for 72 hr before a luciferase assay was performed. 
Surviving Fraction (SF) values were determined. The experiment was repeated three times 
and error bars represent SEM. E) E) Individual siHOIP oligomers were aligned with HOIP 
mRNA.
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reduce the viability of U2OS cells, HEK293 cells and mouse embryonic fibroblasts 
(MEFs) in response to cisplatin.  
At the time it was known that defects in SHARPIN, another component of 
LUBAC, lead to increased TNF-α-induced apoptosis [186]. A possible reason for the 
hypersensitivity to cisplatin of HOIP-deficient cells could therefore be increased 
apoptosis after cisplatin treatment. To determine whether HOIP protects cells against 
cisplatin-induced cell death, HOIP-deficient cells were assessed for increases in 
apoptotic markers.  
 
5.2.2.1 Optimisation of caspase activity assays 
The apoptotic response converges on the activation of effector caspases such 
as caspases-3 and -7. Once activated they act as proteases to activate downstream 
targets and dismantle the cell. Thus caspase-3 and -7 activation can be used as a 
marker for induction of apoptosis. To determine whether apoptosis was increased in 
siHOIP-transfected cells, caspase activity assays were used.  
As cisplatin is a coloured reagent it was first necessary to check that the 
presence of cisplatin did not affect the luminescence read-out of the assay. Complete 
assay medium was incubated in the presence or absence of cisplatin, and Caspase-Glo 
3, 8 or 9 assays were performed. There was no significant difference in luminescence 
values between cisplatin- and vehicle-treated wells (Fig 5-4), so cisplatin was used in 
future caspase assays. 
Initially, U2OS cells were reverse mock-transfected or transfected with 
siHOIP in a 96 well format. Cells were treated with cisplatin and a Caspase-Glo 3/7 
assay was performed. There was a mild increase in mock-transfected cells in the level 
of caspase-3/7 activity after 10 µM cisplatin (Fig 5-5A). This increase was not 
enhanced with siHOIP transfection. However, it was noted that as cisplatin treatment 
results in reduced viability, there may be less cells in these wells, giving a false 
appearance of normal levels of caspase activity. To account for this, an MTS assay 
was performed in parallel with the Caspase-Glo assay. As previously seen, cisplatin 
treatment decreased the viability of siHOIP-transfected cells to a greater extent than 
that of mock-transfected cells (Fig 5-5B). The luminescence values obtained from the 
Caspase-Glo assay were normalised to the relative viability values retrieved from the 
MTS assay. Fold increases in caspase-3/7 activity levels after cisplatin treatment were 
then calculated for each transfected line. When decreased viability was taken into  
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Figure 5-4 Cisplatin treatment does not aect luminescence in 
Caspase-Glo assays
Complete medium used for Caspase-Glo assays (100 µl/well) was placed 
in a 96 well plate and 20 µl of medium to give 0 or 10 µM cisplatin 
concentration was added in triplicate. Media was incubated for 48 hr and 
Caspase-Glo 3, 8 or 9 assays were performed. The experiment was 
repeated at least twice and error bars represent SEM. Multiple t tests 
were used to calculate signicance and a p value of less than 0.05 was 
considered statistically signicant.
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Figure 5-5 Optimisation of Caspase-Glo assays
U2OS cells were reverse transfected at a density of 5000 cells/well in duplicate white and 
clear 96 well dishes and allowed to adhere for 16 – 20 hr. Cells were vehicle treated or treated 
with 10 µM cisplatin in triplicate for 48 hr. Complete Caspase-Glo Assay Reagents were 
added to the white plate while complete MTS reagents were added to the clear plate. Both 
plates were incubated at 37˚C for 3 hr before the luminescence and absorbency were read 
respectively. The increase in caspase-3 activity before MTS values are taken into account is 
shown in A), MTS values in B) and the increase in caspase-3 activity normalised to MTS data 
in C). The experiment was independently repeated three times and multiple t tests were 
used to calculate signicance. A p value of less than 0.05 was considered statistically signi-
cant with * indicating signicant dierences. D) The Caspase-Glo assay workow. The same 
workow was used for MEF cells with the exclusion of the siRNA transfection step.
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consideration, both mock and siHOIP-transfected cells showed increased caspase-3/7 
activity (Fig 5-5C). However, siHOIP-transfected cells showed significantly enhanced 
caspase-3/7 activity in comparison to mock-transfected cells. It was thus decided to 
utilise an MTS assay in conjunction with all Caspase-Glo assays in the future. A 
workflow depicting this process is shown in Fig 5-5D. For caspase studies with 
MEFS (see Chapter 6), the same workflow was used with the exclusion of the siRNA 
transfection step. 
 
5.2.2.2 Cisplatin-induced caspase-3/7 activity is increased in HOIP-depleted cells 
The effect of HOIP depletion on cisplatin-induced apoptosis was further 
analysed using the optimised caspase activity assays. 
Mock- and siHOIP-transfected U2OS cells were treated with varying cisplatin 
concentrations for varying times. MTS and Caspase-Glo 3/7 assays were performed 
and luminescence values were normalised to the MTS viability data. The fold increase 
in activity was calculated for each treatment over both the vehicle treated wells for 
mock-transfected cells. After 24 hr cisplatin treatment, caspase-3/7 activity did not 
increase in mock-transfected cells. Conversely, after 24 hr treatment with 5 and 10 
µM cisplatin, caspase-3/7 activity was significantly increased (Fig 5-6A). After 48 hr 
of treatment, caspase-3/7 activity was further increased in HOIP-depleted cells, and 
significantly so compared to mock-transfected cells with 10 µM cisplatin treatment. 
To further confirm that apoptosis is increased in HOIP-deficient cells, Craig 
MacKay tested whether cleavage of caspase-3, which is required for its activation, is 
increased after cisplatin treatment. In siHOIP-transfected U2OS and HEK293 cells, 
and catalytically dead HOIPC879S/C879S MEFs, cisplatin-induced cleaved caspase-3 
levels are increased compared to mock-transfected cells and wild type MEFs 
respectively [180]. HOIP therefore acts as an anti-apoptotic protein in response to 
cisplatin treatment. 
 
5.2.2.3 Cisplatin-induced activity of caspase-8 and -9 is increased in HOIP-
depleted cells 
To determine how HOIP protects cells from cisplatin-induced apoptosis, the 
activation of upstream apoptotic markers were assessed. Caspases-3 and -7 are 
activated by the removal of their prodomain by initiator caspases such as caspase-8  
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Figure 5-6 Cisplatin-induced caspase-3/7 activity is increased in 
HOIP-depleted cells 
U2OS cells were reverse mock transfected or transfected with siHOIP at 
a density of 5000 cells/well in duplicate 96 well plates. Cells were 
treated with 0, 5 or 10 µM cisplatin for 24 hr (A) or 48 hr (B) in triplicate 
before MTS and Caspase-Glo 3/7 Assay reagents were added and read 
as appropriate. Caspase-Glo 3/7 luminescence values were normalised 
to MTS data. The fold increase in activity over the vehicle treated wells 
for mock-transfected cells was calculated for each treatment. The 
experiments were independently repeated three times and errors bars 
represent SEM. Data was statistically analysed by ANOVA followed by 
multiple comparisons to calculate signicance with * indicating signi-
cant dierences.
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and -9. Initiator caspases are themselves activated by different cell death signalling 
pathways. Thus caspase-8 and -9 activation were used to assess which upstream 
pathway(s) HOIP might act in. 
Mock- and siHOIP-transfected U2OS cells were treated with different doses 
of cisplatin for 48 hr and Caspase-Glo 8 and 9 assays were performed. The fold 
increases in activity over the vehicle treated wells for each treatment were calculated. 
After 10 µM but not 5 µM cisplatin treatment, caspase-8 activity was significantly 
increased in HOIP-defective cells compared to mock-transfected cells (Fig 5-7A). 
Caspase-9 activity was also significantly increased with 10 µM cisplatin treatment in  
siHOIP-transfected cells compared to mock-transfected cells, although this increase 
was not as great as for caspase-8 activity (Fig 5-7B). 
 
5.2.3 HOIP depletion re-sensitises a cisplatin-resistant cancer line to 
cisplatin  
Cisplatin resistance is a major obstruction to its efficacy as a chemotherapeutic 
drug. The discovery of HOIP as a guardian of U2OS cells against apoptosis suggests 
that targeting HOIP could be a potential strategy to re-sensitise cisplatin-resistant 
cancer cells. To test this concept, the effect of HOIP depletion on the sensitivity of a 
resistant cell line was analysed. Cisplatin is used in the treatment of ovarian cancer, 
and so a paired ovarian cancer cell line was obtained. A2780 CisS cells are sensitive to 
cisplatin, while A2780 CisR cells have become resistant to cisplatin through 
continuous culturing in increasing concentrations of this drug [142]. 
RNA interference and knock down of proteins is inefficient in some cancer 
cell lines. Thus it was first confirmed that siHOIP-transfection resulted in adequate 
decreases of HOIP levels in A2780 cell lines. A2780 CisS and CisR cells were reverse 
mock transfected or transfected with siHOIP, lysed and protein levels were analysed 
via Western Blotting. HOIP was expressed at the same level in mock-transfected 
A2780 CisS and CisR cells (Fig 5-8A). After transfection with siHOIP, HOIP levels 
were drastically reduced in both A2780 CisR cells (Fig 5-8A) and CisS cells (data not 
shown). 
Next it was determined whether cisplatin-resistant A2780 CisR cells could be 
re-sensitised to cisplatin. A2780 CisS and CisR cells were reverse mock transfected or 
transfected with siHOIP, treated with a range of cisplatin concentrations and an MTS  
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Figure 5-7 Cisplatin-induced caspase-8 and -9 activities are 
increased in HOIP-depleted cells 
A) U2OS cells were reverse mock transfected or transfected with siHOIP 
at a density of 5000 cells/well in duplicate 96 well plates. Cells were 
treated with 0, 5 or 10 µM cisplatin for 48 hr in triplicate. MTS and 
Caspase-Glo 8 Assay reagents were added and read as appropriate. 
Caspase-Glo 8 luminescence values were normalised to MTS data. The 
fold increase in activity over the vehicle treated wells for mock-
transfected cells was calculated for each treatment. The experiment was 
independently repeated three times and errors bars represent SEM. 
Data was statistically analysed by ANOVA followed by multiple compari-
sons to calculate signicance with * indicating signicant dierences. B) 
As A) except that Caspase-Glo 9 reagents were added.
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Figure 5-8 HOIP depletion resensitises a cisplatin-resistant cancer cell line to cisplatin
A) A2780 cells that are sensitive (CisS) and resistant to cisplatin (CisR), were reverse mock 
transfected or transfected with siHOIP as indicated and lysed after 48 hr. Lysates were 
analysed with Western Blotting with the indicated antibodies. A representative image of 
four replicates is shown. B) A2780 CisS were mock transfected or transfected with siHOIP. 
After 36 hr they were trypsinised and reseeded at a density of 5000 cells/well in 96 well 
plates. Cells were treated with a range of cisplatin concentrations (0 – 10 µM) for 24 hr and 
an MTS assay was performed. The experiment was repeated three times and linear regres-
sion on log10 transformed data was used to determine the statistical signicance of dier-
ences between slopes. Signicant dierences (p < 0.05) are indicated by *. C) As B), except 
that A2780 CisR cells were also included and a cisplatin range of 0 – 25 µM was used.
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assay was performed. HOIP-depletion further sensitised A2780 CisS cells to cisplatin 
(Fig 5-8B). A2780 CisR cells were more resistant to cisplatin treatment than A2780 
CisS cells (Fig 5-8C). However, depletion of HOIP in CisR cells caused a significant 
re-sensitisation of CisR cells to cisplatin.  
 
5.3 Discussion 
After passing stringent criteria, HOIP was the top positive candidate of an 
siRNA screen that identified novel regulators of the cellular response to cisplatin. 
Further investigation by Craig MacKay validated HOIP as a protein whose E3 ligase 
function is essential for cellular viability after cisplatin treatment. At the time the 
screen was completed, there were no reports of a role for HOIP in the DNA damage 
response.  
However, we discovered that defects in HOIP levels or activity cause 
increased cisplatin-induced apoptotic activity, while having no effect on DNA 
damage checkpoint responses or repair. Furthermore, inhibition of caspase-8 reverses 
the sensitivity of HOIP-depleted cells to cisplatin (data not shown). This indicates that 
cisplatin sensitivity in HOIP-deficient cells is primarily due to increased apoptotic cell 
death. Indeed, this conclusion agrees with work published by Niu et al about the same 
time, showing that HOIP-depletion leads to increased etoposide-induced apoptosis 
[193].  
Further investigations into cisplatin-induced apoptosis in HOIP-deficient cells 
revealed that caspase-8 and -9 both show increased activity in HOIP-depleted cells. 
Cross talk between caspase-8 and -9-mediated apoptotic pathways occurs during the 
DNA damage response , making it difficult to decipher the relative contributions of 
caspase-8 and -9 activities to apoptosis in HOIP-defective cells using caspase 
activation assays alone. However, these increases were greater in the case of caspase-
8 activity, implying that caspase-8 might have a greater or more direct impact on 
cisplatin-induced apoptosis in a HOIP mediated pathway. Craig corroborated this by 
pre-treating HOIP-depleted cells with caspase-8 inhibitors, which prevented cisplatin-
induced apoptosis. This suggests that HOIP protects cells from caspase-8 mediated, 
cisplatin-induced, apoptotic cell death.  
Along with increasing our general knowledge of the ICL response, a major 
aim of the screen was to identify targets to help increase the efficacy of cisplatin 
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treatment, particularly in cisplatin-resistant cancer cell lines. We showed that 
reducing HOIP levels in several cancer cell lines increases their sensitivity to cisplatin 
by increasing apoptosis. Moreover, HOIP-depletion re-sensitised three different 
cisplatin-resistant ovarian cancer lines to cisplatin, including A2780 CisR cells, 
suggesting that HOIP protects these cells from cisplatin-induced toxicity. 
A hallmark of cancer cells is their ability to avoid apoptosis [194]. Thus the 
ability to reinstate apoptotic signalling and induce cell death is the aim of many anti-
cancer drugs. The discovery of HOIP as a guardian of cells against apoptosis suggests 
that targeting HOIP could be a potential strategy to prime cancer cells for cell death 
with chemotherapeutic drugs. A similar approach has been seen in the success of 
Smac mimetic drugs, which imitate the inhibitory effect of Smac on IAPs, preventing 
them from blocking apoptosis, and increasing cell death in cancer cells [195]. Small 
molecule inhibitors against HOIP could be used in a combination treatment to 
increase the efficacy of normal courses of cisplatin treatment. Moreover, impeding 
HOIP’s action could be a particularly potent mechanism for improving the clinical 
outcome for patients with cisplatin-resistant disease. 
 The identification of HOIP through the siRNA screen, and its subsequent 
characterisation as an anti-apoptotic regulator have not only increased our 
understanding of cell death in response to ICL inducers, but also potentially provided 
a novel target for anti-cancer drugs to work in combination with cisplatin. 
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6 ABIN1; a novel role in the DNA damage response 
 
6.1 Introduction 
Identifying novel components of the cellular response to cisplatin and 
interstrand crosslinks could increase our understanding of how anti-cancer drugs 
induce cell death. This might help optimise their current use, or even provide novel 
targets for new chemotherapeutic drugs. This chapter describes the discovery that 
A20-binding inhibitor of NF-κB 1 (ABIN1), also known as TNFα-induced protein 3 
(TNFAIP3)-interacting protein 1 (TNIP1), protects cells from cisplatin treatment by 
inhibiting apoptosis.  
 
6.1.1 Ubiquitin binding and ABIN1 
ABIN1 is a polyubiquitin-binding protein that binds to ubiquitin through its 
aptly named ubiquitin binding in ABIN and NEMO (UBAN) domain. ABIN1 can 
bind to M1- and K63-linked chains with a preference for higher molecular weight 
chains [28]. In NEMO the same UBAN domain has highest affinity for linear chains 
[191]. There are no predicted catalytic domains in ABIN1, and subsequently it is 
proposed to act primarily as an adaptor protein. Indeed, the ability of ABIN1 to bind 
ubiquitin is essential for many of its known functions to date.  
ABIN1 has been associated in genome wide association studies (GWAS) with 
autoimmune diseases such as psoriasis, systemic lupus erythematosus (SLE), systemic 
sclerosis (SSc) and rheumatoid arthritis (RA) [155]. Abin1D485N/D485N mice, whose 
ABIN1 cannot bind ubiquitin, develop severe autoimmunity and a lupus-like 
syndrome [28]. Furthermore, ABIN1 has been associated with diffuse large B-cell 
lymphoma (DLBCL), with the identification of point mutants in the UBAN domain 
and truncated versions of ABIN1 expressed in these cells [196]. In addition, ABIN1 
levels are increased in Hodgkin’s lymphoma compared to non-Hodgkin’s lymphoma 
[197]. 
 
6.1.2 ABIN1 regulates signalling pathways  
Notably, ABIN1 protects cells from TNF-induced apoptosis [198] by 
inhibiting the recruitment of caspase-8 to cell death complex II and its subsequent 
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activation [143] (Fig 6-1, point 0). The ability of ABIN1 to bind ubiquitin is essential 
for this process. Indeed, Abin1-/- mice with ubiquitin-binding deficient ABIN1 die 
during embryogenesis with foetal liver apoptosis, anaemia and hypoplasia in a TNF-
dependant manner [143]. 
Consistent with a role in preventing autoimmune diseases, ABIN1 negatively 
regulates the canonical NF-κB pathway in response to allergens and TNF, and inhibits 
expression of genes associated with inflammation [199]. It is proposed to do so by 
binding ubiquitinated NEMO in TNF-induced complex I (see HOIP chapter) [189], 
and recruiting the E3 ligase/DUB A20. A20 then removes ubiquitin from NEMO, 
decreasing IKK activity and preventing release of NF-κB to the nucleus [200, 201] 
(Fig 6-0, point 2). Moreover, ABIN1 also plays an anti-inflammatory role by 
regulating toll-like receptor (TLR) signalling in a ubiquitin-dependant manner. This 
occurs through MyD88-mediated regulation of the transcription factor 
CCAAT/enhancer binding protein β (C/EBPβ) and its target genes [28, 202] (Fig 6-0, 
point 3). 
ABIN1 can also negatively regulate NF-κB signalling by inhibiting the 
processing of p105 to p50 (Fig 6-0, point 4) [203, 204]. P50 is one of the two subunits 
of the most common NF-κB dimer combination, and its reduced levels thus decrease 
the amount of NF-κB available for activation of transcription. 
ABIN1 regulates the epidermal growth factor receptor (EGFR) pathway 
through two separate mechanisms. Firstly it inhibits ERK activity through preventing 
its translocation to the nucleus, and secondly it inhibits EGFR-induced NF-κB 
activation [205, 206] (Fig 6-0, points 5 and 6). ABIN1 may also be directly or 
indirectly involved in the negative regulation of other MAPK stress related kinases, as 
JNK and p38 activity are increased in the B cells and myeloid cells of 
Abin1D485N/D485N mice [28]. 
Furthermore, ABIN1 has also been implicated in nuclear receptor (NR) 
signalling [207, 208] (Fig 6-0, point 7), a role that correlates with its ability to shuttle 
to the nucleus from its predominantly cytosolic localisation [209]. 
Given the many cellular responses ABIN1 is known to be involved in, it is 
likely that it plays as yet uncharacterised roles in other signalling pathways. 
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Figure 6-0 Schematic of ABIN1’s known roles and/or interactions 
 
6.1.3 Regulation of ABIN1 levels 
As ABIN1 does not contain a catalytic domain, a major mechanism for 
regulation of its activity could be by moderating its cellular levels. ABIN1 is 
phosphorylated during M phase and then degraded during the transition from M to G1 
[210]. ABIN1 transcription can also be regulated by NF-κB in a cell type specific 
manner [211–213] and its expression is upregulated in response to TNF and LPS 
treatment. Furthermore, ABIN1 expression is increased after treatment with CARP-1 
functional mimetics (CFMs), inhibitors of the anaphase promoting 
complex/cyclosome (APC/C) that prevent growth of cancer cells, partly by 
stimulating apoptosis [214]. It is possible that ABIN1 activity is regulated by other 
PTMs, degradation and/or transcriptional controls in as yet uncharacterised responses 
to different stimuli. In addition, it should be noted that the functional significance of 
this regulation is not yet clear. 
  
No role has yet been suggested for ABIN1 in the DNA damage response. 
However, as described below, ABIN1 was identified as a positive candidate in the 
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screen to identify novel regulators of the ICL response to cisplatin. Further research 
revealed that ABIN1 is an inhibitor of cisplatin-induced apoptosis and a novel 
regulator of the DDR. 
 
6.2 Results 
6.2.1 ABIN1 was identified as a positive candidate in the siRNA 
screen 
A high-throughput siRNA screen was undertaken to identify novel ubiquitin-
related components of the interstrand crosslink response. Cells were transfected with 
siRNA, treated with cisplatin or MMC, and a luciferase-based assay was used to 
identify wells with reduced viability. siRNAs were considered positive candidates if 
they caused reduced cell viability only after treatment with an ICL inducer. As 
ABIN1 is known to bind ubiquitin chains, siABIN1 was included in the ubiquitinome 
library used in the primary screen. Data relevant to ABIN1 is reproduced below. 
 
6.2.1.1 The primary screen identified siABIN1 as a sensitizer for cisplatin 
The primary screen was performed by Adel Ibrahim. During the primary 
screen, positive siTargets were identified based on their Cell Growth Effect (CGE), 
Surviving Fraction (SF) and Percentage Normalised SF (PNSF) values. Data from the 
first and second replicates were analysed separately and different thresholds decided 
on.  
The cut off values, along with siABIN1 values are shown in Table 6-1. Along 
with 111 other siRNAs, siABIN1 fulfilled the criteria in at least one of the replicates, 
and was considered a positive candidate for reducing cell viability in response to 
cisplatin.  
 
Table 6-1 siABIN1 values from the primary screen. 
 Replicate 
 1 2 
Value Cut off siABIN1 cells Cut off siABIN1 cells 
CGE > 50% 57.70% > 60% 79.24% 
SF < -1.47 -2.15 < -0.77 -0.93 
PNSF > 86% 199.08% > 81% 128.31% 
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6.2.1.2 siABIN1 caused dose dependent sensitivity to cisplatin in the secondary 
screen 
To eliminate false positives, hits that passed the primary screen stage – 
including ABIN1 – were further investigated in the secondary stage of the screen. In 
the secondary screen siTargets that caused dose dependant sensitivity to cisplatin 
were recognised based on their SF and CGE graphs for each replicate. 
In the first replicate, the SF slope of siABIN1-transfected cells was similar to 
the slope of siREV1L-transfected cells (Fig 6-1A). In the second and third replicates 
siABIN1 transfection decreased the SF slopes of cells to an even greater extent than 
siREV1L transfection (Fig C and E).  In each of these replicates the effect of siABIN1 
on cells’ viability was considered ‘high’ and given a score of 2, resulting in the 
optimal overall score of 6. Thus the dose dependant sensitivity to cisplatin induced by 
siABIN1 placed it within the top three of 21 siTargets that passed the secondary stage 
of the screen. 
 
6.2.1.3 siABIN1 also causes dose dependent sensitivity to MMC 
To increase confidence that the positive hits of the secondary screen cause 
sensitivity to ICL inducers in general, the secondary screen was repeated with MMC 
treatment. 
In each of the three replicates siABIN1 caused decreased SF with increased 
MMC compared to the siNT negative control (Fig 6-2). In the first two replicates, this 
decrease was even greater than the positive control, siREV1L (Fig 6-2A and C), and 
in the third was similar to siREV1L (Fig 6-2E). Likewise, in the first and second 
replicates, siABIN1 caused decreased CGE with increasing MMC concentration, 
compared to the siNT control (Fig 6-2B, D and F). Both of these measures of viability 
thus indicated that siABIN1 induces dose dependant sensitivity to MMC in U2OS 
cells. siABIN1 was thereby given a ‘high’ siRNA effect score with 2 points for each  
replicate, again giving it the optimal score of 6 overall, and placing it in top eight 
candidates at this stage of the screen. 
 
6.2.1.4 Two siABIN1 oligomers individually induce sensitivity to cisplatin 
To eliminate siRNAs with off-target effects, the oligomers of the original 
siRNA pools were assessed to determine whether they could individually induce 
sensitivity to cisplatin. The data was analysed separately for each biological replicate,  
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Figure 6-1 siABIN1 caused dose dependent sensitivity to cisplatin in the secondary screen
U2OS cells were reverse transfected with pooled siNT, siREV1L and siABIN1 at a density of 5000 
cells/well of a 96 well plate. Cells were treated with a range of concentrations of cisplatin (0 – 6 μ
M) for 72 hr before a luciferase assay was performed. The experiement was repeated three times 
and Surviving Fraction (SF) (A, C and E) and Cell Growth Eect (CGE) (B, D and F) values are 
presented for each replicate.
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Figure 6-2 siABIN1 also causes dose dependent sensitivity to MMC
U2OS cells were reverse transfected with pooled siNT, siREV1L and siABIN1 at a density of 
5000 cells/well of a 96 well plate. Cells were treated with a range of concentrations of MMC 
(0 – 1 μM) for 72 hr before a luciferase assay was performed. The experiement was repeated 
three times and Surviving Fraction (SF) (A, C and E) and Cell Growth Eect (CGE) (B, D and F) 
values are presented for each replicate.
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however for clearer graphical presentation Fig 6-3A to D show the combined SF 
graphs for three replicates.  
Transfection with siABIN1-05 and -08 caused decreased SF with increased 
cisplatin concentration in a manner similar to (Fig 6-3A) or greater than (Fig 6-3D) 
siREV1L transfection. However, transfection with siABIN1-06 and -07 did not 
decrease cells’ viability in response to cisplatin (Fig 6-3B and C). When analysed on a 
replicate-by-replicate basis, individual oligomers that resulted in an SF slope greater 
or equal to that of REV1L were considered ‘high’ hits. Oligomers whose resulting 
slopes were less than that of siREV1L’s were rejected. In all three replicates 
siABIN1-05 and -08 were classed as ‘high’ hits, while siABIN1-06 and -07 were 
rejected as positive candidates. For candidates to be considered true hits in the 
deconvolution stage of the screen, at least two of its oligomers had to be classed as 
positive. As two out of four siABIN1 oligomers recreated the dose-dependant 
sensitivity to cisplatin seen with pooled siABIN1 (Fig 6-3E), it was verified as a 
positive candidate.   
 
6.2.2 Reduced ABIN1 levels correspond to sensitivity to cisplatin  
During the screen, transfection with pooled siRNA and two siRNA oligomers 
(siABIN1-05 and -08) against ABIN1 induced dose dependant sensitivity to cisplatin 
in U2OS cells. However, transfection with two separate oligomers against ABIN1 
(siABIN1-06 and -07) had no effect on U2OS cell’s viability in response to cisplatin. 
To determine whether cisplatin hypersensitivity corresponds to reduced ABIN1 
protein levels after siRNA transfection, U2OS cells were transfected with non-
targeting siRNA (siNT), four individual siABIN1 oligomers, or pooled siABIN1 for 
18 or 90 hr. These times are equivalent to the transfection periods after which cells 
were treated with cisplatin or a luciferase assay was performed respectively during the 
screen. Cells were lysed and analysed by Western Blotting with a specific antibody 
against human ABIN1. ABIN1 was present as a doublet band in siNT-transfected 
cells (Fig 6-4A). Both band levels were decreased in cells transfected with siABIN1-
05, -07, -08 and the pooled siABIN1 after both 18 and 90 hr of transfection. Although 
ABIN1 levels were also diminished in siABIN1-06-transfected cells it was to a far 
less extent. Thus reduction of ABIN1 with pooled siABIN1, siABIN1-05 and 
siABIN1-08 correspond to increased cisplatin sensitivity. Likewise, inefficient  
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Figure 6-3 Two siABIN1 oligomers individually induce sensitivity to cisplatin
U2OS cells were reverse transfected with pooled siNT, siREV1L and four individual 
siABIN1s (A, B, C and D) at 5000 cells/well of a 96 well plate. Cells were treated with a 
range of concentrations of cisplatin (0 – 6 μM) for 72 hr before a luciferase assay was 
performed. Surviving Fraction (SF) values were determined. The experiment was 
repeated three times and error bars represent SEM. E) A summary of the results for 
siABIN1 deconvolution.
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Figure 6-4 Reduced ABIN1 protein levels correspond to sensitivity to 
cisplatin after siRNA transfection
A) U2OS cells were reverse transfected with siNT, four individual siABIN1 
oligomers, or pooled siABIN1 for 18 or 90 hr. Cells were lysed and analysed by 
Western Blotting with the indicated antibodies. The experiment was 
repeated twice and a representative image is shown. B) Individual siABIN1 
oligomers were aligned with ABIN1 and ABIN2 mRNA.
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reduction of ABIN1 levels by siABIN1-06 correspond to a lack of cisplatin sensitivity. 
However, siABIN1-07 also decreases ABIN1 levels, but does not increase sensitivity 
to cisplatin in U2OS cells. Nevertheless, in general reduced ABIN1 levels correspond 
to sensitivity to cisplatin after siABIN1 transfection.  
ABIN1 and ABIN2 are similar in structure and appear to show some 
redundancy of function in NF-κB signalling [215]. To determine whether siRNA 
against ABIN1 might be capable of also targeting ABIN2, the four siABIN1 
oligomers against ABIN1 were aligned with ABIN1 and ABIN1 mRNA (Fig 6-4B). 
All four oligomers showed total affinity for ABIN1 mRNA, and less, although not 
negligible, sequence similarity to ABIN2 mRNA.  
As siABIN1-08 decreased ABIN1 levels and induced the greatest sensitivity 
to cisplatin it was used for all future experiments requiring transfection with siABIN1. 
 
6.2.3 Cell line expressing siABIN1-resistant ABIN1 is not sensitive to 
cisplatin  
siRNA can sometimes cause off-target effects by knocking down proteins 
other than its intended target. Given that not all siABIN1 oligomers that decrease 
ABIN1 levels induce sensitivity to cisplatin, further validation of siABIN1 as an on-
target siRNA was required. To increase confidence that the phenotype of sensitivity to 
cisplatin seen in cells transfected with siABIN1 is due to knocking down ABIN1 
alone, a cell line expressing ABIN1 that is resistant to siABIN1 was studied. 
 
6.2.3.1 GFP-ABIN1R cell line expresses siABIN1-resistant ABIN1  
The Flp-In system was used to create stable U2OS cell lines that over-express 
GFP-tagged ABIN1 in a tetracycline-inducible manner. One cell line (GFP-ABIN1) 
resulted in the transcription of mRNA for ‘wild type’ ABIN1. A second line (GFP-
ABIN1R) transcribed mRNA with a silent mutation designed to make ABIN1 resistant 
to siABIN1-08.  
To verify that this transcript was resistant to siABIN1, GFP-ABIN1 and GFP-
ABIN1R U2OS cells were mock-transfected or transfected with siABIN1. ABIN1 
expression was induced with 1 µg/ml tetracycline. Cells were lysed and protein 
expression was analysed by Western Blotting with antibodies against GFP and 
ABIN1. On addition of tetracycline, GFP-ABIN1 expression was induced in both 
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GFP-ABIN1 and GFP-ABIN1R cells, while endogenous ABIN1 was still visible 
(lanes 5 and 7, Fig 6-5A). When GFP-ABIN1 cells were also transfected with 
siABIN1, both endogenous ABIN1 and over-expressed GFP-ABIN1 levels were 
reduced (lane 6). However, when GFP-ABIN1R cells were transfected with siABIN1, 
only the endogenous form of ABIN1 was knocked down, and GFP-ABIN1 was still 
present. (lane 8). Thus the GFP-ABIN1R Flp-In cell line stably expresses tetracycline-
inducible siABIN1-resistant ABIN1. 
GFP-ABIN1 was expressed to a higher level in GFP-ABIN1 cells compared to 
GFP-ABIN1R cells when expression was induced with the same concentration of 
tetracycline (Fig 6-5A). To ensure that any contrasting phenotypes observed in these 
cells was not due to differential ABIN1 levels, ABIN1 expression levels were 
optimised using a tetracycline titration. GFP-ABIN1- and GFP-ABIN1R-expressing 
cells were treated with a range of tetracycline concentrations, lysed and GFP-ABIN1 
expression was analysed by Western Blotting with an antibody against ABIN1. GFP-
ABIN1 was expressed in a dose-dependant manner in both cell lines (Fig 6-5B). 
Optimum tetracycline concentrations of 10 ng/ml for GFP-ABIN1-expressing cells, 
and 100 ng/ml for GFP-ABIN1R-expressing cells, were chosen for future experiments. 
GFP-ABIN1 levels were similar in both lines at these concentrations (see arrows, Fig 
6-5B). Interestingly, levels of endogenous ABIN1 appear to decrease as levels of 
GFP-ABIN1 increase (Fig 6-5B). 
 
6.2.3.2 siABIN1 does not induce cisplatin sensitivity in cell line expressing 
siABIN1-resistant ABIN1 
Next, it was determined whether it is the reduction of ABIN1 levels that cause 
sensitivity to cisplatin after siABIN1 transfection. An MTS assay was used to assess 
the GFP-ABIN1R-expressing cell line for sensitivity to cisplatin.  
GFP-ABIN1 and GFP-ABIN1R U2OS cells were mock-transfected or 
transfected with siABIN1, induced with tetracycline and treated with a range of 
cisplatin concentrations. An MTS assay was performed and the metabolic activity in 
each well was calculated as a percentage of the vehicle treatment for each cell 
line/siRNA combination. Simultaneously cells were reverse transfected, tetracycline 
treated, lysed and analysed for ABIN1 knock down via Western Blotting. The 
transfection with siABIN1 in both cells lines corresponded to reduced levels of 
endogenous ABIN1 compared to mock-transfected cells (Fig 6-6A). As previously  
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Figure 6-5 GFP-ABIN1R cell line expresses siABIN1-resistant ABIN1 
A) Flp-In U2OS cells expressing GFP-ABIN1, or GFP-ABIN1 that is resistant to siABIN1 
(GFP-ABIN1R), were mock reverse-transfected or reverse-transfected with siABIN1. 
After 6 - 8 hr cells were left untreated or treated with 1 µg/ml tetracycline overnight. 
Cells were lysed and protein extracts were analysed by Western Blotting with the 
indicated antibodies. B) Cell lines as above were treated with a range of tetracycline 
concentrations overnight. Cells were lysed and protein extracts were analysed by 
Western Blotting with the indicated antibodies. 
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Figure 6-6 Cisplatin sensitivity is rescued by over-expression of siRNA-resistant ABIN1 
A) and B) Flp-In U2OS cells expressing GFP-ABIN1, or GFP-ABIN1 that is resistant to siABIN1 
(GFP-ABIN1R), were mock reverse-transfected or reverse-transfected with siABIN1 in 10 cm 
dishes (A) or 96 well plates (B). After 6 - 8 hr tetracycline was added to a nal concentration 
of 10 ng/ml for GFP-ABIN1 cells and 100 ng/ml for GFP-ABIN1R cells. A) Cells were incubated 
for 72 hr, lysed and protein extracts were analysed by Western Blotting with the indicated 
anitbodies. The experiment was repeated three times and a representative image is 
displayed. B) Tetracycline was added simultaneously with (A) but cells were incubated over-
night before being treated with a range (0 – 10 µM) of cisplatin concentrations, in triplicate, 
for 72 hr. An MTS assay was performed and metabolic activity values were calculated for 
each well as a percentage of the vehicle treatment for each line/siRNA. The experiment was 
repeated three times and error bars represent SEM. Statistical signicance was determined 
by linear regression on log10-transformed data with *** indicating p < 0.001.
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seen, GFP-ABIN1 levels were also decreased after siABIN1-transfection in GFP-
ABIN1, but not GFP-ABIN1R -expressing cells.  
When transfected with siABIN1 the viability of GFP-ABIN1-expressing cells, 
as measured by the metabolic activity of these cells, decreased more rapidly than 
when mock-transfected (Fig 6-6B). However, when siABIN1-transfected, the viability 
of GFP-ABIN1R-expressing cells was not greatly diminished compared to mock-
transfected GFP-ABIN1R cells. It was noted that before siRNA transfection GFP-
ABIN1-expressing cells are more resistant to cisplatin than GFP-ABINR-expressing 
cells (Fig 6-6B). Notwithstanding this, siABIN1-transfection does not sensitise GFP-
ABINR-expressing cells to cisplatin, implying that siABIN1 does not sensitise U2OS 
cells to cisplatin through an off-target effect. 
 
6.2.4 Immortalisation and characterisation of ABIN1-deficient MEF 
lines 
To further confirm the phenotype of cisplatin sensitivity in ABIN1-deficient 
cells and to investigate whether ubiquitin binding is required for ABIN1 to protect 
cells from cisplatin, a genetic approach was taken. Firstly, primary mouse embryonic 
fibroblasts (MEFs) from knock in Abin1D485N/D485N mice were obtained from Sambit 
Nanda of Philip Cohen’s laboratory. These MEFs express ABIN1 with a point 
mutation in ABIN1’s ubiquitin binding (UBAN) domain, which prevent it from 
binding ubiquitin [28]. This cell line should therefore specifically enable the study of 
ABIN1’s ubiquitin binding functions within the ICL response. To further verify 
phenotypes seen in the single-point mutation knock in MEFs, and to search for 
potentially more marked effects, ‘knock out’ Abin1-/- ABIN1 MEFs were also 
acquired from the laboratory of Averil Ma [143]. 
 
6.2.4.1 Immortalisation of Abin1D485N/D485N MEF lines 
Many of the assays used in the study of the DNA damage response require 
cells to grow in culture for prolonged periods of time, and at a known and consistent 
rate that is similar to control cell line growth rates. Primary cell lines stop 
proliferating after a number of passages and often do not divide at the same rate as 
each other to begin with. Thus, it was decided to standardise the primary lines 
obtained from the Cohen lab by immortalising them. To avoid problems with 
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secondary mutations acquired through the immortalisation process, wild type Abin1, 
Abin1wild type/D485N and Abin1D485N/D485N (Clone 3) MEFs were immortalised using two 
separate techniques. 
Wild type Abin1, Abin1wt/D485N and Abin1D485N/D485N (cell lines 3A) MEFs were 
immortalised by Simian virus 40 (SV40) transformation. This virus inhibits the 
activities of p53, and Rb family proteins (reviewed in [146]) and allows the cells to 
continue to proliferate in culture. Freshly isolated primary MEFs were transfected 
with SV40 viral supernatant from pre-prepared cells, incubated for 3 hr and then 
allowed to recover for 24 hr. Cells were then split and the media changed every day 
for up to a week, after which time the cells began to proliferate again. 
Wild type Abin1, Abin1wt/D485N and Abin1D485N/D485N (cell lines 3B) MEFs were 
spontaneously immortalised by serial passage. Freshly isolated primary MEFs were 
simply passaged until they stopped proliferating. The media was then changed every 
two or three days for up to six weeks until the MEFs overcame senescence. 
Immortalised cells were identified when they began to proliferate rapidly and 
by their cellular morphology. Primary or arrested MEFs had large, spherical shapes 
with much cytoplasm (Fig 6-7, upper panel). Immortalised cells were generally more 
extended with larger nuclei to cytoplasm ratios (Fig 6-7, lower panel).  
 
6.2.4.2 SV40-immortalised ABIN1-deficient MEFs proliferate at the same rate as 
their corresponding wild type MEFs 
To study the DNA damage response, and to avoid conclusions based on cells 
with different basal cellular responses, it was necessary to acquire cell lines that 
proliferated at the same rate. Thus growth curves based on MTS assays were used to 
analyse the proliferation rates of immortalised MEFs.  
SV40-immortalised (cell lines 3A) ABIN1-deficient MEFs and their 
corresponding wild type MEFs were allowed to proliferate for up to 6 days with an 
MTS assay being performed every 24 hr. The absorbency of Abin1D485N/D485N (cell line 
3A) MEFs increased over time at the same rate as the absorbency of wild type (cell 
line 3A) MEFs (Fig 6-8A). The absorbency of Abin1wt/D485N (cell line 3A) MEFs also 
increased over time, though at a slightly decreased rate to wild type MEFs.  
The growth curves of spontaneously-immortalised (cell lines 3B) MEFs were 
also analysed using MTS assay. The absorbency of Abin1D485N/D485N (cell line 3B) 
MEFs increased over time, but at a somewhat diminished rate compared to their  
Wild type
Primary MEFs
SV40 transformed MEFs
Abin1D485N/D485N Abin1Wild type/D485N 
Figure 6-7 Pre- and post-immortalisation ABIN1 MEFs display morphological 
dierences
Wild type Abin1, Abin1wt/D485N and Abin1D485N/D485N (cell lines 3A) MEFs were immortalised 
by Simian virus 40 (SV40) transformation. Cells were imaged pre- and post-
immortalisation and representative images from at least two dierent days are shown.
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Figure 6-8 SV40-immortalised ABIN1-decient MEFs proliferate at the same rate as 
their corresponding wild type MEFs
A) Abin1D485N/D485N (cell line 3A), Abin1wild type/D485N (cell line 3A), and their corresponding wild 
type (cell line 3A) MEFs were seeded in triplicate at a density of 2000 cells/well in multiple 
96 well plates, in a nal volume of 100 µl. An MTS assay was performed immediately after 
seeding and every subsequent 24 hr. The experiment was repeated at least three times 
and error bars represent SEM. B) The experiment was repeated in the same manner but 
with Abin1D485N/D485N (cell line 3B), Abin1wild type/D485N (cell line 3B) MEFs and their correspond-
ing wild type (cell line 3B) MEFs.
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corresponding wild type (cell line 3B) cells (Fig 6-8B). Similarly, the absorbency of 
Abin1wt/D485N (cell line 3B) MEFs also increased over time, but again at a reduced rate 
compared to wild type (cell line 3B) cells. 
Thus, SV40-immortalised ABIN1-deficient MEFs proliferate at the same rate 
as their corresponding wild type cells, while spontaneously-immortalised ABIN1-
deficient MEFs grow more slowly than their wild type controls. Therefore, SV40-
immortalised MEFs were considered more reliable tools for the study of ABIN1’s 
function alone and used in subsequent ABIN1 investigations. The spontaneously-
immortalised ABIN1-deficient MEFs were used to confirm some of the phenotypes 
and later results.  
 
6.2.4.3 Abin1-/- MEFs express a truncated form of ABIN1 
To further study the role ABIN1 may play in the ICL response, we obtained 
SV40-immortalised Abin1-/- MEFs from the lab of Averil Ma. Exons 12 – 15 have 
been removed from the Abin1 gene in these MEFs [143] and this mutation was 
reported to eliminate full length ABIN1. To assess whether ABIN1 is expressed in 
these MEFs, Abin1-/- and their corresponding Abin1+/+ wild type MEFs were lysed 
and probed with a specific antibody against mouse ABIN1 by Western Blotting. Full 
length ABIN1 is present as a doublet in Abin1+/+ wild type lysates (Fig 6-9A). 
However, in Abin1-/- lysates the antibody recognises doublet bands of smaller 
molecular weight, indicating that a truncated form of ABIN1 is expressed in these 
cells.  
A cross reference of Abin1’s sequence with Uni-prot reveals that exons 12 – 
15 correspond to a region surrounding ABIN1’s UBAN domain. However this 
mutation also results in an out-of-frame nucleotide at the exon 11/12 boundary, and 
would therefore be expected to lead to a premature end of the protein at this point. A 
schematic of the ABIN1 protein predicted to be expressed is shown in Fig 6-9B.  
Although these MEFs are not ‘knock outs’ of full length ABIN1, the 
expression of a truncated version of ABIN1 provides an additional independent cell 
line in which to verify phenotypes observed in cells expressing point mutation ABIN1. 
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Figure 6-9 Abin1-/- MEFs express a truncated form of ABIN1
A) Abin1-/- and Abin1+/+ MEFs were lysed and analysed by Western Blotting with the indicated 
antibodies. Molecular weight was estimated using Bench Mark ladder. The experiment was 
repeated twice and representative images are shown. A) Schematic showing the predicted 
domains of the ABIN1 expressed in Abin1+/+ and Abin1-/- MEFs. AHD: ABIN homology domain, 
NBD: Nemo binding domain, LZ: leucine zipper, NES: nuclear export signal, NLS: nucelar 
localisation signal, UBAN: ubiquitin binding in ABIN and NEMO. 
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6.2.5 ABIN1-deficient MEFs are not sensitive to short term cisplatin 
or MMC treatment 
U2OS cells transfected with siABIN1 showed hypersensitivity to cisplatin in 
the siRNA screen. To confirm this result, and further investigate the role ubiquitin 
binding may play in ABIN1’s role in the ICL response, MEFs expressing ABIN1 with 
ubiquitin binding deficiencies were employed. Clonogenic survival assays (CSAs) 
were used to determine whether these MEFs are sensitive to cisplatin and MMC. Slx4-
/- MEFs are known to be sensitive to ICL inducers [93], and so were used as a positive 
control cell line.  
SV40-immortalised Abin1D485N/D485N (cell line 3A) and their corresponding 
wild type (cell line 3A) MEFs were treated with a range of cisplatin concentrations 
for 24 hr. Cells were allowed to recover for at least 7 days after which time the plates 
were stained and clones were counted. Viability values were then calculated by 
expressing the average number of colonies for each treatment as a percentage of the 
average vehicle treatment value for that cell line. As expected, SV40-immortalised 
Slx4-/- (3) MEFs show dose dependant sensitivity to cisplatin compared to their 
corresponding wild type (5) MEFs (Fig 6-10A and B). However, the viability of 
Abin1D485N/D485N MEFs is not further reduced after cisplatin treatment compared to 
their wild type cells. Neither is there a reduction in the viability of Abin1wt/D485N MEFs 
compared to wild type MEFs with cisplatin treatment. Abin1D485N/D485N MEFs 
therefore did not appear to be hypersensitive to short-term cisplatin treatment as 
measured by CSAs. 
To determine whether these cells were resistant to cisplatin but hypersensitive 
to other ICL inducers, the CSAs were repeated with MMC treatment and a subsequent 
recovery phase. Slx4-/- MEFs again show dose dependant sensitivity to MMC 
compared to their corresponding wild type MEFs (Fig 6-10C and D). The viabilities 
of Abin1D485N/D485N and Abin1wt/D485N MEFs are not further reduced after MMC 
treatment compared to their wild type cells.  
Cumulatively, these results indicate that ABIN1-deficient MEFs do not have 
defects in the ability to develop into clones after short-term treatment with ICL 
inducers. 
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Figure 6-10 Viability is not decreased in ABIN1-decient MEFs in response to short term cisplatin 
or MMC treatment
Abin1D485N/D485N (cell line 3A), Slx4-/- (cell line 3) MEFs and their corresponding wild type  MEFs were seeded 
at a density of 1000 cells per 10 cm dish. Cells were treated in triplicate with a range of cisplatin (0 – 600 
nM) or MMC (0 – 240 nM) concentrations for 24 hr. The cells were allowed to recover for 7 – 10 days until 
colonies of at least 50 cells were present. A) and C) Plates were stained and the clones were counted. Rep-
resentative images are shown. B) and D) Viability values were calculated by expressing the average 
number of colonies for each treatment as a percentage of the average vehicle treatment value for that 
cell line. Each experiment was repeated at least twice and error bars represent SEM.
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6.2.6 ABIN1-defective MEFs are sensitive to specific genotoxins 
 
6.2.6.1 ABIN1-defective MEFs are sensitive to chronic cisplatin treatment 
siABIN1-transfected U2OS cells displayed reduced viability to cisplatin in 
luciferase-based proliferation assay during the screen. However, ABIN1-deficient 
MEFs did not exhibit increased cisplatin sensitivity in CSA assays. During the screen 
cells were treated with cisplatin and MMC for 72 hr, yet while using the CSA method 
cells were treated for 24 hr and then allowed to recover. The clonogenic survival 
assay is also dependant on a cell’s ability to form clones over a longer time, and may 
miss more subtle effects on viability at earlier time points. For these reasons, a second 
viability assay was used with ABIN1-defective MEFs to determine whether they are 
sensitive to chronic cisplatin treatment. The MTS assay described previously provides 
a relative measure of the amount of metabolic activity in a well, which thus 
corresponds to the viability of cells in question.  
SV40-immortalised Abin1D485N/D485N (cell line 3A) and their corresponding 
wild type (cell line 3A) MEFs were treated with a range of cisplatin concentrations. 
Slx4-/- MEFs, which are sensitive to cisplatin [93], were used as a positive control cell 
line. An MTS assay was performed after 72 hr of chronic treatment and metabolic 
activity was calculated for each treatment as a percentage of the vehicle treatment for 
each line. As expected, SV40-immortalised Slx4-/- (3) MEFs show dose dependant 
sensitivity to cisplatin compared to their corresponding wild type (5) MEFs (Fig 6-
11A). The metabolic activity, or viability, of Abin1D485N/D485N (cell line 3A) decreases 
more rapidly with increasing concentrations of cisplatin than their wild type cells. 
Heterozygous Abin1wt/D485N (cell line 3A) MEFs display an intermediate phenotype 
between the wild type and knock in cell lines. This indicates that cells with defective 
ABIN1 that cannot bind ubiquitin are hypersensitive to cisplatin. To further confirm 
this result and ensure that this hypersensitivity was not due secondary mutations 
acquired during the immortalisation process or subsequent passaging, two further 
ABIN1-defective MEF lines were assessed.  
Firstly, the 72 hr chronic cisplatin treatment and MTS assay were repeated 
with Abin1D485N/D485N (cell line 3B) MEFs, and their corresponding wild type (cell line 
3B) MEFs. These cells had been immortalised using an entirely different method to 
the group 3A cells; that is by serial passage or spontaneous immortalisation. It was  
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Figure 6-11 ABIN1-decient MEFs are sensitive to chronic cisplatin treatment 
A) Abin1D485N/D485N (cell line 3A), Abin1wild type/D485N (cell line 3A), Slx4-/- (cell line 5) and their 
corresponding wild type  MEFs were seeded at a density of 2000 cells/well in a 96 well 
plate. Cells were treated in triplicate with a range (0 – 10 µM) of cisplatin concentrations 
for 72 hr. An MTS assay was performed and metabolic activity values were calculated for 
each well as a percentage of the vehicle treatment for each line. The experiments were 
repeated at least three times and error bars represent SEM. B) As A) except that 
Abin1D485N/D485N (cell line 3B), Abin1wild type/D485N (cell line 3B) MEFs and their corresponding 
wild type (cell line 3B) MEFs were used. C) As A) except that Abin1-/-, Slx4-/- MEFs and their 
corresponding wild type MEFs were used.
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not possible to obtain a spontaneously-immortalised Slx4-/- cell line with a 
corresponding wild type, thus there was no reliable positive control included for these 
cells. Despite this, Abin1D485N/D485N (cell line 3B) MEFs show decreased viability at 
higher concentrations of cisplatin than their wild type cells (Fig 6-11B). Similarly to 
the SV40 immortalised lines, heterozygous Abin1wt/D485N (cell line 3B) MEFs display 
an intermediate phenotype between the wild type and knock in viabilities.  
Despite their different immortalisation methods, both the cell line 3A and 3B 
Abin1D485N/D485N MEFs were derived from the same original primary MEF clone and 
Abin1D485N/D485N mouse. Thus, to further confirm the sensitivity of ABIN1-deficient 
cells to cisplatin, SV40-immortalised Abin1-/- MEFs were obtained from the Averil 
Ma lab. These cells were also treated with a range of cisplatin concentrations for 72 hr 
and tested for cisplatin sensitivity using an MTS assay. Abin1-/- MEFs likewise 
display a greater reduction in viability after cisplatin treatment than their wild type 
cells (Fig 6-11C). 
Thus, as established by MTS assay, ABIN1-deficient MEFs are hypersensitive 
to chronic cisplatin treatment. 
 
6.2.6.2 ABIN1-defective MEFs are sensitive to chronic MMC treatment 
To determine whether ABIN1-deficient MEFs are also hypersensitive to other 
ICL-inducers, the metabolic activity, and hence viability, of these cells was assessed 
after exposure to MMC.  
ABIN1-deficient and their corresponding wild type MEFs were treated with a 
range of MMC concentrations. Slx4-/- MEFs that are sensitive to ICL inducers [93] 
were used as a positive control cell line. An MTS assay was performed after 72 hr of 
chronic treatment and metabolic activity was again calculated as a percentage of the 
vehicle treatment for each line. Throughout these experiments SV40-immortalised 
Slx4-/- (3) MEFs were more sensitive to MMC than their corresponding wild type (5) 
(Fig 6-12A and C). SV40-immortalised Abin1D485N/D485N (cell line 3A) MEFs show 
decreased viability at higher concentrations of MMC compared to their wild type cells 
(Fig 6-12A). Likewise, the viability of spontaneously-immortalised Abin1D485N/D485N 
(cell line 3B) MEFs decreases in a more rapid dose-dependant manner than wild type 
(cell line 3B) MEFs (Fig 6-12B). Furthermore, Abin1-/- MEFs are more sensitive to 
MMC than their wild type cells at lower concentrations, although as the wild type 
cells succumb to higher concentrations this difference is diminished (Fig 6-12C).  
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Figure 6-12 ABIN1-decient MEFs are sensitive to chronic MMC treatment 
A) Abin1D485N/D485N (cell line 3A), Abin1wild type/D485N (cell line 3A), Slx4-/- (cell line 5) and 
their corresponding wild type  MEFs were seeded in triplicate at a density of 2000 
cells/well in a 96 well plate. Cells were treated with a range (0 – 5 µM) of MMC 
concentrations for 72 hr. An MTS assay was performed and metabolic activity 
values were calculated for each well as a percentage of the vehicle treatment for 
each line. The experiments were repeated at least three times and error bars repre-
sent SEM. B) As A) except that Abin1D485N/D485N (cell line 3B), Abin1wild type/D485N (cell line 
3B) MEFs and their corresponding wild type (cell line 3B) MEFs were used. C) As A) 
except that Abin1-/-, Slx4-/- MEFs and their corresponding wild type MEFs were used.
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Thus, as established by MTS assay ABIN1-deficient MEFs are hypersensitive 
to chronic MMC treatment. 
 
6.2.6.3 ABIN1-defective MEFs are sensitive to IR 
ABIN1-deficient MEFs are hypersensitive to cisplatin and MMC. Although 
many of the recognition and repair stages of the DNA damage response can depend 
on the type of DNA lesion involved, some downstream cellular responses are similar 
or shared. By determining whether ABIN1-deficient cells are sensitive to other types 
of DNA damage it may be possible to estimate whether ABIN1 acts in a specific ICL 
response mechanism or a more general DDR pathway. Therefore, ABIN1-deficient 
MEFs were also assessed for sensitivity to other genotoxins.  
To assess whether ABIN1-deficient MEFs are sensitive to IR, ABIN1-
deficient and their corresponding wild type MEFs were treated with a dose range of 
IR. An MTS assay was performed after 72 hr of recovery and metabolic activity was  
calculated as a percentage of the vehicle treatment for each line. SV40-immortalised 
Abin1D485N/D485N (cell line 3A) MEFs show decreased viability at higher doses of IR 
compared to their wild type cells (Fig 6-13A). To confirm this phenotype, the 
experiment was repeated with two more ABIN1 deficient lines. The viability of 
spontaneously-immortalised Abin1D485N/D485N (cell line 3B) MEFs is also reduced in a 
more rapid dose-dependant manner than wild type (cell line 3B) MEFs (Fig 6-13B). 
Similarly, Abin1-/- MEFs are more sensitive to IR than their wild type cells with 
decreased viability at higher IR levels (Fig 6-13C). After IR treatment, heterozygous 
Abin1wt/D485N cells do not show decreased viability compared to their corresponding 
wild type MEFs, regardless of the immortalisation method (Fig A and B). 
Therefore, as established by MTS assay, ABIN1-deficient MEFs are 
hypersensitive to IR treatment. 
 
6.2.6.4 ABIN1-defective MEFs are not sensitive to chronic etoposide or HU 
treatment  
Next, ABIN1-deficient MEFs were assessed for sensitivity to etoposide and 
HU. SV40-immortalised Abin1D485N/D485N (cell line 3A) and their corresponding wild 
type (cell line 3A) MEFs were treated with a range of etoposide or HU concentrations 
for 72 hr. An MTS assay was performed and metabolic activity was calculated as a  
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Figure 6-13 ABIN1-decient MEFs are sensitive to IR
A) Abin1D485N/D485N (cell line 3A), Abin1wild type/D485N (cell line 3A)  and their corresponding wild 
type  MEFs (cell line 3A) were seeded at a density of 2000 cells/well in a 96 well plate. Cells 
were treated in triplicate with a range (0 – 8 Gy) of IR doses and allowed to recover for 72 
hr. An MTS assay was performed and metabolic activity values were calculated for each 
well as a percentage of the vehicle treatment for each line. The experiments were 
repeated at least three times and error bars represent SEM. B) As A) except that 
Abin1D485N/D485N (cell line 3B), Abin1wild type/D485N (cell line 3B) MEFs and their corresponding 
wild type (cell line 3B) MEFs were used. C) As A) except that Abin1-/- MEFs and their corre-
sponding wild type MEFs were used.
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percentage of the vehicle treatment for each line. Abin1D485N/D485N (cell line 3A) MEFs 
do not have significantly reduced viability after etoposide treatment compared to their 
corresponding wild type cells (Fig 6-14A). Similarly, the viability of Abin1D485N/D485N 
(cell line 3A) MEFs does not decrease after HU treatment compared to their 
corresponding wild type cells (Fig 6-14B). Given there was no difference in the 
sensitivity of ABIN1-deficient cells to wild type cells there was no requirement to 
repeat this phenotype with other ABIN1 deficient cell lines. 
 
6.2.7 ABIN1 levels decrease after cisplatin treatment 
ABIN1 transcription is regulated by NF-κB [212, 213, 216] and NF-κB is 
known to be activated during the DNA damage response. To determine whether 
ABIN1 levels were affected by cisplatin treatment, Abin1D485N/D485N and their wild 
type MEFs were treated with cisplatin for a range of times. Cells were lysed and 
ABIN1 levels were analysed by Western Blot. In both wild type and Abin1D485N/D485N 
MEFs ABIN1 levels initially decreased and then reappeared after cisplatin treatment 
(Fig 6-15A).  
To determine whether ABIN1 is being resynthesized after cisplatin treatment, 
these cells were treated with cycloheximide (CHX) and cisplatin, and the experiment 
repeated. On treatment with CHX and cisplatin, ABIN1 levels decreased and were not 
re-instated in both wild type and Abin1D485N/D485N cells (Fig 6-15B).  
 
6.2.8 DNA damage checkpoint activation and repair responses are 
normal in ABIN1-deficient cells 
6.2.8.1 ABIN1-deficient cells exhibit minor differences in cisplatin-induced 
ATM/ATR-mediated cell cycle signalling 
After DNA damage, cell cycle checkpoints are activated, leading to cell cycle 
arrest. This allows the cells to repair the damaged DNA or, if the damage is too great, 
cells can undergo apoptosis. The reduced viability observed in ABIN1-deficient cells 
after cisplatin treatment may have been due to defective checkpoint responses, 
prolonged cell cycle arrest, delayed DNA repair or increased programmed cell death. 
Abin1D485N/D485N MEFs can recover from short-term ICL treatment, yet are less 
capable of proliferation after chronic ICL treatment. Furthermore, ABIN1 is 
phosphorylated during M phase and then degraded during the transition from M to G1  
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Figure 6-14 ABIN1-decient MEFs are not sensitive to chronic HU or etoposide 
treatment 
Abin1D485N/D485N (cell line 3A), Abin1wild type/D485N (cell line 3A) and their corresponding wild 
type  MEFs were seeded at a density of 2000 cells/well in 96 well plates. Cells were treated 
in triplicate with a range of A) etoposide (0 – 5 µM) and B) HU (0 – 100 µM) concentrations 
for 72 hr. MTS assays were performed and metabolic activity values were calculated for 
each well as a percentage of the vehicle treatment for each line. The experiments were 
repeated at least three times and error bars represent SEM.
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Figure 6-15 ABIN1 levels decrease after cisplatin treatment
A) Abin1D485N/D485N (cell line 3A) and wild type (cell line 3A) MEFs were vehicle 
treated or treated with 2 µM cisplatin for the indicated time. Cells were lysed 
and protein extracts were analysed by Western Blotting with the indicated anti-
bodies. The experiments were repeated four times and a representative image 
is shown. B) As (A) except that cells were vehicle treated or treated with 2 µM 
cisplatin and 10 µg/ml CHX for the indicated time, and the experiment was 
repeated twice.
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[210]. Thus to identify whether ABIN1 may act in cell cycle responses after ICL 
induction, regulators of the cell cycle were analysed in ABIN1-deficient cells. On 
recognition of DNA damage signalling molecules such as ATM and ATR can 
phosphorylate checkpoint kinases Chk2 and Chk1, leading to activation of a DNA 
damage-induced checkpoint response. Phosphorylation of these proteins can therefore 
be used as markers of efficient DNA damage-induced checkpoint activation. 
Mock-transfected and siABIN1-transfected U2OS cells, and wild type and 
Abin1D485N/D485N MEFs, were treated with cycloheximide (CHX) and cisplatin for 
varying times. Cells were lysed and analysed by Western Blot with specific antibodies 
against pChk1[S345], pChk2[T68] (U2OS only) and pSMC1[S966] (U2OS only). In 
U2OS cells pChk1 levels appear somewhat increased in siABIN1 cells after 6 hr of 
cisplatin treatment compared to mock transfected cells (Fig 6-16A). In siABIN1 
U2OS cells pChk2 and pSMC1 levels peak after 12 hr cisplatin treatment, while in 
mock transfected cells they peak after 24 hr. Abin1D485N/D485N MEFs display a modest 
increase in pChk1 levels compared to wild type cells, particularly after 3 and 6 hr of 
cisplatin treatment (Fig 6-16B). However, basal pChk1 levels are also increased in 
Abin1D485N/D485N MEFs compared to wild type MEFs without any treatment, which 
may account for overall increases in pChk1 levels. Thus both human and mouse 
derived ABIN1-deficient cells display minor differences in cisplatin-induced 
checkpoint markers compared to their corresponding control cells, implying that there 
may be a modest defect in ICL-induced ATM/ATR-mediated checkpoint signalling in 
these cells. 
 
6.2.8.2 Cisplatin-induced FANCD2 ubiquitination is normal in ABIN1-deficient 
cells 
As ABIN1-deficient cells display only minor defects in checkpoint markers, it 
was possible that defects in DNA repair were contributing to reduced viability in 
these cells. After induction of an ICL, damage is recognised by the Fanconi Anaemia 
core complex (FACC) [178]. This E3 ligase monoubiquitinates FANCD2 and FANCI, 
which consequently co-localise with and recruit downstream repair factors. The 
ubiquitination of FANCD2 can therefore be used as a marker for the effective 
activation of ICL repair signalling, and ABIN1-deficient cells were assessed for 
defects in this indicator after cisplatin treatment.  
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Figure 6-16 ABIN1-decient cells exhibit minor dierences in cisplatin-induced 
ATM/ATR-mediated checkpoint signalling
A) U2OS cells were mock transfected or transfected with siABIN1. After 36 hr cells 
were vehicle treated or treated with 10 µg/ml CHX and 5 µM cisplatin for the indi-
cated time. B) Abin1D485N/D485N (cell line 3A) MEFs, along with their corresponding wild 
type cells, were vehicle treated or treated with 10 µg/ml CHX and 2 µM cisplatin for 
the indicated time. Cells were lysed and protein extracts were analysed by Western 
Blotting with the indicated antibodies. Representative images are shown from two 
independent experiments.
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siABIN1-transfected U2OS cells and Abin1D485N/D485N MEFs, along with their 
control cell lines, were treated with cisplatin for varying times. Cells were lysed and 
the monoubiquitinated and non-ubiquitinated forms of FANCD2 were detected by 
Western Blot with a specific antibody against FANCD2. The intensities of these 
bands were quantified and the ratio of ubiquitinated FANCD2 to non-ubiquitinated 
FANCD2 was calculated for each sample. After 24 hr and 48 hr of cisplatin treatment 
FANCD2 ubiquitination is increased in both mock- and siABIN1-transfected cells 
(Fig 6-17A). The ratio of ubiquitinated FANCD2 (Ub-FANCD2) to non-ubiquitinated 
FANCD2 is moderately reduced in siABIN1-transfected cells, however this is not 
statistically significant at any timepoint (Fig 6-17B). Likewise, after 12, 24 hr and 48 
hr of cisplatin treatment FANCD2 ubiquitination is increased in wild type and 
Abin1D485N/D485N MEFs (Fig 6-17C). There is also no statistically significant difference 
between the Ub-FANCD2/FANCD2 ratios of ABIN1-deficient MEFs and their 
corresponding control cells (Fig 6-17D). Thus, cisplatin-induced FANCD2 
ubiquitination is normal in ABIN1-deficient cells, and the ICL response is activated 
as usual in these cells. 
 
6.2.8.3 Cisplatin-induced γH2AX foci are normal in ABIN1-deficient cells 
The co-localisation of DDR factors at sites of damage results in the formation 
of DNA damage foci which mediate DNA repair. During this process the histone 
H2AX is phosphorylated, an action that is reversed once damage has been resolved. 
Thus the induction and subsequent resolution of γH2AX foci can be used as a marker 
for the effective repair of ICLs and this indicator was used to assess ABIN1-deficient 
cells for defects in the repair of cisplatin-induced damage.  
siABIN1-transfected U2OS cells and Abin1D485N/D485N MEFs, along with their 
control cell lines, were treated with cisplatin for 2 hr before being allowed to recover 
for the indicated time. Cells were fixed, stained with anti-γH2AX and imaged. The 
percentage of γH2AX foci-positive cells was calculated for each sample. In U2OS 
cells there are very few γH2AX foci-positive cells present immediately after cisplatin 
treatment (Fig 6-18A and B). After 24 hr of recovery the number of γH2AX foci-
positive mock-transfected cells increases, and then decreases over time. Likewise in 
siABIN1-transfected cells a similar trend is observed. Similar to U2OS cells, the 
percentage of wild type MEFs with foci initially increases after 24 hr recovery, and  
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Figure 6-17 Cisplatin-induced FANCD2 ubiquitination is normal in ABIN1 decient cells 
A) U2OS cells were mock transfected or transfected with siABIN1. After 36 hr cells were vehicle 
treated or treated with 5 µM cisplatin for the indicated time. C) Abin1D485N/D485N (cell line 3A) and 
their corresponding wild type MEFs were vehicle treated or treated with 2 µM cisplatin for the 
indicated time. Cells were lysed and protein extracts were analysed by Western Blotting with the 
indicated antibodies. B) and D) FANCD2 band intensities were quantied and the ratio of ubiquit-
inated FANCD2 to non-ubiquitinated FANCD2 was determined for each sample. Representative 
images are shown from, and quantication represents, at least two independent experiments. 
Error bars indicate SEM. Data was statistically analysed by ANOVA followed by multiple compari-
sons to calculate signicance.
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Figure 6-18 Cisplatin-induced γH2AX foci are normal in ABIN1-depleted cells
U2OS cells were mock transfected or transfected with siABIN1. After 36 hr cells were 
treated with 8 µM cisplatin for 2 hr before being allowed to recover in fresh medium for 
the indicated time. A) Cells were xed and stained with anti-γH2AX before being analysed 
by microscopy. B) The percentage of γH2AX foci-positive cells was calculated for each 
sample; cells with 10 or more foci were classed as ‘positive’ cells. Representative images are 
shown from, and quantication represents, three independent experiments. White scale 
bars represent 30 µm and error bars indicate SEM. Data was statistically analysed by 
ANOVA followed by multiple comparisons to calculate signicance.
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Figure 6-19 Cisplatin-induced γH2AX foci are normal in ABIN1-decient MEFs
Abin1D485N/D485N (cell line 3A) and their corresponding wild type MEFs were treated with 8 
µM cisplatin for 2 hr before being allowed to recover in fresh medium for the indicated 
time. A) Cells were xed and stained with anti-γH2AX before being analysed by micros-
copy. B) The percentage of γH2AX foci-positive cells was calculated for each sample; cells 
with 10 or more foci were classed as ‘positive’ cells. Representative images are shown from, 
and quantication represents, three independent experiments. White scale bars represent 
30 µm and error bars indicate SEM. Data was statistically analysed by ANOVA followed by 
multiple comparisons to calculate signicance.
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then decreases over time (Fig 6-19A and B). There are also no significant differences 
in the percentage of γH2AX positive Abin1D485N/D485N cells compared wild type cells 
at any time point. Thus induction and resolution of cisplatin-induced γH2AX foci is 
normal in ABIN1-deficient cells.  
 
These results imply that the ICL response is initiated, proceeds and is 
completed regardless of deficiencies in ABIN1’s protein levels or ability to bind 
ubiquitin.  
 
6.2.9 Cisplatin-induced apoptosis is increased in ABIN1-deficient 
cells 
DNA damage checkpoint activation and repair responses are mostly 
functioning in ABIN1-deficient cells. A further reason for the hypersensitivity to 
cisplatin of ABIN1-deficient cells could be increased cell death after cisplatin 
treatment. It is also known that ABIN1 has a protective role against TNF-induced 
apoptosis [143, 198]. To determine whether ABIN1 plays a similar role in protecting 
cells against cisplatin-induced apoptosis, ABIN1-deficient cells were assessed for 
increases in apoptotic markers.  
 
6.2.9.1 Cisplatin-induced cleaved caspase-3 levels are increased in ABIN1-
deficient cells 
Upstream signalling during the apoptotic response leads to the cleavage of 
effector caspases such as caspases-3 and -7, thereby activating them. To determine 
whether ABIN1 deficiencies lead to increased cisplatin-induced cell death, cleaved 
caspase-3 levels were used as a marker for increased apoptosis. 
siABIN1-transfected U2OS cells, Abin1D485N/D485N MEFs, Abin1-/- MEFs and 
their corresponding control cells were treated with cisplatin for 0, 24 or 48 hr. Cells 
were lysed and analysed by Western Blot with a specific antibody against the cleaved 
form of caspase-3. U2OS cells transfected with siABIN1 have higher levels of basal 
cleaved caspase-3 levels compared to mock-transfected U2OS cells (Fig 6-20A). With 
increased treatment time caspase-3 is cleaved to a far greater extent in siABIN1 cells 
than mock-transfected cells, with the difference being most prominent after 48 hr  
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Figure 6-20 Cisplatin-induced cleaved caspases-3 levels are increased in 
ABIN1 decient cells 
A) U2OS cells were mock transfected or transfected with siABIN1. After 36 hr 
cells were vehicle treated or treated with 5 µM cisplatin for the indicated time. 
B) Abin1D485N/D485N (cell line 3A) and C) Abin1-/- MEFs, along with their correspond-
ing wild type MEFs, were vehicle treated or treated with 2 µM cisplatin for the 
indicated time. Cells were lysed and protein extracts were analysed by Western 
Blotting with the indicated antibodies. The experiments were repeated at least 
three times and representative images are shown.
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treatment. Likewise, cleaved caspsae-3 levels are greatly increased in Abin1D485N/D485N 
MEFs compared to wild type MEFs, particularly after 48 hr cisplatin treatment (Fig 6-
20B). In Abin1-/- MEFs cleaved caspase-3 levels are increased after 24 and 48 hr 
cisplatin treatment (Fig 6-20C). However this does not represent an escalation 
compared to their corresponding wild type, as Abin1+/+ levels are also greatly 
increased after cisplatin treatment. Due to the higher levels of cleaved caspase-3 in 
these wild type cells it may be difficult to identify increases due to ABIN1 
deficiencies. 
 
6.2.9.2 Cisplatin-induced caspase-3/7 activity is increased in ABIN1-deficient 
cells 
To implement apoptosis effector caspases such as caspases-3 and -7 are 
required to be activated by the removal of their prodomain. Once activated they act as 
proteases themselves to activate downstream targets and dismantle the cell. To 
determine whether the increased levels of cleaved caspase-3 observed in ABIN1 
deficient cells corresponded with increased caspase-3/7 activity, a Caspase-Glo assay 
was used. HOIP has a protective effect against cisplatin-induced apoptosis, and 
caspase-3/7 activity is increased after cisplatin treatment in siHOIP-transfected U2OS 
cells [180]. siHOIP was therefore used as a positive control for Caspase-Glo assays 
with U2OS cells. 
siABIN1-transfected U2OS cells, Abin1D485N/D485N MEFs and their control 
cells were treated with cisplatin as indicated in Fig 6-21. MTS and Caspase-Glo 3/7  
assays were performed and the caspase-3/7 activity was normalised to relative cell 
numbers, as determined by MTS assay. The fold increase in caspase-3 activity was 
calculated over the vehicle treated wells for the mock or wild type cells as appropriate. 
In response to cisplatin siHOIP-transfected cells show significantly enhanced caspase-
3 activity compared to mock-transfected cells in a dose and time dependant manner 
(Fig 6-21A and B). Caspase-3 activity is similarly enhanced in siABIN1-transfected 
cells compared to mock-transfected cells. Likewise, upregulation of caspase-3 activity 
is greater in Abin1D485N/D485N MEFs than wild type MEFs at higher doses of cisplatin 
treatment (Fig 6-21C and D). 
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Figure 6-21 Cisplatin-induced caspase-3/7 activity is increased in ABIN1-decient 
cells
U2OS cells were reverse mock transfected or transfected with siABIN1 or siHOIP in 
duplicate 96 well plates. Cells were treated with 0, 5 or 10 µM cisplatin for 24 hr (A) or 48 
hr (B). Abin1D485N/D485N (cell line 3A) and wild type (cell line 3A) MEFs were seeded in two 
96 well plates and treated in triplicate with 0, 2 or 5 µM cisplatin for 24 hr (C) or 48 hr (D). 
MTS and Caspase-Glo 3/7 Assay reagents were added to the appropriate plate and read 
as appropriate. Caspase-Glo 3/7 luminescence values were normalised to MTS viability 
data. The fold increase in activity over the vehicle treated wells for each siRNA/cell line 
was calculated for each treatment. The experiments were independently repeated 
three times and error bars represent SEM. Data was statistically analysed by ANOVA 
followed by multiple comparisons to calculate signicance with * indicating signicant 
dierences. 
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6.2.9.3 siABIN1-resistant line also exhibits increased cisplatin-induced cleaved 
caspase-3 
To determine whether increased levels of apoptosis seen in ABIN1-deficient 
cells are also seen when ABIN1 cannot be knocked down, the GFP-ABIN1R cell line 
was used. Flp-In U2OS cells expressing GFP-ABIN1, or GFP-ABIN1 that is resistant 
to siABIN1 (GFP-ABIN1R), were mock-transfected or siABIN1-transfected and 
protein expression was induced. Cells were treated with cisplatin, lysed and cleaved 
caspase-3 levels were analysed by Western Blotting. After siABIN1-transfection, both 
basal and cisplatin-induced cleaved caspase-3 levels are increased in GFP-ABIN1 
expressing cells (Fig 6-22), confirming the phenotype seen before. However, similar 
basal and cisplatin-induced levels of cleaved caspase-3 are also seen in GFP-ABIN1R 
expressing cells after siABIN1 transfection. Therefore a cell line with siABIN1-
resistant ABIN1 expression is not capable of rescuing the phenotype of increased 
cisplatin-induced cleaved caspase-3 levels after siABIN1 transfection.  
 
6.2.10 Dissection of apoptotic signalling in ABIN1-deficient cells 
To determine which apoptotic signalling pathways are activated in ABIN1-
deficient cells a dissection of upstream apoptosis pathways was initiated.  
 
6.2.10.1 Activities of cisplatin-induced caspase-8 and -9 are increased in ABIN1-
deficient cells 
Effector caspases such as caspase-3 and -7 are activated by initiator caspases 
such as caspase-8 and -9. These caspases are themselves activated by different 
upstream apoptotic signalling pathways. To determine whether ABIN1 is involved in 
inhibiting apoptosis upstream of caspase-3 cleavage, and to identify which, if any, 
upstream pathways may be activated in ABIN1 deficient cells, caspase-8 and -9 
activities were assessed after cisplatin treatment. 
siABIN1-transfected U2OS cells, Abin1D485N/D485N MEFs and their control 
cells were treated with cisplatin as indicated in Fig 6-23. MTS and Caspase-Glo 3/7 
assays were performed and the caspase-8 and -9 activities were normalised to relative 
cell numbers, as determined by MTS assay. The fold increase in caspase activity was 
calculated over the vehicle treated wells for the mock or wild type cells as appropriate.  
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Figure 6-22 Cisplatin-induced cleaved caspase-3 levels are also 
increased in an siABIN1-resistant line 
Flp-In U2OS cells expressing GFP-ABIN1, or GFP-ABIN1 that is resistant to 
siABIN1 (GFP-ABIN1R), were mock reverse-transfected or reverse-
transfected with siABIN1. After 6 - 8 hr tetracycline was added to a nal 
concentration of 10 ng/ml for GFP-ABIN1 cells and 100 ng/ml for GFP-
ABIN1R cells. Cells were incubated overnight before being vehicle treated 
or treated with 5 µM cisplatin for 48 hr. They were then lysed and protein 
extracts were analysed by Western Blotting with the indicated antibodies. 
Representative images from two independent experiments are shown.
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Figure 6-23 Cisplatin-induced caspase-8 and -9 activities are increased in ABIN1-
decient cells 
A) and B) U2OS cells were reverse mock transfected or transfected with siABIN1 or siHOIP 
in duplicate 96 well plates. Cells were treated with 0, 5 or 10 µM cisplatin for 48 hr. C) and 
D) Abin1D485N/D485N (cell line 3A) and wild type (cell line 3A) MEFs were seeded in two 96 well 
plates and treated in triplicate with 0, 2 or 5 µM cisplatin for 48 hr. MTS and Caspase-Glo 8 
or 9 Assay reagents were added to the appropriate plate and read as appropriate. 
Caspase-Glo luminescence values were normalised to MTS viability data. The fold increase 
in activity over the vehicle treated wells for the mock or wild type was calculated for each 
treatment. The experiments were independently repeated three times and error bars 
represent SEM. Data was statistically analysed by ANOVA followed by multiple compari-
sons to calculate signicance with * indicating signicant dierences. 
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siHOIP-transfected cells show significantly enhanced caspase-8 and 9 activity 
compared to mock-transfected cells when treated with 10 µM cisplatin (Fig 6-23A 
and B). Similarly, caspase-8 and 9 activities are increased in siABIN1-transfected 
cells compared to mock-transfected cells. In MEFs cisplatin-induced caspase-8 and 9 
activities increase in a dose and time dependant manner (Fig 6-23C and D). However, 
this increase is significantly enhanced in Abin1D485N/D485N MEFs compared to wild 
type MEFs at 5 µM cisplatin.  
Thus, cisplatin-induced caspase-8 and -9 activities are both increased in 
ABIN1-deficent cells. 
 
6.2.11 Simultaneous knockdown of ABIN1 and HOIP does not 
increase sensitivity to cisplatin compared to transfection with 
siHOIP alone 
Cells transfected with siABIN1 and siHOIP display similar phenotypes of 
hypersensitivity to cisplatin and increased cisplatin-induced apoptosis. HOIP is the 
catalytic component of LUBAC, the multi-subunit E3 ligase required for creating 
linear ubiquitin chains [22], and ABIN1 is capable of binding linear chains [28]. It is 
possible that ABIN1 and HOIP may act in the same pathway to inhibit apoptosis in 
response to cisplatin, with ABIN1 perhaps recognising linear chains created by HOIP. 
To test this hypothesis, sensitivity to cisplatin and cisplatin-induced apoptosis were 
tested in cells with a double siABIN1/siHOIP transfection. 
 
6.2.11.1 Simultaneous knockdown of ABIN1 and HOIP does not decrease 
viability of U2OS cells compared to transfection with siHOIP alone 
To determine whether a co-transfection of siABIN1 with siHOIP could further 
sensitise U2OS cells to cisplatin, their viability was analysed using relative metabolic 
activity as a measure of sensitivity.  
U2OS cells were mock transfected or transfected with siABIN1 alone, siHOIP 
alone or siABIN1 and siHOIP together. Cells were vehicle treated or treated with 10 
µM cisplatin and an MTS assay was performed to assess the effect on cellular 
metabolism and hence viability. Metabolic activity after each treatment was 
calculated as a percentage of the vehicle treatment well for each siRNA. Transfection 
with siABIN1 and siHOIP separately decreased the viability of U2OS cells by a 
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statistically significant amount compared to mock-transfected cells (Fig 6-24A and B), 
as previously seen. Transfection with siABIN1 and siHOIP together 
(siABIN1+siHOIP) also decreased their viability by a statistically significant amount 
compared to mock-transfected cells. However this double transfection did not cause a 
further statistically significant decrease in viability compared to transfection with 
siHOIP alone. When compared to transfection with siABIN1 alone, the decrease was 
just outside the range of statistical significance (p = 0.058). Thus simultaneous 
knockdown of ABIN1 and HOIP does not further decrease the viability of U2OS cells 
compared to either transfection alone. 
 
6.2.11.2 Simultaneous knockdown of ABIN1 and HOIP does not increase 
cisplatin-induced apoptosis compared to transfection with siHOIP alone 
To further study whether ABIN1 and HOIP act in a common apoptotic 
pathway, apoptotic markers were analysed. 
U2OS cells were mock transfected or transfected with siABIN1 alone, siHOIP 
alone or siABIN1 and siHOIP together (siABIN1+siHOIP). Cells were vehicle treated 
or treated with 5 µM cisplatin, lysed and their cleaved caspase-3 levels were analysed 
via Western Blot. The protein levels of both ABIN1 and HOIP are clearly reduced in 
the siABIN1+siHOIP-transfected cells, indicating efficient simultaneous knockdown 
(Fig 6-25A). Interestingly, ABIN1 protein levels are further decreased after cisplatin 
treatment with siHOIP-transfection compared to mock-transfection. As previously 
seen, cleaved caspase-3 levels are increased in siABIN1- and siHOIP-transfected cells 
after cisplatin treatment. There was a further minor increase in cleaved caspase-3 
levels in cells transfected with both siABIN1 and siHOIP compared to cells 
transfected with either siRNA alone. However, due to technical difficulties obtaining 
protein from these cells it was difficult to obtain reliable caspase-3 Western Blots of 
these samples. 
Therefore, Caspase-Glo 3/7 assays were used as a second method to verify 
whether apoptosis is increased in cells transfected with both siABIN1 and siHOIP. 
U2OS cells were again mock transfected or transfected with siABIN1 alone, siHOIP 
alone or siABIN1 and siHOIP together. Cells were vehicle treated or treated with 
cisplatin and MTS and Caspase-Glo 3/7 assays were performed to assess the effect on 
caspase-3/7 activity. Caspase-Glo luminescence values were normalised to MTS data 
and activity was presented as a fold increase of the cisplatin-treated well over the  
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Figure 6-24 Simultaneous knockdown of ABIN1 and HOIP does not 
decrease viability of U2OS cells compared to transfection with 
siHOIP alone
U2OS cells were reverse mock transfected or transfected with siABIN1 
and/or siHOIP in duplicate 96 well plates. Cells were vehicle treated or 
treated with 10 µM cisplatin in triplicate for 48 hr. An MTS assay was 
performed and A) metabolic activity values for each treatment were 
calculated as a percentage of the vehicle treatment well for each siRNA. 
The experiment was independently repeated three times and error bars 
represent SEM. B) Unpaired t-tests were used to calculate signicance and 
p values are presented in the table. P values of <0.05 are indicated by *, 
while ** indicates p values of <0.01.
ABIN1
β-Actin
-     +    -    +     -    +    -     +Cisplatin
Cleaved caspase-3
HOIP
Moc
k siAB
IN1
siAB
IN1+
siHO
IP
siHO
IP
A)
B)
Fo
ld
 in
cr
ea
se
 c
as
pa
se
-3
/7
Mo
ck
siA
BI
N1
siH
OI
P
siA
BI
N1
+s
iH
OI
P
0
5
10
15
20
25
0 M
10 M
***
***
*
Figure 6-25 Simultaneous knockdown of ABIN1 and HOIP does not increase 
cisplatin-induced apoptosis compared to transfection with siHOIP alone
A) U2OS cells were mock transfected or transfected with siABIN1 and/or siHOIP. 
After 36 hr cells were vehicle treated or treated with 5 µM cisplatin for the indi-
cated time. Cells were lysed and protein extracts were analysed by Western Blot-
ting with the indicated antibodies. The experiment was repeated at least twice 
and a representative image is shown. B) U2OS cells were reverse mock transfected 
or transfected with siABIN1 and/or siHOIP in duplicate 96 well plates. Cells were 
vehicle treated or treated with 10 µM cisplatin in triplicate for 48 hr. MTS and 
Caspase-Glo 3/7 Assay reagents were added to the appropriate plate and read as 
appropriate. Caspase-Glo luminescence values were normalised to MTS data and 
fold increase values in caspase-3/7 activity over the mock-transfected vehicle 
treated wells were calculated. The experiment was independently repeated three 
times and error bars represent SEM. Data was statistically analysed by ANOVA 
followed by multiple comparisons to calculate signicance with * indicating 
signicant dierences. 
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mock transfection vehicle treated well. Despite a significant increase in caspase-3/7 
activity in siHOIP-transfected cells (6-25B), the addition of siABIN1 did not further 
enhance the activity of caspase-3/7 compared to transfection with siHOIP alone. 
Cumulatively, these results imply that co-transfection with siABIN1 and 
siHOIP does not increase cisplatin-induced apoptosis in U2OS cells compared to 
transfection with siHOIP alone. 
 
6.2.12 GFP-ABIN1 forms macro-molecular structures in the cytosol  
ABIN1 is predominantly found in the cytosol, but is believed to shuttle 
between the cytosol and nucleus in a crm-dependant manner [209]. To further 
investigate where and how ABIN1 may act in the cisplatin-induced ICL response, its 
subcellular localisation was analysed.  
 
6.2.12.1 Creation of GFP-ABIN1-expressing cell lines  
Microscopy is a commonly-used technique for studying the subcellular 
localisation of tagged proteins. To study ABIN1’s location, cell lines designed to 
express GFP-ABIN1, GFP-ABIN1[D472N] (human equivalent of the mouse D485N 
mutant) and GFP-ABIN1[ΔUBAN], a truncated form of ABIN1 missing the UBAN 
domain, were created (Fig 6-26A). These latter two mutants should not be able to 
bind ubiquitin. U2OS cell lines that over-expressed these proteins in a tetracycline-
inducible manner were developed using the Flp-In system as described in the 
Methods chapter. 
To assess these cell lines for GFP and ABIN1 expression, cells were treated 
with tetracycline for varying times. Cells were lysed and the protein extracts were 
analysed GFP and ABIN1 expression by Western Blotting. A previously created Flp-
In U2OS cell line that stably expressed GFP-only was used as a control line. GFP-
ABIN1 expression is induced with tetracycline treatment in a time dependant manner 
(Fig 6-26B) and plateaued after 24 hr of treatment. In lysates from the GFP-
ABIN1[ΔUBAN] cell line a protein of smaller molecular weight than ‘wild type’ 
GFP-ABIN1 is identified by the GFP and ABIN1 proteins. This was to be expected as 
this protein was designed to be form of ABIN1 truncated at the ubiquitin-binding 
domain. There was also some ‘leakiness’ in this cell line, whereby this protein is 
expressed in the absence of tetracycline. Endogenous ABIN1 is also expressed in  
0     8   16   24    0    8    16  24     0    8    16  24    0    8   16   24
GFP-A
BIN1[D
472N]
IB: GFP
IB: ABIN1
GFP-ABIN1
GFP
β-Actin
ABIN1
GFP-ABIN1
Tetracycline (hr) 
GFP-A
BIN1
GFP-
ABIN
1[∆UB
AN]
GFP-
only
Figure 6-26 Creation of GFP-ABIN1-expressing cell lines 
A) Schematic representing the GFP, GFP-ABIN1, GFP-ABIN1[D472N] and GFP-ABIN1[ΔUBAN] 
to be expressed by Flp-In U2OS cells. AHD: ABIN homology domain, NBD: Nemo binding 
domain, LZ: leucine zipper, NES: nuclear export signal, NLS: nucelar localisation signal, 
UBAN: ubiquitin binding in ABIN and NEMO. B) Flp-In U2OS cell lines designed to express 
GFP, GFP-ABIN1, GFP-ABIN1[D472N] and GFP-ABIN1[ΔUBAN] were allowed to adhere over-
night to 10 cm dishes. Cells were treated with 1 µg/ml of tetracycline for the indicated times. 
Cells were lysed and the protein extracts were analysed by Western Blotting with the indi-
cated antibodies.
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these cells lines, although its levels appear to decrease after over-expression of GFP-
ABIN1.  
 
6.2.12.2 GFP-ABIN1 forms macro-molecular structures in the cytosol  
To discover the sub-cellular localisation of ABIN1, GFP-only, GFP-ABIN1, 
GFP-ABIN1[D472N] and GFP-ABIN1[ΔUBAN] Flp-In U2OS cells were fixed and 
analysed by microscopy. GFP is localised throughout the cell in GFP-only expressing 
cells (Fig 6-27, top panel). GFP-ABIN1 forms macro-molecular structures in the 
cytosol (second panel). These aggregates do not appear to be present in the nucleus. 
GFP-ABIN1[D472N] is also found in similar complexes in the cytosol (third panel). 
However, in GFP-ABIN1[ΔUBAN]-expressing cells these bodies are not present 
(final panel), and the GFP signal is instead diffuse throughout the cytoplasm. 
 
6.2.12.3 Some GFP-ABIN1 structures co-localise with ubiquitin  
GFP-ABIN1 forms complexes in the cell, but GFP-ABIN1[ΔUBAN], which 
cannot bind ubiquitin, do not. To investigate whether the GFP-ABIN1 complexes co-
localised with ubiquitin, GFP-ABIN1-expressing Flp-In U2OS cells were fixed, 
stained with an antibody against ubiquitin, and analysed by microscopy. As 
previously seen GFP-ABIN1 localises mostly to macro-molecular structures in the 
cytosol (Fig 6-28). Ubiquitin staining is also seen in structures, which are found 
throughout the cell. Furthermore, within the cytosol some GFP-ABIN1 complexes co-
localise with some ubiquitin-containing complexes (white arrow indicates 
representative co-localised structure).  
 
6.2.12.4 GFP-ABIN1 intensity decreases after cisplatin treatment 
To determine whether cisplatin treatment had any effect on the size, shape or 
frequency of the GFP-ABIN1 structures, GFP-ABIN1 and GFP-ABIN1[ΔUBAN]-
expressing Flp-In U2OS cells were treated with cisplatin for the indicated times, fixed 
and analysed by microscopy. After both 24 hr and 48 hr cisplatin treatment, GFP-
ABIN1 forms macro-molecular structures in the cytosol that are similar to those 
formed in vehicle-treated cells (Fig 6-29). However, after 48 hr of stimulation with 
cisplatin, the intensity of the GFP signal is less, indicating that levels of GFP-ABIN1 
in the cell and/or speckles are reduced.  
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Figure 6-27 GFP-ABIN1 forms macro-molecular structures in the cytosol 
GFP-only, GFP-ABIN1, GFP-ABIN1[D472N] and GFP-ABIN1[ΔUBAN] Flp-In U2OS cells were 
seeded on coverslips and treated with 1 µg/ml of tetracycline. Cells were xed and stained 
before being analysed by microscopy. The experiment was repeated twice and a representative 
image is shown. White scale bars represent 30 µm.
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Figure 6-28 Some GFP-ABIN1 structures co-localise with ubiquitin 
GFP-ABIN1 Flp-In U2OS cells were seeded on coverslips, and treated with 1 
µg/ml of tetracycline. Cells were xed and stained before being analysed by 
microscopy. White arrows indicate representative co-localised structures. 
White scale bars represent 30 µm.
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Figure 6-29 GFP-ABIN1 intensity decreases after cisplatin treatment
GFP-ABIN1 and GFP-ABIN1[ΔUBAN] expression was induced in Flp-In U2OS 
cells with 1 µg/ml of tetracycline. Cells were treated with 10 µM cisplatin for 
24 or 48 hr before being xed, stained and analysed by microscopy. The 
experiment was repeated twice and a representative image is shown. White 
scale bars represent 30 µm. 
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Cisplatin treatment had little effect on the diffuse nature of GFP-
ABIN1[ΔUBAN] in the cytosol. GFP-ABIN1[ΔUBAN] appears to bind to the 
cytoplasmic membrane at 0 and 24 hr cisplatin treatment, and to lesser extent with 48 
hr treatment, although it is difficult to discern further details at this level of  
microscopy. 
 
Thus GFP-ABIN1 amalgamates into cytosolic structures that co-localise with 
ubiquitin. Furthermore, the intensity of GFP-ABIN1 within speckles decreases upon 
cisplatin-induced damage.  
 
6.3 Discussion 
 
After passing stringent criteria, ABIN1 was one of the top eight positive 
candidates of an siRNA screen to identify novel regulators of the cellular response to 
cisplatin. No role has yet been suggested for ABIN1 in the DNA damage response. 
However, ABIN1 is known to bind linear ubiquitin chains and we found that the 
ability of HOIP to create M1 chains is required to protect cells from cisplatin-induced 
apoptosis [180]. Thus ABIN1 was further investigated as a potential mediator of the 
ICL response. 
 
6.3.1 ABIN1 is a regulator of the response to genotoxins 
Initially ABIN1 was a validated as a regulator of the ICL response. In general 
reduction of ABIN1 protein levels correlates with increased cisplatin sensitivity. Two 
siRNA oligomers against ABIN1 (siABIN1-05 and -08) both decrease ABIN1’s 
protein levels and result in hypersensitivity to cisplatin, while one oligomer that 
inefficiently reduces ABIN1 levels fails to increase resistance to cisplatin. However, 
one oligomer (siABIN1-07) decreases ABIN1 protein but does not induce 
hypersensitivity to cisplatin in U2OS cells. ABIN1 and ABIN2 are similar in structure 
and appear to show some redundancy of function in NF-κB signalling [215]. It is 
possible they also play redundant roles in the ICL response and that siABIN1-05 and -
08 are capable of knocking down both proteins, while siABIN1-07 only reduces 
ABIN1 levels. Individual siABIN1 oligomers all show some sequence similarity to 
ABIN2 mRNA but it is not possible to predict exactly the knock down efficacy of an 
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siRNA from its sequence alone. Therefore this hypothesis should be tested by 
analysing ABIN2 protein or mRNA levels after transfection with siABIN1. 
Given this discrepancy between ABIN1 levels and cisplatin sensitivity, further 
validation of siABIN1 as an on-target siRNA was required. In a cell line that 
expresses a variant of ABIN1 that is resistant to siABIN1-08, transfection with this 
siRNA does not increase sensitivity to cisplatin. This confirms that it is the reduction 
of ABIN1 alone, and not an off-target effect, that sensitises siABIN1-transfected cells 
to cisplatin. 
ABIN1 is a ubiquitin-binding protein with no predicted catalytic domains. The 
immortalisation of Abin1D485N/D485N MEFs that express ubiquitin-binding deficient 
ABIN1 enabled the discovery that ubiquitin binding is required to allow ABIN1 
maintain resistance to cisplatin. A further Abin1-/- MEF line previously described as 
lacking full length ABIN1 [143] but actually expressing a truncated form of ABIN1, 
confirmed that disruption of ABIN1 in mouse cells leads to sensitivity to cisplatin. 
Cells expressing ABIN1 deficient in binding ubiquitin are also hypersensitive 
to MMC and IR, but not etoposide or HU. These agents can damage DNA in different 
ways, and although there is a general DDR, different types of damage can lead to 
different signalling pathways being activated. Thus ABIN1 probably acts in a 
pathway that is activated by cisplatin, MMC and IR-induced damage, but not 
etoposide or HU-induced damage. This implies that, unlike HOIP, ABIN1 may not be 
involved in a general stress response. To determine whether this is the case, ABIN1-
deficient cells could be assessed for sensitivity to non-genotoxic cell stressors. 
However, it should be noted that the sensitivity of MEFs to chronic genotoxic 
treatment was determined using MTS assays. These assays assess the relative 
metabolic activity of cells, which is used as a surrogate measure of viability of cells. 
MTS assays are thus not considered to be as reliable measures of viability as CSAs, 
which directly measure the ability of individual cells to grow into clones. CSAs were 
used to analyse the effect of short-term genotoxin treatment on Abin1D485N/D485N MEFs, 
and found that they were not hypersensitive to short-term cisplatin or MMC treatment. 
These CSA experiments should be repeated with chronic genotoxic treatment to 
confirm that the viability of ABIN1-deficient cells is reduced in response to cisplatin, 
MMC and IR. 
Furthermore, to provide final confirmation that the increased sensitivity of 
ABIN1-deficient MEFs to cisplatin treatment is due entirely to defects in ABIN1, a 
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complemented Abin1D485N/D485N+wild type MEF line could be created and analysed for 
reduced viability in response to cisplatin. 
 
6.3.2 Cisplatin-induced apoptosis is increased in ABIN1-deficient 
cells 
 
To determine why ABIN1-deficient cells are hypersensitive to chronic 
cisplatin treatment, cells were assessed for markers of the DDR, including regulators 
of the cell cycle, repair and apoptosis, in response to DNA damage.  
ABIN1-deficient cells display modest defects in cisplatin-induced 
phosphorylation of Chk1 and pChk2; modifications that help regulate the cell cycle in 
response to DNA damage. ABIN1-deficient cells should be further analysed to 
determine whether defects in cell cycle control account for reduced viability in 
response to cisplatin. For example, cisplatin-treated cells could be assessed for cell 
cycle progression and/or arrest using flow cytommetry. Furthermore, the experiments 
presented here were performed with unsynchronised cells. ABIN1 is known to be 
phosphorylated and degraded during the cell cycle [210], and thus synchronising 
ABIN1-deficient cells before cisplatin treatment may help to gain a clearer picture of 
any role ABIN1 might play in regulating the cell cycle.  
ABIN1-deficient cells exhibit no defects in markers for DNA repair such as 
cisplatin-induced FANCD2 monoubiquitination or γH2AX foci formation and 
resolution. The hypersensitivity of ABIN1-deficient cells to cisplatin is thus unlikely 
to be caused by defects or delays in the repair of ICLs, and ABIN1 is unlikely to play 
a role in regulating the repair of cisplatin-induced damage.  
Conversely, cisplatin-induced levels of cleaved caspase-3 and caspase-3/7 
activity are increased in both ABIN1-depleted U2OS cells and Abin1D485N/D485N MEFs. 
This initially implied that ABIN1 might play a role in protecting cells from cisplatin-
induced apoptosis. However, in Abin1-/- MEFs cleaved caspase-3 levels are not 
heightened compared to their wild type cells. This may be because the cleaved 
caspase-3 levels of corresponding wild type Abin1+/+ cells are already greatly 
increased after cisplatin treatment, making it hard to compare cell lines and perhaps 
masking effects due to deficiencies in ABIN1. Perhaps by analysing other markers of 
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apoptosis it might be possible to detect increases in apoptosis in these cells compared 
to their wild type cells. 
Furthermore, the perceived increase in cisplatin-induced apoptosis in ABIN1-
depleted U2OS cells and Abin1D485N/D485N MEFs is based on two measures of caspase 
activation. To further confirm this increase, additional markers for apoptosis could 
also be assessed in these cells. These might include checking cells for the 
characteristic morphological features of apoptotic cells, terminal deoxynucleotidyl 
transferase dUTP nick end labeling (TUNEL) assays, flow cytommetry in conjunction 
with propidium iodide (PI) or Annexin V staining, or analysis of Bcl-2 family 
members and PARP cleavage patterns via Western Blotting. 
Abin1-/-  MEFs are hypersensitive to cisplatin but do not exhibit increased 
cisplatin-induced cleaved caspase-3 levels compared to their wild type cells. Thus 
sensitivity to genotoxins in ABIN1-deficient cells is not necessarily due to increased 
cisplatin-induced apoptosis alone. However, given the significant increase in caspase-
3 cleavage and activity in ABIN1-depleted U2OS cells and Abin1D485N/D485N MEFs, 
apoptosis may contribute to sensitivity to cisplatin to some extent in these cells. To 
determine what, if any, contribution apoptosis has on the viability of ABIN1-deficient 
cells after genotoxic treatment, apoptosis could be inhibited using caspase inhibitors 
and the viability of cisplatin-treated cells then analysed by CSA. Other reasons for 
sensitivity such as defects in cell cycle progression, or other forms of cell death 
including necroptosis, should also be investigated. 
Further validation of the role of ABIN1 in regulating cisplatin-induced 
apoptosis was attempted using a cell line expressing siABIN1-resistant GFP-ABIN1. 
This cell line is not capable of preventing increased cisplatin-induced cleaved 
caspase-3 levels after siABIN1 transfection. Thus it is possible that increased 
apoptosis after siRNA-transfection is due to an effect other than the reduction of 
ABIN1 levels. However, Abin1D485N/D485N MEFs also show increased cisplatin-
induced apoptosis. Thus it is more likely that the GFP-ABIN1R that remains after 
endogenous ABIN1 is depleted is somehow insufficient to fulfil ABIN1’s protective 
role after cisplatin treatment. It is possible that the GFP tag on ABIN1 affects its 
conformation and/or ability to bind ubiquitin or regulators of the ICL response, thus 
preventing it from engaging in signalling and inhibiting apoptosis. This hypothesis 
could be tested by the creation of cell lines that over-express ABIN1 without any tag, 
including both siABIN1-susceptible and siABIN1-resistant proteins. 
 212 
Both caspase-8 and -9 activities are increased in ABIN1-deficient cells. Cross 
talk is possible between caspase-8 and -9-mediated apoptotic pathways, for example 
through caspase-8-mediated activation of tBid and subsequent activation of the 
intrinsic apoptotic pathway [136]. Thus it is difficult to decipher the relative 
contributions of caspase-8 and -9 activities to apoptosis in ABIN1-defective cells 
using caspase activation assays alone. To further investigate DDR-dependant 
apoptosis in ABIN1-deficient cells, specific inhibitors against caspase-8 and -9 could 
be employed. These inhibitors cannot be exploited with Caspase Glo assays as they 
quench the luminescence output signal (data not shown). However, their use could be 
optimised to assess cleaved caspase-3 levels, or sensitivity to cisplatin, in ABIN1-
deficient cells. Other upstream markers of the apoptotic response, such as Bcl-2 
family members, could also be analysed by Western Blotting to assess differences in 
apoptotic signalling between ABIN1-defective and ABIN1-competent cells. 
 
6.3.3 GFP-ABIN1 aggregates 
In GFP-ABIN1- and GFP-ABIN1[D472N]-expressing cells, GFP-ABIN1 
aggregates into macro-molecular structures in the cytosol, some of which co-localise 
with ubiquitin. GFP-ABIN1[ΔUBAN] is not capable of forming these structures and 
is mostly spread diffusely throughout the cytosol. It should be noted that over-
expression of proteins can sometimes lead to aggregation that not occur under normal 
physiological conditions. Furthermore, a previous report from Gupta et al showed that 
non-tagged but overexpressed ABIN1 is seen diffuse throughout the cytoplasm of 
HeLa cells [209], rather than constitutively found in speckles. This discrepancy could 
be due to the different cell types used – perhaps ABIN1 is differentially regulated 
depending on the signalling background of cells. However, it could also be due to an 
artefact caused by overexpression or the GFP tag fused to ABIN1. It is therefore 
imperative to verify whether endogenous ABIN1 also forms ubiquitin-associated 
speckles. To determine whether overexpression of ABIN1 affects its ability to form 
these speckles, in situ tagging of ABIN1 with a GFP tag using the CRISPR system 
could be used. Using this system ABIN1 would be expressed under its endogenous 
promoter and at endogenous levels. To determine whether the GFP tag affects 
aggregation of ABIN1, a non-tagged version of ABIN1, or one with a different tag, 
could be overexpressed. 
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The formation of these aggregates is dependant on ABIN1 having a complete 
UBAN domain, and MEFs with mutations in or removal of their UBAN domain are 
sensitive to cisplatin. Therefore GFP-ABIN1 aggregates should be further studied to 
determine whether they have a functional significance in the context of ABIN1’s role 
in the ICL response. Given that GFP-ABIN1[D472N] forms speckles, yet 
Abin1D485N/D485N (the mouse equivalent numbering) MEFs exhibit increased apoptosis, 
the formation of ABIN1 speckles may not be related to cisplatin-induced apoptosis. 
However, the composition of the speckles might be different in cells expressing ‘wild 
type’ GFP-ABIN1 and GFP-ABIN1[D472N]. Suggested experiments for studying the 
role of these speckles, such as by identifying other components of the aggregates, are 
discussed in the future work section below. 
 
6.3.4 Regulation of ABIN1 
In both human and MEF cells, ABIN1 is visible as a doublet band using 
species-specific antibodies against full length ABIN1. According to the literature, 
multiple splice variants of ABIN1 can be expressed in humans, and use of alternative 
promoters can further lead to different versions of the ABIN1 protein [217–219]. As 
both bands disappear on transfection with siABIN1 it is unlikely that one is a non-
specific band recognised by the antibody. Instead it is possible these bands represent 
two splice variants of ABIN1. However, GFP-ABIN1 is also visible as a doublet band. 
Again both bands disappear on transfection with siABIN1, indicating that they both 
represent ABIN1. As over-expression of GFP-ABIN1 is based on transfected cDNA 
we would not expect to see splice variants of this fusion protein. It is therefore 
possible that ABIN1 is subject to post-translational modifications, such as 
monoubiquitination or cleavage, which are visualised as separate ABIN1 bands. It is 
noted that as well as occurring in wild type cells, these versions of ABIN1 are visible 
in MEFs and human cells expressing ABIN1 that cannot bind ubiquitin. Thus whether 
these bands represent splice variants or PTMs, they are not affected by these 
mutations. 
It is intriguing to see that ABIN1 protein levels decrease in MEFs in response 
to cisplatin treatment as determined by Western Blotting. Furthermore, the intensity 
of GFP-ABIN1 aggregates diminishes after cisplatin treatment as observed by 
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immunofluorescence. It remains to be seen whether the aggregates are themselves 
regulated or whether their reduction is a result of the overall decrease in ABIN1 levels. 
The latter raises the possibility that ABIN1’s role in the ICL response may be 
regulated by controlling its levels. Given that ABIN1 does not contain any catalytic 
domains it would not be surprising that its function within the ICL response would be 
regulated through the availability of this protein by controlling its levels or subcellular 
localisation through protein binding or aggregation. To determine whether ABIN1 is 
actively degraded in response to cisplatin a proteasome inhibitor such as MG132 
could be used to prevent ubiquitin-dependant degradation. ABIN1 could also be 
assessed for PTMs such as ubiquitin and phosphorylation using a combination of 
immunoprecipitation and Western Blotting or mass spectrometry. Furthermore, the 
reappearance of ABIN1 levels over time is blocked by treatment with CHX. Thus 
ABIN1 may be initially degraded and later re-synthesised after cisplatin treatment. 
QRT-PCR could be used to assess the effect of cisplatin treatment on the transcription 
of ABIN1 mRNA.  
ABIN1 levels are reduced in both wild type and Abin1D485N/D485N MEFs after 
cisplatin treatment. Furthermore, GFP-ABIN1[D472N] forms cytosolic aggregates in 
a manner similar to GFP-ABIN1. Thus the ability of ABIN1 to bind ubiquitin, or at 
least the function of this residue, does not appear to be required for the regulation of 
GFP-ABIN1 aggregation or of ABIN1 levels in the context of the ICL response. 
Instead, this amino acid may be required for ABIN1 to perpetuate DDR signalling 
downstream of its own regulation.  
 
6.3.5 Open questions 
When considering cells that express the point mutation and truncated forms of 
ABIN1, discrepancies exist in both the cisplatin-induced regulation of ABIN1 and the 
cellular response to cisplatin. Point mutation Abin1D485N/D485N MEFs display increased 
apoptosis compared to wild type MEFs, yet Abin1-/- cells that express a more 
disrupted form of ABIN1 do not. Furthermore GFP-ABIN1[D472N] forms cytosolic 
aggregates in a manner similar to GFP-ABIN1, while GFP-ABIN1[∆UBAN] is found 
diffuse throughout the cytosol. Moreover, ABIN1 protein levels are reduced in 
Abin1D485N/D485N MEFs after cisplatin treatment, yet the intensity of the GFP signal is 
not reduced in GFP-ABIN1[∆UBAN]-expressing cells after cisplatin-induced damage. 
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To further explore these discrepancies, different GFP-ABIN1-expressing cells could 
be assessed by Western Blot to determine whether levels of GFP-ABIN and GFP-
ABIN1[∆UBAN] are differentially decreased after cisplatin treatment. They could 
also be analysed for sensitivity to cisplatin and for increased cisplatin-induced 
apoptosis. It is possible that the complete UBAN domain or other regions of ABIN1, 
such as the NLS or parts of the coiled-coil that are missing from the truncated forms 
of ABIN1, fulfil functions other than simply ubiquitin binding. Alternatively, removal 
of this region of the protein may affect the overall structure or stability of the protein, 
thereby affecting the function of other ABIN1 domains outside this region. 
Expression of GFP-ABIN1 missing specific amino acids of different ABIN1 domains, 
such as the NLS, could help to pinpoint the role that ABIN1’s different areas play in 
the ICL response, and in how it is regulated during this process. Furthermore, 
although Nanda et al and Oshima et al have separately shown that ABIN1 from 
Abin1D485N/D485N and Abin1-/- MEFs has diminished capacity to bind ubiquitin [28, 
143], it would be interesting to compare the ability of GFP-ABIN1[D472N] and GFP-
ABIN1[∆UBAN] to bind ubiquitin side by side.  
It should be noted that differences between the point mutation and truncated 
forms of ABIN1 are also to be seen in the literature. Abin1-/- mice die during 
embryogenesis with foetal liver apoptosis [143], while Abin1D485N/D485N mice exhibit 
an autoimmune lupus-like phenotype [28]. These mice were created on different 
genetic backgrounds, which could explain the differing phenotypes of the MEFs. 
ABIN1 may play different roles in response to cisplatin depending on the genetic or 
signalling background of a cell. Alternatively, different signals downstream of 
ABIN1’s role could change the outcome of its actions. This might lead to the 
activation of different pathways or even different types of cell death, such as 
apoptosis or necroptosis, in Abin1D485N/D485N and Abin1-/- MEFs. This should be 
assessed by looking at markers for necroptosis, and repeating the analysis of cell 
cycle markers, in Abin1-/- MEFs in response to cisplatin. 
 
ABIN1 was identified as a positive candidate of the siRNA screen, and 
subsequently shown to be a regulator of the response to cisplatin. However, several 
major questions remain as to exactly what role it plays in the ICL response. For 
example, how does ABIN1 prevent sensitivity to cisplatin, and is it involved in 
regulating cisplatin-induced apoptosis? What exactly is the role of the UBAN, or 
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other ABIN1 domains, in this process? Are ABIN1 levels regulated and if so, how 
and why? What, if any, is the function of the GFP-ABIN1 speckles?  
Although ABIN1’s role in the ICL response has only started to be explored 
and these questions remain, the results discussed in this chapter present an exciting 
new player in the ICL response.  
 
6.3.6 Future work  
Further investigation of ABIN1’s role in response to cisplatin may expand our 
knowledge of how cell viability is decreased or maintained after DNA damage. In 
addition to the experiments mentioned above for clarification of the work already 
done, the following are some suggested experiments that could be conducted to 
further investigate how ABIN1 promotes resistance to cisplatin. 
  
6.3.6.1 Dissecting the ABIN1-dependent ICL response 
ABIN1 is an inhibitor of NF-κB signalling, and NF-κB signalling can regulate 
cell death, including through Fas-mediated apoptosis [220]. NF-κB can also affect 
ABIN1 transcription [211–213], implying that feedback loops are employed in the 
regulation of these proteins. NF-κB signalling could be studied to determine whether 
it is implicated in ABIN1’s role in preventing sensitivity to cisplatin. Cisplatin-
induced IκBα degradation is normal in ABIN1-depleted cells (data not shown). This 
preliminary data indicates a robust and timely activation of the NF-κB response and 
implies that ABIN1 does not regulate the ICL response through downstream NF-κB 
signalling. However, ABIN1 protein levels appear to be regulated in response to 
cisplatin. Thus to assess whether NF-κB can regulate ABIN1’s expression and/or 
function within the DDR, a cell line in which NF-κB activation is inhibited could be 
used [180].  This cell line could be assessed for sensitivity to cisplatin and/or 
increased apoptosis when ABIN1 has been depleted to determine whether these 
phenotypes are NF-κB-dependant. QRT-PCR could also be employed using this line 
to determine whether expression of ABIN1 mRNA is affected after cisplatin treatment 
in an NF-κB-dependant manner. 
To further explore the mechanism by which ABIN1 regulates the DDR, other 
upstream regulators and signalling pathways of the ICL response could be assessed. 
To determine whether the action of kinases such as ATM, ATR, JNK and p38 are 
 217 
required for increased apoptosis in ABIN1-deficient cells, inhibitors of these 
regulators could be employed.  
 
6.3.6.2 GFP-ABIN1 speckle studies 
GFP-ABIN1 speckle signals decrease over time with cisplatin treatment, but it 
is not clear whether this corresponds to reduced speckle size or speckle number. To 
gain a further understanding of the dynamics of the GFP-ABIN1 speckles, high 
content microscopy could be used in conjunction with software that can differentiate 
between the number of aggregates per cell and the intensity per aggregate. Cells could 
also be co-stained with ubiquitin to determine whether the ubiquitin aggregates are 
also altered after cisplatin treatment. Furthermore, GFP-ABIN1[D472N] also forms 
aggregates while GFP-ABIN1[ΔUBAN] does not. To determine whether there are 
less obvious defects in the number or intensity of GFP-ABIN1[D472N] speckles 
compared to GFP-ABIN1 speckles both of these cell lines could be analysed by the 
same method. Moreover, high resolution microscopy could be used to further assess 
the structure of the speckles and/or GFP-ABIN1[ΔUBAN] localisation to the 
cytoplasmic membrane. 
Our understanding of the functional significance of the speckles would be 
aided by discovering which other components they might contain, and whether their 
composition changes in response to DNA damage. To identify proteins that ABIN1 
interacts with in the cytosolic speckles, immunoprecipitation (IP) assays could be 
used to ‘pull down’ proteins that bind to ABIN1 before and after cisplatin treatment. 
The GFP-ABIN1[∆UBAN] cell line could be used to identify interactors that are 
missing when ABIN1 does not form aggregates. IP products could be probed to 
identify whether proteins that are already known to associate with ABIN1 in other 
pathways, such as A20, are bound to ABIN1 after cisplatin-induced damage. They 
could also be analysed by mass spectrometry to identify novel binding partners.  
Once known components of the speckles have been identified a further 
understanding of the kinetics of speckle formation could be obtained. By reducing the 
identified proteins through RNAi and detecting which components are missing we 
could determine which regulators or signals are required for the recruitment of others. 
Indeed, it would be interesting to determine whether ABIN1 is recruited to speckles 
by binding to linear chains, which could be assessed by first depleting HOIP and then 
analysing the speckles. 
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Not all GFP-ABIN1 speckles co-localise with ubiquitin. While it is not 
unexpected that ubiquitin would be constitutively associated with other complexes, 
the ubiquitin-ABIN1 interaction may be better perceived by further optimisation of 
the staining method. The pre-extraction of non-tethered proteins in the cytosol could 
remove non-bound proteins, including ABIN1 and ubiquitin, and allow for easier 
visualisation of large complexes.  
Although predominantly found in the cytosol ABIN1 is reported to shuttle 
between the nucleus and cytoplasm in a Crm1-dependent manner [209]. GFP-ABIN1 
localisation does not appear to change after stimulation with cisplatin. However, to 
distinguish more subtle effects of DNA damage on its location, GFP-ABIN1 cells 
could be subfractionated and analysed by Western Blotting. 
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7 Final discussion  
 
HOIP and ABIN1 were two of the top candidates identified in an siRNA 
screen to discover novel components of the response to cisplatin. Both candidates 
were validated as regulators of the ICL response, as HOIP- or ABIN1-deficient cells 
are hypersensitive to cisplatin and MMC. This chapter discusses potential roles for 
these proteins in regulating cellular pathways upon cisplatin-induced damage. 
 
7.1.1 Do ABIN1 and HOIP act in a common cisplatin-induced 
pathway?  
HOIP is part of LUBAC, which creates linear chains [22], and ABIN1 is 
capable of binding linear chains [28]. Both ABIN1- and HOIP-deficient cells display 
similar phenotypes of increased sensitivity and apoptosis in response to cisplatin 
treatment. It is thus tempting to speculate that HOIP and ABIN1 act in a common 
pathway to maintain resistance to ICL inducers. Indeed, cells transfected with both 
siHOIP and siABIN1 do not show decreased viability after cisplatin treatment 
compared to siHOIP-transfected cells alone. Likewise, caspase-3 activity is not 
increased in siHOIP and siABIN1 co-transfected cells, implying that they may 
function in the same pathway. However, cleaved caspase-3 levels appear to be further 
enhanced when both ABIN1 and HOIP levels are simultaneously reduced, compared 
to depletion of HOIP alone. Thus it is possible that the effect of HOIP depletion alone 
is so intense that is difficult to detect further effects of siABIN1 transfection using the 
viability and caspase assays. Moreover, siRNA transfection efficiency was not 
analysed in conjunction with the viability or caspase activity assays, and it is thus 
possible that the effect of combined HOIP and ABIN1 depletion on sensitivity has 
been underestimated due to the knock down actually being ineffective. Therefore 
further experimentation would be helpful to conclusively determine whether HOIP 
and ABIN1 act in the same cisplatin-induced pathway. One approach to circumvent 
difficulties with siRNA could be the generation of a double HOIPC879S/C879S 
/Abin1D485N/D485N knock in mouse. MEFs generated from this mouse could be assessed 
to determine whether defects in HOIP and ABIN1 lead to greater sensitivity or 
increased apoptosis when combined. 
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In addition to the above points, not all phenotypes in HOIP- or ABIN1-
deficient cells are the same. HOIP-depletion causes greater sensitivity and more 
apoptosis in response to cisplatin than ABIN1 depletion. Furthermore, HOIP 
depletion leads to increased apoptosis in response to multiple types of cell stressors, 
while ABIN1 defects only sensitise MEF cells to certain genotoxins. To date HOIP is 
the only ligase known to create linear chains. In response to cisplatin-induced damage 
HOIP may ubiquitinate multiple substrates, which could be recognised many linear 
ubiquitin-binding proteins. ABIN1 may be one of these proteins and might regulate 
the ICL response by interacting with the ubiquitin chains generated by HOIP. HOIP 
may even affect more than one pathway in response to cisplatin-induced damage, with 
ABIN1 playing a less extensive role in regulating downstream ICL signalling. 
 
7.1.2 Suggested mechanisms for HOIP- and ABIN1-mediated 
regulation of the response to cisplatin 
Cisplatin-induced apoptosis is increased in HOIP-deficient cells, while 
checkpoint regulators and repair are unaffected. Furthermore, inhibition of caspase-8 
reverses the sensitivity of HOIP-depleted cells to cisplatin. This implies that HOIP 
protects cells from caspase-8 mediated cisplatin-induced apoptosis.  
While cisplatin-induced apoptosis is increased in ABIN1-depleted U2OS cells 
and Abin1D485N/D485N MEFs, preliminary experiments indicate that it is not increased 
in Abin1-/- MEFs. Yet these cells are sensitive to cisplatin, MMC and IR. Thus, unlike 
in the case of HOIP-deficient cells, sensitivity to genotoxins in ABIN1-deficient cells 
does not strictly correlate with increased cisplatin-induced apoptosis.  
Cisplatin has cytostatic as well as cytotoxic effects – that is, it can reduce the 
proliferation of cells as well as induce cell death. As discussed in Chapter 6, ABIN1-
deficient cells show minor differences in cisplatin-induced modifications of 
checkpoint kinases. In response to stimuli such as TNF, ABIN1 regulates NF-κB 
activity [199], a transcription factor that can regulate the cell cycle [221]. Thus further 
experiments as previously described are required to determine whether ABIN1 
regulates the cell cycle in an NF-κB-dependant or independent manner in response to 
cisplatin. 
However, more than one ABIN1-deficient cell line displays drastic increases 
in cisplatin-induced apoptosis and only minor dissimilarities in checkpoint markers 
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compared to control lines. Thus it is likely that apoptosis contributes to sensitivity to 
cisplatin to some extent in these cells and ABIN1 may also regulate the ICL response 
to cisplatin by preventing increased cell death.  
 
One potential means for HOIP and ABIN1 to regulate cisplatin-induced PCD 
could be through control of cell death signalling complexes such as the ripoptosome. 
The ripoptosome forms in response to genotoxic stress [128, 129] and acts as a switch 
between DNA damage-induced apoptosis and necroptosis. It includes RIP1–FADD–
caspase-8 and is thus similar in composition to TNF-induced complex II [120–122]. 
ABIN1 is known to protect cells from TNF-induced apoptosis by binding to caspase-8 
and preventing it from accessing and being activated in Complex II [143]. 
Furthermore, both RIP1 and caspase-8 can be polyubiquitinated, and, in the case of 
RIP1 at least, these chains can be linear [119, 188]. GFP-ABIN1 aggregates into 
macro-molecular structures in the cytosol, some of which co-localise with ubiquitin, 
and the formation of which depends on the UBAN domain of ABIN1. Although the 
functional relevance of these aggregates is not yet known, it is tempting to speculate 
that they are related to ABIN1’s role in the ICL response. Might they even represent 
cell death signalling complexes similar to the ripoptosome? 
I hypothesise that, in response to cisplatin-induced damage, HOIP adds linear 
ubiquitin chains to a component(s) of a cell death platform like the ripoptosome. This 
enables the recruitment of ubiquitin-binding proteins such as ABIN1. ABIN1 might 
regulate the composition of the complex by recruiting other anti-cell death regulators, 
or preventing the binding of pro-apoptotic components such as caspase-8. This would 
prevent the formation or activation of the ripoptosome, inhibit the propagation of pro-
death signals and result in cell survival in response to cisplatin. When either HOIP or 
ABIN1 are lacking, pro-death signals prevail, leading to apoptosis or necroptosis 
depending on the cellular background. ABIN1 protein levels, and/or ABIN1 
aggregate intensity appear to be regulated after cisplatin treatment. Thus in addition to 
regulation of this complex through ubiquitination of substrates by HOIP, the 
regulation of ABIN1 levels might provide another mechanism to control the 
activation of these complexes. Deciphering the composition of the GFP-ABIN1 
speckles as previously described could help determine whether they contain similar 
components to the ripoptosome. Furthermore, this model could be tested by 
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determining whether the complexes depend on HOIP function or the creation of linear 
chains. 
 
In response to cisplatin-induced damage, multiple signalling pathways are 
activated that could interact with, activate or otherwise regulate HOIP and ABIN1-
dependant cisplatin-induced cell death pathways.  
Niu et al [193] maintained that HOIP protects cells from etoposide-induced 
apoptosis by promoting ATM-mediated NF-κB activation. However, while ATM 
activity is required for cisplatin-induced apoptosis, both basal and cisplatin-induced 
cleaved caspase-3 levels are increased in a cell line in which NF-κB activation is 
inhibited when HOIP is depleted [180]. This suggests that HOIP performs its anti-
apoptotic role in response to cisplatin in a manner that is independent of NF-κB 
signalling. Preliminary experiments also show that NF-κB signalling is normal in 
ABIN1-depleted cells, although further work is required to determine whether the 
increased apoptosis in ABIN1-deficient cells requires NF-κB activation.  
Conversely, JNK activity is required for increased cisplatin-induced apoptosis 
in HOIP-depleted HEK293 cells, but not U2OS cells. Therefore, like ABIN1, HOIP 
may act to protect cells from apoptosis in a cell-type specific manner. Interestingly, 
Chang et al [222] claim that JNK regulates TNF-induced caspase-8 activation through 
indirect mediation of cFLIP levels. It is intriguing to speculate that JNK may also 
decrease cFLIPL levels in response to cisplatin, acting in parallel to HOIP and/or 
ABIN1 to activate caspase-8 within a ripoptosome structure. Experiments such as 
those proposed in Chapter 6 could help determine whether ABIN1’s role in the ICL 
response is also regulated by upstream DDR or stress regulators such as ATM and 
JNK respectively.  
 
7.1.3 Screen candidates and DDR-induced apoptosis  
It is interesting to note that many of the top candidates of the screen were 
already known or have now been shown to be associated with apoptotic signalling 
during the DDR. Along with HOIP and ABIN1, BIRC2 was identified as a positive 
hit in the screen. BIRC2, also known as cIAP1, is involved in progressing anti-
apoptotic NF-κB-mediated signalling in response to camptothecin and IR [223, 224]. 
Perhaps the strict criteria applied during the screen inadvertently selected for the 
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stronger phenotype of increased cell death after cisplatin treatment. This may have 
unintentionally biased the identification process towards the discovery of proteins 
involved in maintaining cell viability, rather than, for example, DNA repair factors. 
 
7.2 Conclusion 
This thesis describes the identification of novel ubiquitin-related regulators of 
the response to cisplatin. Using a robust high throughput siRNA screen to target 
ubiquitin-related proteins, nine candidates, including RNF113B, HOIP and ABIN1, 
were recognised as potential components of the ICL response (Chapter 3). While 
RNF113B was subsequently not validated as a positive candidate (Chapter 4), the 
screen formed the basis of further studies describing HOIP as a protector against 
cisplatin-induced apoptosis (Chapters 5), and ABIN1 as a regulator of the ICL 
response (Chapter 6).  
By advancing our understanding of the mechanisms by which normal cells 
decide their fate after DNA damage, we can attempt to manipulate this balance in the 
direction of cell death during anti-cancer treatment. Further investigation is required 
to determine exactly how HOIP and ABIN1 protect cells from cisplatin-induced 
damage. Nevertheless, the research presented in this thesis has not only increased our 
knowledge of how ubiquitin-dependant pathways might regulate the DNA damage 
response, but also identified a potential novel target for anti-cancer therapeutics.  
 
 
  
 224 
8 References 
1. Bertani G: Lysogeny at mid-twentieth century: P1, P2, and other experimental 
systems. J Bacteriol 2004, 186:595–600. 
2. Hershko A, Ciechanover A: The ubiquitin system. Annu Rev Biochem 1998, 
67:425–479. 
3. Handley PM, Mueckler M, Siegel NR, Ciechanover A, Schwartz AL: Molecular 
cloning, sequence, and tissue distribution of the human ubiquitin-activating 
enzyme E1. Proc Natl Acad Sci U S A 1991, 88:258–262. 
4. Jin J, Li X, Gygi SP, Harper JW: Dual E1 activation systems for ubiquitin 
differentially regulate E2 enzyme charging. Nature 2007, 447:1135–1138. 
5. Pelzer C, Kassner I, Matentzoglu K, Singh RK, Wollscheid H-P, Scheffner M, 
Schmidtke G, Groettrup M: UBE1L2, a novel E1 enzyme specific for ubiquitin. J 
Biol Chem 2007, 282:23010–23014. 
6. Chiu Y-H, Sun Q, Chen ZJ: E1-L2 activates both ubiquitin and FAT10. Mol Cell 
2007, 27:1014–1023. 
7. Michelle C, Vourc’h P, Mignon L, Andres CR: What was the set of ubiquitin and 
ubiquitin-like conjugating enzymes in the eukaryote common ancestor? J Mol 
Evol 2009, 68:616–628. 
8. Li W, Bengtson MH, Ulbrich A, Matsuda A, Reddy VA, Orth A, Chanda SK, 
Batalov S, Joazeiro CAP: Genome-wide and functional annotation of human E3 
ubiquitin ligases identifies MULAN, a mitochondrial E3 that regulates the 
organelle&apos;s dynamics and signaling. PLoS One 2008, 3:e1487. 
9. Komander D: Mechanism, specificity and structure of the deubiquitinases. 
Subcell Biochem 2010, 54:69–87. 
 225 
10. Plechanovová A, Jaffray EG, McMahon SA, Johnson KA, Navrátilová I, Naismith 
JH, Hay RT: Mechanism of ubiquitylation by dimeric RING ligase RNF4. Nat 
Struct Mol Biol 2011, 18:1052–9. 
11. Plechanovová A, Jaffray EG, Tatham MH, Naismith JH, Hay RT, Plechanovova 
A: Structure of a RING E3 ligase and ubiquitin-loaded E2 primed for catalysis. 
Nature 2012, 489:115–120. 
12. Das R, Liang Y-H, Mariano J, Li J, Huang T, King A, Tarasov SG, Weissman 
AM, Ji X, Byrd RA: Allosteric regulation of E2:E3 interactions promote a 
processive ubiquitination machine. EMBO J 2013, 32:2504–16. 
13. Metzger MB, Pruneda JN, Klevit RE, Weissman AM: RING-type E3 ligases: 
Master manipulators of E2 ubiquitin-conjugating enzymes and ubiquitination. 
Biochim Biophys Acta - Mol Cell Res 2013. 
14. Kee Y, Huibregtse JM: Regulation of catalytic activities of HECT ubiquitin 
ligases. Biochem Biophys Res Commun 2007:329–333. 
15. Huang L, Kinnucan E, Wang G, Beaudenon S, Howley PM, Huibregtse JM, 
Pavletich NP: Structure of an E6AP-UbcH7 complex: insights into ubiquitination 
by the E2-E3 enzyme cascade. Science 1999, 286:1321–1326. 
16. Van der Reijden BA, Erpelinck-Verschueren CA, Löwenberg B, Jansen JH: 
TRIADs: a new class of proteins with a novel cysteine-rich signature. Protein Sci 
1999, 8:1557–61. 
17. Morett E, Bork P: A novel transactivation domain in parkin. Trends Biochem 
Sci 1999, 24:229–231. 
18. Wenzel DM, Lissounov A, Brzovic PS, Klevit RE: UBCH7 reactivity profile 
reveals parkin and HHARI to be RING/HECT hybrids. Nature 2011, 474:105–
108. 
19. Marin I, Lucas JI, Gradilla AC, Ferrus A: Parkin and relatives: the RBR family 
of ubiquitin ligases. Physiol Genomics 2004, 17:253–263. 
 226 
20. Smit JJ, Monteferrario D, Noordermeer SM, van Dijk WJ, van der Reijden BA, 
Sixma TK: The E3 ligase HOIP specifies linear ubiquitin chain assembly through 
its RING-IBR-RING domain and the unique LDD extension. EMBO J 
2012:3833–3844. 
21. Stieglitz B, Morris-Davies AC, Koliopoulos MG, Christodoulou E, Rittinger K: 
LUBAC synthesizes linear ubiquitin chains via a thioester intermediate. EMBO 
Rep 2012, 13:840–846. 
22. Kirisako T, Kamei K, Murata S, Kato M, Fukumoto H, Kanie M, Sano S, 
Tokunaga F, Tanaka K, Iwai K: A ubiquitin ligase complex assembles linear 
polyubiquitin chains. EMBO J 2006, 25:4877–4887. 
23. Ikeda F, Dikic I: Atypical ubiquitin chains: new molecular signals. “Protein 
Modifications: Beyond the Usual Suspects” review series. EMBO Rep 2008, 
9:536–542. 
24. Nakasone MA, Livnat-Levanon N, Glickman MH, Cohen RE, Fushman D: 
Mixed-linkage ubiquitin chains send mixed messages. Structure 2013, 21:727–40. 
25. Emmerich CH, Ordureau A, Strickson S, Arthur JSC, Pedrioli PGA, Komander D, 
Cohen P: Activation of the canonical IKK complex by K63/M1-linked hybrid 
ubiquitin chains. Proc Natl Acad Sci U S A 2013, 110:15247–15252. 
26. Chernorudskiy AL, Gainullin MR: Ubiquitin system: direct effects join the 
signaling. Sci Signal 2013, 6:pe22. 
27. Dikic I, Wakatsuki S, Walters KJ: Ubiquitin-binding domains - from structures 
to functions. Nat Rev Mol Cell Biol 2009, 10:659–671. 
28. Nanda SK, Venigalla RK, Ordureau A, Patterson-Kane JC, Powell DW, Toth R, 
JS CA, Cohen P: Polyubiquitin binding to ABIN1 is required to prevent 
autoimmunity. J Exp Med 2011, 208:1215–1228. 
 227 
29. Lo Y-C, Lin S-C, Rospigliosi CC, Conze DB, Wu C-J, Ashwell JD, Eliezer D, 
Wu H: Structural basis for recognition of diubiquitins by NEMO. Mol Cell 2009, 
33:602–15. 
30. Glickman MH, Ciechanover A: The Ubiquitin-Proteasome Proteolytic 
Pathway: Destruction for the Sake of Construction. Physiol Rev 2002, 82:373–
428. 
31. Kerscher O, Felberbaum R, Hochstrasser M: Modification of proteins by 
ubiquitin and ubiquitin-like proteins. Annu Rev Cell Dev Biol 2006, 22:159–180. 
32. Xirodimas DP, Sundqvist A, Nakamura A, Shen L, Botting C, Hay RT: 
Ribosomal proteins are targets for the NEDD8 pathway. EMBO Rep 2008, 9:280–
286. 
33. Tatham MH, Jaffray E, Vaughan OA, Desterro JM, Botting CH, Naismith JH, 
Hay RT: Polymeric chains of SUMO-2 and SUMO-3 are conjugated to protein 
substrates by SAE1/SAE2 and Ubc9. J Biol Chem 2001, 276:35368–35374. 
34. Hecker C-M, Rabiller M, Haglund K, Bayer P, Dikic I: Specification of SUMO1- 
and SUMO2-interacting motifs. J Biol Chem 2006, 281:16117–16127. 
35. Bologna S, Ferrari S: It takes two to tango: Ubiquitin and SUMO in the DNA 
damage response. Front Genet 2013, 4:106. 
36. Jackson SP, Durocher D: Regulation of DNA damage responses by ubiquitin 
and SUMO. Mol Cell 2013, 49:795–807. 
37. Brulikova L, Hlavac J, Hradil P: DNA Interstrand Cross-Linking Agents and 
their Chemotherapeutic Potential. Curr Med Chem 2012:364–385. 
38. Auerbach AD: Fanconi anemia and its diagnosis. Mutat Res 2009, 668:4–10. 
39. Clauson C, Schärer OD, Niedernhofer L: Advances in understanding the 
complex mechanisms of DNA interstrand cross-link repair. Cold Spring Harb 
Perspect Biol 2013, 5:a012732. 
 228 
40. Guan L, Greenberg MM: DNA interstrand cross-link formation by the 1,4-
dioxobutane abasic lesion. J Am Chem Soc 2009, 131:15225–31. 
41. Dutta S, Chowdhury G, Gates KS: Interstrand cross-links generated by abasic 
sites in duplex DNA. J Am Chem Soc 2007, 129:1852–3. 
42. Kirchner JJ, Sigurdsson ST, Hopkins PB: Interstrand cross-linking of duplex 
DNA by nitrous acid: covalent structure of the dG-to-dG cross-link at the 
sequence 5’-CG. J Am Chem Soc 1992, 114:4021–4027. 
43. Rajski SR, Williams RM: DNA Cross-Linking Agents as Antitumor Drugs. 
Chem Rev 1998, 98:2723–2796. 
44. Rosenberg B, VanCamp L, Trosko JE, Mansour VH: Platinum compounds: a 
new class of potent antitumour agents. Nature 1969, 222:385–386. 
45. Harrap KR: Preclinical studies identifying carboplatin as a viable cisplatin 
alternative. Cancer Treat Rev 1985, 12 Suppl A:21–33. 
46. Kidani Y, Inagaki K, Iigo M, Hoshi A, Kuretani K: Antitumor activity of 1,2-
diaminocyclohexane--platinum complexes against sarcoma-180 ascites form. J 
Med Chem 1978, 21:1315–1318. 
47. Kelland L: The resurgence of platinum-based cancer chemotherapy. Nat Rev 
Cancer 2007, 7:573–584. 
48. Noll DM, Mason TM, Miller PS: Formation and repair of interstrand cross-
links in DNA. Chem Rev 2006, 106:277–301. 
49. Reishus JW, Martin DS: cis-Dichlorodiammineplatinum(II). Acid Hydrolysis 
and Isotopic Exchange of the Chloride Ligands 1. J Am Chem Soc 1961, 83:2457–
2462. 
50. Coste F, Malinge JM, Serre L, Shepard W, Roth M, Leng M, Zelwer C: Crystal 
structure of a double-stranded DNA containing a cisplatin interstrand cross-link 
at 1.63 A resolution: hydration at the platinated site. Nucleic Acids Res 1999, 
27:1837–46. 
 229 
51. Paquet F, Pérez C, Leng M, Lancelot G, Malinge JM: NMR solution structure of 
a DNA decamer containing an interstrand cross-link of the antitumor drug cis-
diamminedichloroplatinum (II). J Biomol Struct Dyn 1996, 14:67–77. 
52. Huang H, Zhu L, Reid BR, Drobny GP, Hopkins PB: Solution structure of a 
cisplatin-induced DNA interstrand cross-link. Science 1995, 270:1842–5. 
53. Malinge JM, Pérez C, Leng M: Base sequence-independent distorsions induced 
by interstrand cross-links in cis-diamminedichloroplatinum (II)-modified DNA. 
Nucleic Acids Res 1994, 22:3834–9. 
54. Norman D, Live D, Sastry M, Lipman R, Hingerty BE, Tomasz M, Broyde S, 
Patel DJ: NMR and computational characterization of mitomycin cross-linked to 
adjacent deoxyguanosines in the minor groove of the d(T-A-C-G-T-A).d(T-A-C-
G-T-A) duplex. Biochemistry 1990, 29:2861–75. 
55. Rink SM, Lipman R, Alley SC, Hopkins PB, Tomasz M: Bending of DNA by the 
mitomycin C-induced, GpG intrastrand cross-link. Chem Res Toxicol 1996, 
9:382–9. 
56. Andegeko Y, Moyal L, Mittelman L, Tsarfaty I, Shiloh Y, Rotman G: Nuclear 
retention of ATM at sites of DNA double strand breaks. J Biol Chem 2001, 
276:38224–38230. 
57. Helt CE, Cliby WA, Keng PC, Bambara RA, O’Reilly MA: Ataxia telangiectasia 
mutated (ATM) and ATM and Rad3-related protein exhibit selective target 
specificities in response to different forms of DNA damage. J Biol Chem 2005, 
280:1186–92. 
58. Ward IM, Minn K, Chen J: UV-induced ataxia-telangiectasia-mutated and 
Rad3-related (ATR) activation requires replication stress. J Biol Chem 2004, 
279:9677–9680. 
59. Lovejoy CA, Cortez D: Common mechanisms of PIKK regulation. DNA Repair 
2009, 8:1004–1008. 
 230 
60. Podhorecka M, Skladanowski A, Bozko P: H2AX Phosphorylation: Its Role in 
DNA Damage Response and Cancer Therapy. J Nucleic Acids 2010, 2010. 
61. Bermudez VP, Lindsey-Boltz LA, Cesare AJ, Maniwa Y, Griffith JD, Hurwitz J, 
Sancar A: Loading of the human 9-1-1 checkpoint complex onto DNA by the 
checkpoint clamp loader hRad17-replication factor C complex in vitro. Proc Natl 
Acad Sci U S A 2003, 100:1633–1638. 
62. Sancar A, Lindsey-Boltz LA, Unsal-Kaçmaz K, Linn S, Unsal-Kacmaz K: 
Molecular mechanisms of mammalian DNA repair and the DNA damage 
checkpoints. Annu Rev Biochem 2004, 73:39–85. 
63. Niida H, Nakanishi M: DNA damage checkpoints in mammals. Mutagenesis 
2006, 21:3–9. 
64. Shiloh Y: ATM and related protein kinases: safeguarding genome integrity. 
Nat Rev Cancer 2003, 3:155–168. 
65. Falck J, Mailand N, Syljuasen RG, Bartek J, Lukas J: The ATM-Chk2-Cdc25A 
checkpoint pathway guards against radioresistant DNA synthesis. Nature 2001, 
410:842–847. 
66. Dasika GK, Lin SC, Zhao S, Sung P, Tomkinson A, Lee EY: DNA damage-
induced cell cycle checkpoints and DNA strand break repair in development and 
tumorigenesis. Oncogene 1999, 18:7883–7899. 
67. Lukas J, Lukas C, Bartek J: Mammalian cell cycle checkpoints: signalling 
pathways and their organization in space and time. DNA Repair 2004, 3:997–
1007. 
68. Bartek J, Lukas C, Lukas J: Checking on DNA damage in S phase. Nat Rev Mol 
Cell Biol 2004, 5:792–804. 
69. Räschle M, Knipscheer P, Knipsheer P, Enoiu M, Angelov T, Sun J, Griffith JD, 
Ellenberger TE, Schärer OD, Walter JC, Raschle M, Scharer OD: Mechanism of 
replication-coupled DNA interstrand crosslink repair. Cell 2008, 134:969–980. 
 231 
70. Moldovan G-LL, D’Andrea AD: How the fanconi anemia pathway guards the 
genome. Annu Rev Genet 2009, 43:223–249. 
71. Ciccia A, Ling C, Coulthard R, Yan Z, Xue Y, Meetei AR, Laghmani el H, Joenje 
H, McDonald N, de Winter JP, Wang W, West SC: Identification of FAAP24, a 
Fanconi anemia core complex protein that interacts with FANCM. Mol Cell 
2007, 25:331–343. 
72. Yan Z, Delannoy M, Ling C, Daee D, Osman F, Muniandy PA, Shen X, Oostra 
AB, Du H, Steltenpool J, Lin T, Schuster B, Decaillet C, Stasiak A, Stasiak AZ, Stone 
S, Hoatlin ME, Schindler D, Woodcock CL, Joenje H, Sen R, de Winter JP, Li L, 
Seidman MM, Whitby MC, Myung K, Constantinou A, Wang W: A histone-fold 
complex and FANCM form a conserved DNA-remodeling complex to maintain 
genome stability. Mol Cell 2010, 37:865–878. 
73. Huang M, Kim JM, Shiotani B, Yang K, Zou L, D’Andrea AD: The 
FANCM/FAAP24 complex is required for the DNA interstrand crosslink-
induced checkpoint response. Mol Cell 2010, 39:259–268. 
74. Vare D, Groth P, Carlsson R, Johansson F, Erixon K, Jenssen D: DNA 
interstrand crosslinks induce a potent replication block followed by formation 
and repair of double strand breaks in intact mammalian cells. DNA Repair (Amst) 
2012, 11:976–85. 
75. Ben-Yehoyada M, Wang LC, Kozekov ID, Rizzo CJ, Gottesman ME, Gautier J: 
Checkpoint signaling from a single DNA interstrand crosslink. Mol Cell 2009, 
35:704–715. 
76. Yan Z, Guo R, Paramasivam M, Shen W, Ling C, Fox D, Wang Y, Oostra AB, 
Kuehl J, Lee D-Y, Takata M, Hoatlin ME, Schindler D, Joenje H, de Winter JP, Li L, 
Seidman MM, Wang W: A ubiquitin-binding protein, FAAP20, links RNF8-
mediated ubiquitination to the Fanconi anemia DNA repair network. Mol Cell 
2012, 47:61–75. 
 232 
77. Alpi AF, Pace PE, Babu MM, Patel KJ: Mechanistic insight into site-restricted 
monoubiquitination of FANCD2 by Ube2t, FANCL, and FANCI. Mol Cell 2008, 
32:767–777. 
78. Machida YYJ, Chen Y, Gurtan AM, Kupfer GM, D’Andrea AD, Dutta A: 
UBE2T is the E2 in the Fanconi anemia pathway and undergoes negative 
autoregulation. Mol Cell 2006, 23:589–596. 
79. Alpi A, Langevin F, Mosedale G, Machida YJ, Dutta A, Patel KJ: UBE2T, the 
Fanconi anemia core complex, and FANCD2 are recruited independently to 
chromatin: a basis for the regulation of FANCD2 monoubiquitination. Mol Cell 
Biol 2007, 27:8421–8430. 
80. Meetei AR, de Winter JP, Medhurst AL, Wallisch M, Waisfisz Q, van de Vrugt 
HJ, Oostra AB, Yan Z, Ling C, Bishop CE, Hoatlin ME, Joenje H, Wang W: A novel 
ubiquitin ligase is deficient in Fanconi anemia. Nat Genet 2003, 35:165–170. 
81. Kratz K, Schopf B, Kaden S, Sendoel A, Eberhard R, Lademann C, Cannavo E, 
Sartori AA, Hengartner MO, Jiricny J: Deficiency of FANCD2-associated nuclease 
KIAA1018/FAN1 sensitizes cells to interstrand crosslinking agents. Cell , 142:77–
88. 
82. Smogorzewska A, Desetty R, Saito TT, Schlabach M, Lach FP, Sowa ME, Clark 
AB, Kunkel TA, Harper JW, Colaiácovo MP, Elledge SJ, Colaiacovo MP: A genetic 
screen identifies FAN1, a Fanconi anemia-associated nuclease necessary for DNA 
interstrand crosslink repair. Mol Cell 2010, 39:36–47. 
83. MacKay C, Déclais A-C, Lundin C, Agostinho A, Deans AJ, MacArtney TJ, 
Hofmann K, Gartner A, West SC, Helleday T, Lilley DMJ, Rouse J, Declais AC: 
Identification of KIAA1018/FAN1, a DNA repair nuclease recruited to DNA 
damage by monoubiquitinated FANCD2. Cell 2010, 142:65–76. 
84. Liu T, Ghosal G, Yuan J, Chen J, Huang J: FAN1 acts with FANCI-FANCD2 to 
promote DNA interstrand cross-link repair. Science (80- ) 2010, 329:693–696. 
 233 
85. Niedzwiedz W, Mosedale G, Johnson M, Ong CY, Pace P, Patel KJ: The Fanconi 
anaemia gene FANCC promotes homologous recombination and error-prone 
DNA repair. Mol Cell 2004, 15:607–620. 
86. Nojima K, Hochegger H, Saberi A, Fukushima T, Kikuchi K, Yoshimura M, 
Orelli BJ, Bishop DK, Hirano S, Ohzeki M, Ishiai M, Yamamoto K, Takata M, 
Arakawa H, Buerstedde JM, Yamazoe M, Kawamoto T, Araki K, Takahashi JA, 
Hashimoto N, Takeda S, Sonoda E: Multiple repair pathways mediate tolerance to 
chemotherapeutic cross-linking agents in vertebrate cells. Cancer Res 2005, 
65:11704–11711. 
87. Kee Y, D’Andrea AD: Expanded roles of the Fanconi anemia pathway in 
preserving genomic stability. Genes Dev 2010, 24:1680–1694. 
88. Nijman SM, Huang TT, Dirac AM, Brummelkamp TR, Kerkhoven RM, 
D’Andrea AD, Bernards R: The deubiquitinating enzyme USP1 regulates the 
Fanconi anemia pathway. Mol Cell 2005, 17:331–339. 
89. Cohn MA, Kowal P, Yang K, Haas W, Huang TT, Gygi SP, D’Andrea AD: A 
UAF1-containing multisubunit protein complex regulates the Fanconi anemia 
pathway. Mol Cell 2007, 28:786–797. 
90. Oestergaard VH, Langevin F, Kuiken HJ, Pace P, Niedzwiedz W, Simpson LJ, 
Ohzeki M, Takata M, Sale JE, Patel KJ: Deubiquitination of FANCD2 is required 
for DNA crosslink repair. Mol Cell 2007, 28:798–809. 
91. Kim JM, Parmar K, Huang M, Weinstock DM, Ruit CA, Kutok JL, D’Andrea 
AD: Inactivation of murine Usp1 results in genomic instability and a Fanconi 
anemia phenotype. Dev Cell 2009, 16:314–320. 
92. Niedernhofer LJ, Odijk H, Budzowska M, van Drunen E, Maas A, Theil AF, de 
Wit J, Jaspers NG, Beverloo HB, Hoeijmakers JH, Kanaar R: The structure-specific 
endonuclease Ercc1-Xpf is required to resolve DNA interstrand cross-link-
induced double-strand breaks. Mol Cell Biol 2004, 24:5776–5787. 
 234 
93. Castor D, Nair N, Déclais AC, Lachaud C, Toth R, Macartney TJ, Lilley DMJ, 
Arthur JSC, Rouse J: Cooperative control of holliday junction resolution and 
DNA Repair by the SLX1 and MUS81-EME1 nucleases. Mol Cell 2013, 52:221–
233. 
94. Munoz IM, Hain K, Declais AC, Gardiner M, Toh GW, Sanchez-Pulido L, 
Heuckmann JM, Toth R, Macartney T, Eppink B, Kanaar R, Ponting CP, Lilley DM, 
Rouse J: Coordination of structure-specific nucleases by human SLX4/BTBD12 
is required for DNA repair. Mol Cell 2009, 35:116–127. 
95. Dronkert ML, de Wit J, Boeve M, Vasconcelos ML, van Steeg H, Tan TL, 
Hoeijmakers JH, Kanaar R: Disruption of mouse SNM1 causes increased 
sensitivity to the DNA interstrand cross-linking agent mitomycin C. Mol Cell Biol 
2000, 20:4553–4561. 
96. Knobel PA, Marti TM: Translesion DNA synthesis in the context of cancer 
research. Cancer Cell Int 2011:39. 
97. Stallons LJ, McGregor WG: Translesion synthesis polymerases in the 
prevention and promotion of carcinogenesis. J Nucleic Acids 2010, 2010. 
98. Sonoda E, Okada T, Zhao GY, Tateishi S, Araki K, Yamaizumi M, Yagi T, 
Verkaik NS, van Gent DC, Takata M, Takeda S: Multiple roles of Rev3, the 
catalytic subunit of polzeta in maintaining genome stability in vertebrates. 
EMBO J 2003, 22:3188–3197. 
99. Duquette ML, Zhu Q, Taylor ER, Tsay AJ, Shi LZ, Berns MW, McGowan CH: 
CtIP is required to initiate replication-dependent interstrand crosslink repair. 
PLoS Genet 2012, 8:e1003050. 
100. Hinz JM: Role of homologous recombination in DNA interstrand crosslink 
repair. Environ Mol Mutagen 2010, 51:582–603. 
101. Kitao H, Yamamoto K, Matsushita N, Ohzeki M, Ishiai M, Takata M: 
Functional interplay between BRCA2/FancD1 and FancC in DNA repair. J Biol 
Chem 2006, 281:21312–20. 
 235 
102. Venkitaraman AR: Cancer Susceptibility and the Functions of BRCA1 and 
BRCA2. Cell 2002, 108:171–182. 
103. Long DT, Räschle M, Joukov V, Walter JC: Mechanism of RAD51-dependent 
DNA interstrand cross-link repair. Science 2011, 333:84–7. 
104. Czabotar PE, Lessene G, Strasser A, Adams JM: Control of apoptosis by the 
BCL-2 protein family: implications for physiology and therapy. Nat Rev Mol Cell 
Biol 2014, 15:49–63. 
105. Zou H, Henzel WJ, Liu X, Lutschg A, Wang X: Apaf-1, a human protein 
homologous to C. elegans CED-4, participates in cytochrome c-dependent 
activation of caspase-3. Cell 1997, 90:405–13. 
106. Kluck RM, Bossy-Wetzel E, Green DR, Newmeyer DD: The release of 
cytochrome c from mitochondria: a primary site for Bcl-2 regulation of 
apoptosis. Science 1997, 275:1132–6. 
107. Riedl SJ, Salvesen GS: The apoptosome: signalling platform of cell death. 
Nat Rev Mol Cell Biol 2007, 8:405–413. 
108. Li P, Nijhawan D, Budihardjo I, Srinivasula SM, Ahmad M, Alnemri ES, Wang 
X: Cytochrome c and dATP-dependent formation of Apaf-1/caspase-9 complex 
initiates an apoptotic protease cascade. Cell 1997, 91:479–489. 
109. Eckelman BP, Salvesen GS, Scott FL: Human inhibitor of apoptosis proteins: 
why XIAP is the black sheep of the family. EMBO Rep 2006, 7:988–94. 
110. Fadeel B, Ottosson A, Pervaiz S: Big wheel keeps on turning: apoptosome 
regulation and its role in chemoresistance. Cell Death Differ 2008, 15:443–452. 
111. Du C, Fang M, Li Y, Li L, Wang X: Smac, a mitochondrial protein that 
promotes cytochrome c-dependent caspase activation by eliminating IAP 
inhibition. Cell 2000, 102:33–42. 
112. Vousden KH, Lane DP: p53 in health and disease. Nat Rev Mol Cell Biol 2007, 
8:275–283. 
 236 
113. Haupt S, Berger M, Goldberg Z, Haupt Y: Apoptosis - the p53 network. J Cell 
Sci 2003, 116(Pt 20):4077–85. 
114. Gutekunst M, Oren M, Weilbacher A, Dengler MA, Markwardt C, Thomale J, 
Aulitzky WE, van der Kuip H: P53 hypersensitivity is the predominant mechanism 
of the unique responsiveness of testicular germ cell tumor (TGCT) cells to 
Cisplatin. PLoS One 2011, 6. 
115. Lavrik I, Golks A, Krammer PH: Death receptor signaling. J Cell Sci 2005, 
118(Pt 2):265–7. 
116. Pennarun B, Meijer A, de Vries EGE, Kleibeuker JH, Kruyt F, de Jong S: 
Playing the DISC: turning on TRAIL death receptor-mediated apoptosis in 
cancer. Biochim Biophys Acta 2010, 1805:123–40. 
117. Ashkenazi A, Dixit VM: Apoptosis control by death and decoy receptors. 
Curr Opin Cell Biol 1999, 11:255–60. 
118. Peter ME, Krammer PH: The CD95(APO-1/Fas) DISC and beyond. Cell 
Death Differ 2003, 10:26–35. 
119. Jin Z, Li Y, Pitti R, Lawrence D, Pham VC, Lill JR, Ashkenazi A: Cullin3-
based polyubiquitination and p62-dependent aggregation of caspase-8 mediate 
extrinsic apoptosis signaling. Cell 2009, 137:721–735. 
120. Ashkenazi A: Targeting death and decoy receptors of the tumour-necrosis 
factor superfamily. Nat Rev Cancer 2002, 2:420–430. 
121. Rath PC, Aggarwal BB: TNF-induced signaling in apoptosis. J Clin Immunol 
1999, 19:350–64. 
122. Han J, Zhong C-Q, Zhang D-W: Programmed necrosis: backup to and 
competitor with apoptosis in the immune system. Nat Immunol 2011, 12:1143–9. 
123. Safa AR: c-FLIP, a master anti-apoptotic regulator. Exp Oncol 2012, 34:176–
84. 
 237 
124. De Almagro MC, Vucic D: The inhibitor of apoptosis (IAP) proteins are 
critical regulators of signaling pathways and targets for anti-cancer therapy. Exp 
Oncol 2012, 34:200–11. 
125. Mansouri A, Ridgway LD, Korapati AL, Zhang Q, Tian L, Wang Y, Siddik ZH, 
Mills GB, Claret FX: Sustained activation of JNK/p38 MAPK pathways in 
response to cisplatin leads to Fas ligand induction and cell death in ovarian 
carcinoma cells. J Biol Chem 2003, 278:19245–19256. 
126. Abedini MR, Muller EJ, Brun J, Bergeron R, Gray DA, Tsang BK: Cisplatin 
induces p53-dependent FLICE-like inhibitory protein ubiquitination in ovarian 
cancer cells. Cancer Res 2008, 68:4511–4517. 
127. Persons DL, Yazlovitskaya EM, Pelling JC: Effect of extracellular signal-
regulated kinase on p53 accumulation in response to cisplatin. J Biol Chem 2000, 
275:35778–35785. 
128. Tenev T, Bianchi K, Darding M, Broemer M, Langlais C, Wallberg F, Zachariou 
A, Lopez J, MacFarlane M, Cain K, Meier P: The Ripoptosome, a signaling 
platform that assembles in response to genotoxic stress and loss of IAPs. Mol Cell 
2011, 43:432–448. 
129. Feoktistova M, Geserick P, Kellert B, Dimitrova DP, Langlais C, Hupe M, Cain 
K, MacFarlane M, Hacker G, Leverkus M: cIAPs block Ripoptosome formation, a 
RIP1/caspase-8 containing intracellular cell death complex differentially 
regulated by cFLIP isoforms. Mol Cell 2011, 43:449–463. 
130. Imre G, Larisch S, Rajalingam K: Ripoptosome: a novel IAP-regulated cell 
death-signalling platform. J Mol Cell Biol 2011, 3:324–326. 
131. Bertrand MJ, Vandenabeele P: The Ripoptosome: death decision in the 
cytosol. Mol Cell 2011, 43:323–325. 
132. Hengartner MO: The biochemistry of apoptosis. Nature 2000, 407:770–6. 
 238 
133. Earnshaw WC, Martins LM, Kaufmann SH: Mammalian caspases: structure, 
activation, substrates, and functions during apoptosis. Annu Rev Biochem 1999, 
68:383–424. 
134. Thornberry NA, Rano TA, Peterson EP, Rasper DM, Timkey T, Garcia-Calvo 
M, Houtzager VM, Nordstrom PA, Roy S, Vaillancourt JP, Chapman KT, Nicholson 
DW: A combinatorial approach defines specificities of members of the caspase 
family and granzyme B. Functional relationships established for key mediators 
of apoptosis. J Biol Chem 1997, 272:17907–11. 
135. Kumar S: Caspase function in programmed cell death. Cell Death Differ 
2007, 14:32–43. 
136. Li H, Zhu H, Xu CJ, Yuan J: Cleavage of BID by caspase 8 mediates the 
mitochondrial damage in the Fas pathway of apoptosis. Cell 1998, 94:491–501. 
137. Napetschnig J, Wu H: Molecular basis of NF-κB signaling. Annu Rev Biophys 
2013, 42:443–68. 
138. Brzóska K, Szumiel I: Signalling loops and linear pathways: NF-kappaB 
activation in response to genotoxic stress. Mutagenesis 2009, 24:1–8. 
139. Huang TT, Wuerzberger-Davis SM, Wu Z-H, Miyamoto S: Sequential 
modification of NEMO/IKKgamma by SUMO-1 and ubiquitin mediates NF-
kappaB activation by genotoxic stress. Cell 2003, 115:565–576. 
140. Roos WP, Kaina B: DNA damage-induced cell death: from specific DNA 
lesions to the DNA damage response and apoptosis. Cancer Lett 2013, 332:237–
248. 
141. Isfort RJ, Cody DB, Lovell G, Doersen CJ: Analysis of oncogenes, tumor 
suppressor genes, autocrine growth-factor production, and differentiation state 
of human osteosarcoma cell lines. Mol Carcinog 1995, 14:170–178. 
142. Louie KG, Behrens BC, Kinsella TJ, Hamilton TC, Grotzinger KR, McKoy 
WM, Winker MA, Ozols RF: Radiation survival parameters of antineoplastic 
 239 
drug-sensitive and -resistant human ovarian cancer cell lines and their 
modification by buthionine sulfoximine. Cancer Res 1985, 45:2110–5. 
143. Oshima S, Turer EE, Callahan JA, Chai S, Advincula R, Barrera J, Shifrin N, 
Lee B, Benedict Yen TS, Woo T, Malynn BA, Ma A: ABIN-1 is a ubiquitin sensor 
that restricts cell death and sustains embryonic development. Nature 2009, 
457:906–909. 
144. Baba TW, Giroir BP, Humphries EH: Cell lines derived from avian 
lymphomas exhibit two distinct phenotypes. Virology 1985, 144:139–151. 
145. O’Gorman S, Fox DT, Wahl GM: Recombinase-mediated gene activation and 
site-specific integration in mammalian cells. Science 1991, 251:1351–1355. 
146. Pipas JM: SV40: Cell transformation and tumorigenesis. Virology 2009, 
384:294–303. 
147. Nijwening JH, Kuiken HJ, Beijersbergen RL: Screening for modulators of 
cisplatin sensitivity: unbiased screens reveal common themes. Cell Cycle 2011, 
10:380–386. 
148. Smogorzewska A, Matsuoka S, Vinciguerra P, McDonald ER, Hurov KE, Luo J, 
Ballif BA, Gygi SP, Hofmann K, D’Andrea AD, Elledge SJ, McDonald  3rd ER: 
Identification of the FANCI protein, a monoubiquitinated FANCD2 paralog 
required for DNA repair. Cell 2007, 129:289–301. 
149. Aressy B, Jullien D, Cazales M, Marcellin M, Bugler B, Burlet-Schiltz O, 
Ducommun B: A screen for deubiquitinating enzymes involved in the G₂/M 
checkpoint identifies USP50 as a regulator of HSP90-dependent Wee1 stability. 
Cell Cycle 2010, 9:3815–3822. 
150. Shen X, Jun S, O’Neal LE, Sonoda E, Bemark M, Sale JE, Li L: REV3 and 
REV1 play major roles in recombination-independent repair of DNA interstrand 
cross-links mediated by monoubiquitinated proliferating cell nuclear antigen 
(PCNA). J Biol Chem 2006, 281:13869–72. 
 240 
151. Enoiu M, Jiricny J, Schärer OD: Repair of cisplatin-induced DNA interstrand 
crosslinks by a replication-independent pathway involving transcription-coupled 
repair and translesion synthesis. Nucleic Acids Res 2012, 40:8953–64. 
152. Lee H, Alpi AF, Park MS, Rose A, Koo HS: C. elegans Ring Finger Protein 
RNF-113 Is Involved in Interstrand DNA Crosslink Repair and Interacts with a 
RAD51C Homolog. PLoS One 2013, 8. 
153. Niu J, Shi Y, Iwai K, Wu Z-H: LUBAC regulates NF-κB activation upon 
genotoxic stress by promoting linear ubiquitination of NEMO. EMBO J 2011, 
30:3741–3753. 
154. Rieser E, Cordier SM, Walczak H: Linear ubiquitination: a newly discovered 
regulator of cell signalling. Trends Biochem Sci 2013, 38:94–102. 
155. Ramirez VP, Gurevich I, Aneskievich BJ: Emerging roles for TNIP1 in 
regulating post-receptor signaling. Cytokine Growth Factor Rev 2012, 23:109–18. 
156. Scheffner M, Huibregtse JM, Howley PM: Identification of a human 
ubiquitin-conjugating enzyme that mediates the E6-AP-dependent 
ubiquitination of p53. Proc Natl Acad Sci U S A 1994, 91:8797–801. 
157. Simicek M, Lievens S, Laga M, Guzenko D, Aushev VN, Kalev P, Baietti MF, 
Strelkov S V, Gevaert K, Tavernier J, Sablina AA: The deubiquitylase USP33 
discriminates between RALB functions in autophagy and innate immune 
response. Nat Cell Biol 2013, 15:1220–30. 
158. Yuasa-Kawada J, Kinoshita-Kawada M, Rao Y, Wu JY: Deubiquitinating 
enzyme USP33/VDU1 is required for Slit signaling in inhibiting breast cancer 
cell migration. Proc Natl Acad Sci U S A 2009, 106:14530–5. 
159. Berthouze M, Venkataramanan V, Li Y, Shenoy SK: The deubiquitinases 
USP33 and USP20 coordinate beta2 adrenergic receptor recycling and 
resensitization. EMBO J 2009, 28:1684–96. 
 241 
160. Burrows AC, Prokop J, Summers MK: Skp1-Cul1-F-box ubiquitin ligase 
(SCF(βTrCP))-mediated destruction of the ubiquitin-specific protease USP37 
during G2-phase promotes mitotic entry. J Biol Chem 2012, 287:39021–9. 
161. Das CM, Taylor P, Gireud M, Singh A, Lee D, Fuller G, Ji L, Fangusaro J, 
Rajaram V, Goldman S, Eberhart C, Gopalakrishnan V: The deubiquitylase USP37 
links REST to the control of p27 stability and cell proliferation. Oncogene 2013, 
32:1691–701. 
162. Huang X, Summers MK, Pham V, Lill JR, Liu J, Lee G, Kirkpatrick DS, Jackson 
PK, Fang G, Dixit VM: Deubiquitinase USP37 is activated by CDK2 to antagonize 
APC(CDH1) and promote S phase entry. Mol Cell 2011, 42:511–23. 
163. Hock AK, Vigneron AM, Carter S, Ludwig RL, Vousden KH: Regulation of 
p53 stability and function by the deubiquitinating enzyme USP42. EMBO J 2011, 
30:4921–30. 
164. Boutros M, Ahringer J: The art and design of genetic screens: RNA 
interference. Nat Rev Genet 2008, 9:554–66. 
165. Boulton SJ, Gartner A, Reboul J, Vaglio P, Dyson N, Hill DE, Vidal M: 
Combined functional genomic maps of the C. elegans DNA damage response. 
Science 2002, 295:127–131. 
166. Li S, Armstrong CM, Bertin N, Ge H, Milstein S, Boxem M, Vidalain P-O, Han 
J-DJ, Chesneau A, Hao T, Goldberg DS, Li N, Martinez M, Rual J-F, Lamesch P, Xu 
L, Tewari M, Wong SL, Zhang L V, Berriz GF, Jacotot L, Vaglio P, Reboul J, 
Hirozane-Kishikawa T, Li Q, Gabel HW, Elewa A, Baumgartner B, Rose DJ, Yu H, 
et al.: A map of the interactome network of the metazoan C. elegans. Science 
2004, 303:540–543. 
167. Youds JL, Barber LJ, Boulton SJ: C. elegans: a model of Fanconi anemia and 
ICL repair. Mutat Res 2009, 668:103–116. 
 242 
168. Goldfeder MB, Oliveira CC: Cwc24p, a novel Saccharomyces cerevisiae 
nuclear ring finger protein, affects pre-snoRNA U3 splicing. J Biol Chem 2008, 
283:2644–53. 
169. Coltri PP, Oliveira CC: Cwc24p is a general Saccharomyces cerevisiae 
splicing factor required for the stable U2 snRNP binding to primary transcripts. 
PLoS One 2012, 7:e45678. 
170. Ohi MD, Gould KL: Characterization of interactions among the Cef1p-
Prp19p-associated splicing complex. RNA 2002, 8:798–815. 
171. Ohi MD, Link AJ, Ren L, Jennings JL, McDonald WH, Gould KL: Proteomics 
analysis reveals stable multiprotein complexes in both fission and budding yeasts 
containing Myb-related Cdc5p/Cef1p, novel pre-mRNA splicing factors, and 
snRNAs. Mol Cell Biol 2002, 22:2011–24. 
172. Kerins JA, Hanazawa M, Dorsett M, Schedl T: PRP-17 and the pre-mRNA 
splicing pathway are preferentially required for the proliferation versus meiotic 
development decision and germline sex determination in Caenorhabditis elegans. 
Dev Dyn 2010, 239:1555–1572. 
173. Szczesniak MW, Ciomborowska J, Nowak W, Rogozin IB, Makalowska I, 
Szcześniak MW, Makałowska I: Primate and rodent specific intron gains and the 
origin of retrogenes with splice variants. Mol Biol Evol 2011, 28:33–37. 
174. Lee O-H, Kim H, He Q, Baek HJ, Yang D, Chen L-Y, Liang J, Chae HK, Safari 
A, Liu D, Songyang Z: Genome-wide YFP fluorescence complementation screen 
identifies new regulators for telomere signaling in human cells. Mol Cell 
Proteomics 2011, 10:M110.001628. 
175. Hegele A, Kamburov A, Grossmann A, Sourlis C, Wowro S, Weimann M, Will 
CL, Pena V, Lührmann R, Stelzl U: Dynamic protein-protein interaction wiring of 
the human spliceosome. Mol Cell 2012, 45:567–80. 
176. Cliby WA, Roberts CJ, Cimprich KA, Stringer CM, Lamb JR, Schreiber SL, 
Friend SH: Overexpression of a kinase-inactive ATR protein causes sensitivity to 
 243 
DNA-damaging agents and defects in cell cycle checkpoints. Embo J 1998, 
17:159–169. 
177. Wright JA, Keegan KS, Herendeen DR, Bentley NJ, Carr AM, Hoekstra MF, 
Concannon P: Protein kinase mutants of human ATR increase sensitivity to UV 
and ionizing radiation and abrogate cell cycle checkpoint control. Proc Natl Acad 
Sci U S A 1998, 95:7445–50. 
178. Deans AJ, West SC: FANCM connects the genome instability disorders 
Bloom’s Syndrome and Fanconi Anemia. Mol Cell 2009, 36:943–953. 
179. Riedl SJ, Shi Y: Molecular mechanisms of caspase regulation during 
apoptosis. Nat Rev Mol Cell Biol 2004, 5:897–907. 
180. MacKay C, Carroll E, Ibrahim AFM, Garg A, Inman GJ, Hay RT, Alpi AF: E3 
Ubiquitin Ligase HOIP Attenuates Apoptotic Cell Death Induced by Cisplatin. 
Cancer Res 2014:0008–5472.CAN–13–2131–. 
181. Lee DW, Peggie M, Deak M, Toth R, Gage ZO, Wood N, Schilde C, Kurz T, 
Knebel A: The Dac-tag, an affinity tag based on penicillin-binding protein 5. Anal 
Biochem 2012, 428:64–72. 
182. Sir J-H, Barr AR, Nicholas AK, Carvalho OP, Khurshid M, Sossick A, Reichelt 
S, D’Santos C, Woods CG, Gergely F: A primary microcephaly protein complex 
forms a ring around parental centrioles. Nat Genet 2011:1147–1153. 
183. Kelsall IR, Langenick J, Mackay C, Patel KJ, Alpi AF: The Fanconi Anaemia 
Components UBE2T and FANCM Are Functionally Linked to Nucleotide 
Excision Repair. PLoS One 2012, 7:e36970. 
184. Ulrich E, Boehmelt G, Bird A, Beug H: Immortalization of conditionally 
transformed chicken cells: loss of normal p53 expression is an early step that is 
independent of cell transformation. Genes Dev 1992, 6:876–87. 
185. Takao N, Kato H, Mori R, Morrison C, Sonada E, Sun X, Shimizu H, Yoshioka 
K, Takeda S, Yamamoto K: Disruption of ATM in p53-null cells causes multiple 
 244 
functional abnormalities in cellular response to ionizing radiation. Oncogene 
1999, 18:7002–9. 
186. Ikeda F, Deribe YL, Skanland SS, Stieglitz B, Grabbe C, Franz-Wachtel M, van 
Wijk SJ, Goswami P, Nagy V, Terzic J, Tokunaga F, Androulidaki A, Nakagawa T, 
Pasparakis M, Iwai K, Sundberg JP, Schaefer L, Rittinger K, Macek B, Dikic I: 
SHARPIN forms a linear ubiquitin ligase complex regulating NF-kappaB 
activity and apoptosis. Nature 2011, 471:637–641. 
187. Tokunaga F, Nakagawa T, Nakahara M, Saeki Y, Taniguchi M, Sakata S, 
Tanaka K, Nakano H, Iwai K: SHARPIN is a component of the NF-kappaB-
activating linear ubiquitin chain assembly complex. Nature , 471:633–636. 
188. Gerlach B, Cordier SM, Schmukle AC, Emmerich CH, Rieser E, Haas TL, Webb 
AI, Rickard JA, Anderton H, Wong WW-L, Nachbur U, Gangoda L, Warnken U, 
Purcell AW, Silke J, Walczak H: Linear ubiquitination prevents inflammation and 
regulates immune signalling. Nature 2011, 471:591–6. 
189. Haas TL, Emmerich CH, Gerlach B, Schmukle AC, Cordier SM, Rieser E, 
Feltham R, Vince J, Warnken U, Wenger T, Koschny R, Komander D, Silke J, 
Walczak H: Recruitment of the linear ubiquitin chain assembly complex 
stabilizes the TNF-R1 signaling complex and is required for TNF-mediated gene 
induction. Mol Cell 2009, 36:831–44. 
190. Tokunaga F, Sakata S, Saeki Y, Satomi Y, Kirisako T, Kamei K, Nakagawa T, 
Kato M, Murata S, Yamaoka S, Yamamoto M, Akira S, Takao T, Tanaka K, Iwai K: 
Involvement of linear polyubiquitylation of NEMO in NF-kappaB activation. Nat 
Cell Biol 2009, 11:123–132. 
191. Rahighi S, Ikeda F, Kawasaki M, Akutsu M, Suzuki N, Kato R, Kensche T, 
Uejima T, Bloor S, Komander D, Randow F, Wakatsuki S, Dikic I: Specific 
recognition of linear ubiquitin chains by NEMO is important for NF-kappaB 
activation. Cell 2009, 136:1098–109. 
 245 
192. HogenEsch H, Gijbels MJ, Offerman E, van Hooft J, van Bekkum DW, Zurcher 
C: A spontaneous mutation characterized by chronic proliferative dermatitis in 
C57BL mice. Am J Pathol 1993, 143:972–982. 
193. Niu J, Shi Y, Iwai K, Wu ZH: LUBAC regulates NF-kappaB activation upon 
genotoxic stress by promoting linear ubiquitination of NEMO. EMBO J 2011, 
30:3741–3753. 
194. Hanahan D, Weinberg RA: The Hallmarks of Cancer. Cell 2000, 100:57–70. 
195. Chen DJ, Huerta S: Smac mimetics as new cancer therapeutics. Anticancer 
Drugs 2009, 20:646–58. 
196. Dong G, Chanudet E, Zeng N, Appert A, Chen Y-W, Au W-Y, Hamoudi RA, 
Watkins AJ, Ye H, Liu H, Gao Z, Chuang S-S, Srivastava G, Du M-Q: A20, ABIN-
1/2, and CARD11 mutations and their prognostic value in gastrointestinal 
diffuse large B-cell lymphoma. Clin Cancer Res 2011, 17:1440–51. 
197. Hinz M, Lemke P, Anagnostopoulos I, Hacker C, Krappmann D, Mathas S, 
Dörken B, Zenke M, Stein H, Scheidereit C: Nuclear factor kappaB-dependent 
gene expression profiling of Hodgkin’s disease tumor cells, pathogenetic 
significance, and link to constitutive signal transducer and activator of 
transcription 5a activity. J Exp Med 2002, 196:605–617. 
198. Wullaert A, Wielockx B, Van Huffel S, Bogaert V, De Geest B, Papeleu P, 
Schotte P, El Bakkouri K, Heyninck K, Libert C, Beyaert R: Adenoviral gene 
transfer of ABIN-1 protects mice from TNF/galactosamine-induced acute liver 
failure and lethality. Hepatology 2005, 42:381–389. 
199. El Bakkouri K, Wullaert A, Haegman M, Heyninck K, Beyaert R: Adenoviral 
gene transfer of the NF-kappa B inhibitory protein ABIN-1 decreases allergic 
airway inflammation in a murine asthma model. J Biol Chem 2005, 280:17938–
17944. 
 246 
200. Mauro C, Pacifico F, Lavorgna A, Mellone S, Iannetti A, Acquaviva R, 
Formisano S, Vito P, Leonardi A: ABIN-1 binds to NEMO/IKKgamma and co-
operates with A20 in inhibiting NF-kappaB. J Biol Chem 2006, 281:18482–8. 
201. Wagner S, Carpentier I, Rogov V, Kreike M, Ikeda F, Löhr F, Wu C-JJ, Ashwell 
JD, Dötsch V, Dikic I, Beyaert R, Lohr F, Dotsch V: Ubiquitin binding mediates 
the NF-kappaB inhibitory potential of ABIN proteins. Oncogene 2008, 27:3739–
3745. 
202. Zhou J, Wu R, High AA, Slaughter CA, Finkelstein D, Rehg JE, Redecke V, 
Häcker H: A20-binding inhibitor of NF-κB (ABIN1) controls Toll-like receptor-
mediated CCAAT/enhancer-binding protein β activation and protects from 
inflammatory disease. Proc Natl Acad Sci U S A 2011, 108:E998–1006. 
203. Cohen S, Ciechanover A, Kravtsova-Ivantsiv Y, Lapid D, Lahav-Baratz S: 
ABIN-1 negatively regulates NF-kappaB by inhibiting processing of the p105 
precursor. Biochem Biophys Res Commun 2009, 389:205–10. 
204. Bouwmeester T, Bauch A, Ruffner H, Angrand P-O, Bergamini G, Croughton K, 
Cruciat C, Eberhard D, Gagneur J, Ghidelli S, Hopf C, Huhse B, Mangano R, Michon 
A-M, Schirle M, Schlegl J, Schwab M, Stein MA, Bauer A, Casari G, Drewes G, 
Gavin A-C, Jackson DB, Joberty G, Neubauer G, Rick J, Kuster B, Superti-Furga G: 
A physical and functional map of the human TNF-alpha/NF-kappa B signal 
transduction pathway. Nat Cell Biol 2004, 6:97–105. 
205. Huang L, Verstrepen L, Heyninck K, Wullaert A, Revets H, De Baetselier P, 
Beyaert R: ABINs inhibit EGF receptor-mediated NF-kappaB activation and 
growth of EGF receptor-overexpressing tumour cells. Oncogene 2008, 27:6131–
6140. 
206. Zhang S, Fukushi M, Hashimoto S, Gao C, Huang L, Fukuyo Y, Nakajima T, 
Amagasa T, Enomoto S, Koike K, Miura O, Yamamoto N, Tsuchida N: A new ERK2 
binding protein, Naf1, attenuates the EGF/ERK2 nuclear signaling. Biochem 
Biophys Res Commun 2002, 297:17–23. 
 247 
207. Flores AM, Gurevich I, Zhang C, Ramirez VP, Devens TR, Aneskievich BJ: 
TNIP1 is a corepressor of agonist-bound PPARs. Arch Biochem Biophys 2011, 
516:58–66. 
208. Gurevich I, Aneskievich BJ: Liganded RARα and RARγ interact with but are 
repressed by TNIP1. Biochem Biophys Res Commun 2009, 389:409–414. 
209. Gupta K, Ott D, Hope TJ, Siliciano RF, Boeke JD: A human nuclear shuttling 
protein that interacts with human immunodeficiency virus type 1 matrix is 
packaged into virions. J Virol 2000, 74:11811–11824. 
210. Zhang S, Mahalingam M, Tsuchida N: Naf1α is phosphorylated in mitotic 
phase and required to protect cells against apoptosis. Biochem Biophys Res 
Commun 2008, 367:364–369. 
211. Nosil P, Funk DJ, Ortiz-Barrientos D: Divergent selection and heterogeneous 
genomic divergence. Mol Ecol 2009, 18:375–402. 
212. Tian B, Nowak DE, Jamaluddin M, Wang S, Brasier AR: Identification of 
direct genomic targets downstream of the nuclear factor-kappaB transcription 
factor mediating tumor necrosis factor signaling. J Biol Chem 2005, 280:17435–
17448. 
213. Massa PE, Li X, Hanidu A, Siamas J, Pariali M, Pareja J, Savitt AG, Catron KM, 
Li J, Marcu KB: Gene expression profiling in conjunction with physiological 
rescues of IKKalpha-null cells with wild type or mutant IKKalpha reveals 
distinct classes of IKKalpha/NF-kappaB-dependent genes. J Biol Chem 2005, 
280:14057–14069. 
214. Ashour AE, Jamal S, Cheryan VT, Muthu M, Zoheir KMA, Alafeefy AM, Abd-
Allah AR, Levi E, Tarca AL, Polin LA, Rishi AK: CARP-1 Functional Mimetics: A 
Novel Class of Small Molecule Inhibitors of Medulloblastoma Cell Growth. PLoS 
One 2013, 8. 
 248 
215. Verstrepen L, Carpentier I, Verhelst K, Beyaert R: ABINs: A20 binding 
inhibitors of NF-kappa B and apoptosis signaling. Biochem Pharmacol 2009, 
78:105–14. 
216. Hinata K, Gervin AM, Jennifer Zhang Y, Khavari PA: Divergent gene 
regulation and growth effects by NF-kappa B in epithelial and mesenchymal 
cells of human skin. Oncogene 2003, 22:1955–1964. 
217. Fukushi M, Dixon J, Kimura T, Tsurutani N, Dixon MJ, Yamamoto N: 
Identification and cloning of a novel cellular protein Naf1, Nef-associated factor 
1, that increases cell surface CD4 expression. FEBS Lett 1999, 442:83–88. 
218. Shiote Y, Ouchida M, Jitsumori Y, Ogama Y, Matsuo Y, Ishimaru F, Tanimoto 
M, Shimizu K: Multiple splicing variants of Naf1/ABIN-1 transcripts and their 
alterations in hematopoietic tumors. Int J Mol Med 2006, 18:917–923. 
219. Favre M, Butticaz C, Stevenson B, Jongeneel CV, Telenti A: High frequency of 
alternative splicing of human genes participating in the HIV-1 life cycle: a model 
using TSG101, betaTrCP, PPIA, INI1, NAF1, and PML. J Acquir Immune Defic 
Syndr 2003, 34:127–133. 
220. Liu F, Bardhan K, Yang D, Thangaraju M, Ganapathy V, Waller JL, Liles GB, 
Lee JR, Liu K: NF-κB directly regulates Fas transcription to modulate Fas-
mediated apoptosis and tumor suppression. J Biol Chem 2012, 287:25530–40. 
221. Joyce D, Albanese C, Steer J, Fu M, Bouzahzah B, Pestell RG: NF-kappaB and 
cell-cycle regulation: the cyclin connection. Cytokine Growth Factor Rev 2001, 
12:73–90. 
222. Chang L, Kamata H, Solinas G, Luo JL, Maeda S, Venuprasad K, Liu YC, Karin 
M: The E3 ubiquitin ligase itch couples JNK activation to TNFα-induced cell 
death by inducing c-FLIPL turnover. Cell 2006, 124:601–613. 
223. Hinz M, Stilmann M, Arslan SÇ, Khanna KK, Dittmar G, Scheidereit C: A 
cytoplasmic ATM-TRAF6-cIAP1 module links nuclear DNA damage signaling to 
ubiquitin-mediated NF-κB activation. Mol Cell 2010, 40:63–74. 
 249 
224. Jin H-S, Lee D-H, Kim D-H, Chung J-H, Lee S-J, Lee TH: cIAP1, cIAP2, and 
XIAP act cooperatively via nonredundant pathways to regulate genotoxic stress-
induced nuclear factor-kappaB activation. Cancer Res 2009, 69:1782–1791.  
 
Appendix	  1
Quality	  control	  for	  the	  primary	  screen
Replicate and treatment Plate ID siREV1L Avg siREV1L CV REV1L Stdev siNT Avg siNT CV siNT Stdev NonTransfected Avg NonTransfected CV NonTransfected Stdev SB Zprime
A-­‐100690 21977.00 13.26 2913.47 51092.57 2.61 1332.12 51023.00 2.69 1374.53 2.32 0.56
A-­‐100691 23273.00 5.87 1367.16 52368.00 4.79 2506.68 54594.00 2.83 1547.13 2.25 0.60
A-­‐100692 21794.00 5.79 1261.83 52858.86 6.09 3221.59 54012.00 2.84 1534.87 2.43 0.57
A-­‐100693 23930.00 13.96 3340.44 54592.50 3.07 1677.65 50858.00 17.75 9029.80 2.28 0.51
A-­‐100695 21899.00 8.37 1832.05 51723.00 5.03 2601.20 52669.00 6.05 3185.33 2.36 0.55
A-­‐100696 20309.33 1.73 351.55 50891.00 6.25 3178.60 52102.00 3.32 1727.47 2.51 0.65
A-­‐100697 23138.00 5.42 1254.03 54201.71 6.53 3541.21 52170.00 1.66 864.84 2.34 0.54
A-­‐100698 19031.00 7.40 1408.40 47319.50 5.30 2507.41 47589.00 0.79 376.49 2.49 0.58
A-­‐100700 17148.00 8.46 1451.17 45971.50 7.19 3303.22 46288.00 7.76 3593.52 2.68 0.51
A-­‐100701 13304.00 3.44 457.89 39612.00 9.05 3585.54 38770.67 21.92 8497.02 2.98 0.54
A-­‐100702 11715.00 7.61 891.50 33532.00 5.47 1832.85 32800.00 21.54 7063.77 2.86 0.63
A-­‐100703 17238.00 2.08 358.88 43792.00 6.42 2812.56 44609.00 10.02 4470.64 2.54 0.64
A-­‐100763 134898.00 3.58 4832.35 197097.71 1.68 3315.90 185772.00 2.96 5501.09 1.46 0.61
A-­‐100764 123946.00 4.95 6132.73 193083.00 2.21 4270.97 187703.00 3.04 5707.90 1.56 0.55
A-­‐100765 126177.00 3.35 4222.30 189346.00 1.81 3422.62 182850.00 1.26 2312.63 1.50 0.64
A-­‐100707 53143.00 9.41 4999.15 84751.50 3.75 3177.28 80967.00 4.33 3505.57 1.59 0.22
A-­‐100708 64437.00 3.93 2532.21 88671.50 3.37 2988.87 85293.00 1.59 1360.01 1.38 0.32
A-­‐100709 59916.00 6.39 3828.99 88280.00 3.22 2844.86 84225.00 4.65 3917.82 1.47 0.29
A-­‐100710 57603.00 7.43 4282.40 82921.00 1.68 1390.95 81441.00 2.88 2344.61 1.44 0.33
A-­‐100712 59468.00 8.48 5045.62 87395.50 4.41 3853.52 85913.00 5.45 4680.94 1.47 0.04
A-­‐100713 57344.00 4.39 2515.98 87190.00 4.96 4322.44 87104.00 9.85 8578.82 1.52 0.31
A-­‐100714 53588.00 7.72 4137.66 81384.50 4.04 3287.71 79164.00 5.01 3967.82 1.52 0.20
A-­‐100715 54192.00 9.66 5236.98 79153.00 8.08 6394.26 81874.00 2.96 2423.71 1.46 -­‐0.40
A-­‐100717 55384.00 5.95 3294.52 76472.00 4.14 3166.07 79444.00 7.83 6223.84 1.38 0.08
A-­‐100718 53152.00 14.21 7552.99 87899.00 9.03 7936.16 82352.00 3.43 2828.08 1.65 -­‐0.34
A-­‐100719 47749.00 5.66 2700.98 79932.50 5.16 4126.52 79741.33 8.43 6720.74 1.67 0.36
A-­‐100720 47737.00 10.34 4934.37 75453.50 7.59 5723.94 75003.00 6.71 5029.72 1.58 -­‐0.15
A-­‐100767 209512.00 2.54 5327.40 221038.50 2.49 5511.35 211020.00 3.88 8178.18 1.06 -­‐1.82
A-­‐100768 210292.00 2.20 4630.26 225864.00 1.70 3839.20 214956.00 2.71 5832.38 1.07 -­‐0.63
A-­‐100769 211081.00 0.51 1069.77 225781.00 1.58 3570.55 211681.00 1.53 3233.17 1.07 0.05
A-­‐100727 95180.00 5.48 5211.34 146730.00 2.06 3047.83 145229.00 4.13 6001.69 1.54 0.53
A-­‐100728 95463.00 3.17 3022.54 153110.50 3.47 5320.52 144333.00 5.23 7546.15 1.60 0.57
A-­‐100729 95142.00 2.36 2246.70 148809.00 4.27 6346.99 146280.00 5.94 8693.86 1.56 0.52
A-­‐100730 96991.00 3.47 3368.02 150719.00 2.66 4011.00 154907.00 4.96 7681.56 1.55 0.59
A-­‐100733 86496.00 1.74 1507.30 147909.50 5.08 7515.44 140117.00 5.34 7475.37 1.71 0.56
A-­‐100734 95418.00 2.02 1922.99 149546.50 3.15 4708.28 141389.00 5.66 8006.43 1.57 0.63
A-­‐100735 93113.33 3.28 3055.50 142923.50 2.35 3501.05 142546.00 6.64 9460.65 1.47 0.61
A-­‐100736 93528.00 1.66 1554.20 148122.00 2.81 4155.07 151123.00 5.45 8240.48 1.58 0.69
A-­‐100737 84329.00 2.93 2473.78 134040.00 3.30 4423.68 127656.00 5.02 6414.29 1.59 0.58
A-­‐100738 99360.00 3.11 3094.52 152488.00 1.84 2803.86 145049.00 1.53 2220.85 1.53 0.67
A-­‐100739 93313.00 2.31 2154.82 148327.50 3.65 5420.75 143752.00 4.54 6530.29 1.59 0.59
A-­‐100740 127229.00 1.88 2388.91 203281.50 1.83 3727.43 187746.00 3.12 5858.48 1.60 0.76
A-­‐100757 132377.00 1.73 2294.74 201308.00 3.19 6431.61 193383.00 3.44 6644.97 1.52 0.62
A-­‐100815 174230.00 2.14 3727.82 247512.00 2.83 7015.70 232775.00 3.21 7475.49 1.42 0.56
A-­‐100817 186002.67 2.78 5175.95 243816.00 2.29 5615.34 233298.00 2.79 6520.20 1.28 0.45
A-­‐100741 215600.00 2.12 4580.13 228771.50 2.17 4957.85 218870.00 3.96 8660.80 1.06 -­‐1.17
A-­‐100744 174589.00 2.23 3894.10 187064.57 2.48 4634.89 187545.33 1.91 3576.40 1.07 -­‐1.05
A-­‐100745 177452.00 3.27 5799.18 192255.00 1.61 5699.21 184581.33 1.06 1956.55 1.08 -­‐1.33
A-­‐100746 181551.00 0.94 1703.54 194822.50 2.57 5002.75 189850.67 2.19 4156.86 1.07 -­‐0.52
A-­‐100747 176713.00 2.31 4079.66 201072.50 2.15 4327.34 188448.00 1.94 3651.20 1.14 -­‐0.04
A-­‐100750 179329.00 3.42 6137.04 199820.50 2.57 5133.20 196070.67 2.53 4965.94 1.11 -­‐0.65
A-­‐100751 184565.00 1.72 3168.30 198600.00 3.19 6339.03 185038.00 2.70 5004.08 1.08 -­‐1.03
A-­‐100752 178053.00 1.66 2953.52 191971.50 2.61 5009.24 185907.00 3.34 6207.16 1.08 -­‐0.72
A-­‐100753 178994.00 4.06 7274.36 190471.50 1.70 3232.02 183641.00 2.80 5144.30 1.06 -­‐1.75
A-­‐100754 180079.00 4.03 7265.86 194195.50 2.17 4204.62 191689.00 2.13 4087.60 1.08 -­‐1.44
A-­‐100755 188421.00 5.72 10777.25 201165.00 3.03 6098.13 192468.00 4.04 7768.33 1.07 -­‐2.97
A-­‐100756 179396.00 3.56 6378.35 197194.50 4.71 9295.51 186252.00 4.61 8590.89 1.10 -­‐1.64
A-­‐100758 220691.00 2.29 5055.16 228501.50 2.90 6619.46 218186.00 2.14 4673.64 1.04 -­‐3.48
A-­‐100816 225765.00 2.82 6377.16 235912.00 2.43 5722.91 222191.00 3.86 8582.43 1.04 -­‐2.58
A-­‐100818 235658.00 1.94 4568.18 238228.50 3.34 7965.63 225853.33 5.96 13453.55 1.01 -­‐13.63
Replicate	  1,	  3.25	  µM	  cisplatin
Replicate	  1,	  mock	  treatment
Replicate	  2,	  3	  µM	  cisplatin
Replicate	  2,	  mock	  treatment
Appendix	  2
Primary	  screen	  siTarget	  data
Rep Plate ID Compound ID Target Gene Locus ID Cisplatin (µM) CGE PNSF SF Rep Plate ID Compound ID Target Gene Locus ID Cisplatin (µM) CGE PNSF SF
1 A-­‐100707 RNAi00001 AKTIP 64400 3.25 95.64 17.62 -­‐0.83 2 A-­‐100744 RNAi00053 UBE2C 11065 3 90.26 -­‐6.16 -­‐0.30
2 A-­‐100744 RNAi00001 AKTIP 64400 3 87.51 32.77 -­‐0.51 1 A-­‐100707 RNAi00054 UBE2D1 7321 3.25 77.03 -­‐17.76 -­‐0.63
1 A-­‐100707 RNAi00002 ARIH1 25820 3.25 83.12 25.99 -­‐0.87 2 A-­‐100744 RNAi00054 UBE2D1 7321 3 77.35 -­‐18.11 -­‐0.24
2 A-­‐100744 RNAi00002 ARIH1 25820 3 89.75 44.57 -­‐0.58 1 A-­‐100707 RNAi00055 UBE2D2 7322 3.25 57.56 146.15 -­‐1.52
1 A-­‐100707 RNAi00003 BIRC6 57448 3.25 85.20 18.87 -­‐0.83 2 A-­‐100744 RNAi00055 UBE2D2 7322 3 59.86 102.58 -­‐0.89
2 A-­‐100744 RNAi00003 BIRC6 57448 3 98.45 23.85 -­‐0.46 1 A-­‐100707 RNAi00056 UBE2D3 7323 3.25 34.77 137.50 -­‐1.48
1 A-­‐100707 RNAi00004 C10ORF46 143384 3.25 43.02 7.19 -­‐0.77 2 A-­‐100744 RNAi00056 UBE2D3 7323 3 42.59 119.89 -­‐0.98
2 A-­‐100744 RNAi00004 C10ORF46 143384 3 76.12 56.85 -­‐0.64 1 A-­‐100707 RNAi00057 UBE2D4 51619 3.25 66.66 76.81 -­‐1.15
1 A-­‐100707 RNAi00005 FLJ34154 283450 3.25 81.22 50.09 -­‐1.00 2 A-­‐100744 RNAi00057 UBE2D4 51619 3 80.95 32.38 -­‐0.51
2 A-­‐100744 RNAi00005 FLJ34154 283450 3 80.60 12.06 -­‐0.40 1 A-­‐100707 RNAi00058 UBE2E1 7324 3.25 34.01 -­‐106.79 -­‐0.15
1 A-­‐100707 RNAi00006 TIP120A 55832 3.25 32.93 -­‐7.58 -­‐0.69 2 A-­‐100744 RNAi00058 UBE2E1 7324 3 50.47 -­‐51.99 -­‐0.06
2 A-­‐100744 RNAi00006 TIP120A 55832 3 41.94 -­‐29.52 -­‐0.18 1 A-­‐100707 RNAi00059 UBE2E2 7325 3.25 53.58 -­‐69.41 -­‐0.35
1 A-­‐100707 RNAi00007 CAND2 23066 3.25 80.00 53.35 -­‐1.02 2 A-­‐100744 RNAi00059 UBE2E2 7325 3 65.18 -­‐49.16 -­‐0.07
2 A-­‐100744 RNAi00007 CAND2 23066 3 87.95 18.02 -­‐0.43 1 A-­‐100707 RNAi00060 UBE2E3 10477 3.25 77.60 9.07 -­‐0.78
1 A-­‐100707 RNAi00008 CDC34 997 3.25 62.98 85.31 -­‐1.19 2 A-­‐100744 RNAi00060 UBE2E3 10477 3 85.54 10.84 -­‐0.39
2 A-­‐100744 RNAi00008 CDC34 997 3 80.87 51.67 -­‐0.61 1 A-­‐100707 RNAi00061 UBE2F 140739 3.25 81.96 48.96 -­‐1.00
1 A-­‐100707 RNAi00009 CUL1 8454 3.25 53.04 -­‐18.76 -­‐0.63 2 A-­‐100744 RNAi00061 UBE2F 140739 3 94.75 11.20 -­‐0.40
2 A-­‐100744 RNAi00009 CUL1 8454 3 66.57 -­‐23.05 -­‐0.21 1 A-­‐100707 RNAi00062 UBE2G1 7326 3.25 84.59 52.52 -­‐1.02
1 A-­‐100707 RNAi00010 CUL2 8453 3.25 54.44 69.64 -­‐1.11 2 A-­‐100744 RNAi00062 UBE2G1 7326 3 81.63 12.29 -­‐0.40
2 A-­‐100744 RNAi00010 CUL2 8453 3 59.60 23.81 -­‐0.46 1 A-­‐100707 RNAi00063 UBE2G2 7327 3.25 47.77 41.09 -­‐0.95
1 A-­‐100707 RNAi00011 CUL3 8452 3.25 75.19 25.71 -­‐0.87 2 A-­‐100744 RNAi00063 UBE2G2 7327 3 70.07 42.77 -­‐0.57
2 A-­‐100744 RNAi00011 CUL3 8452 3 95.20 60.09 -­‐0.66 1 A-­‐100707 RNAi00064 UBE2H 7328 3.25 66.46 -­‐36.40 -­‐0.53
1 A-­‐100707 RNAi00012 CUL4A 8451 3.25 96.64 -­‐1.80 -­‐0.72 2 A-­‐100744 RNAi00064 UBE2H 7328 3 82.23 18.38 -­‐0.44
2 A-­‐100744 RNAi00012 CUL4A 8451 3 94.51 3.36 -­‐0.35 1 A-­‐100707 RNAi00065 UBE2I 7329 3.25 55.07 -­‐47.28 -­‐0.47
1 A-­‐100707 RNAi00013 CUL4B 8450 3.25 86.05 7.59 -­‐0.77 2 A-­‐100744 RNAi00065 UBE2I 7329 3 68.72 -­‐40.95 -­‐0.12
2 A-­‐100744 RNAi00013 CUL4B 8450 3 95.57 -­‐0.69 -­‐0.33 1 A-­‐100707 RNAi00066 UBE2J1 51465 3.25 40.27 -­‐83.39 -­‐0.28
1 A-­‐100707 RNAi00014 CUL5 8065 3.25 76.23 -­‐20.56 -­‐0.62 2 A-­‐100744 RNAi00066 UBE2J1 51465 3 48.86 -­‐62.76 0.00
2 A-­‐100744 RNAi00014 CUL5 8065 3 82.50 -­‐1.21 -­‐0.33 1 A-­‐100707 RNAi00067 UBE2J2 118424 3.25 68.53 25.29 -­‐0.87
1 A-­‐100707 RNAi00015 CUL7 9820 3.25 91.05 54.67 -­‐1.03 2 A-­‐100744 RNAi00067 UBE2J2 118424 3 74.05 -­‐8.12 -­‐0.29
2 A-­‐100744 RNAi00015 CUL7 9820 3 95.23 25.11 -­‐0.47 1 A-­‐100707 RNAi00068 UBE2L3 7332 3.25 40.30 13.41 -­‐0.80
1 A-­‐100707 RNAi00016 DCUN1D1 54165 3.25 85.67 86.58 -­‐1.20 2 A-­‐100744 RNAi00068 UBE2L3 7332 3 51.49 68.00 -­‐0.70
2 A-­‐100744 RNAi00016 DCUN1D1 54165 3 86.93 0.79 -­‐0.34 1 A-­‐100707 RNAi00069 UBE2L6 9246 3.25 93.65 43.20 -­‐0.97
1 A-­‐100707 RNAi00017 DCUN1D2 55208 3.25 91.43 17.65 -­‐0.83 2 A-­‐100744 RNAi00069 UBE2L6 9246 3 102.92 38.73 -­‐0.54
2 A-­‐100744 RNAi00017 DCUN1D2 55208 3 100.84 21.54 -­‐0.45 1 A-­‐100707 RNAi00070 UBE2M 9040 3.25 84.43 94.11 -­‐1.24
1 A-­‐100707 RNAi00018 DCUN1D3 123879 3.25 72.20 122.55 -­‐1.40 2 A-­‐100744 RNAi00070 UBE2M 9040 3 98.76 30.43 -­‐0.50
2 A-­‐100744 RNAi00018 DCUN1D3 123879 3 87.36 109.08 -­‐0.92 1 A-­‐100707 RNAi00071 UBE2N 7334 3.25 40.58 138.39 -­‐1.48
1 A-­‐100707 RNAi00019 DCUN1D4 23142 3.25 99.43 46.15 -­‐0.98 2 A-­‐100744 RNAi00071 UBE2N 7334 3 74.26 96.83 -­‐0.86
2 A-­‐100744 RNAi00019 DCUN1D4 23142 3 95.18 -­‐4.04 -­‐0.31 1 A-­‐100707 RNAi00072 UBE2NL 389898 3.25 31.40 173.74 -­‐1.67
1 A-­‐100707 RNAi00020 DCUN1D5 84259 3.25 53.79 35.80 -­‐0.92 2 A-­‐100744 RNAi00072 UBE2NL 389898 3 40.93 76.50 -­‐0.75
2 A-­‐100744 RNAi00020 DCUN1D5 84259 3 73.23 11.69 -­‐0.40 1 A-­‐100707 RNAi00073 UBE2O 63893 3.25 94.59 24.81 -­‐0.87
1 A-­‐100707 RNAi00021 EDD1 51366 3.25 18.16 76.30 -­‐1.15 2 A-­‐100744 RNAi00073 UBE2O 63893 3 92.25 12.58 -­‐0.40
2 A-­‐100744 RNAi00021 EDD1 51366 3 20.70 34.97 -­‐0.52 1 A-­‐100707 RNAi00074 UBE2Q1 55585 3.25 82.28 -­‐13.14 -­‐0.66
1 A-­‐100707 RNAi00022 FLJ25076 134111 3.25 86.44 51.01 -­‐1.01 2 A-­‐100744 RNAi00074 UBE2Q1 55585 3 96.46 -­‐0.08 -­‐0.34
2 A-­‐100744 RNAi00022 FLJ25076 134111 3 83.67 0.46 -­‐0.34 1 A-­‐100707 RNAi00075 UBE2Q2 92912 3.25 84.58 -­‐7.92 -­‐0.69
1 A-­‐100707 RNAi00023 HACE1 57531 3.25 65.32 20.28 -­‐0.84 2 A-­‐100744 RNAi00075 UBE2Q2 92912 3 91.09 -­‐11.04 -­‐0.28
2 A-­‐100744 RNAi00023 HACE1 57531 3 79.07 37.21 -­‐0.54 1 A-­‐100707 RNAi00076 UBE2R2 54926 3.25 85.76 -­‐13.46 -­‐0.66
1 A-­‐100707 RNAi00024 HECTD1 25831 3.25 96.40 29.20 -­‐0.89 2 A-­‐100744 RNAi00076 UBE2R2 54926 3 90.62 -­‐16.25 -­‐0.25
2 A-­‐100744 RNAi00024 HECTD1 25831 3 99.90 -­‐0.73 -­‐0.33 1 A-­‐100707 RNAi00077 UBE2S 27338 3.25 52.42 -­‐11.24 -­‐0.67
1 A-­‐100707 RNAi00025 HECTD2 143279 3.25 15.40 12.02 -­‐0.80 2 A-­‐100744 RNAi00077 UBE2S 27338 3 68.17 -­‐9.22 -­‐0.29
2 A-­‐100744 RNAi00025 HECTD2 143279 3 16.66 11.04 -­‐0.40 1 A-­‐100707 RNAi00078 UBE2T 29089 3.25 46.96 70.08 -­‐1.11
1 A-­‐100707 RNAi00026 HECTD3 79654 3.25 82.28 35.42 -­‐0.92 2 A-­‐100744 RNAi00078 UBE2T 29089 3 77.27 80.96 -­‐0.77
2 A-­‐100744 RNAi00026 HECTD3 79654 3 87.85 8.18 -­‐0.38 1 A-­‐100707 RNAi00079 UBE2U 148581 3.25 68.73 -­‐9.63 -­‐0.68
1 A-­‐100707 RNAi00027 HECW1 23072 3.25 86.43 -­‐8.50 -­‐0.68 2 A-­‐100744 RNAi00079 UBE2U 148581 3 60.60 -­‐43.57 -­‐0.10
2 A-­‐100744 RNAi00027 HECW1 23072 3 84.23 -­‐26.81 -­‐0.19 1 A-­‐100707 RNAi00080 UBE2V1 7335 3.25 98.99 49.21 -­‐1.00
1 A-­‐100707 RNAi00028 HECW2 57520 3.25 78.14 -­‐8.07 -­‐0.69 2 A-­‐100744 RNAi00080 UBE2V1 7335 3 99.16 15.30 -­‐0.42
2 A-­‐100744 RNAi00028 HECW2 57520 3 86.11 -­‐8.86 -­‐0.29 1 A-­‐100708 RNAi00081 UBE2V2 7336 3.25 51.64 55.47 -­‐1.15
1 A-­‐100707 RNAi00029 HERC1 8925 3.25 89.79 22.10 -­‐0.85 2 A-­‐100745 RNAi00081 UBE2V2 7336 3 66.95 23.92 -­‐0.46
2 A-­‐100744 RNAi00029 HERC1 8925 3 98.98 24.40 -­‐0.47 1 A-­‐100708 RNAi00082 UBE2W 55284 3.25 52.01 101.47 -­‐1.48
1 A-­‐100707 RNAi00030 HERC2 8924 3.25 79.54 99.90 -­‐1.27 2 A-­‐100745 RNAi00082 UBE2W 55284 3 65.11 56.40 -­‐0.65
2 A-­‐100744 RNAi00030 HERC2 8924 3 89.80 51.09 -­‐0.61 1 A-­‐100708 RNAi00083 UBE2Z 65264 3.25 89.12 8.44 -­‐0.82
1 A-­‐100707 RNAi00031 HERC3 8916 3.25 69.82 53.84 -­‐1.02 2 A-­‐100745 RNAi00083 UBE2Z 65264 3 100.20 18.25 -­‐0.43
2 A-­‐100744 RNAi00031 HERC3 8916 3 73.21 -­‐26.04 -­‐0.20 1 A-­‐100708 RNAi00084 UBE3A 7337 3.25 60.45 14.33 -­‐0.86
1 A-­‐100707 RNAi00032 HERC4 26091 3.25 93.64 27.25 -­‐0.88 2 A-­‐100745 RNAi00084 UBE3A 7337 3 63.30 1.24 -­‐0.34
2 A-­‐100744 RNAi00032 HERC4 26091 3 92.04 1.16 -­‐0.34 1 A-­‐100708 RNAi00085 UBE3B 89910 3.25 71.14 -­‐13.95 -­‐0.66
1 A-­‐100707 RNAi00033 HERC5 51191 3.25 81.30 86.36 -­‐1.20 2 A-­‐100745 RNAi00085 UBE3B 89910 3 79.27 29.17 -­‐0.49
2 A-­‐100744 RNAi00033 HERC5 51191 3 92.49 20.70 -­‐0.45 1 A-­‐100708 RNAi00086 UBE3C 9690 3.25 85.32 -­‐40.35 -­‐0.47
1 A-­‐100707 RNAi00034 HERC6 55008 3.25 31.13 -­‐26.43 -­‐0.59 2 A-­‐100745 RNAi00086 UBE3C 9690 3 89.45 17.45 -­‐0.43
2 A-­‐100744 RNAi00034 HERC6 55008 3 41.54 35.92 -­‐0.53 1 A-­‐100708 RNAi00087 UEVLD 55293 3.25 85.42 21.57 -­‐0.91
1 A-­‐100707 RNAi00035 HIP2 3093 3.25 62.97 5.64 -­‐0.76 2 A-­‐100745 RNAi00087 UEVLD 55293 3 88.85 19.89 -­‐0.44
2 A-­‐100744 RNAi00035 HIP2 3093 3 76.11 4.93 -­‐0.36 1 A-­‐100708 RNAi00088 WWP1 11059 3.25 84.65 9.54 -­‐0.83
1 A-­‐100707 RNAi00036 HUWE1 10075 3.25 62.21 -­‐2.01 -­‐0.72 2 A-­‐100745 RNAi00088 WWP1 11059 3 88.81 15.43 -­‐0.42
2 A-­‐100744 RNAi00036 HUWE1 10075 3 70.53 -­‐9.58 -­‐0.28 1 A-­‐100708 RNAi00089 WWP2 11060 3.25 83.83 5.98 -­‐0.80
1 A-­‐100707 RNAi00037 ITCH 83737 3.25 87.91 38.30 -­‐0.94 2 A-­‐100745 RNAi00089 WWP2 11060 3 88.37 29.36 -­‐0.49
2 A-­‐100744 RNAi00037 ITCH 83737 3 97.22 17.73 -­‐0.43 1 A-­‐100709 RNAi00090 LOC196394 196394 3.25 90.00 19.53 -­‐0.88
1 A-­‐100707 RNAi00038 KIAA0317 9870 3.25 47.57 90.35 -­‐1.22 2 A-­‐100746 RNAi00090 LOC196394 196394 3 95.52 57.28 -­‐0.70
2 A-­‐100744 RNAi00038 KIAA0317 9870 3 71.39 47.90 -­‐0.59 1 A-­‐100709 RNAi00091 ANKRD9 122416 3.25 43.16 24.25 -­‐0.91
1 A-­‐100707 RNAi00039 KUA-­‐UEV 387522 3.25 90.76 -­‐3.98 -­‐0.71 2 A-­‐100746 RNAi00091 ANKRD9 122416 3 39.75 -­‐40.23 -­‐0.17
2 A-­‐100744 RNAi00039 KUA-­‐UEV 387522 3 98.74 11.65 -­‐0.40 1 A-­‐100709 RNAi00092 ASB1 51665 3.25 80.33 31.17 -­‐0.96
1 A-­‐100707 RNAi00040 NEDD4 4734 3.25 74.67 4.78 -­‐0.76 2 A-­‐100746 RNAi00092 ASB1 51665 3 79.93 22.38 -­‐0.51
2 A-­‐100744 RNAi00040 NEDD4 4734 3 72.79 -­‐26.89 -­‐0.19 1 A-­‐100709 RNAi00093 ASB10 136371 3.25 55.92 40.77 -­‐1.03
1 A-­‐100707 RNAi00041 NEDD4L 23327 3.25 86.87 -­‐0.04 -­‐0.73 2 A-­‐100746 RNAi00093 ASB10 136371 3 74.16 43.82 -­‐0.63
2 A-­‐100744 RNAi00041 NEDD4L 23327 3 87.28 -­‐5.30 -­‐0.31 1 A-­‐100709 RNAi00094 ASB11 140456 3.25 58.86 45.41 -­‐1.07
1 A-­‐100707 RNAi00042 SMURF1 57154 3.25 69.77 16.60 -­‐0.82 2 A-­‐100746 RNAi00094 ASB11 140456 3 68.03 -­‐16.42 -­‐0.30
2 A-­‐100744 RNAi00042 SMURF1 57154 3 65.80 -­‐59.30 -­‐0.02 1 A-­‐100709 RNAi00095 ASB12 142689 3.25 70.53 42.12 -­‐1.04
1 A-­‐100707 RNAi00043 SMURF2 64750 3.25 89.83 49.24 -­‐1.00 2 A-­‐100746 RNAi00095 ASB12 142689 3 77.99 56.10 -­‐0.69
2 A-­‐100744 RNAi00043 SMURF2 64750 3 97.62 24.01 -­‐0.47 1 A-­‐100709 RNAi00096 ASB13 79754 3.25 91.70 -­‐15.04 -­‐0.63
1 A-­‐100707 RNAi00044 TRIP12 9320 3.25 78.57 -­‐2.56 -­‐0.72 2 A-­‐100746 RNAi00096 ASB13 79754 3 99.16 14.93 -­‐0.47
2 A-­‐100744 RNAi00044 TRIP12 9320 3 85.97 -­‐8.83 -­‐0.29 1 A-­‐100709 RNAi00097 ASB14 142686 3.25 70.34 16.18 -­‐0.86
1 A-­‐100707 RNAi00045 TSG101 7251 3.25 41.31 57.95 -­‐1.05 2 A-­‐100746 RNAi00097 ASB14 142686 3 94.48 56.28 -­‐0.69
2 A-­‐100744 RNAi00045 TSG101 7251 3 70.51 57.64 -­‐0.65 1 A-­‐100709 RNAi00098 ASB15 142685 3.25 77.79 -­‐5.27 -­‐0.70
1 A-­‐100707 RNAi00046 UBE1 7317 3.25 67.82 29.65 -­‐0.89 2 A-­‐100746 RNAi00098 ASB15 142685 3 99.53 68.71 -­‐0.76
2 A-­‐100744 RNAi00046 UBE1 7317 3 85.24 47.39 -­‐0.59 1 A-­‐100709 RNAi00099 ASB16 92591 3.25 78.09 1.45 -­‐0.75
1 A-­‐100707 RNAi00047 UBE1C 9039 3.25 87.52 37.86 -­‐0.94 2 A-­‐100746 RNAi00099 ASB16 92591 3 70.43 1099.02 -­‐6.36
2 A-­‐100744 RNAi00047 UBE1C 9039 3 84.38 -­‐4.50 -­‐0.31 1 A-­‐100709 RNAi00100 ASB17 127247 3.25 97.77 -­‐19.72 -­‐0.60
1 A-­‐100707 RNAi00048 UBE1DC1 79876 3.25 82.67 50.82 -­‐1.01 2 A-­‐100746 RNAi00100 ASB17 127247 3 103.30 11.18 -­‐0.45
2 A-­‐100744 RNAi00048 UBE1DC1 79876 3 91.05 23.46 -­‐0.46 1 A-­‐100709 RNAi00101 ASB18 401036 3.25 82.65 46.21 -­‐1.07
1 A-­‐100707 RNAi00049 UBE1L 7318 3.25 84.18 -­‐18.40 -­‐0.63 2 A-­‐100746 RNAi00101 ASB18 401036 3 103.40 85.26 -­‐0.85
2 A-­‐100744 RNAi00049 UBE1L 7318 3 80.13 -­‐19.01 -­‐0.23 1 A-­‐100709 RNAi00102 ASB2 51676 3.25 88.74 -­‐0.31 -­‐0.74
1 A-­‐100707 RNAi00050 UBE1L2 55236 3.25 88.26 1.89 -­‐0.74 2 A-­‐100746 RNAi00102 ASB2 51676 3 89.11 11.93 -­‐0.45
2 A-­‐100744 RNAi00050 UBE1L2 55236 3 88.30 -­‐15.76 -­‐0.25 1 A-­‐100709 RNAi00103 ASB3 51130 3.25 39.75 131.36 -­‐1.68
1 A-­‐100707 RNAi00051 UBE2A 7319 3.25 103.54 53.05 -­‐1.02 2 A-­‐100746 RNAi00103 ASB3 51130 3 49.77 184.11 -­‐1.39
2 A-­‐100744 RNAi00051 UBE2A 7319 3 97.04 16.34 -­‐0.42 1 A-­‐100709 RNAi00104 ASB4 51666 3.25 84.69 56.75 -­‐1.15
1 A-­‐100707 RNAi00052 UBE2B 7320 3.25 100.76 54.84 -­‐1.03 2 A-­‐100746 RNAi00104 ASB4 51666 3 89.69 44.56 -­‐0.63
2 A-­‐100744 RNAi00052 UBE2B 7320 3 100.90 38.54 -­‐0.54 1 A-­‐100709 RNAi00105 ASB5 140458 3.25 84.70 -­‐1.59 -­‐0.73
1 A-­‐100707 RNAi00053 UBE2C 11065 3.25 87.40 8.21 -­‐0.77 2 A-­‐100746 RNAi00105 ASB5 140458 3 86.70 12.58 -­‐0.46
Rep Plate ID Compound ID Target Gene Locus ID Cisplatin (µM) CGE PNSF SF Rep Plate ID Compound ID Target Gene Locus ID Cisplatin (µM) CGE PNSF SF
1 A-­‐100709 RNAi00106 ASB6 140459 3.25 104.17 3.31 -­‐0.76 1 A-­‐100709 RNAi00162 FBXO46 23403 3.25 93.57 16.90 -­‐0.86
2 A-­‐100746 RNAi00106 ASB6 140459 3 102.28 8.19 -­‐0.43 2 A-­‐100746 RNAi00162 FBXO46 23403 3 90.31 -­‐12.23 -­‐0.32
1 A-­‐100709 RNAi00107 ASB7 140460 3.25 75.44 -­‐39.16 -­‐0.46 1 A-­‐100709 RNAi00163 FBXO47 494188 3.25 81.25 18.72 -­‐0.87
2 A-­‐100746 RNAi00107 ASB7 140460 3 87.19 -­‐19.89 -­‐0.28 2 A-­‐100746 RNAi00163 FBXO47 494188 3 95.90 30.23 -­‐0.55
1 A-­‐100709 RNAi00108 ASB8 140461 3.25 89.97 -­‐0.71 -­‐0.73 1 A-­‐100709 RNAi00164 FBXO5 26271 3.25 28.02 67.01 -­‐1.22
2 A-­‐100746 RNAi00108 ASB8 140461 3 88.42 5.37 -­‐0.42 2 A-­‐100746 RNAi00164 FBXO5 26271 3 34.04 87.92 -­‐0.87
1 A-­‐100709 RNAi00109 ASB9 140462 3.25 83.60 69.09 -­‐1.24 1 A-­‐100709 RNAi00165 FBXO6 26270 3.25 80.47 64.92 -­‐1.21
2 A-­‐100746 RNAi00109 ASB9 140462 3 92.53 63.91 -­‐0.74 2 A-­‐100746 RNAi00165 FBXO6 26270 3 93.16 68.14 -­‐0.76
1 A-­‐100709 RNAi00110 BTRC 8945 3.25 109.86 -­‐0.69 -­‐0.73 1 A-­‐100709 RNAi00166 FBXO7 25793 3.25 102.29 26.71 -­‐0.93
2 A-­‐100746 RNAi00110 BTRC 8945 3 106.43 23.74 -­‐0.52 2 A-­‐100746 RNAi00166 FBXO7 25793 3 93.58 6.07 -­‐0.42
1 A-­‐100709 RNAi00111 CCNF 899 3.25 56.78 -­‐15.90 -­‐0.63 1 A-­‐100709 RNAi00167 FBXO8 26269 3.25 85.88 45.12 -­‐1.06
2 A-­‐100746 RNAi00111 CCNF 899 3 81.74 29.52 -­‐0.55 2 A-­‐100746 RNAi00167 FBXO8 26269 3 89.01 29.59 -­‐0.55
1 A-­‐100709 RNAi00112 CISH 1154 3.25 74.93 36.04 -­‐1.00 1 A-­‐100709 RNAi00168 FBXO9 26268 3.25 84.73 42.84 -­‐1.05
2 A-­‐100746 RNAi00112 CISH 1154 3 88.89 30.08 -­‐0.55 2 A-­‐100746 RNAi00168 FBXO9 26268 3 81.50 1.68 -­‐0.40
1 A-­‐100709 RNAi00113 FBXL10 84678 3.25 62.30 16.09 -­‐0.86 1 A-­‐100709 RNAi00169 FBXW10 10517 3.25 67.49 97.02 -­‐1.44
2 A-­‐100746 RNAi00113 FBXL10 84678 3 53.81 -­‐42.96 -­‐0.16 2 A-­‐100746 RNAi00169 FBXW10 10517 3 88.63 78.19 -­‐0.81
1 A-­‐100709 RNAi00114 FBXL11 22992 3.25 79.11 -­‐39.98 -­‐0.45 1 A-­‐100710 RNAi00170 FBXW11 23291 3.25 83.06 105.64 -­‐1.30
2 A-­‐100746 RNAi00114 FBXL11 22992 3 81.00 -­‐3.56 -­‐0.37 2 A-­‐100747 RNAi00170 FBXW11 23291 3 92.11 149.92 -­‐1.09
1 A-­‐100709 RNAi00115 FBXL12 54850 3.25 77.80 -­‐12.96 -­‐0.65 1 A-­‐100710 RNAi00171 FBXW12 285231 3.25 69.58 49.54 -­‐0.93
2 A-­‐100746 RNAi00115 FBXL12 54850 3 81.10 14.37 -­‐0.47 2 A-­‐100747 RNAi00171 FBXW12 285231 3 74.99 37.63 -­‐0.59
1 A-­‐100709 RNAi00116 FBXL13 222235 3.25 77.95 50.31 -­‐1.10 1 A-­‐100710 RNAi00172 FBXW2 26190 3.25 98.08 65.02 -­‐1.03
2 A-­‐100746 RNAi00116 FBXL13 222235 3 89.64 40.06 -­‐0.61 2 A-­‐100747 RNAi00172 FBXW2 26190 3 93.33 3.49 -­‐0.43
1 A-­‐100709 RNAi00117 FBXL14 144699 3.25 77.64 73.55 -­‐1.27 1 A-­‐100710 RNAi00173 SHFM3 6468 3.25 44.79 -­‐19.34 -­‐0.47
2 A-­‐100746 RNAi00117 FBXL14 144699 3 98.61 69.69 -­‐0.77 2 A-­‐100747 RNAi00173 SHFM3 6468 3 57.84 -­‐23.17 -­‐0.31
1 A-­‐100709 RNAi00118 FBXL15 79176 3.25 89.37 15.36 -­‐0.85 1 A-­‐100710 RNAi00174 FBXW5 54461 3.25 50.69 -­‐25.95 -­‐0.43
2 A-­‐100746 RNAi00118 FBXL15 79176 3 104.24 18.73 -­‐0.49 2 A-­‐100747 RNAi00174 FBXW5 54461 3 50.79 -­‐27.12 -­‐0.29
1 A-­‐100709 RNAi00119 FBXL16 146330 3.25 89.99 3.17 -­‐0.76 1 A-­‐100710 RNAi00175 FBXW7 55294 3.25 77.19 54.78 -­‐0.97
2 A-­‐100746 RNAi00119 FBXL16 146330 3 87.08 6.87 -­‐0.43 2 A-­‐100747 RNAi00175 FBXW7 55294 3 84.17 8.44 -­‐0.45
1 A-­‐100709 RNAi00120 FBXL17 64839 3.25 89.11 0.18 -­‐0.74 1 A-­‐100710 RNAi00176 FBXW8 26259 3.25 83.86 8.19 -­‐0.66
2 A-­‐100746 RNAi00120 FBXL17 64839 3 87.34 -­‐1.25 -­‐0.38 2 A-­‐100747 RNAi00176 FBXW8 26259 3 92.76 -­‐9.83 -­‐0.37
1 A-­‐100709 RNAi00121 FBXL18 80028 3.25 85.19 27.43 -­‐0.94 1 A-­‐100710 RNAi00177 FBXW9 84261 3.25 73.27 -­‐20.51 -­‐0.47
2 A-­‐100746 RNAi00121 FBXL18 80028 3 88.93 -­‐4.29 -­‐0.37 2 A-­‐100747 RNAi00177 FBXW9 84261 3 79.24 -­‐32.18 -­‐0.27
1 A-­‐100709 RNAi00122 FBXL19 54620 3.25 65.91 33.94 -­‐0.98 1 A-­‐100710 RNAi00178 FLJ10916 55258 3.25 78.74 53.44 -­‐0.96
2 A-­‐100746 RNAi00122 FBXL19 54620 3 84.78 31.19 -­‐0.56 2 A-­‐100747 RNAi00178 FLJ10916 55258 3 88.31 15.23 -­‐0.48
1 A-­‐100709 RNAi00123 FBXL2 25827 3.25 71.47 53.84 -­‐1.13 1 A-­‐100710 RNAi00179 LGR6 59352 3.25 94.02 7.06 -­‐0.65
2 A-­‐100746 RNAi00123 FBXL2 25827 3 83.66 5.75 -­‐0.42 2 A-­‐100747 RNAi00179 LGR6 59352 3 87.75 -­‐34.94 -­‐0.26
1 A-­‐100709 RNAi00124 FBXL20 84961 3.25 79.95 3.71 -­‐0.77 1 A-­‐100710 RNAi00180 LOC342897 342897 3.25 52.28 -­‐0.32 -­‐0.60
2 A-­‐100746 RNAi00124 FBXL20 84961 3 80.41 -­‐20.73 -­‐0.28 2 A-­‐100747 RNAi00180 LOC342897 342897 3 45.55 -­‐64.92 -­‐0.12
1 A-­‐100709 RNAi00125 FBXL3P 26223 3.25 83.23 14.79 -­‐0.85 1 A-­‐100710 RNAi00181 LOC441920 441920 3.25 93.19 68.47 -­‐1.06
2 A-­‐100746 RNAi00125 FBXL3P 26223 3 85.73 -­‐6.59 -­‐0.35 2 A-­‐100747 RNAi00181 LOC441920 441920 3 96.25 14.56 -­‐0.48
1 A-­‐100709 RNAi00126 FBXL22 283807 3.25 75.50 -­‐29.09 -­‐0.53 1 A-­‐100710 RNAi00182 LOC554251 554251 3.25 70.69 47.26 -­‐0.92
2 A-­‐100746 RNAi00126 FBXL22 283807 3 87.05 10.24 -­‐0.44 2 A-­‐100747 RNAi00182 LOC554251 554251 3 81.85 21.17 -­‐0.51
1 A-­‐100709 RNAi00127 FBXL3A 26224 3.25 86.52 17.23 -­‐0.86 1 A-­‐100710 RNAi00183 LRRC29 26231 3.25 52.58 -­‐17.17 -­‐0.49
2 A-­‐100746 RNAi00127 FBXL3A 26224 3 92.92 -­‐3.49 -­‐0.37 2 A-­‐100747 RNAi00183 LRRC29 26231 3 52.13 -­‐58.96 -­‐0.15
1 A-­‐100709 RNAi00128 FBXL4 26235 3.25 93.18 -­‐30.30 -­‐0.52 1 A-­‐100710 RNAi00184 NEURL2 140825 3.25 81.43 21.97 -­‐0.75
2 A-­‐100746 RNAi00128 FBXL4 26235 3 94.79 -­‐22.11 -­‐0.27 2 A-­‐100747 RNAi00184 NEURL2 140825 3 91.51 -­‐27.82 -­‐0.29
1 A-­‐100709 RNAi00129 FBXL5 26234 3.25 56.79 34.78 -­‐0.99 1 A-­‐100710 RNAi00185 NLRC5 84166 3.25 58.59 -­‐7.27 -­‐0.55
2 A-­‐100746 RNAi00129 FBXL5 26234 3 95.53 50.32 -­‐0.66 2 A-­‐100747 RNAi00185 NLRC5 84166 3 76.24 -­‐4.24 -­‐0.40
1 A-­‐100709 RNAi00130 FBXL6 26233 3.25 64.82 27.18 -­‐0.94 1 A-­‐100710 RNAi00186 RAB40A 142684 3.25 100.77 38.82 -­‐0.86
2 A-­‐100746 RNAi00130 FBXL6 26233 3 68.35 -­‐14.38 -­‐0.31 2 A-­‐100747 RNAi00186 RAB40A 142684 3 93.78 -­‐5.86 -­‐0.39
1 A-­‐100709 RNAi00131 FBXL7 23194 3.25 90.58 39.39 -­‐1.02 1 A-­‐100710 RNAi00187 RAB40B 10966 3.25 81.62 18.62 -­‐0.73
2 A-­‐100746 RNAi00131 FBXL7 23194 3 89.76 -­‐7.70 -­‐0.35 2 A-­‐100747 RNAi00187 RAB40B 10966 3 89.18 -­‐14.24 -­‐0.35
1 A-­‐100709 RNAi00132 FBXL8 55336 3.25 53.47 55.72 -­‐1.14 1 A-­‐100710 RNAi00188 RAB40C 57799 3.25 71.48 -­‐29.50 -­‐0.41
2 A-­‐100746 RNAi00132 FBXL8 55336 3 62.49 34.13 -­‐0.57 2 A-­‐100747 RNAi00188 RAB40C 57799 3 71.71 -­‐43.79 -­‐0.22
1 A-­‐100709 RNAi00133 FBXO10 26267 3.25 94.27 -­‐1.93 -­‐0.73 1 A-­‐100710 RNAi00189 SKP2 6502 3.25 92.38 19.10 -­‐0.73
2 A-­‐100746 RNAi00133 FBXO10 26267 3 88.05 -­‐6.61 -­‐0.35 2 A-­‐100747 RNAi00189 SKP2 6502 3 96.02 -­‐5.22 -­‐0.39
1 A-­‐100709 RNAi00134 FBXO11 80204 3.25 63.79 -­‐4.01 -­‐0.71 1 A-­‐100710 RNAi00190 SOCS1 8651 3.25 69.16 46.01 -­‐0.91
2 A-­‐100746 RNAi00134 FBXO11 80204 3 58.01 -­‐34.74 -­‐0.20 2 A-­‐100747 RNAi00190 SOCS1 8651 3 70.20 -­‐3.93 -­‐0.40
1 A-­‐100709 RNAi00135 FBXO15 201456 3.25 90.59 31.50 -­‐0.97 1 A-­‐100710 RNAi00191 SOCS2 8835 3.25 41.86 114.07 -­‐1.36
2 A-­‐100746 RNAi00135 FBXO15 201456 3 96.64 20.94 -­‐0.50 2 A-­‐100747 RNAi00191 SOCS2 8835 3 40.02 227.68 -­‐1.44
1 A-­‐100709 RNAi00136 FBXO16 157574 3.25 73.01 30.93 -­‐0.96 1 A-­‐100710 RNAi00192 SOCS3 9021 3.25 92.98 44.66 -­‐0.90
2 A-­‐100746 RNAi00136 FBXO16 157574 3 76.34 27.80 -­‐0.54 2 A-­‐100747 RNAi00192 SOCS3 9021 3 80.99 3.81 -­‐0.43
1 A-­‐100709 RNAi00137 FBXO17 115290 3.25 61.05 10.05 -­‐0.81 1 A-­‐100710 RNAi00193 SOCS4 122809 3.25 84.22 18.22 -­‐0.72
2 A-­‐100746 RNAi00137 FBXO17 115290 3 76.41 -­‐4.04 -­‐0.37 2 A-­‐100747 RNAi00193 SOCS4 122809 3 94.30 14.16 -­‐0.48
1 A-­‐100709 RNAi00138 FBXO18 84893 3.25 82.11 -­‐3.02 -­‐0.72 1 A-­‐100710 RNAi00194 SOCS5 9655 3.25 90.93 2.58 -­‐0.62
2 A-­‐100746 RNAi00138 FBXO18 84893 3 90.92 -­‐17.60 -­‐0.29 2 A-­‐100747 RNAi00194 SOCS5 9655 3 95.08 -­‐28.20 -­‐0.29
1 A-­‐100709 RNAi00139 FBXO2 26232 3.25 69.88 88.63 -­‐1.38 1 A-­‐100710 RNAi00195 SOCS6 9306 3.25 99.41 9.30 -­‐0.66
2 A-­‐100746 RNAi00139 FBXO2 26232 3 83.02 118.40 -­‐1.03 2 A-­‐100747 RNAi00195 SOCS6 9306 3 93.74 -­‐28.99 -­‐0.29
1 A-­‐100709 RNAi00140 FBXO21 23014 3.25 93.30 49.61 -­‐1.10 1 A-­‐100710 RNAi00196 SOCS7 30837 3.25 91.17 -­‐22.26 -­‐0.46
2 A-­‐100746 RNAi00140 FBXO21 23014 3 91.85 8.97 -­‐0.44 2 A-­‐100747 RNAi00196 SOCS7 30837 3 93.13 -­‐35.41 -­‐0.26
1 A-­‐100709 RNAi00141 FBXO22 26263 3.25 78.82 48.63 -­‐1.09 1 A-­‐100710 RNAi00197 SPSB1 80176 3.25 67.13 -­‐3.95 -­‐0.58
2 A-­‐100746 RNAi00141 FBXO22 26263 3 89.81 8.06 -­‐0.43 2 A-­‐100747 RNAi00197 SPSB1 80176 3 85.94 -­‐25.19 -­‐0.30
1 A-­‐100709 RNAi00142 FBXO24 26261 3.25 82.22 27.48 -­‐0.94 1 A-­‐100710 RNAi00198 SPSB2 84727 3.25 76.82 37.05 -­‐0.85
2 A-­‐100746 RNAi00142 FBXO24 26261 3 79.74 15.87 -­‐0.47 2 A-­‐100747 RNAi00198 SPSB2 84727 3 91.24 21.68 -­‐0.51
1 A-­‐100709 RNAi00143 FBXO25 26260 3.25 80.31 -­‐5.25 -­‐0.70 1 A-­‐100710 RNAi00199 SPSB3 90864 3.25 45.62 29.10 -­‐0.80
2 A-­‐100746 RNAi00143 FBXO25 26260 3 84.40 -­‐5.88 -­‐0.36 2 A-­‐100747 RNAi00199 SPSB3 90864 3 64.14 25.18 -­‐0.53
1 A-­‐100709 RNAi00144 FBXO27 126433 3.25 78.54 -­‐31.34 -­‐0.51 1 A-­‐100710 RNAi00200 SPSB4 92369 3.25 31.53 -­‐23.24 -­‐0.45
2 A-­‐100746 RNAi00144 FBXO27 126433 3 83.45 -­‐0.68 -­‐0.39 2 A-­‐100747 RNAi00200 SPSB4 92369 3 43.79 -­‐22.91 -­‐0.31
1 A-­‐100709 RNAi00145 FBXO28 23219 3.25 91.50 10.96 -­‐0.82 1 A-­‐100710 RNAi00201 TULP4 56995 3.25 78.91 31.36 -­‐0.81
2 A-­‐100746 RNAi00145 FBXO28 23219 3 81.80 -­‐30.84 -­‐0.22 2 A-­‐100747 RNAi00201 TULP4 56995 3 80.90 -­‐19.33 -­‐0.33
1 A-­‐100709 RNAi00146 FBXO3 26273 3.25 76.12 -­‐3.86 -­‐0.71 1 A-­‐100710 RNAi00202 WDR71 80227 3.25 97.99 -­‐16.34 -­‐0.49
2 A-­‐100746 RNAi00146 FBXO3 26273 3 85.62 -­‐0.46 -­‐0.39 2 A-­‐100747 RNAi00202 WDR71 80227 3 89.22 -­‐30.67 -­‐0.28
1 A-­‐100709 RNAi00147 FBXO30 84085 3.25 89.64 -­‐3.64 -­‐0.71 1 A-­‐100710 RNAi00203 WSB1 26118 3.25 98.60 56.77 -­‐0.98
2 A-­‐100746 RNAi00147 FBXO30 84085 3 87.48 12.34 -­‐0.46 2 A-­‐100747 RNAi00203 WSB1 26118 3 98.11 15.94 -­‐0.49
1 A-­‐100709 RNAi00148 FBXO31 79791 3.25 68.65 -­‐20.27 -­‐0.59 1 A-­‐100710 RNAi00204 WSB2 55884 3.25 83.82 -­‐30.21 -­‐0.40
2 A-­‐100746 RNAi00148 FBXO31 79791 3 76.38 -­‐10.65 -­‐0.33 2 A-­‐100747 RNAi00204 WSB2 55884 3 84.76 -­‐9.67 -­‐0.37
1 A-­‐100709 RNAi00149 FBXO32 114907 3.25 78.48 16.83 -­‐0.86 1 A-­‐100767 RNAi00205 MARCH-­‐I 55016 3.25 86.09 4.61 -­‐0.20
2 A-­‐100746 RNAi00149 FBXO32 114907 3 83.51 1.52 -­‐0.40 2 A-­‐100816 RNAi00205 MARCH-­‐I 55016 3 94.83 9.34 0.03
1 A-­‐100709 RNAi00150 FBXO33 254170 3.25 71.01 70.80 -­‐1.25 1 A-­‐100767 RNAi00206 MARCH-­‐II 51257 3.25 80.65 37.25 -­‐0.35
2 A-­‐100746 RNAi00150 FBXO33 254170 3 71.18 57.96 -­‐0.70 2 A-­‐100816 RNAi00206 MARCH-­‐II 51257 3 86.37 14.18 0.01
1 A-­‐100709 RNAi00151 FBXO34 55030 3.25 68.41 59.97 -­‐1.17 1 A-­‐100767 RNAi00207 MARCH-­‐III 115123 3.25 72.94 99.81 -­‐0.63
2 A-­‐100746 RNAi00151 FBXO34 55030 3 88.46 55.58 -­‐0.69 2 A-­‐100816 RNAi00207 MARCH-­‐III 115123 3 78.01 37.45 -­‐0.10
1 A-­‐100709 RNAi00152 FBXO36 130888 3.25 83.83 34.66 -­‐0.99 1 A-­‐100767 RNAi00208 MARCH-­‐IV 57574 3.25 8.25 79.94 -­‐0.54
2 A-­‐100746 RNAi00152 FBXO36 130888 3 85.69 36.66 -­‐0.59 2 A-­‐100816 RNAi00208 MARCH-­‐IV 57574 3 11.23 95.21 -­‐0.35
1 A-­‐100709 RNAi00153 FBXO38 81545 3.25 59.91 9.17 -­‐0.81 1 A-­‐100767 RNAi00209 MARCH-­‐V 54708 3.25 85.41 3.49 -­‐0.19
2 A-­‐100746 RNAi00153 FBXO38 81545 3 51.95 -­‐49.91 -­‐0.12 2 A-­‐100816 RNAi00209 MARCH-­‐V 54708 3 87.09 -­‐4.13 0.09
1 A-­‐100709 RNAi00154 FBXO39 162517 3.25 53.29 49.68 -­‐1.10 1 A-­‐100767 RNAi00210 MARCH-­‐VI 10299 3.25 79.27 -­‐12.30 -­‐0.12
2 A-­‐100746 RNAi00154 FBXO39 162517 3 68.13 16.35 -­‐0.48 2 A-­‐100816 RNAi00210 MARCH-­‐VI 10299 3 82.89 -­‐4.31 0.09
1 A-­‐100709 RNAi00155 FBXO4 26272 3.25 49.68 43.38 -­‐1.05 1 A-­‐100767 RNAi00211 MARCH-­‐VII 64844 3.25 95.86 5.98 -­‐0.20
2 A-­‐100746 RNAi00155 FBXO4 26272 3 73.37 46.35 -­‐0.64 2 A-­‐100816 RNAi00211 MARCH-­‐VII 64844 3 98.53 1.83 0.06
1 A-­‐100709 RNAi00156 FBXO40 51725 3.25 72.46 30.10 -­‐0.96 1 A-­‐100767 RNAi00212 MARCH-­‐VIII 220972 3.25 82.55 9.40 -­‐0.22
2 A-­‐100746 RNAi00156 FBXO40 51725 3 66.55 -­‐9.69 -­‐0.34 2 A-­‐100816 RNAi00212 MARCH-­‐VIII 220972 3 97.31 18.76 -­‐0.01
1 A-­‐100709 RNAi00157 FBXO41 150726 3.25 81.79 0.92 -­‐0.75 1 A-­‐100767 RNAi00213 MARCH-­‐IX 92979 3.25 93.99 15.09 -­‐0.25
2 A-­‐100746 RNAi00157 FBXO41 150726 3 72.25 -­‐35.72 -­‐0.19 2 A-­‐100816 RNAi00213 MARCH-­‐IX 92979 3 94.01 -­‐0.26 0.07
1 A-­‐100709 RNAi00158 FBXO42 54455 3.25 103.42 34.90 -­‐0.99 1 A-­‐100767 RNAi00214 AIRE 326 3.25 84.79 76.32 -­‐0.53
2 A-­‐100746 RNAi00158 FBXO42 54455 3 105.82 23.27 -­‐0.52 2 A-­‐100816 RNAi00214 AIRE 326 3 98.56 61.42 -­‐0.20
1 A-­‐100709 RNAi00159 FBXO43 286151 3.25 82.96 -­‐4.11 -­‐0.71 1 A-­‐100767 RNAi00215 AMFR 267 3.25 75.40 107.83 -­‐0.67
2 A-­‐100746 RNAi00159 FBXO43 286151 3 87.19 -­‐12.40 -­‐0.32 2 A-­‐100816 RNAi00215 AMFR 267 3 93.84 93.56 -­‐0.35
1 A-­‐100709 RNAi00160 FBXO44 93611 3.25 36.90 141.15 -­‐1.75 1 A-­‐100767 RNAi00216 ANAPC11 51529 3.25 82.67 -­‐4.23 -­‐0.16
2 A-­‐100746 RNAi00160 FBXO44 93611 3 31.18 185.62 -­‐1.40 2 A-­‐100816 RNAi00216 ANAPC11 51529 3 92.38 29.38 -­‐0.06
1 A-­‐100709 RNAi00161 LOC200933 200933 3.25 83.44 7.75 -­‐0.80 1 A-­‐100767 RNAi00217 ANKIB1 54467 3.25 92.79 29.02 -­‐0.31
2 A-­‐100746 RNAi00161 LOC200933 200933 3 79.10 -­‐13.78 -­‐0.31 2 A-­‐100816 RNAi00217 ANKIB1 54467 3 90.56 -­‐6.08 0.10
Rep Plate ID Compound ID Target Gene Locus ID Cisplatin (µM) CGE PNSF SF Rep Plate ID Compound ID Target Gene Locus ID Cisplatin (µM) CGE PNSF SF
1 A-­‐100767 RNAi00218 AOF1 221656 3.25 78.51 24.86 -­‐0.29 1 A-­‐100767 RNAi00274 ISL1 3670 3.25 88.80 39.42 -­‐0.36
2 A-­‐100816 RNAi00218 AOF1 221656 3 80.61 3.13 0.06 2 A-­‐100816 RNAi00274 ISL1 3670 3 94.47 17.80 -­‐0.01
1 A-­‐100767 RNAi00219 ARIH1 25820 3.25 102.21 87.20 -­‐0.58 1 A-­‐100767 RNAi00275 JARID1B 10765 3.25 93.36 40.98 -­‐0.37
2 A-­‐100816 RNAi00219 ARIH1 25820 3 109.10 51.75 -­‐0.16 2 A-­‐100816 RNAi00275 JARID1B 10765 3 103.19 36.43 -­‐0.09
1 A-­‐100767 RNAi00220 ARIH2 10425 3.25 106.21 37.47 -­‐0.35 1 A-­‐100767 RNAi00276 KIAA0644 9865 3.25 87.35 38.78 -­‐0.35
2 A-­‐100816 RNAi00220 ARIH2 10425 3 110.55 15.99 0.00 2 A-­‐100816 RNAi00276 KIAA0644 9865 3 82.55 -­‐8.12 0.11
1 A-­‐100767 RNAi00221 BAHD1 22893 3.25 104.47 53.45 -­‐0.42 1 A-­‐100767 RNAi00277 KIAA0804 23355 3.25 88.88 3.35 -­‐0.19
2 A-­‐100816 RNAi00221 BAHD1 22893 3 109.51 23.50 -­‐0.03 2 A-­‐100816 RNAi00277 KIAA0804 23355 3 94.10 15.89 0.00
1 A-­‐100767 RNAi00222 BARD1 580 3.25 89.68 115.33 -­‐0.71 1 A-­‐100767 RNAi00278 KIAA1333 55632 3.25 92.72 4.40 -­‐0.20
2 A-­‐100816 RNAi00222 BARD1 580 3 86.37 108.31 -­‐0.41 2 A-­‐100816 RNAi00278 KIAA1333 55632 3 92.90 -­‐4.31 0.09
1 A-­‐100767 RNAi00223 BAZ1B 9031 3.25 69.79 3.53 -­‐0.19 1 A-­‐100767 RNAi00279 KIAA1542 57661 3.25 91.33 -­‐2.75 -­‐0.16
2 A-­‐100816 RNAi00223 BAZ1B 9031 3 83.77 42.73 -­‐0.12 2 A-­‐100816 RNAi00279 KIAA1542 57661 3 94.34 -­‐6.43 0.10
1 A-­‐100767 RNAi00224 BAZ2B 29994 3.25 93.96 6.91 -­‐0.21 1 A-­‐100767 RNAi00280 KIAA1718 80853 3.25 100.07 29.37 -­‐0.31
2 A-­‐100816 RNAi00224 BAZ2B 29994 3 86.85 -­‐46.40 0.27 2 A-­‐100816 RNAi00280 KIAA1718 80853 3 101.15 23.78 -­‐0.04
1 A-­‐100767 RNAi00225 BFAR 51283 3.25 88.85 53.91 -­‐0.42 1 A-­‐100767 RNAi00281 KRTAP5-­‐9 3846 3.25 60.62 324.98 -­‐1.66
2 A-­‐100816 RNAi00225 BFAR 51283 3 96.98 48.87 -­‐0.15 2 A-­‐100816 RNAi00281 KRTAP5-­‐9 3846 3 85.33 329.26 -­‐1.39
1 A-­‐100767 RNAi00226 BIRC2 329 3.25 74.42 177.47 -­‐0.99 1 A-­‐100767 RNAi00282 LINCR 93082 3.25 97.76 13.21 -­‐0.24
2 A-­‐100816 RNAi00226 BIRC2 329 3 94.11 122.04 -­‐0.47 2 A-­‐100816 RNAi00282 LINCR 93082 3 97.60 1.99 0.06
1 A-­‐100767 RNAi00227 BIRC3 330 3.25 87.66 -­‐1.90 -­‐0.17 1 A-­‐100767 RNAi00283 LMO6 4007 3.25 101.63 20.24 -­‐0.27
2 A-­‐100816 RNAi00227 BIRC3 330 3 83.55 -­‐22.25 0.17 2 A-­‐100816 RNAi00283 LMO6 4007 3 96.24 -­‐8.87 0.11
1 A-­‐100767 RNAi00228 BIRC4 331 3.25 84.92 9.71 -­‐0.22 1 A-­‐100767 RNAi00284 LMO7 4008 3.25 82.72 54.44 -­‐0.43
2 A-­‐100816 RNAi00228 BIRC4 331 3 85.36 4.68 0.05 2 A-­‐100816 RNAi00284 LMO7 4008 3 81.55 9.96 0.03
1 A-­‐100767 RNAi00229 BIRC7 79444 3.25 53.39 81.69 -­‐0.55 1 A-­‐100712 RNAi00285 LMTK3 114783 3.25 74.43 21.69 -­‐0.91
2 A-­‐100816 RNAi00229 BIRC7 79444 3 80.16 61.28 -­‐0.20 2 A-­‐100818 RNAi00285 LMTK3 114783 3 90.58 29.79 -­‐0.07
1 A-­‐100767 RNAi00230 BIRC8 112401 3.25 93.61 12.14 -­‐0.23 1 A-­‐100712 RNAi00286 LMX1B 4010 3.25 71.27 42.14 -­‐1.05
2 A-­‐100816 RNAi00230 BIRC8 112401 3 86.81 -­‐22.11 0.17 2 A-­‐100818 RNAi00286 LMX1B 4010 3 99.26 46.15 -­‐0.12
1 A-­‐100767 RNAi00231 BRAP 8315 3.25 83.54 -­‐3.48 -­‐0.16 1 A-­‐100712 RNAi00287 LNX1 84708 3.25 73.17 -­‐0.46 -­‐0.75
2 A-­‐100816 RNAi00231 BRAP 8315 3 79.92 -­‐17.64 0.15 2 A-­‐100818 RNAi00287 LNX1 84708 3 98.41 13.96 -­‐0.01
1 A-­‐100767 RNAi00232 BRCA1 672 3.25 78.30 86.16 -­‐0.57 1 A-­‐100712 RNAi00288 LNX2 222484 3.25 56.13 11.28 -­‐0.83
2 A-­‐100816 RNAi00232 BRCA1 672 3 83.87 99.90 -­‐0.37 2 A-­‐100818 RNAi00288 LNX2 222484 3 96.40 24.10 -­‐0.05
1 A-­‐100767 RNAi00233 BRPF1 7862 3.25 89.49 -­‐21.91 -­‐0.08 1 A-­‐100712 RNAi00289 LOC120126 120126 3.25 72.45 38.68 -­‐1.02
2 A-­‐100816 RNAi00233 BRPF1 7862 3 87.00 -­‐19.25 0.15 2 A-­‐100818 RNAi00289 LOC120126 120126 3 106.28 51.08 -­‐0.14
1 A-­‐100767 RNAi00234 BRPF3 27154 3.25 99.55 75.06 -­‐0.52 1 A-­‐100712 RNAi00290 LOC390231 390231 3.25 94.34 16.40 -­‐0.87
2 A-­‐100816 RNAi00234 BRPF3 27154 3 105.65 40.67 -­‐0.11 2 A-­‐100818 RNAi00290 LOC390231 390231 3 98.37 -­‐16.21 0.09
1 A-­‐100767 RNAi00235 C13ORF7 79596 3.25 83.23 -­‐4.18 -­‐0.16 1 A-­‐100712 RNAi00291 LOC399940 399940 3.25 66.04 50.13 -­‐1.10
2 A-­‐100816 RNAi00235 C13ORF7 79596 3 87.72 29.94 -­‐0.06 2 A-­‐100818 RNAi00291 LOC399940 399940 3 111.70 51.67 -­‐0.14
1 A-­‐100767 RNAi00236 C16orf28 65259 3.25 96.62 1.59 -­‐0.18 1 A-­‐100712 RNAi00292 LOC441061 441061 3.25 69.05 44.02 -­‐1.06
2 A-­‐100816 RNAi00236 C16orf28 65259 3 91.10 -­‐4.87 0.09 2 A-­‐100818 RNAi00292 LOC441061 441061 3 103.27 5.61 0.01
1 A-­‐100767 RNAi00237 C17ORF27 57674 3.25 87.75 4.43 -­‐0.20 1 A-­‐100712 RNAi00293 LOC51136 51136 3.25 57.14 52.97 -­‐1.12
2 A-­‐100816 RNAi00237 C17ORF27 57674 3 89.07 11.25 0.02 2 A-­‐100818 RNAi00293 LOC51136 51136 3 93.59 95.18 -­‐0.29
1 A-­‐100767 RNAi00238 C1orf164 55182 3.25 89.70 -­‐15.01 -­‐0.11 1 A-­‐100712 RNAi00294 LOC51255 51255 3.25 65.93 -­‐32.29 -­‐0.54
2 A-­‐100816 RNAi00238 C1orf164 55182 3 80.73 -­‐47.06 0.28 2 A-­‐100818 RNAi00294 LOC51255 51255 3 96.71 65.68 -­‐0.19
1 A-­‐100767 RNAi00239 C1orf166 79594 3.25 83.96 -­‐16.39 -­‐0.10 1 A-­‐100712 RNAi00295 LOC642219 642219 3.25 81.08 -­‐11.35 -­‐0.68
2 A-­‐100816 RNAi00239 C1orf166 79594 3 83.71 -­‐16.30 0.14 2 A-­‐100818 RNAi00295 LOC642219 642219 3 95.21 -­‐12.51 0.08
1 A-­‐100767 RNAi00240 C20ORF18 10616 3.25 99.25 195.89 -­‐1.07 1 A-­‐100712 RNAi00296 LOC643596 643596 3.25 16.19 177.27 -­‐1.97
2 A-­‐100816 RNAi00240 C20ORF18 10616 3 102.24 170.18 -­‐0.68 2 A-­‐100818 RNAi00296 LOC643596 643596 3 100.92 293.06 -­‐0.97
1 A-­‐100767 RNAi00241 C6ORF49 29964 3.25 89.26 16.22 -­‐0.25 1 A-­‐100712 RNAi00297 LOC643904 643904 3.25 24.51 46.77 -­‐1.08
2 A-­‐100816 RNAi00241 C6ORF49 29964 3 85.37 19.68 -­‐0.02 2 A-­‐100818 RNAi00297 LOC643904 643904 3 87.05 207.27 -­‐0.67
1 A-­‐100767 RNAi00242 CBL 867 3.25 95.13 -­‐18.36 -­‐0.09 1 A-­‐100712 RNAi00298 LOC644006 644006 3.25 80.19 -­‐2.94 -­‐0.74
2 A-­‐100816 RNAi00242 CBL 867 3 90.78 -­‐13.82 0.13 2 A-­‐100818 RNAi00298 LOC644006 644006 3 90.21 -­‐8.61 0.06
1 A-­‐100767 RNAi00243 CBLB 868 3.25 94.77 -­‐8.54 -­‐0.14 1 A-­‐100712 RNAi00299 LOC646862 646862 3.25 57.97 -­‐41.58 -­‐0.47
2 A-­‐100816 RNAi00243 CBLB 868 3 90.38 -­‐0.50 0.07 2 A-­‐100818 RNAi00299 LOC646862 646862 3 73.19 69.27 -­‐0.20
1 A-­‐100767 RNAi00244 CBLC 23624 3.25 81.44 201.79 -­‐1.10 1 A-­‐100712 RNAi00300 LOC648245 648245 3.25 86.82 -­‐6.08 -­‐0.72
2 A-­‐100816 RNAi00244 CBLC 23624 3 98.63 197.28 -­‐0.80 2 A-­‐100818 RNAi00300 LOC648245 648245 3 91.14 14.06 -­‐0.01
1 A-­‐100767 RNAi00245 CBLL1 79872 3.25 79.98 -­‐21.57 -­‐0.08 1 A-­‐100712 RNAi00301 LOC652557 652557 3.25 44.62 82.38 -­‐1.32
2 A-­‐100816 RNAi00245 CBLL1 79872 3 78.04 40.09 -­‐0.11 2 A-­‐100818 RNAi00301 LOC652557 652557 3 166.67 249.32 -­‐0.82
1 A-­‐100767 RNAi00246 CCL20 6364 3.25 103.27 38.28 -­‐0.35 1 A-­‐100712 RNAi00302 LOC652591 652591 3.25 81.16 38.25 -­‐1.02
2 A-­‐100816 RNAi00246 CCL20 6364 3 104.34 44.63 -­‐0.13 2 A-­‐100818 RNAi00302 LOC652591 652591 3 106.24 40.81 -­‐0.11
1 A-­‐100767 RNAi00247 CGRRF1 10668 3.25 80.57 2.41 -­‐0.19 1 A-­‐100712 RNAi00303 LOC652673 652673 3.25 84.50 -­‐48.88 -­‐0.42
2 A-­‐100816 RNAi00247 CGRRF1 10668 3 75.08 -­‐5.50 0.09 2 A-­‐100818 RNAi00303 LOC652673 652673 3 90.74 -­‐47.97 0.20
1 A-­‐100767 RNAi00248 CHD4 1108 3.25 77.03 44.87 -­‐0.38 1 A-­‐100712 RNAi00304 LONRF1 91694 3.25 82.68 -­‐16.11 -­‐0.65
2 A-­‐100816 RNAi00248 CHD4 1108 3 77.89 39.98 -­‐0.11 2 A-­‐100818 RNAi00304 LONRF1 91694 3 96.08 -­‐24.50 0.12
1 A-­‐100767 RNAi00249 CHD5 26038 3.25 56.81 83.25 -­‐0.56 1 A-­‐100712 RNAi00305 LONRF2 164832 3.25 50.21 -­‐87.62 -­‐0.16
2 A-­‐100816 RNAi00249 CHD5 26038 3 77.36 49.74 -­‐0.15 2 A-­‐100818 RNAi00305 LONRF2 164832 3 72.61 -­‐46.82 0.19
1 A-­‐100767 RNAi00250 CHFR 55743 3.25 87.40 87.44 -­‐0.58 1 A-­‐100712 RNAi00306 LONRF3 79836 3.25 75.48 60.28 -­‐1.17
2 A-­‐100816 RNAi00250 CHFR 55743 3 90.59 105.40 -­‐0.40 2 A-­‐100818 RNAi00306 LONRF3 79836 3 89.97 21.64 -­‐0.04
1 A-­‐100767 RNAi00251 CNOT4 4850 3.25 101.84 35.59 -­‐0.34 1 A-­‐100712 RNAi00307 LPXN 9404 3.25 44.82 -­‐6.14 -­‐0.71
2 A-­‐100816 RNAi00251 CNOT4 4850 3 87.15 -­‐26.73 0.19 2 A-­‐100818 RNAi00307 LPXN 9404 3 66.99 26.82 -­‐0.06
1 A-­‐100767 RNAi00252 CXXC1 30827 3.25 83.37 -­‐7.69 -­‐0.14 1 A-­‐100712 RNAi00308 LRSAM1 90678 3.25 50.31 -­‐21.06 -­‐0.61
2 A-­‐100816 RNAi00252 CXXC1 30827 3 86.70 -­‐10.65 0.12 2 A-­‐100818 RNAi00308 LRSAM1 90678 3 103.73 37.37 -­‐0.09
1 A-­‐100767 RNAi00253 DKFZP547C195 257160 3.25 77.32 42.14 -­‐0.37 1 A-­‐100712 RNAi00309 MAP3K1 4214 3.25 81.09 -­‐6.95 -­‐0.71
2 A-­‐100816 RNAi00253 DKFZP547C195 257160 3 76.72 -­‐6.70 0.10 2 A-­‐100818 RNAi00309 MAP3K1 4214 3 95.52 14.76 -­‐0.02
1 A-­‐100767 RNAi00254 DPF1 8193 3.25 84.10 26.46 -­‐0.30 1 A-­‐100712 RNAi00310 MDM2 4193 3.25 58.52 -­‐9.84 -­‐0.69
2 A-­‐100816 RNAi00254 DPF1 8193 3 84.76 1.96 0.06 2 A-­‐100818 RNAi00310 MDM2 4193 3 93.47 102.48 -­‐0.32
1 A-­‐100767 RNAi00255 DPF2 5977 3.25 76.00 -­‐19.54 -­‐0.09 1 A-­‐100712 RNAi00311 MDM4 4194 3.25 80.65 45.24 -­‐1.07
2 A-­‐100816 RNAi00255 DPF2 5977 3 86.12 52.63 -­‐0.16 2 A-­‐100818 RNAi00311 MDM4 4194 3 100.28 12.36 -­‐0.01
1 A-­‐100767 RNAi00256 DPF3 8110 3.25 88.23 -­‐0.62 -­‐0.17 1 A-­‐100712 RNAi00312 MEFV 4210 3.25 87.77 1.52 -­‐0.77
2 A-­‐100816 RNAi00256 DPF3 8110 3 87.74 11.22 0.02 2 A-­‐100818 RNAi00312 MEFV 4210 3 83.95 -­‐30.63 0.14
1 A-­‐100767 RNAi00257 DTX1 1840 3.25 86.87 -­‐33.96 -­‐0.02 1 A-­‐100712 RNAi00313 LOC92312 92312 3.25 79.06 15.72 -­‐0.86
2 A-­‐100816 RNAi00257 DTX1 1840 3 76.82 -­‐39.76 0.25 2 A-­‐100818 RNAi00313 LOC92312 92312 3 114.90 -­‐7.55 0.06
1 A-­‐100767 RNAi00258 DTX2 113878 3.25 95.83 9.21 -­‐0.22 1 A-­‐100712 RNAi00314 MGRN1 23295 3.25 75.42 4.13 -­‐0.79
2 A-­‐100816 RNAi00258 DTX2 113878 3 96.20 -­‐4.12 0.09 2 A-­‐100818 RNAi00314 MGRN1 23295 3 100.86 9.34 0.00
1 A-­‐100767 RNAi00259 DTX3 196403 3.25 62.71 79.55 -­‐0.54 1 A-­‐100712 RNAi00315 MIB1 57534 3.25 72.73 -­‐27.69 -­‐0.57
2 A-­‐100816 RNAi00259 DTX3 196403 3 81.18 118.37 -­‐0.46 2 A-­‐100818 RNAi00315 MIB1 57534 3 100.68 -­‐6.09 0.05
1 A-­‐100767 RNAi00260 DTX3L 151636 3.25 96.15 5.26 -­‐0.20 1 A-­‐100712 RNAi00316 MIB2 142678 3.25 90.23 -­‐1.07 -­‐0.75
2 A-­‐100816 RNAi00260 DTX3L 151636 3 89.62 -­‐4.51 0.09 2 A-­‐100818 RNAi00316 MIB2 142678 3 97.67 -­‐48.11 0.20
1 A-­‐100767 RNAi00261 DTX4 23220 3.25 66.29 -­‐29.26 -­‐0.04 1 A-­‐100712 RNAi00317 MID1 4281 3.25 90.00 35.04 -­‐1.00
2 A-­‐100816 RNAi00261 DTX4 23220 3 74.66 -­‐15.39 0.14 2 A-­‐100818 RNAi00317 MID1 4281 3 101.86 51.35 -­‐0.14
1 A-­‐100767 RNAi00262 DZIP3 9666 3.25 77.17 -­‐8.62 -­‐0.14 1 A-­‐100712 RNAi00318 MID2 11043 3.25 67.87 -­‐18.57 -­‐0.63
2 A-­‐100816 RNAi00262 DZIP3 9666 3 83.70 25.71 -­‐0.04 2 A-­‐100818 RNAi00318 MID2 11043 3 107.91 38.85 -­‐0.10
1 A-­‐100767 RNAi00263 EEA1 8411 3.25 96.04 41.17 -­‐0.37 1 A-­‐100712 RNAi00319 MKRN1 23608 3.25 75.40 -­‐35.85 -­‐0.51
2 A-­‐100816 RNAi00263 EEA1 8411 3 92.50 -­‐3.85 0.09 2 A-­‐100818 RNAi00319 MKRN1 23608 3 86.98 34.14 -­‐0.08
1 A-­‐100767 RNAi00264 FLJ31951 153830 3.25 93.22 -­‐5.75 -­‐0.15 1 A-­‐100712 RNAi00320 MKRN2 23609 3.25 74.27 -­‐32.37 -­‐0.54
2 A-­‐100816 RNAi00264 FLJ31951 153830 3 81.97 -­‐66.30 0.36 2 A-­‐100818 RNAi00320 MKRN2 23609 3 91.07 21.40 -­‐0.04
1 A-­‐100767 RNAi00265 FSD1L 83856 3.25 90.73 -­‐13.57 -­‐0.12 1 A-­‐100712 RNAi00321 MKRN3 7681 3.25 104.16 11.65 -­‐0.84
2 A-­‐100816 RNAi00265 FSD1L 83856 3 91.24 8.37 0.03 2 A-­‐100818 RNAi00321 MKRN3 7681 3 98.41 15.20 -­‐0.02
1 A-­‐100767 RNAi00266 HBXAP 51773 3.25 90.19 97.73 -­‐0.62 1 A-­‐100712 RNAi00322 MLL2 8085 3.25 71.45 34.89 -­‐1.00
2 A-­‐100816 RNAi00266 HBXAP 51773 3 84.30 19.01 -­‐0.01 2 A-­‐100818 RNAi00322 MLL2 8085 3 98.44 61.59 -­‐0.18
1 A-­‐100767 RNAi00267 HR 55806 3.25 75.83 8.70 -­‐0.22 1 A-­‐100712 RNAi00323 MLL3 58508 3.25 93.12 15.42 -­‐0.86
2 A-­‐100816 RNAi00267 HR 55806 3 90.85 37.19 -­‐0.10 2 A-­‐100818 RNAi00323 MLL3 58508 3 99.25 -­‐13.78 0.08
1 A-­‐100767 RNAi00268 HRC 3270 3.25 76.16 49.48 -­‐0.40 1 A-­‐100712 RNAi00324 MLL4 9757 3.25 52.12 8.54 -­‐0.82
2 A-­‐100816 RNAi00268 HRC 3270 3 80.65 11.45 0.02 2 A-­‐100818 RNAi00324 MLL4 9757 3 80.39 143.68 -­‐0.46
1 A-­‐100767 RNAi00269 IBRDC1 154214 3.25 88.83 37.01 -­‐0.35 1 A-­‐100712 RNAi00325 MLLT10 8028 3.25 78.59 -­‐9.72 -­‐0.69
2 A-­‐100816 RNAi00269 IBRDC1 154214 3 88.65 -­‐1.66 0.08 2 A-­‐100818 RNAi00325 MLLT10 8028 3 96.21 55.27 -­‐0.16
1 A-­‐100767 RNAi00270 IBRDC2 255488 3.25 103.10 90.92 -­‐0.59 1 A-­‐100712 RNAi00326 MLLT6 4302 3.25 58.52 90.41 -­‐1.38
2 A-­‐100816 RNAi00270 IBRDC2 255488 3 99.56 30.28 -­‐0.06 2 A-­‐100818 RNAi00326 MLLT6 4302 3 87.48 63.23 -­‐0.18
1 A-­‐100767 RNAi00271 IBRDC3 127544 3.25 92.72 -­‐10.27 -­‐0.13 1 A-­‐100712 RNAi00327 MNAT1 4331 3.25 77.17 -­‐10.63 -­‐0.68
2 A-­‐100816 RNAi00271 IBRDC3 127544 3 94.01 15.21 0.00 2 A-­‐100818 RNAi00327 MNAT1 4331 3 105.92 126.91 -­‐0.40
1 A-­‐100767 RNAi00272 INTS12 57117 3.25 83.79 95.08 -­‐0.61 1 A-­‐100712 RNAi00328 MSL2L1 55167 3.25 73.98 -­‐24.04 -­‐0.59
2 A-­‐100816 RNAi00272 INTS12 57117 3 77.59 37.09 -­‐0.10 2 A-­‐100818 RNAi00328 MSL2L1 55167 3 170.11 240.85 -­‐0.79
1 A-­‐100767 RNAi00273 IRF2BP1 26145 3.25 94.31 23.57 -­‐0.29 1 A-­‐100712 RNAi00329 M96 22823 3.25 65.99 -­‐40.14 -­‐0.48
2 A-­‐100816 RNAi00273 IRF2BP1 26145 3 95.32 -­‐0.01 0.07 2 A-­‐100818 RNAi00329 M96 22823 3 104.77 102.42 -­‐0.32
Rep Plate ID Compound ID Target Gene Locus ID Cisplatin (µM) CGE PNSF SF Rep Plate ID Compound ID Target Gene Locus ID Cisplatin (µM) CGE PNSF SF
1 A-­‐100712 RNAi00330 MYCBP2 23077 3.25 86.68 7.34 -­‐0.81 1 A-­‐100713 RNAi00386 RCHY1 25898 3.25 92.98 16.37 -­‐0.89
2 A-­‐100818 RNAi00330 MYCBP2 23077 3 96.16 43.94 -­‐0.12 2 A-­‐100750 RNAi00386 RCHY1 25898 3 80.93 -­‐20.26 -­‐0.31
1 A-­‐100712 RNAi00331 MYLIP 29116 3.25 85.16 6.99 -­‐0.80 1 A-­‐100713 RNAi00387 RFFL 117584 3.25 89.32 11.82 -­‐0.86
2 A-­‐100818 RNAi00331 MYLIP 29116 3 93.66 -­‐17.23 0.09 2 A-­‐100750 RNAi00387 RFFL 117584 3 92.87 4.76 -­‐0.46
1 A-­‐100712 RNAi00332 NDP52 10241 3.25 86.86 9.91 -­‐0.82 1 A-­‐100713 RNAi00388 RFP 5987 3.25 66.97 -­‐39.89 -­‐0.49
2 A-­‐100818 RNAi00332 NDP52 10241 3 91.95 -­‐18.13 0.10 2 A-­‐100750 RNAi00388 RFP 5987 3 88.64 -­‐8.19 -­‐0.38
1 A-­‐100712 RNAi00333 NEURL 9148 3.25 36.54 27.58 -­‐0.95 1 A-­‐100713 RNAi00389 RFP2 10206 3.25 68.97 -­‐5.98 -­‐0.73
2 A-­‐100818 RNAi00333 NEURL 9148 3 72.49 130.58 -­‐0.41 2 A-­‐100750 RNAi00389 RFP2 10206 3 80.29 9.98 -­‐0.50
1 A-­‐100712 RNAi00334 NHLRC1 378884 3.25 103.10 82.91 -­‐1.32 1 A-­‐100713 RNAi00390 RFPL1 5988 3.25 111.19 28.71 -­‐0.98
2 A-­‐100818 RNAi00334 NHLRC1 378884 3 97.09 -­‐0.91 0.04 2 A-­‐100750 RNAi00390 RFPL1 5988 3 99.14 -­‐7.93 -­‐0.38
1 A-­‐100712 RNAi00335 NSD1 64324 3.25 95.14 -­‐18.24 -­‐0.63 1 A-­‐100713 RNAi00391 RFPL2 10739 3.25 45.81 125.46 -­‐1.68
2 A-­‐100818 RNAi00335 NSD1 64324 3 106.17 22.16 -­‐0.04 2 A-­‐100750 RNAi00391 RFPL2 10739 3 68.61 84.31 -­‐0.95
1 A-­‐100712 RNAi00336 OIT3 170392 3.25 93.12 32.92 -­‐0.98 1 A-­‐100713 RNAi00392 RFPL3 10738 3.25 97.37 -­‐2.27 -­‐0.76
2 A-­‐100818 RNAi00336 OIT3 170392 3 94.45 32.52 -­‐0.08 2 A-­‐100750 RNAi00392 RFPL3 10738 3 97.40 -­‐2.78 -­‐0.42
1 A-­‐100712 RNAi00337 PARC 23113 3.25 43.92 23.37 -­‐0.92 1 A-­‐100713 RNAi00393 LOC342931 342931 3.25 72.28 14.52 -­‐0.88
2 A-­‐100818 RNAi00337 PARC 23113 3 88.54 110.99 -­‐0.35 2 A-­‐100750 RNAi00393 LOC342931 342931 3 78.97 4.26 -­‐0.46
1 A-­‐100712 RNAi00338 PARK2 5071 3.25 68.83 1.90 -­‐0.77 1 A-­‐100713 RNAi00394 RFPL4B 442247 3.25 76.03 7.66 -­‐0.83
2 A-­‐100818 RNAi00338 PARK2 5071 3 102.06 111.93 -­‐0.35 2 A-­‐100750 RNAi00394 RFPL4B 442247 3 80.31 4.15 -­‐0.46
1 A-­‐100712 RNAi00339 PCGF1 84759 3.25 74.29 2.86 -­‐0.78 1 A-­‐100713 RNAi00395 RFWD2 64326 3.25 86.85 -­‐14.13 -­‐0.67
2 A-­‐100818 RNAi00339 PCGF1 84759 3 86.57 1.86 0.03 2 A-­‐100750 RNAi00395 RFWD2 64326 3 90.91 -­‐14.91 -­‐0.34
1 A-­‐100712 RNAi00340 PCGF2 7703 3.25 81.83 -­‐16.07 -­‐0.65 1 A-­‐100713 RNAi00396 RFWD3 55159 3.25 59.34 47.45 -­‐1.12
2 A-­‐100818 RNAi00340 PCGF2 7703 3 86.67 -­‐16.85 0.09 2 A-­‐100750 RNAi00396 RFWD3 55159 3 57.05 -­‐9.17 -­‐0.38
1 A-­‐100712 RNAi00341 PCGF3 10336 3.25 91.72 18.45 -­‐0.88 1 A-­‐100713 RNAi00397 RING1 6015 3.25 90.62 9.25 -­‐0.84
2 A-­‐100818 RNAi00341 PCGF3 10336 3 85.89 -­‐29.83 0.14 2 A-­‐100750 RNAi00397 RING1 6015 3 94.27 -­‐8.23 -­‐0.38
1 A-­‐100712 RNAi00342 BMI1 648 3.25 81.14 -­‐6.96 -­‐0.71 1 A-­‐100713 RNAi00398 RKHD1 399664 3.25 60.95 -­‐16.69 -­‐0.66
2 A-­‐100818 RNAi00342 BMI1 648 3 92.33 8.96 0.00 2 A-­‐100750 RNAi00398 RKHD1 399664 3 70.46 -­‐9.12 -­‐0.38
1 A-­‐100712 RNAi00343 BMI1 648 3.25 79.51 4.38 -­‐0.79 1 A-­‐100713 RNAi00399 RKHD2 51320 3.25 85.18 22.78 -­‐0.94
2 A-­‐100818 RNAi00343 BMI1 648 3 85.69 -­‐15.94 0.09 2 A-­‐100750 RNAi00399 RKHD2 51320 3 91.16 12.52 -­‐0.51
1 A-­‐100712 RNAi00344 PCGF5 84333 3.25 88.19 54.24 -­‐1.13 1 A-­‐100713 RNAi00400 RKHD3 84206 3.25 73.35 44.76 -­‐1.10
2 A-­‐100818 RNAi00344 PCGF5 84333 3 122.15 83.46 -­‐0.25 2 A-­‐100750 RNAi00400 RKHD3 84206 3 92.94 44.19 -­‐0.71
1 A-­‐100712 RNAi00345 PCGF6 84108 3.25 91.64 -­‐0.49 -­‐0.75 1 A-­‐100713 RNAi00401 RNF10 9921 3.25 71.36 21.61 -­‐0.93
2 A-­‐100818 RNAi00345 PCGF6 84108 3 121.80 71.41 -­‐0.21 2 A-­‐100750 RNAi00401 RNF10 9921 3 84.29 20.78 -­‐0.56
1 A-­‐100712 RNAi00346 PDC 5132 3.25 99.86 59.88 -­‐1.17 1 A-­‐100713 RNAi00402 RNF103 7844 3.25 101.33 13.83 -­‐0.88
2 A-­‐100818 RNAi00346 PDC 5132 3 91.50 -­‐7.13 0.06 2 A-­‐100750 RNAi00402 RNF103 7844 3 98.14 -­‐1.12 -­‐0.43
1 A-­‐100712 RNAi00347 PDZRN3 23024 3.25 81.97 39.60 -­‐1.03 1 A-­‐100713 RNAi00403 RNF11 26994 3.25 93.70 -­‐11.14 -­‐0.70
2 A-­‐100818 RNAi00347 PDZRN3 23024 3 96.32 76.86 -­‐0.23 2 A-­‐100750 RNAi00403 RNF11 26994 3 98.40 -­‐6.18 -­‐0.40
1 A-­‐100712 RNAi00348 PDZRN4 29951 3.25 52.29 -­‐10.87 -­‐0.68 1 A-­‐100713 RNAi00404 RNF111 54778 3.25 87.57 25.80 -­‐0.96
2 A-­‐100818 RNAi00348 PDZRN4 29951 3 102.84 55.17 -­‐0.15 2 A-­‐100750 RNAi00404 RNF111 54778 3 92.99 5.36 -­‐0.47
1 A-­‐100712 RNAi00349 PEX10 5192 3.25 27.80 -­‐95.97 -­‐0.10 1 A-­‐100713 RNAi00405 RNF113A 7737 3.25 52.40 -­‐94.98 -­‐0.09
2 A-­‐100818 RNAi00349 PEX10 5192 3 71.14 43.79 -­‐0.12 2 A-­‐100750 RNAi00405 RNF113A 7737 3 67.96 -­‐54.11 -­‐0.10
1 A-­‐100712 RNAi00350 PHF1 5252 3.25 30.12 -­‐86.67 -­‐0.16 1 A-­‐100713 RNAi00406 RNF113B 140432 3.25 66.38 117.22 -­‐1.62
2 A-­‐100818 RNAi00350 PHF1 5252 3 69.74 58.42 -­‐0.17 2 A-­‐100750 RNAi00406 RNF113B 140432 3 73.19 3.20 -­‐0.45
1 A-­‐100712 RNAi00351 PHF10 55274 3.25 85.95 66.10 -­‐1.21 1 A-­‐100713 RNAi00407 RNF12 51132 3.25 90.78 62.95 -­‐1.23
2 A-­‐100818 RNAi00351 PHF10 55274 3 108.76 75.78 -­‐0.23 2 A-­‐100750 RNAi00407 RNF12 51132 3 100.23 19.54 -­‐0.55
1 A-­‐100712 RNAi00352 PHF11 51131 3.25 100.35 37.84 -­‐1.02 1 A-­‐100713 RNAi00408 RNF121 55298 3.25 33.40 10.98 -­‐0.86
2 A-­‐100818 RNAi00352 PHF11 51131 3 102.19 -­‐1.42 0.04 2 A-­‐100750 RNAi00408 RNF121 55298 3 38.09 18.00 -­‐0.55
1 A-­‐100712 RNAi00353 PHF12 57649 3.25 45.61 32.18 -­‐0.98 1 A-­‐100713 RNAi00409 RNF122 79845 3.25 52.24 4.43 -­‐0.81
2 A-­‐100818 RNAi00353 PHF12 57649 3 96.71 256.76 -­‐0.84 2 A-­‐100750 RNAi00409 RNF122 79845 3 61.59 -­‐23.57 -­‐0.29
1 A-­‐100712 RNAi00354 PHF13 148479 3.25 102.28 43.59 -­‐1.06 1 A-­‐100713 RNAi00410 RNF123 63891 3.25 45.70 -­‐1.56 -­‐0.77
2 A-­‐100818 RNAi00354 PHF13 148479 3 110.52 30.18 -­‐0.07 2 A-­‐100750 RNAi00410 RNF123 63891 3 44.13 -­‐61.49 -­‐0.05
1 A-­‐100712 RNAi00355 PHF14 9678 3.25 79.39 -­‐0.37 -­‐0.75 1 A-­‐100713 RNAi00411 RNF125 54941 3.25 89.46 31.52 -­‐1.00
2 A-­‐100818 RNAi00355 PHF14 9678 3 93.58 23.38 -­‐0.05 2 A-­‐100750 RNAi00411 RNF125 54941 3 86.74 -­‐14.63 -­‐0.34
1 A-­‐100712 RNAi00356 PHF15 23338 3.25 101.81 97.93 -­‐1.43 1 A-­‐100713 RNAi00412 RNF126 55658 3.25 44.71 -­‐5.47 -­‐0.74
2 A-­‐100818 RNAi00356 PHF15 23338 3 99.30 19.84 -­‐0.03 2 A-­‐100750 RNAi00412 RNF126 55658 3 58.07 -­‐9.96 -­‐0.37
1 A-­‐100712 RNAi00357 PHF16 9767 3.25 65.47 -­‐22.96 -­‐0.60 1 A-­‐100713 RNAi00413 RNF128 79589 3.25 100.61 16.88 -­‐0.90
2 A-­‐100818 RNAi00357 PHF16 9767 3 95.66 37.58 -­‐0.09 2 A-­‐100750 RNAi00413 RNF128 79589 3 99.17 -­‐0.31 -­‐0.43
1 A-­‐100712 RNAi00358 PHF17 79960 3.25 81.52 -­‐9.04 -­‐0.69 1 A-­‐100713 RNAi00414 RNF13 11342 3.25 91.41 16.04 -­‐0.89
2 A-­‐100818 RNAi00358 PHF17 79960 3 112.70 17.00 -­‐0.02 2 A-­‐100750 RNAi00414 RNF13 11342 3 95.02 -­‐5.66 -­‐0.40
1 A-­‐100712 RNAi00359 PHF19 26147 3.25 50.29 -­‐64.25 -­‐0.32 1 A-­‐100713 RNAi00415 RNF130 55819 3.25 33.74 13.30 -­‐0.87
2 A-­‐100818 RNAi00359 PHF19 26147 3 88.59 21.10 -­‐0.04 2 A-­‐100750 RNAi00415 RNF130 55819 3 45.31 63.73 -­‐0.83
1 A-­‐100712 RNAi00360 PHF2 5253 3.25 72.21 1.93 -­‐0.77 1 A-­‐100713 RNAi00416 RNF133 168433 3.25 92.29 56.66 -­‐1.19
2 A-­‐100818 RNAi00360 PHF2 5253 3 97.41 16.81 -­‐0.02 2 A-­‐100750 RNAi00416 RNF133 168433 3 89.01 4.43 -­‐0.46
1 A-­‐100712 RNAi00361 PHF20 51230 3.25 101.39 47.91 -­‐1.08 1 A-­‐100713 RNAi00417 RNF135 84282 3.25 77.36 16.45 -­‐0.90
2 A-­‐100818 RNAi00361 PHF20 51230 3 93.88 -­‐5.06 0.05 2 A-­‐100750 RNAi00417 RNF135 84282 3 87.23 4.56 -­‐0.46
1 A-­‐100712 RNAi00362 PHF20L1 51105 3.25 106.26 26.61 -­‐0.94 1 A-­‐100713 RNAi00418 RNF138 51444 3.25 88.35 21.96 -­‐0.94
2 A-­‐100818 RNAi00362 PHF20L1 51105 3 103.05 3.53 0.02 2 A-­‐100750 RNAi00418 RNF138 51444 3 91.80 -­‐6.85 -­‐0.39
1 A-­‐100712 RNAi00363 PHF21A 51317 3.25 37.75 46.15 -­‐1.07 1 A-­‐100713 RNAi00419 RNF139 11236 3.25 70.43 21.76 -­‐0.93
2 A-­‐100818 RNAi00363 PHF21A 51317 3 97.29 275.22 -­‐0.91 2 A-­‐100750 RNAi00419 RNF139 11236 3 85.73 13.53 -­‐0.52
1 A-­‐100712 RNAi00364 PHF21B 112885 3.25 103.66 41.82 -­‐1.04 1 A-­‐100713 RNAi00420 RNF14 9604 3.25 97.65 19.46 -­‐0.92
2 A-­‐100818 RNAi00364 PHF21B 112885 3 118.81 91.65 -­‐0.28 2 A-­‐100750 RNAi00420 RNF14 9604 3 99.41 -­‐5.29 -­‐0.40
1 A-­‐100713 RNAi00365 PHF23 79142 3.25 52.80 61.87 -­‐1.22 1 A-­‐100713 RNAi00421 RNF141 50862 3.25 58.80 -­‐6.76 -­‐0.73
2 A-­‐100750 RNAi00365 PHF23 79142 3 60.23 36.24 -­‐0.66 2 A-­‐100750 RNAi00421 RNF141 50862 3 59.53 -­‐46.03 -­‐0.15
1 A-­‐100713 RNAi00366 PHF3 23469 3.25 86.52 30.17 -­‐0.99 1 A-­‐100713 RNAi00422 RNF144 9781 3.25 85.38 57.60 -­‐1.19
2 A-­‐100750 RNAi00366 PHF3 23469 3 81.49 6.08 -­‐0.47 2 A-­‐100750 RNAi00422 RNF144 9781 3 101.94 13.54 -­‐0.52
1 A-­‐100713 RNAi00367 PHF5A 84844 3.25 34.94 -­‐42.83 -­‐0.47 1 A-­‐100713 RNAi00423 RNF146 81847 3.25 61.46 10.35 -­‐0.85
2 A-­‐100750 RNAi00367 PHF5A 84844 3 47.74 -­‐13.68 -­‐0.35 2 A-­‐100750 RNAi00423 RNF146 81847 3 95.28 23.57 -­‐0.58
1 A-­‐100713 RNAi00368 PHF6 84295 3.25 77.42 44.06 -­‐1.09 1 A-­‐100713 RNAi00424 RNF148 378925 3.25 91.15 83.91 -­‐1.38
2 A-­‐100750 RNAi00368 PHF6 84295 3 84.32 -­‐25.75 -­‐0.27 2 A-­‐100750 RNAi00424 RNF148 378925 3 103.17 40.23 -­‐0.68
1 A-­‐100713 RNAi00369 PHF7 51533 3.25 59.38 71.00 -­‐1.29 1 A-­‐100713 RNAi00425 RNF149 284996 3.25 90.27 -­‐8.84 -­‐0.71
2 A-­‐100750 RNAi00369 PHF7 51533 3 67.57 44.94 -­‐0.71 2 A-­‐100750 RNAi00425 RNF149 284996 3 96.89 -­‐14.05 -­‐0.35
1 A-­‐100713 RNAi00370 PHF8 23133 3.25 95.64 0.68 -­‐0.78 1 A-­‐100713 RNAi00426 RNF150 57484 3.25 68.04 117.58 -­‐1.62
2 A-­‐100750 RNAi00370 PHF8 23133 3 92.35 -­‐17.13 -­‐0.33 2 A-­‐100750 RNAi00426 RNF150 57484 3 56.83 5.98 -­‐0.47
1 A-­‐100713 RNAi00371 PJA1 64219 3.25 76.41 -­‐3.55 -­‐0.75 1 A-­‐100713 RNAi00427 RNF151 146310 3.25 60.84 10.05 -­‐0.85
2 A-­‐100750 RNAi00371 PJA1 64219 3 85.01 -­‐27.24 -­‐0.27 2 A-­‐100750 RNAi00427 RNF151 146310 3 72.30 2.79 -­‐0.45
1 A-­‐100713 RNAi00372 PJA2 9867 3.25 65.70 -­‐23.98 -­‐0.60 1 A-­‐100713 RNAi00428 RNF152 220441 3.25 79.46 -­‐15.26 -­‐0.67
2 A-­‐100750 RNAi00372 PJA2 9867 3 63.87 -­‐49.51 -­‐0.13 2 A-­‐100750 RNAi00428 RNF152 220441 3 81.90 -­‐21.61 -­‐0.30
1 A-­‐100713 RNAi00373 PML 5371 3.25 56.41 70.74 -­‐1.29 1 A-­‐100713 RNAi00429 RNF157 114804 3.25 61.35 -­‐37.80 -­‐0.50
2 A-­‐100750 RNAi00373 PML 5371 3 60.91 46.20 -­‐0.72 2 A-­‐100750 RNAi00429 RNF157 114804 3 82.45 -­‐0.12 -­‐0.43
1 A-­‐100713 RNAi00374 PPIL2 23759 3.25 68.33 58.51 -­‐1.20 1 A-­‐100713 RNAi00430 RNF165 494470 3.25 63.99 -­‐3.49 -­‐0.75
2 A-­‐100750 RNAi00374 PPIL2 23759 3 86.84 46.38 -­‐0.72 2 A-­‐100750 RNAi00430 RNF165 494470 3 68.24 -­‐17.60 -­‐0.33
1 A-­‐100713 RNAi00375 PRICKLE1 144165 3.25 60.86 -­‐39.37 -­‐0.49 1 A-­‐100713 RNAi00431 RNF166 115992 3.25 83.55 78.57 -­‐1.34
2 A-­‐100750 RNAi00375 PRICKLE1 144165 3 76.45 2.96 -­‐0.45 2 A-­‐100750 RNAi00431 RNF166 115992 3 91.29 40.31 -­‐0.68
1 A-­‐100713 RNAi00376 PRICKLE2 166336 3.25 60.31 37.39 -­‐1.05 1 A-­‐100713 RNAi00432 RNF167 26001 3.25 85.89 58.07 -­‐1.20
2 A-­‐100750 RNAi00376 PRICKLE2 166336 3 56.13 -­‐27.43 -­‐0.26 2 A-­‐100750 RNAi00432 RNF167 26001 3 94.54 40.67 -­‐0.69
1 A-­‐100713 RNAi00377 PRPF19 27339 3.25 44.56 -­‐3.58 -­‐0.75 1 A-­‐100713 RNAi00433 RNF168 165918 3.25 92.25 55.46 -­‐1.18
2 A-­‐100750 RNAi00377 PRPF19 27339 3 53.13 -­‐9.19 -­‐0.38 2 A-­‐100750 RNAi00433 RNF168 165918 3 93.23 27.77 -­‐0.61
1 A-­‐100713 RNAi00378 PXMP3 5828 3.25 63.48 70.87 -­‐1.29 1 A-­‐100713 RNAi00434 RNF169 254225 3.25 87.35 43.42 -­‐1.09
2 A-­‐100750 RNAi00378 PXMP3 5828 3 86.75 32.25 -­‐0.63 2 A-­‐100750 RNAi00434 RNF169 254225 3 88.68 -­‐5.28 -­‐0.40
1 A-­‐100713 RNAi00379 RAD18 56852 3.25 85.90 8.62 -­‐0.84 1 A-­‐100713 RNAi00435 RNF17 56163 3.25 78.31 -­‐36.56 -­‐0.51
2 A-­‐100750 RNAi00379 RAD18 56852 3 88.89 30.36 -­‐0.62 2 A-­‐100750 RNAi00435 RNF17 56163 3 86.48 0.64 -­‐0.44
1 A-­‐100713 RNAi00380 RAG1 5896 3.25 80.93 61.63 -­‐1.22 1 A-­‐100713 RNAi00436 RNF170 81790 3.25 97.18 59.45 -­‐1.21
2 A-­‐100750 RNAi00380 RAG1 5896 3 83.53 41.67 -­‐0.69 2 A-­‐100750 RNAi00436 RNF170 81790 3 94.09 17.56 -­‐0.54
1 A-­‐100713 RNAi00381 RAPSN 5913 3.25 91.22 44.18 -­‐1.10 1 A-­‐100713 RNAi00437 RNF175 285533 3.25 66.78 28.85 -­‐0.98
2 A-­‐100750 RNAi00381 RAPSN 5913 3 81.95 -­‐9.30 -­‐0.38 2 A-­‐100750 RNAi00437 RNF175 285533 3 86.58 31.32 -­‐0.63
1 A-­‐100713 RNAi00382 RBBP6 5930 3.25 79.52 -­‐35.81 -­‐0.52 1 A-­‐100713 RNAi00438 RNF180 285671 3.25 63.00 -­‐14.66 -­‐0.67
2 A-­‐100750 RNAi00382 RBBP6 5930 3 83.21 -­‐33.71 -­‐0.23 2 A-­‐100750 RNAi00438 RNF180 285671 3 66.26 -­‐25.03 -­‐0.28
1 A-­‐100713 RNAi00383 RBX1 9978 3.25 59.35 -­‐5.15 -­‐0.74 1 A-­‐100713 RNAi00439 RNF182 221687 3.25 66.37 -­‐34.56 -­‐0.53
2 A-­‐100750 RNAi00383 RBX1 9978 3 71.60 18.04 -­‐0.55 2 A-­‐100750 RNAi00439 RNF182 221687 3 90.20 -­‐11.20 -­‐0.36
1 A-­‐100713 RNAi00384 RC3H1 149041 3.25 93.57 69.76 -­‐1.28 1 A-­‐100713 RNAi00440 RNF183 138065 3.25 91.69 2.27 -­‐0.79
2 A-­‐100750 RNAi00384 RC3H1 149041 3 110.10 50.61 -­‐0.75 2 A-­‐100750 RNAi00440 RNF183 138065 3 91.48 -­‐29.03 -­‐0.25
1 A-­‐100713 RNAi00385 RC3H2 54542 3.25 90.62 -­‐17.96 -­‐0.65 1 A-­‐100713 RNAi00441 RNF185 91445 3.25 83.39 8.62 -­‐0.84
2 A-­‐100750 RNAi00385 RC3H2 54542 3 104.92 6.37 -­‐0.47 2 A-­‐100750 RNAi00441 RNF185 91445 3 79.04 -­‐18.08 -­‐0.32
Rep Plate ID Compound ID Target Gene Locus ID Cisplatin (µM) CGE PNSF SF Rep Plate ID Compound ID Target Gene Locus ID Cisplatin (µM) CGE PNSF SF
1 A-­‐100713 RNAi00442 RNF186 54546 3.25 84.27 29.54 -­‐0.99 1 A-­‐100714 RNAi00498 TRIM11 81559 3.25 80.54 -­‐4.26 -­‐0.56
2 A-­‐100750 RNAi00442 RNF186 54546 3 83.35 27.89 -­‐0.61 2 A-­‐100751 RNAi00498 TRIM11 81559 3 94.59 -­‐5.29 -­‐0.38
1 A-­‐100713 RNAi00443 RNF187 149603 3.25 60.34 0.43 -­‐0.78 1 A-­‐100714 RNAi00499 TRIM14 9830 3.25 68.82 -­‐7.20 -­‐0.54
2 A-­‐100750 RNAi00443 RNF187 149603 3 71.42 19.73 -­‐0.56 2 A-­‐100751 RNAi00499 TRIM14 9830 3 89.92 41.91 -­‐0.64
1 A-­‐100713 RNAi00444 RNF19 25897 3.25 87.83 44.27 -­‐1.10 1 A-­‐100714 RNAi00500 TRIM15 89870 3.25 58.86 16.92 -­‐0.69
2 A-­‐100750 RNAi00444 RNF19 25897 3 85.41 -­‐33.13 -­‐0.23 2 A-­‐100751 RNAi00500 TRIM15 89870 3 81.83 32.01 -­‐0.59
1 A-­‐100714 RNAi00445 RNF190 162333 3.25 87.45 21.24 -­‐0.72 1 A-­‐100714 RNAi00501 TRIM17 51127 3.25 79.50 -­‐12.68 -­‐0.51
2 A-­‐100751 RNAi00445 RNF190 162333 3 98.33 18.12 -­‐0.51 2 A-­‐100751 RNAi00501 TRIM17 51127 3 82.69 -­‐6.62 -­‐0.37
1 A-­‐100714 RNAi00446 RNF2 6045 3.25 88.06 49.02 -­‐0.89 1 A-­‐100714 RNAi00502 TRIM2 23321 3.25 61.85 -­‐20.61 -­‐0.46
2 A-­‐100751 RNAi00446 RNF2 6045 3 95.45 28.62 -­‐0.57 2 A-­‐100751 RNAi00502 TRIM2 23321 3 77.59 -­‐11.78 -­‐0.34
1 A-­‐100714 RNAi00447 RNF20 56254 3.25 98.47 103.13 -­‐1.23 1 A-­‐100714 RNAi00503 SSA1 6737 3.25 66.03 17.75 -­‐0.70
2 A-­‐100751 RNAi00447 RNF20 56254 3 101.76 21.14 -­‐0.53 2 A-­‐100751 RNAi00503 SSA1 6737 3 84.72 20.32 -­‐0.52
1 A-­‐100714 RNAi00448 RNF207 388591 3.25 78.95 -­‐35.26 -­‐0.37 1 A-­‐100714 RNAi00504 TRIM22 10346 3.25 90.43 0.91 -­‐0.59
2 A-­‐100751 RNAi00448 RNF207 388591 3 95.47 4.25 -­‐0.43 2 A-­‐100751 RNAi00504 TRIM22 10346 3 95.23 -­‐5.93 -­‐0.38
1 A-­‐100714 RNAi00449 RNF208 727800 3.25 56.55 -­‐42.38 -­‐0.32 1 A-­‐100714 RNAi00505 TRIM23 373 3.25 78.60 13.78 -­‐0.67
2 A-­‐100751 RNAi00449 RNF208 727800 3 73.87 -­‐4.40 -­‐0.39 2 A-­‐100751 RNAi00505 TRIM23 373 3 81.68 -­‐14.73 -­‐0.33
1 A-­‐100714 RNAi00450 RNF215 200312 3.25 87.40 -­‐23.71 -­‐0.44 1 A-­‐100714 RNAi00506 TIF1 8805 3.25 84.98 20.53 -­‐0.71
2 A-­‐100751 RNAi00450 RNF215 200312 3 76.47 -­‐76.82 0.01 2 A-­‐100751 RNAi00506 TIF1 8805 3 99.00 19.31 -­‐0.52
1 A-­‐100714 RNAi00451 RNF24 11237 3.25 89.81 27.30 -­‐0.76 1 A-­‐100714 RNAi00507 TRIM25 7706 3.25 40.31 50.99 -­‐0.91
2 A-­‐100751 RNAi00451 RNF24 11237 3 97.46 29.85 -­‐0.57 2 A-­‐100751 RNAi00507 TRIM25 7706 3 58.71 -­‐4.02 -­‐0.39
1 A-­‐100714 RNAi00452 RNF25 64320 3.25 82.79 -­‐14.18 -­‐0.50 1 A-­‐100714 RNAi00508 TRIM26 7726 3.25 76.11 60.28 -­‐0.96
2 A-­‐100751 RNAi00452 RNF25 64320 3 92.62 4.38 -­‐0.43 2 A-­‐100751 RNAi00508 TRIM26 7726 3 92.34 5.91 -­‐0.44
1 A-­‐100714 RNAi00453 RNF26 79102 3.25 51.66 38.36 -­‐0.83 1 A-­‐100714 RNAi00509 TRIM28 10155 3.25 72.36 -­‐23.16 -­‐0.44
2 A-­‐100751 RNAi00453 RNF26 79102 3 66.17 7.06 -­‐0.45 2 A-­‐100751 RNAi00509 TRIM28 10155 3 92.76 2.10 -­‐0.42
1 A-­‐100714 RNAi00454 RNF31 55072 3.25 66.39 114.34 -­‐1.30 1 A-­‐100714 RNAi00510 TRIM29 23650 3.25 85.53 -­‐48.27 -­‐0.28
2 A-­‐100751 RNAi00454 RNF31 55072 3 94.93 181.17 -­‐1.41 2 A-­‐100751 RNAi00510 TRIM29 23650 3 95.67 -­‐6.11 -­‐0.38
1 A-­‐100714 RNAi00455 RNF32 140545 3.25 73.15 9.99 -­‐0.65 1 A-­‐100714 RNAi00511 TRIM3 10612 3.25 82.63 -­‐15.66 -­‐0.49
2 A-­‐100751 RNAi00455 RNF32 140545 3 87.05 22.98 -­‐0.54 2 A-­‐100751 RNAi00511 TRIM3 10612 3 91.99 2.88 -­‐0.43
1 A-­‐100714 RNAi00456 RNF34 80196 3.25 68.85 92.00 -­‐1.16 1 A-­‐100714 RNAi00512 TRIM31 11074 3.25 45.82 84.00 -­‐1.11
2 A-­‐100751 RNAi00456 RNF34 80196 3 97.30 78.40 -­‐0.84 2 A-­‐100751 RNAi00512 TRIM31 11074 3 61.61 49.87 -­‐0.68
1 A-­‐100714 RNAi00457 RNF38 152006 3.25 65.05 12.95 -­‐0.67 1 A-­‐100714 RNAi00513 TRIM32 22954 3.25 67.01 20.85 -­‐0.72
2 A-­‐100751 RNAi00457 RNF38 152006 3 68.79 -­‐13.05 -­‐0.34 2 A-­‐100751 RNAi00513 TRIM32 22954 3 92.72 45.41 -­‐0.66
1 A-­‐100714 RNAi00458 RNF39 80352 3.25 81.16 -­‐45.26 -­‐0.30 1 A-­‐100714 RNAi00514 TRIM33 51592 3.25 88.49 32.08 -­‐0.79
2 A-­‐100751 RNAi00458 RNF39 80352 3 101.16 -­‐3.32 -­‐0.39 2 A-­‐100751 RNAi00514 TRIM33 51592 3 99.02 10.65 -­‐0.47
1 A-­‐100714 RNAi00459 RNF4 6047 3.25 31.27 -­‐21.42 -­‐0.45 1 A-­‐100714 RNAi00515 TRIM34 53840 3.25 86.55 26.24 -­‐0.75
2 A-­‐100751 RNAi00459 RNF4 6047 3 42.31 66.85 -­‐0.78 2 A-­‐100751 RNAi00515 TRIM34 53840 3 82.90 2.44 -­‐0.42
1 A-­‐100714 RNAi00460 RNF40 9810 3.25 72.21 -­‐14.67 -­‐0.49 1 A-­‐100714 RNAi00516 TRIM35 23087 3.25 69.92 30.38 -­‐0.78
2 A-­‐100751 RNAi00460 RNF40 9810 3 91.04 -­‐26.04 -­‐0.27 2 A-­‐100751 RNAi00516 TRIM35 23087 3 89.96 20.67 -­‐0.52
1 A-­‐100714 RNAi00461 RNF41 10193 3.25 85.62 25.47 -­‐0.75 1 A-­‐100714 RNAi00517 TRIM36 55521 3.25 70.78 107.24 -­‐1.26
2 A-­‐100751 RNAi00461 RNF41 10193 3 91.94 7.59 -­‐0.45 2 A-­‐100751 RNAi00517 TRIM36 55521 3 75.31 26.71 -­‐0.56
1 A-­‐100714 RNAi00462 RNF43 54894 3.25 59.62 0.22 -­‐0.59 1 A-­‐100714 RNAi00518 TRIM37 4591 3.25 75.45 17.71 -­‐0.70
2 A-­‐100751 RNAi00462 RNF43 54894 3 65.40 -­‐43.36 -­‐0.17 2 A-­‐100751 RNAi00518 TRIM37 4591 3 87.71 -­‐4.97 -­‐0.38
1 A-­‐100714 RNAi00463 RNF44 22838 3.25 88.90 -­‐30.65 -­‐0.39 1 A-­‐100714 RNAi00519 TRIM38 10475 3.25 78.43 -­‐38.38 -­‐0.35
2 A-­‐100751 RNAi00463 RNF44 22838 3 96.16 -­‐9.67 -­‐0.36 2 A-­‐100751 RNAi00519 TRIM38 10475 3 92.21 15.09 -­‐0.49
1 A-­‐100714 RNAi00464 RNF5 6048 3.25 86.97 -­‐11.65 -­‐0.51 1 A-­‐100714 RNAi00520 TRIM39 56658 3.25 53.59 -­‐47.53 -­‐0.29
2 A-­‐100751 RNAi00464 RNF5 6048 3 87.34 -­‐53.90 -­‐0.11 2 A-­‐100751 RNAi00520 TRIM39 56658 3 64.67 13.73 -­‐0.48
1 A-­‐100714 RNAi00465 RNF5P1 286140 3.25 92.29 22.33 -­‐0.73 1 A-­‐100714 RNAi00521 TRIM4 89122 3.25 79.51 2.69 -­‐0.60
2 A-­‐100751 RNAi00465 RNF5P1 286140 3 105.09 -­‐2.78 -­‐0.39 2 A-­‐100751 RNAi00521 TRIM4 89122 3 86.42 -­‐14.10 -­‐0.33
1 A-­‐100714 RNAi00466 RNF6 6049 3.25 75.97 -­‐5.85 -­‐0.55 1 A-­‐100714 RNAi00522 TRIM40 135644 3.25 81.10 48.15 -­‐0.89
2 A-­‐100751 RNAi00466 RNF6 6049 3 99.50 22.37 -­‐0.53 2 A-­‐100751 RNAi00522 TRIM40 135644 3 91.97 28.40 -­‐0.57
1 A-­‐100714 RNAi00467 RNF7 9616 3.25 81.45 51.71 -­‐0.91 1 A-­‐100714 RNAi00523 TRIM41 90933 3.25 92.24 20.97 -­‐0.72
2 A-­‐100751 RNAi00467 RNF7 9616 3 90.47 14.93 -­‐0.49 2 A-­‐100751 RNAi00523 TRIM41 90933 3 89.10 37.75 -­‐0.62
1 A-­‐100714 RNAi00468 RNF8 9025 3.25 87.50 12.22 -­‐0.66 1 A-­‐100714 RNAi00524 TRIM42 287015 3.25 45.19 -­‐49.86 -­‐0.27
2 A-­‐100751 RNAi00468 RNF8 9025 3 92.23 0.80 -­‐0.41 2 A-­‐100751 RNAi00524 TRIM42 287015 3 64.12 -­‐17.36 -­‐0.31
1 A-­‐100714 RNAi00469 RSPRY1 89970 3.25 53.05 36.91 -­‐0.82 1 A-­‐100715 RNAi00525 TRIM43 129868 3.25 83.49 -­‐33.27 -­‐0.49
2 A-­‐100751 RNAi00469 RSPRY1 89970 3 82.18 54.59 -­‐0.71 2 A-­‐100752 RNAi00525 TRIM43 129868 3 76.16 -­‐33.12 -­‐0.26
1 A-­‐100714 RNAi00470 RUFY1 80230 3.25 82.88 -­‐23.33 -­‐0.44 1 A-­‐100715 RNAi00526 TRIM45 80263 3.25 65.06 -­‐20.81 -­‐0.58
2 A-­‐100751 RNAi00470 RUFY1 80230 3 94.53 8.17 -­‐0.45 2 A-­‐100752 RNAi00526 TRIM45 80263 3 59.85 -­‐21.39 -­‐0.32
1 A-­‐100714 RNAi00471 SCEL 8796 3.25 87.53 -­‐13.95 -­‐0.50 1 A-­‐100715 RNAi00527 TRIM46 80128 3.25 87.10 14.87 -­‐0.86
2 A-­‐100751 RNAi00471 SCEL 8796 3 95.20 -­‐16.14 -­‐0.32 2 A-­‐100752 RNAi00527 TRIM46 80128 3 85.55 -­‐13.11 -­‐0.36
1 A-­‐100714 RNAi00472 SH3MD2 57630 3.25 92.47 27.67 -­‐0.76 1 A-­‐100715 RNAi00528 TRIM47 91107 3.25 87.90 -­‐17.90 -­‐0.60
2 A-­‐100751 RNAi00472 SH3MD2 57630 3 95.03 22.27 -­‐0.53 2 A-­‐100752 RNAi00528 TRIM47 91107 3 101.62 29.05 -­‐0.57
1 A-­‐100714 RNAi00473 SH3MD4 344558 3.25 79.50 38.07 -­‐0.82 1 A-­‐100715 RNAi00529 TRIM48 79097 3.25 83.20 47.74 -­‐1.11
2 A-­‐100751 RNAi00473 SH3MD4 344558 3 101.35 -­‐1.67 -­‐0.40 2 A-­‐100752 RNAi00529 TRIM48 79097 3 95.55 59.69 -­‐0.73
1 A-­‐100714 RNAi00474 SH3RF2 153769 3.25 36.16 -­‐14.62 -­‐0.49 1 A-­‐100715 RNAi00530 TRIM49 57093 3.25 73.50 92.62 -­‐1.45
2 A-­‐100751 RNAi00474 SH3RF2 153769 3 65.30 12.29 -­‐0.48 2 A-­‐100752 RNAi00530 TRIM49 57093 3 83.56 35.95 -­‐0.61
1 A-­‐100714 RNAi00475 SHPRH 257218 3.25 95.82 7.82 -­‐0.64 1 A-­‐100715 RNAi00531 TRIM5 85363 3.25 110.74 51.23 -­‐1.14
2 A-­‐100751 RNAi00475 SHPRH 257218 3 101.07 -­‐9.25 -­‐0.36 2 A-­‐100752 RNAi00531 TRIM5 85363 3 99.60 1.61 -­‐0.43
1 A-­‐100714 RNAi00476 SIAH2 6478 3.25 43.63 73.44 -­‐1.05 1 A-­‐100715 RNAi00532 TRIM50A 135892 3.25 70.42 -­‐12.80 -­‐0.64
2 A-­‐100751 RNAi00476 SIAH2 6478 3 61.98 25.51 -­‐0.55 2 A-­‐100752 RNAi00532 TRIM50A 135892 3 80.50 -­‐23.33 -­‐0.31
1 A-­‐100714 RNAi00477 SMARCA3 6596 3.25 77.03 27.29 -­‐0.76 1 A-­‐100715 RNAi00533 TRIM52 84851 3.25 104.82 -­‐3.50 -­‐0.72
2 A-­‐100751 RNAi00477 SMARCA3 6596 3 96.13 18.14 -­‐0.51 2 A-­‐100752 RNAi00533 TRIM52 84851 3 100.88 -­‐32.83 -­‐0.26
1 A-­‐100714 RNAi00478 JARID1C 8242 3.25 75.04 43.17 -­‐0.86 1 A-­‐100715 RNAi00534 TRIM54 57159 3.25 73.26 -­‐15.93 -­‐0.62
2 A-­‐100751 RNAi00478 JARID1C 8242 3 103.46 69.35 -­‐0.79 2 A-­‐100752 RNAi00534 TRIM54 57159 3 87.53 50.25 -­‐0.68
1 A-­‐100714 RNAi00479 JARID1D 8284 3.25 72.33 3.64 -­‐0.61 1 A-­‐100715 RNAi00535 TRIM55 84675 3.25 101.96 33.11 -­‐1.00
2 A-­‐100751 RNAi00479 JARID1D 8284 3 89.30 73.13 -­‐0.81 2 A-­‐100752 RNAi00535 TRIM55 84675 3 98.77 5.93 -­‐0.46
1 A-­‐100714 RNAi00480 SPRYD5 84767 3.25 71.03 -­‐22.13 -­‐0.45 1 A-­‐100715 RNAi00536 TRIM56 81844 3.25 79.99 4.54 -­‐0.78
2 A-­‐100751 RNAi00480 SPRYD5 84767 3 91.35 13.53 -­‐0.48 2 A-­‐100752 RNAi00536 TRIM56 81844 3 73.21 -­‐23.13 -­‐0.31
1 A-­‐100714 RNAi00481 STUB1 10273 3.25 90.49 13.70 -­‐0.67 1 A-­‐100715 RNAi00537 TRIM58 25893 3.25 54.83 -­‐5.53 -­‐0.70
2 A-­‐100751 RNAi00481 STUB1 10273 3 93.70 -­‐3.39 -­‐0.39 2 A-­‐100752 RNAi00537 TRIM58 25893 3 68.61 1.31 -­‐0.43
1 A-­‐100714 RNAi00482 SYTL3 94120 3.25 61.19 37.48 -­‐0.82 1 A-­‐100715 RNAi00538 TRIM59 286827 3.25 94.41 39.79 -­‐1.05
2 A-­‐100751 RNAi00482 SYTL3 94120 3 83.34 58.47 -­‐0.73 2 A-­‐100752 RNAi00538 TRIM59 286827 3 102.82 14.96 -­‐0.50
1 A-­‐100714 RNAi00483 SYTL4 94121 3.25 62.15 -­‐54.97 -­‐0.24 1 A-­‐100715 RNAi00539 TRIM6 117854 3.25 66.20 -­‐3.50 -­‐0.72
2 A-­‐100751 RNAi00483 SYTL4 94121 3 68.55 -­‐31.27 -­‐0.24 2 A-­‐100752 RNAi00539 TRIM6 117854 3 75.84 1.42 -­‐0.43
1 A-­‐100714 RNAi00484 SYVN1 84447 3.25 25.38 65.93 -­‐1.00 1 A-­‐100715 RNAi00540 TRIM60 166655 3.25 32.17 89.90 -­‐1.43
2 A-­‐100751 RNAi00484 SYVN1 84447 3 40.21 36.26 -­‐0.61 2 A-­‐100752 RNAi00540 TRIM60 166655 3 53.72 21.28 -­‐0.53
1 A-­‐100714 RNAi00485 FLJ14627 84900 3.25 60.19 -­‐5.55 -­‐0.55 1 A-­‐100715 RNAi00541 TRIM61 391712 3.25 92.16 -­‐18.48 -­‐0.60
2 A-­‐100751 RNAi00485 FLJ14627 84900 3 66.62 -­‐19.28 -­‐0.30 2 A-­‐100752 RNAi00541 TRIM61 391712 3 83.36 -­‐55.43 -­‐0.14
1 A-­‐100714 RNAi00486 TNFAIP3 7128 3.25 83.21 53.07 -­‐0.92 1 A-­‐100715 RNAi00542 TRIM62 55223 3.25 60.38 33.37 -­‐1.00
2 A-­‐100751 RNAi00486 TNFAIP3 7128 3 106.60 53.53 -­‐0.70 2 A-­‐100752 RNAi00542 TRIM62 55223 3 84.65 22.31 -­‐0.54
1 A-­‐100714 RNAi00487 TNFRSF25 8718 3.25 70.52 32.08 -­‐0.79 1 A-­‐100715 RNAi00543 TRIM63 84676 3.25 56.61 6.70 -­‐0.79
2 A-­‐100751 RNAi00487 TNFRSF25 8718 3 92.68 2.75 -­‐0.42 2 A-­‐100752 RNAi00543 TRIM63 84676 3 72.81 -­‐18.29 -­‐0.33
1 A-­‐100714 RNAi00488 TOPORS 10210 3.25 94.30 73.74 -­‐1.05 1 A-­‐100715 RNAi00544 TRIM64 120146 3.25 97.94 30.75 -­‐0.98
2 A-­‐100751 RNAi00488 TOPORS 10210 3 97.02 10.39 -­‐0.47 2 A-­‐100752 RNAi00544 TRIM64 120146 3 102.25 59.66 -­‐0.73
1 A-­‐100714 RNAi00489 TRAF2 7186 3.25 34.78 80.72 -­‐1.09 1 A-­‐100715 RNAi00545 TRIM65 201292 3.25 76.65 18.29 -­‐0.88
2 A-­‐100751 RNAi00489 TRAF2 7186 3 45.88 109.92 -­‐1.01 2 A-­‐100752 RNAi00545 TRIM65 201292 3 78.53 2.46 -­‐0.44
1 A-­‐100714 RNAi00490 TRAF3 7187 3.25 102.59 23.51 -­‐0.73 1 A-­‐100715 RNAi00546 TRIM67 440730 3.25 74.10 28.03 -­‐0.96
2 A-­‐100751 RNAi00490 TRAF3 7187 3 93.66 3.67 -­‐0.43 2 A-­‐100752 RNAi00546 TRIM67 440730 3 89.08 -­‐13.87 -­‐0.35
1 A-­‐100714 RNAi00491 TRAF4 9618 3.25 67.75 -­‐23.74 -­‐0.44 1 A-­‐100715 RNAi00547 TRIM68 55128 3.25 42.87 -­‐40.33 -­‐0.43
2 A-­‐100751 RNAi00491 TRAF4 9618 3 74.97 -­‐18.06 -­‐0.31 2 A-­‐100752 RNAi00547 TRIM68 55128 3 73.61 14.49 -­‐0.50
1 A-­‐100714 RNAi00492 TRAF5 7188 3.25 92.25 57.37 -­‐0.95 1 A-­‐100715 RNAi00548 TRIM69 140691 3.25 75.38 7.50 -­‐0.80
2 A-­‐100751 RNAi00492 TRAF5 7188 3 100.50 19.30 -­‐0.52 2 A-­‐100752 RNAi00548 TRIM69 140691 3 100.19 17.65 -­‐0.52
1 A-­‐100714 RNAi00493 TRAF6 7189 3.25 70.63 21.86 -­‐0.72 1 A-­‐100715 RNAi00549 TRIM6-­‐TRIM3445372 3.25 42.47 -­‐11.50 -­‐0.65
2 A-­‐100751 RNAi00493 TRAF6 7189 3 80.72 -­‐2.79 -­‐0.39 2 A-­‐100752 RNAi00549 TRIM6-­‐TRIM3445372 3 62.25 41.24 -­‐0.64
1 A-­‐100714 RNAi00494 TRAF7 84231 3.25 21.16 348.98 -­‐2.77 1 A-­‐100715 RNAi00550 TRIM7 81786 3.25 23.64 49.82 -­‐1.12
2 A-­‐100751 RNAi00494 TRAF7 84231 3 35.84 146.86 -­‐1.22 2 A-­‐100752 RNAi00550 TRIM7 81786 3 22.61 43.57 -­‐0.65
1 A-­‐100714 RNAi00495 TRIP 10293 3.25 77.20 41.58 -­‐0.85 1 A-­‐100715 RNAi00551 TRIM71 131405 3.25 61.52 118.38 -­‐1.65
2 A-­‐100751 RNAi00495 TRIP 10293 3 86.31 18.49 -­‐0.51 2 A-­‐100752 RNAi00551 TRIM71 131405 3 99.11 60.39 -­‐0.73
1 A-­‐100714 RNAi00496 TRIAD3 54476 3.25 82.77 69.39 -­‐1.02 1 A-­‐100715 RNAi00552 TRIM72 493829 3.25 79.73 -­‐20.40 -­‐0.59
2 A-­‐100751 RNAi00496 TRIAD3 54476 3 95.19 13.27 -­‐0.48 2 A-­‐100752 RNAi00552 TRIM72 493829 3 85.90 5.93 -­‐0.46
1 A-­‐100714 RNAi00497 TRIM10 10107 3.25 65.30 35.73 -­‐0.81 1 A-­‐100715 RNAi00553 TRIM73 375593 3.25 80.50 48.32 -­‐1.11
2 A-­‐100751 RNAi00497 TRIM10 10107 3 73.02 -­‐7.28 -­‐0.37 2 A-­‐100752 RNAi00553 TRIM73 375593 3 95.92 51.11 -­‐0.69
Rep Plate ID Compound ID Target Gene Locus ID Cisplatin (µM) CGE PNSF SF Rep Plate ID Compound ID Target Gene Locus ID Cisplatin (µM) CGE PNSF SF
1 A-­‐100715 RNAi00554 TRIM74 378108 3.25 68.86 9.97 -­‐0.82 1 A-­‐100768 RNAi00610 FLJ13063 79798 3.25 86.26 -­‐5.03 -­‐0.20
2 A-­‐100752 RNAi00554 TRIM74 378108 3 86.52 37.96 -­‐0.62 2 A-­‐100753 RNAi00610 FLJ13063 79798 3 89.27 -­‐3.50 -­‐0.34
1 A-­‐100715 RNAi00555 TRIM75 391714 3.25 81.71 28.28 -­‐0.96 1 A-­‐100768 RNAi00611 ASC1P100 84164 3.25 96.40 3.93 -­‐0.25
2 A-­‐100752 RNAi00555 TRIM75 391714 3 90.42 10.05 -­‐0.48 2 A-­‐100753 RNAi00611 ASC1P100 84164 3 100.84 13.94 -­‐0.44
1 A-­‐100715 RNAi00556 TRIM8 81603 3.25 81.05 111.14 -­‐1.60 1 A-­‐100768 RNAi00612 ATRX 546 3.25 65.88 -­‐37.70 -­‐0.02
2 A-­‐100752 RNAi00556 TRIM8 81603 3 87.04 35.54 -­‐0.61 2 A-­‐100753 RNAi00612 ATRX 546 3 65.37 -­‐17.89 -­‐0.26
1 A-­‐100715 RNAi00557 TRIML1 339976 3.25 80.67 16.34 -­‐0.87 1 A-­‐100768 RNAi00613 MJD 4287 3.25 106.21 31.83 -­‐0.40
2 A-­‐100752 RNAi00557 TRIML1 339976 3 86.39 17.15 -­‐0.51 2 A-­‐100753 RNAi00613 MJD 4287 3 107.11 55.33 -­‐0.68
1 A-­‐100715 RNAi00558 TTC3 7267 3.25 93.46 11.04 -­‐0.83 1 A-­‐100768 RNAi00614 SCA7 6314 3.25 84.80 -­‐14.03 -­‐0.15
2 A-­‐100752 RNAi00558 TTC3 7267 3 88.66 -­‐32.22 -­‐0.26 2 A-­‐100753 RNAi00614 SCA7 6314 3 86.69 -­‐8.47 -­‐0.31
1 A-­‐100715 RNAi00559 UBE4A 9354 3.25 78.89 40.73 -­‐1.05 1 A-­‐100768 RNAi00615 MGC33190 222255 3.25 99.15 3.58 -­‐0.25
2 A-­‐100752 RNAi00559 UBE4A 9354 3 85.23 7.27 -­‐0.46 2 A-­‐100753 RNAi00615 MGC33190 222255 3 100.81 2.73 -­‐0.38
1 A-­‐100715 RNAi00560 UBE4B 10277 3.25 107.63 69.71 -­‐1.28 1 A-­‐100768 RNAi00616 MGC46534 127002 3.25 85.78 -­‐5.82 -­‐0.20
2 A-­‐100752 RNAi00560 UBE4B 10277 3 107.01 65.73 -­‐0.76 2 A-­‐100753 RNAi00616 MGC46534 127002 3 87.72 6.29 -­‐0.40
1 A-­‐100715 RNAi00561 UBOX5 22888 3.25 93.14 32.95 -­‐1.00 1 A-­‐100768 RNAi00617 DKFZP761G211356970 3.25 81.22 14.04 -­‐0.30
2 A-­‐100752 RNAi00561 UBOX5 22888 3 95.53 18.94 -­‐0.52 2 A-­‐100753 RNAi00617 DKFZP761G211356970 3 81.04 36.55 -­‐0.57
1 A-­‐100715 RNAi00562 UBR1 197131 3.25 82.32 13.83 -­‐0.85 1 A-­‐100768 RNAi00618 AUP1 550 3.25 104.63 25.20 -­‐0.36
2 A-­‐100752 RNAi00562 UBR1 197131 3 86.39 3.24 -­‐0.44 2 A-­‐100753 RNAi00618 AUP1 550 3 97.97 9.54 -­‐0.42
1 A-­‐100715 RNAi00563 UBR2 23304 3.25 109.90 12.65 -­‐0.84 1 A-­‐100768 RNAi00619 BACH1 571 3.25 93.99 -­‐15.58 -­‐0.14
2 A-­‐100752 RNAi00563 UBR2 23304 3 98.60 6.64 -­‐0.46 2 A-­‐100753 RNAi00619 BACH1 571 3 93.15 -­‐3.24 -­‐0.34
1 A-­‐100715 RNAi00564 UHRF1 29128 3.25 79.84 39.69 -­‐1.05 1 A-­‐100768 RNAi00620 BACH2 60468 3.25 84.41 3.98 -­‐0.25
2 A-­‐100752 RNAi00564 UHRF1 29128 3 99.25 63.40 -­‐0.75 2 A-­‐100753 RNAi00620 BACH2 60468 3 78.92 -­‐7.72 -­‐0.32
1 A-­‐100715 RNAi00565 UHRF2 115426 3.25 91.37 -­‐0.66 -­‐0.74 1 A-­‐100768 RNAi00621 BAP1 8314 3.25 93.16 -­‐27.67 -­‐0.08
2 A-­‐100752 RNAi00565 UHRF2 115426 3 93.53 -­‐11.00 -­‐0.37 2 A-­‐100753 RNAi00621 BAP1 8314 3 95.38 -­‐8.16 -­‐0.32
1 A-­‐100715 RNAi00566 UNK 85451 3.25 81.05 10.69 -­‐0.82 1 A-­‐100768 RNAi00622 BCL6 604 3.25 87.06 -­‐9.60 -­‐0.17
2 A-­‐100752 RNAi00566 UNK 85451 3 87.21 6.10 -­‐0.46 2 A-­‐100753 RNAi00622 BCL6 604 3 90.03 -­‐3.99 -­‐0.34
1 A-­‐100715 RNAi00567 VPS11 55823 3.25 60.67 32.31 -­‐0.99 1 A-­‐100768 RNAi00623 BCL6B 255877 3.25 92.00 100.93 -­‐0.77
2 A-­‐100752 RNAi00567 VPS11 55823 3 60.45 26.58 -­‐0.56 2 A-­‐100753 RNAi00623 BCL6B 255877 3 84.81 70.62 -­‐0.77
1 A-­‐100715 RNAi00568 VPS18 57617 3.25 79.77 23.38 -­‐0.92 1 A-­‐100768 RNAi00624 CXORF53 79184 3.25 89.41 0.05 -­‐0.23
2 A-­‐100752 RNAi00568 VPS18 57617 3 86.95 -­‐4.81 -­‐0.40 2 A-­‐100753 RNAi00624 CXORF53 79184 3 90.25 -­‐8.94 -­‐0.31
1 A-­‐100715 RNAi00569 VPS41 27072 3.25 81.75 7.06 -­‐0.80 1 A-­‐100768 RNAi00625 BRE 9577 3.25 76.55 0.62 -­‐0.23
2 A-­‐100752 RNAi00569 VPS41 27072 3 78.31 -­‐1.85 -­‐0.42 2 A-­‐100753 RNAi00625 BRE 9577 3 71.11 -­‐28.70 -­‐0.20
1 A-­‐100715 RNAi00570 WDR24 84219 3.25 124.91 55.72 -­‐1.17 1 A-­‐100768 RNAi00626 KIAA1811 84446 3.25 102.69 27.13 -­‐0.37
2 A-­‐100752 RNAi00570 WDR24 84219 3 99.33 4.80 -­‐0.45 2 A-­‐100753 RNAi00626 KIAA1811 84446 3 103.50 27.47 -­‐0.52
1 A-­‐100715 RNAi00571 WDR59 79726 3.25 102.82 51.63 -­‐1.14 1 A-­‐100768 RNAi00627 STK29 9024 3.25 88.58 1.36 -­‐0.23
2 A-­‐100752 RNAi00571 WDR59 79726 3 90.40 -­‐9.02 -­‐0.38 2 A-­‐100753 RNAi00627 STK29 9024 3 82.53 -­‐16.11 -­‐0.27
1 A-­‐100715 RNAi00572 WDSUB1 151525 3.25 91.27 27.15 -­‐0.95 1 A-­‐100768 RNAi00628 BTBD1 53339 3.25 90.84 14.64 -­‐0.30
2 A-­‐100752 RNAi00572 WDSUB1 151525 3 81.03 -­‐22.76 -­‐0.31 2 A-­‐100753 RNAi00628 BTBD1 53339 3 86.22 3.23 -­‐0.38
1 A-­‐100715 RNAi00573 WHSC1 7468 3.25 98.36 -­‐5.35 -­‐0.70 1 A-­‐100768 RNAi00629 GMRP-­‐1 84280 3.25 86.78 -­‐4.82 -­‐0.20
2 A-­‐100752 RNAi00573 WHSC1 7468 3 92.36 -­‐31.51 -­‐0.27 2 A-­‐100753 RNAi00629 GMRP-­‐1 84280 3 82.33 -­‐0.74 -­‐0.36
1 A-­‐100715 RNAi00574 WHSC1L1 54904 3.25 100.35 43.25 -­‐1.07 1 A-­‐100768 RNAi00630 BTBD11 121551 3.25 99.84 -­‐0.27 -­‐0.22
2 A-­‐100752 RNAi00574 WHSC1L1 54904 3 99.98 -­‐14.63 -­‐0.35 2 A-­‐100753 RNAi00630 BTBD11 121551 3 100.14 2.11 -­‐0.37
1 A-­‐100715 RNAi00575 ZA20D1 56957 3.25 102.79 35.57 -­‐1.02 1 A-­‐100768 RNAi00631 BTBD12 84464 3.25 85.29 31.05 -­‐0.39
2 A-­‐100752 RNAi00575 ZA20D1 56957 3 95.49 28.44 -­‐0.57 2 A-­‐100753 RNAi00631 BTBD12 84464 3 80.60 29.36 -­‐0.53
1 A-­‐100715 RNAi00576 ZNF216 7763 3.25 54.64 32.25 -­‐0.99 1 A-­‐100768 RNAi00632 LOC388419 388419 3.25 91.96 9.03 -­‐0.27
2 A-­‐100752 RNAi00576 ZNF216 7763 3 63.37 -­‐16.25 -­‐0.34 2 A-­‐100753 RNAi00632 LOC388419 388419 3 90.73 21.80 -­‐0.49
1 A-­‐100715 RNAi00577 ZFAND6 54469 3.25 89.77 20.13 -­‐0.90 1 A-­‐100768 RNAi00633 BTBD2 55643 3.25 98.31 -­‐1.15 -­‐0.22
2 A-­‐100752 RNAi00577 ZFAND6 54469 3 94.44 -­‐23.19 -­‐0.31 2 A-­‐100753 RNAi00633 BTBD2 55643 3 103.89 21.43 -­‐0.49
1 A-­‐100715 RNAi00578 ZMYND11 10771 3.25 81.30 15.60 -­‐0.86 1 A-­‐100768 RNAi00634 BTBD3 22903 3.25 98.52 7.16 -­‐0.26
2 A-­‐100752 RNAi00578 ZMYND11 10771 3 94.55 30.31 -­‐0.58 2 A-­‐100753 RNAi00634 BTBD3 22903 3 98.43 20.31 -­‐0.48
1 A-­‐100715 RNAi00579 ZNF179 7732 3.25 71.82 25.45 -­‐0.94 1 A-­‐100768 RNAi00635 BTBD6 90135 3.25 88.54 -­‐19.62 -­‐0.12
2 A-­‐100752 RNAi00579 ZNF179 7732 3 82.78 -­‐2.50 -­‐0.41 2 A-­‐100753 RNAi00635 BTBD6 90135 3 95.40 2.17 -­‐0.38
1 A-­‐100715 RNAi00580 ZNF185 7739 3.25 73.88 65.64 -­‐1.25 1 A-­‐100768 RNAi00636 BTBD7 55727 3.25 90.73 -­‐31.48 -­‐0.06
2 A-­‐100752 RNAi00580 ZNF185 7739 3 78.20 18.28 -­‐0.52 2 A-­‐100753 RNAi00636 BTBD7 55727 3 93.29 -­‐17.56 -­‐0.26
1 A-­‐100715 RNAi00581 ZNF278 23598 3.25 101.51 19.59 -­‐0.89 1 A-­‐100768 RNAi00637 BTBD8 284697 3.25 96.58 -­‐1.52 -­‐0.22
2 A-­‐100752 RNAi00581 ZNF278 23598 3 91.86 -­‐1.54 -­‐0.42 2 A-­‐100753 RNAi00637 BTBD8 284697 3 98.75 32.44 -­‐0.55
1 A-­‐100715 RNAi00582 ZNF294 26046 3.25 80.37 35.68 -­‐1.02 1 A-­‐100768 RNAi00638 BTBD9 114781 3.25 89.42 5.43 -­‐0.26
2 A-­‐100752 RNAi00582 ZNF294 26046 3 77.25 -­‐17.91 -­‐0.33 2 A-­‐100753 RNAi00638 BTBD9 114781 3 80.67 -­‐3.01 -­‐0.35
1 A-­‐100715 RNAi00583 ZNF313 55905 3.25 71.69 14.72 -­‐0.86 1 A-­‐100768 RNAi00639 C14ORF4 64207 3.25 89.57 -­‐15.34 -­‐0.14
2 A-­‐100752 RNAi00583 ZNF313 55905 3 71.04 -­‐23.34 -­‐0.31 2 A-­‐100753 RNAi00639 C14ORF4 64207 3 88.52 -­‐11.34 -­‐0.30
1 A-­‐100715 RNAi00584 ZNF330 27309 3.25 94.57 18.24 -­‐0.88 1 A-­‐100768 RNAi00640 DKFZP547N04383932 3.25 82.35 -­‐7.64 -­‐0.19
2 A-­‐100752 RNAi00584 ZNF330 27309 3 84.33 -­‐23.32 -­‐0.31 2 A-­‐100753 RNAi00640 DKFZP547N04383932 3 79.52 -­‐13.12 -­‐0.29
1 A-­‐100715 RNAi00585 ZNF364 27246 3.25 15.55 133.81 -­‐1.77 1 A-­‐100768 RNAi00641 FLJ31031 199990 3.25 97.47 5.78 -­‐0.26
2 A-­‐100752 RNAi00585 ZNF364 27246 3 18.36 136.98 -­‐1.12 2 A-­‐100753 RNAi00641 FLJ31031 199990 3 101.03 18.26 -­‐0.47
1 A-­‐100715 RNAi00586 ZNF547 284306 3.25 90.24 54.48 -­‐1.16 1 A-­‐100768 RNAi00642 KIAA1536 57658 3.25 78.96 -­‐16.04 -­‐0.14
2 A-­‐100752 RNAi00586 ZNF547 284306 3 97.89 11.43 -­‐0.48 2 A-­‐100753 RNAi00642 KIAA1536 57658 3 76.67 26.37 -­‐0.51
1 A-­‐100715 RNAi00587 ZNF592 9640 3.25 85.59 30.31 -­‐0.97 1 A-­‐100768 RNAi00643 CBX4 8535 3.25 94.25 9.45 -­‐0.28
2 A-­‐100752 RNAi00587 ZNF592 9640 3 88.53 6.06 -­‐0.46 2 A-­‐100753 RNAi00643 CBX4 8535 3 94.76 6.50 -­‐0.40
1 A-­‐100715 RNAi00588 ZNF645 158506 3.25 90.77 17.61 -­‐0.88 1 A-­‐100768 RNAi00644 CCDC50 152137 3.25 79.82 7.51 -­‐0.27
2 A-­‐100752 RNAi00588 ZNF645 158506 3 90.79 -­‐2.52 -­‐0.41 2 A-­‐100753 RNAi00644 CCDC50 152137 3 70.38 -­‐17.56 -­‐0.26
1 A-­‐100715 RNAi00589 ZNF650 130507 3.25 41.72 75.19 -­‐1.32 1 A-­‐100768 RNAi00645 CCIN 881 3.25 82.97 9.94 -­‐0.28
2 A-­‐100752 RNAi00589 ZNF650 130507 3 72.49 57.79 -­‐0.72 2 A-­‐100753 RNAi00645 CCIN 881 3 80.16 -­‐1.85 -­‐0.35
1 A-­‐100715 RNAi00590 ZNRF1 84937 3.25 115.86 31.55 -­‐0.98 1 A-­‐100768 RNAi00646 CCNB1IP1 57820 3.25 86.08 48.71 -­‐0.49
2 A-­‐100752 RNAi00590 ZNRF1 84937 3 99.82 -­‐2.75 -­‐0.41 2 A-­‐100753 RNAi00646 CCNB1IP1 57820 3 75.14 26.71 -­‐0.52
1 A-­‐100715 RNAi00591 ZNRF2 223082 3.25 107.79 69.79 -­‐1.28 1 A-­‐100768 RNAi00647 CDC16 8881 3.25 83.44 -­‐14.79 -­‐0.15
2 A-­‐100752 RNAi00591 ZNRF2 223082 3 97.32 9.17 -­‐0.47 2 A-­‐100753 RNAi00647 CDC16 8881 3 80.51 -­‐22.00 -­‐0.24
1 A-­‐100715 RNAi00592 ZNRF3 84133 3.25 104.07 42.24 -­‐1.07 1 A-­‐100768 RNAi00648 CDC20 991 3.25 68.13 -­‐1.46 -­‐0.22
2 A-­‐100752 RNAi00592 ZNRF3 84133 3 99.02 -­‐12.39 -­‐0.36 2 A-­‐100753 RNAi00648 CDC20 991 3 47.62 -­‐67.27 0.02
1 A-­‐100715 RNAi00593 ZNRF4 148066 3.25 50.15 42.21 -­‐1.07 1 A-­‐100768 RNAi00649 CDC23 8697 3.25 83.22 -­‐13.72 -­‐0.15
2 A-­‐100752 RNAi00593 ZNRF4 148066 3 61.89 18.09 -­‐0.52 2 A-­‐100753 RNAi00649 CDC23 8697 3 75.35 -­‐26.62 -­‐0.21
1 A-­‐100715 RNAi00594 ZSWIM2 151112 3.25 71.34 120.98 -­‐1.67 1 A-­‐100768 RNAi00650 CDC26 246184 3.25 80.21 -­‐20.05 -­‐0.12
2 A-­‐100752 RNAi00594 ZSWIM2 151112 3 90.71 78.50 -­‐0.83 2 A-­‐100753 RNAi00650 CDC26 246184 3 78.67 -­‐16.71 -­‐0.27
1 A-­‐100768 RNAi00595 ABTB1 80325 3.25 74.38 11.78 -­‐0.29 1 A-­‐100768 RNAi00651 CDC27 996 3.25 70.88 -­‐39.08 -­‐0.02
2 A-­‐100753 RNAi00595 ABTB1 80325 3 70.30 35.46 -­‐0.57 2 A-­‐100753 RNAi00651 CDC27 996 3 60.31 -­‐51.82 -­‐0.07
1 A-­‐100768 RNAi00596 ABTB2 25841 3.25 105.32 35.47 -­‐0.42 1 A-­‐100768 RNAi00652 C10ORF3 55165 3.25 87.75 -­‐31.60 -­‐0.06
2 A-­‐100753 RNAi00596 ABTB2 25841 3 98.88 45.10 -­‐0.62 2 A-­‐100753 RNAi00652 C10ORF3 55165 3 88.78 -­‐24.65 -­‐0.22
1 A-­‐100768 RNAi00597 LOC196394 196394 3.25 95.31 41.31 -­‐0.45 1 A-­‐100768 RNAi00653 COPS5 10987 3.25 81.27 -­‐4.73 -­‐0.20
2 A-­‐100753 RNAi00597 LOC196394 196394 3 90.70 40.83 -­‐0.60 2 A-­‐100753 RNAi00653 COPS5 10987 3 75.19 -­‐23.25 -­‐0.23
1 A-­‐100768 RNAi00598 ANAPC1 64682 3.25 69.12 8.81 -­‐0.27 1 A-­‐100768 RNAi00654 COPS6 10980 3.25 94.08 41.00 -­‐0.45
2 A-­‐100753 RNAi00598 ANAPC1 64682 3 59.79 -­‐10.26 -­‐0.30 2 A-­‐100753 RNAi00654 COPS6 10980 3 85.60 51.47 -­‐0.66
1 A-­‐100768 RNAi00599 ANAPC10 10393 3.25 87.81 57.33 -­‐0.53 1 A-­‐100768 RNAi00655 CPSF1 29894 3.25 23.14 129.58 -­‐0.92
2 A-­‐100753 RNAi00599 ANAPC10 10393 3 78.17 69.78 -­‐0.76 2 A-­‐100753 RNAi00655 CPSF1 29894 3 18.14 110.21 -­‐0.99
1 A-­‐100768 RNAi00600 ANAPC13 25847 3.25 92.65 -­‐0.62 -­‐0.22 1 A-­‐100768 RNAi00656 CUEDC1 404093 3.25 91.64 29.30 -­‐0.38
2 A-­‐100753 RNAi00600 ANAPC13 25847 3 91.78 6.70 -­‐0.40 2 A-­‐100753 RNAi00656 CUEDC1 404093 3 92.68 89.35 -­‐0.88
1 A-­‐100768 RNAi00601 ANAPC2 29882 3.25 68.24 -­‐17.29 -­‐0.13 1 A-­‐100768 RNAi00657 CYLD 1540 3.25 88.27 7.58 -­‐0.27
2 A-­‐100753 RNAi00601 ANAPC2 29882 3 59.07 -­‐46.87 -­‐0.09 2 A-­‐100753 RNAi00657 CYLD 1540 3 81.78 10.28 -­‐0.42
1 A-­‐100768 RNAi00602 ANAPC4 29945 3.25 75.90 -­‐28.82 -­‐0.07 1 A-­‐100768 RNAi00658 DCST1 149095 3.25 89.28 -­‐11.45 -­‐0.16
2 A-­‐100753 RNAi00602 ANAPC4 29945 3 69.62 -­‐24.99 -­‐0.22 2 A-­‐100753 RNAi00658 DCST1 149095 3 85.56 0.47 -­‐0.37
1 A-­‐100768 RNAi00603 ANAPC5 51433 3.25 90.63 11.21 -­‐0.29 1 A-­‐100768 RNAi00659 DDB1 1642 3.25 76.91 50.94 -­‐0.50
2 A-­‐100753 RNAi00603 ANAPC5 51433 3 85.34 2.07 -­‐0.37 2 A-­‐100753 RNAi00659 DDB1 1642 3 74.78 18.74 -­‐0.47
1 A-­‐100768 RNAi00604 ANKFY1 51479 3.25 44.66 73.05 -­‐0.62 1 A-­‐100768 RNAi00660 DHX57 90957 3.25 97.23 10.41 -­‐0.28
2 A-­‐100753 RNAi00604 ANKFY1 51479 3 32.66 57.47 -­‐0.69 2 A-­‐100753 RNAi00660 DHX57 90957 3 101.12 13.33 -­‐0.44
1 A-­‐100768 RNAi00605 ANKRD13 88455 3.25 95.92 -­‐4.50 -­‐0.20 1 A-­‐100768 RNAi00661 DMRT3 58524 3.25 95.22 36.05 -­‐0.42
2 A-­‐100753 RNAi00605 ANKRD13 88455 3 98.58 20.25 -­‐0.48 2 A-­‐100753 RNAi00661 DMRT3 58524 3 96.35 68.86 -­‐0.76
1 A-­‐100768 RNAi00606 FLJ25555 124930 3.25 92.26 61.37 -­‐0.56 1 A-­‐100768 RNAi00662 DMRTA1 63951 3.25 90.34 -­‐25.64 -­‐0.09
2 A-­‐100753 RNAi00606 FLJ25555 124930 3 83.63 77.42 -­‐0.81 2 A-­‐100753 RNAi00662 DMRTA1 63951 3 93.33 -­‐26.11 -­‐0.21
1 A-­‐100768 RNAi00607 LOC338692 338692 3.25 90.88 78.30 -­‐0.65 1 A-­‐100768 RNAi00663 DMRTA2 63950 3.25 98.61 11.74 -­‐0.29
2 A-­‐100753 RNAi00607 LOC338692 338692 3 80.83 62.33 -­‐0.72 2 A-­‐100753 RNAi00663 DMRTA2 63950 3 98.01 5.76 -­‐0.40
1 A-­‐100768 RNAi00608 ANKRD9 122416 3.25 64.72 15.25 -­‐0.31 1 A-­‐100768 RNAi00664 DNAJB2 3300 3.25 72.00 1.77 -­‐0.24
2 A-­‐100753 RNAi00608 ANKRD9 122416 3 53.39 4.78 -­‐0.39 2 A-­‐100753 RNAi00664 DNAJB2 3300 3 61.09 25.22 -­‐0.51
1 A-­‐100768 RNAi00609 ANUBL1 93550 3.25 98.18 61.65 -­‐0.56 1 A-­‐100768 RNAi00665 DUB1A 402164 3.25 73.57 17.16 -­‐0.32
2 A-­‐100753 RNAi00609 ANUBL1 93550 3 89.69 57.66 -­‐0.69 2 A-­‐100753 RNAi00665 DUB1A 402164 3 74.21 26.50 -­‐0.51
Rep Plate ID Compound ID Target Gene Locus ID Cisplatin (µM) CGE PNSF SF Rep Plate ID Compound ID Target Gene Locus ID Cisplatin (µM) CGE PNSF SF
1 A-­‐100768 RNAi00666 DUB3 377630 3.25 87.84 -­‐0.07 -­‐0.23 1 A-­‐100717 RNAi00722 KCNA6 3742 3.25 110.55 18.44 -­‐0.91
2 A-­‐100753 RNAi00666 DUB3 377630 3 93.07 38.58 -­‐0.58 2 A-­‐100754 RNAi00722 KCNA6 3742 3 108.16 21.53 -­‐0.66
1 A-­‐100768 RNAi00667 LOC345930 345930 3.25 82.27 -­‐28.61 -­‐0.07 1 A-­‐100717 RNAi00723 KCNA7 3743 3.25 94.12 7.05 -­‐0.80
2 A-­‐100753 RNAi00667 LOC345930 345930 3 82.63 -­‐28.86 -­‐0.20 2 A-­‐100754 RNAi00723 KCNA7 3743 3 90.74 -­‐7.63 -­‐0.49
1 A-­‐100768 RNAi00668 EIF2AK4 440275 3.25 74.65 -­‐16.21 -­‐0.14 1 A-­‐100717 RNAi00724 KCNB1 3745 3.25 71.63 -­‐20.87 -­‐0.53
2 A-­‐100753 RNAi00668 EIF2AK4 440275 3 77.52 14.16 -­‐0.44 2 A-­‐100754 RNAi00724 KCNB1 3745 3 68.01 -­‐57.79 -­‐0.21
1 A-­‐100768 RNAi00669 EIF3S5 8665 3.25 58.57 3.21 -­‐0.24 1 A-­‐100717 RNAi00725 KCNB2 9312 3.25 82.01 78.07 -­‐1.48
2 A-­‐100753 RNAi00669 EIF3S5 8665 3 54.91 -­‐27.21 -­‐0.21 2 A-­‐100754 RNAi00725 KCNB2 9312 3 89.98 56.19 -­‐0.85
1 A-­‐100768 RNAi00670 EIF3S3 8667 3.25 66.91 -­‐3.26 -­‐0.21 1 A-­‐100717 RNAi00726 KCNC1 3746 3.25 79.15 81.12 -­‐1.51
2 A-­‐100753 RNAi00670 EIF3S3 8667 3 61.11 -­‐27.63 -­‐0.20 2 A-­‐100754 RNAi00726 KCNC1 3746 3 91.66 40.30 -­‐0.76
1 A-­‐100768 RNAi00671 ENC1 8507 3.25 108.92 18.02 -­‐0.32 1 A-­‐100717 RNAi00727 KCNC2 3747 3.25 75.63 7.96 -­‐0.81
2 A-­‐100753 RNAi00671 ENC1 8507 3 109.35 16.52 -­‐0.46 2 A-­‐100754 RNAi00727 KCNC2 3747 3 92.41 10.24 -­‐0.59
1 A-­‐100768 RNAi00672 EPN1 29924 3.25 66.61 43.34 -­‐0.46 1 A-­‐100717 RNAi00728 KCNC3 3748 3.25 56.50 -­‐7.83 -­‐0.66
2 A-­‐100753 RNAi00672 EPN1 29924 3 55.96 14.61 -­‐0.45 2 A-­‐100754 RNAi00728 KCNC3 3748 3 78.97 -­‐2.35 -­‐0.52
1 A-­‐100768 RNAi00673 EPN2 22905 3.25 88.94 8.49 -­‐0.27 1 A-­‐100717 RNAi00729 KCNC4 3749 3.25 101.39 22.83 -­‐0.95
2 A-­‐100753 RNAi00673 EPN2 22905 3 90.30 19.53 -­‐0.47 2 A-­‐100754 RNAi00729 KCNC4 3749 3 93.13 10.40 -­‐0.59
1 A-­‐100768 RNAi00674 EPN3 55040 3.25 86.22 -­‐11.19 -­‐0.17 1 A-­‐100717 RNAi00730 KCND1 3750 3.25 79.92 64.08 -­‐1.35
2 A-­‐100753 RNAi00674 EPN3 55040 3 85.52 -­‐16.75 -­‐0.27 2 A-­‐100754 RNAi00730 KCND1 3750 3 87.59 46.24 -­‐0.79
1 A-­‐100717 RNAi00675 EPS15 2060 3.25 64.08 32.57 -­‐1.05 1 A-­‐100717 RNAi00731 KCND2 3751 3.25 86.61 40.83 -­‐1.13
2 A-­‐100754 RNAi00675 EPS15 2060 3 82.06 35.31 -­‐0.73 2 A-­‐100754 RNAi00731 KCND2 3751 3 95.32 40.71 -­‐0.76
1 A-­‐100717 RNAi00676 EPS15L1 58513 3.25 95.79 16.42 -­‐0.89 1 A-­‐100717 RNAi00732 KCND3 3752 3.25 59.21 88.08 -­‐1.58
2 A-­‐100754 RNAi00676 EPS15L1 58513 3 98.03 2.94 -­‐0.55 2 A-­‐100754 RNAi00732 KCND3 3752 3 72.49 52.82 -­‐0.83
1 A-­‐100717 RNAi00677 ERCC5 2073 3.25 88.39 13.83 -­‐0.87 1 A-­‐100717 RNAi00733 KCNG1 3755 3.25 94.38 38.82 -­‐1.11
2 A-­‐100754 RNAi00677 ERCC5 2073 3 94.95 14.14 -­‐0.61 2 A-­‐100754 RNAi00733 KCNG1 3755 3 94.99 21.96 -­‐0.66
1 A-­‐100717 RNAi00678 FAF1 11124 3.25 57.80 -­‐48.94 -­‐0.27 1 A-­‐100717 RNAi00734 KCNG3 170850 3.25 75.64 -­‐49.26 -­‐0.26
2 A-­‐100754 RNAi00678 FAF1 11124 3 87.94 11.20 -­‐0.60 2 A-­‐100754 RNAi00734 KCNG3 170850 3 99.65 -­‐10.21 -­‐0.48
1 A-­‐100717 RNAi00679 ETEA 23197 3.25 77.42 10.90 -­‐0.84 1 A-­‐100717 RNAi00735 KCNRG 283518 3.25 94.85 34.96 -­‐1.07
2 A-­‐100754 RNAi00679 ETEA 23197 3 91.84 32.24 -­‐0.72 2 A-­‐100754 RNAi00735 KCNRG 283518 3 102.36 24.57 -­‐0.67
1 A-­‐100717 RNAi00680 LOC124402 124402 3.25 75.07 -­‐10.64 -­‐0.63 1 A-­‐100717 RNAi00736 KCNS1 3787 3.25 66.83 259.82 -­‐3.22
2 A-­‐100754 RNAi00680 LOC124402 124402 3 73.60 -­‐14.07 -­‐0.46 2 A-­‐100754 RNAi00736 KCNS1 3787 3 77.23 -­‐18.67 -­‐0.43
1 A-­‐100717 RNAi00681 MGC29814 283991 3.25 74.68 -­‐6.64 -­‐0.67 1 A-­‐100717 RNAi00737 KCNS2 3788 3.25 52.79 -­‐2.03 -­‐0.71
2 A-­‐100754 RNAi00681 MGC29814 283991 3 89.20 17.66 -­‐0.63 2 A-­‐100754 RNAi00737 KCNS2 3788 3 57.50 -­‐23.63 -­‐0.40
1 A-­‐100717 RNAi00682 CGI-­‐62 51101 3.25 90.69 -­‐7.51 -­‐0.66 1 A-­‐100717 RNAi00738 KCNS3 3790 3.25 71.26 -­‐31.37 -­‐0.43
2 A-­‐100754 RNAi00682 CGI-­‐62 51101 3 99.21 21.21 -­‐0.65 2 A-­‐100754 RNAi00738 KCNS3 3790 3 82.15 -­‐48.20 -­‐0.27
1 A-­‐100717 RNAi00683 LOC153918 153918 3.25 92.11 9.17 -­‐0.82 1 A-­‐100717 RNAi00739 KCNV1 27012 3.25 80.39 -­‐17.58 -­‐0.57
2 A-­‐100754 RNAi00683 LOC153918 153918 3 101.19 15.61 -­‐0.62 2 A-­‐100754 RNAi00739 KCNV1 27012 3 99.69 13.84 -­‐0.61
1 A-­‐100717 RNAi00684 FLJ11280 55793 3.25 93.49 -­‐37.84 -­‐0.37 1 A-­‐100717 RNAi00740 KCTD1 284252 3.25 95.48 70.21 -­‐1.41
2 A-­‐100754 RNAi00684 FLJ11280 55793 3 98.14 19.87 -­‐0.65 2 A-­‐100754 RNAi00740 KCTD1 284252 3 96.35 46.51 -­‐0.80
1 A-­‐100717 RNAi00685 KIAA1164 54629 3.25 98.79 11.44 -­‐0.84 1 A-­‐100717 RNAi00741 KCTD10 83892 3.25 57.96 15.85 -­‐0.89
2 A-­‐100754 RNAi00685 KIAA1164 54629 3 102.54 3.50 -­‐0.55 2 A-­‐100754 RNAi00741 KCTD10 83892 3 69.70 33.06 -­‐0.72
1 A-­‐100717 RNAi00686 FANCL 55120 3.25 88.07 13.84 -­‐0.87 1 A-­‐100717 RNAi00742 KCTD12 115207 3.25 61.54 -­‐9.01 -­‐0.65
2 A-­‐100754 RNAi00686 FANCL 55120 3 91.77 -­‐3.59 -­‐0.51 2 A-­‐100754 RNAi00742 KCTD12 115207 3 77.37 21.88 -­‐0.66
1 A-­‐100717 RNAi00687 GAN 8139 3.25 74.50 -­‐14.58 -­‐0.59 1 A-­‐100717 RNAi00743 KCTD13 253980 3.25 97.51 18.00 -­‐0.91
2 A-­‐100754 RNAi00687 GAN 8139 3 76.41 -­‐7.84 -­‐0.49 2 A-­‐100754 RNAi00743 KCTD13 253980 3 102.25 15.66 -­‐0.62
1 A-­‐100717 RNAi00688 GGA1 26088 3.25 41.34 -­‐49.87 -­‐0.26 1 A-­‐100717 RNAi00744 KCTD14 65987 3.25 11.21 -­‐267.90 1.83
2 A-­‐100754 RNAi00688 GGA1 26088 3 58.03 -­‐35.99 -­‐0.33 2 A-­‐100754 RNAi00744 KCTD14 65987 3 72.31 -­‐0.47 -­‐0.53
1 A-­‐100717 RNAi00689 GGA2 23062 3.25 89.96 -­‐8.72 -­‐0.65 1 A-­‐100717 RNAi00745 KCTD15 79047 3.25 98.89 24.22 -­‐0.97
2 A-­‐100754 RNAi00689 GGA2 23062 3 94.79 9.73 -­‐0.59 2 A-­‐100754 RNAi00745 KCTD15 79047 3 98.29 -­‐10.63 -­‐0.48
1 A-­‐100717 RNAi00690 GGA3 23163 3.25 92.14 -­‐7.39 -­‐0.66 1 A-­‐100717 RNAi00746 KCTD16 57528 3.25 85.41 39.27 -­‐1.11
2 A-­‐100754 RNAi00690 GGA3 23163 3 98.98 -­‐1.73 -­‐0.53 2 A-­‐100754 RNAi00746 KCTD16 57528 3 87.61 -­‐4.69 -­‐0.51
1 A-­‐100717 RNAi00691 GCL 64395 3.25 70.01 -­‐9.85 -­‐0.64 1 A-­‐100717 RNAi00747 KCTD17 79734 3.25 62.26 9.49 -­‐0.83
2 A-­‐100754 RNAi00691 GCL 64395 3 71.03 -­‐36.80 -­‐0.33 2 A-­‐100754 RNAi00747 KCTD17 79734 3 74.60 -­‐21.18 -­‐0.42
1 A-­‐100717 RNAi00692 GTF2H2 2966 3.25 93.78 -­‐27.69 -­‐0.47 1 A-­‐100717 RNAi00748 KCTD2 23510 3.25 90.37 80.77 -­‐1.51
2 A-­‐100754 RNAi00692 GTF2H2 2966 3 88.23 -­‐28.74 -­‐0.37 2 A-­‐100754 RNAi00748 KCTD2 23510 3 88.42 10.73 -­‐0.59
1 A-­‐100717 RNAi00693 ZNF336 64412 3.25 93.74 1.52 -­‐0.75 1 A-­‐100717 RNAi00749 KCTD20 222658 3.25 74.16 13.84 -­‐0.87
2 A-­‐100754 RNAi00693 ZNF336 64412 3 91.22 -­‐12.19 -­‐0.47 2 A-­‐100754 RNAi00749 KCTD20 222658 3 83.33 5.58 -­‐0.57
1 A-­‐100717 RNAi00694 HDAC6 10013 3.25 95.96 -­‐20.99 -­‐0.53 1 A-­‐100717 RNAi00750 LOC283219 283219 3.25 63.10 42.51 -­‐1.14
2 A-­‐100754 RNAi00694 HDAC6 10013 3 96.35 6.29 -­‐0.57 2 A-­‐100754 RNAi00750 LOC283219 283219 3 89.72 14.57 -­‐0.62
1 A-­‐100717 RNAi00695 HGS 9146 3.25 31.09 59.73 -­‐1.31 1 A-­‐100717 RNAi00751 KCTD3 51133 3.25 56.38 117.01 -­‐1.85
2 A-­‐100754 RNAi00695 HGS 9146 3 45.68 132.67 -­‐1.28 2 A-­‐100754 RNAi00751 KCTD3 51133 3 84.16 105.46 -­‐1.13
1 A-­‐100717 RNAi00696 HIC1 3090 3.25 70.75 22.77 -­‐0.95 1 A-­‐100717 RNAi00752 KCTD4 386618 3.25 98.11 46.28 -­‐1.18
2 A-­‐100754 RNAi00696 HIC1 3090 3 82.43 15.64 -­‐0.62 2 A-­‐100754 RNAi00752 KCTD4 386618 3 97.99 -­‐24.38 -­‐0.40
1 A-­‐100717 RNAi00697 HIC2 23119 3.25 85.81 -­‐15.22 -­‐0.59 1 A-­‐100717 RNAi00753 KCTD5 54442 3.25 67.10 41.95 -­‐1.14
2 A-­‐100754 RNAi00697 HIC2 23119 3 82.52 -­‐28.67 -­‐0.37 2 A-­‐100754 RNAi00753 KCTD5 54442 3 85.17 4.76 -­‐0.56
1 A-­‐100717 RNAi00698 HYPK 25764 3.25 85.20 -­‐9.65 -­‐0.64 1 A-­‐100717 RNAi00754 KCTD6 200845 3.25 96.54 75.26 -­‐1.45
2 A-­‐100754 RNAi00698 HYPK 25764 3 75.41 -­‐19.48 -­‐0.43 2 A-­‐100754 RNAi00754 KCTD6 200845 3 97.23 0.11 -­‐0.54
1 A-­‐100717 RNAi00699 IBTK 25998 3.25 86.61 6.42 -­‐0.80 1 A-­‐100718 RNAi00755 KCTD7 154881 3.25 93.85 10.79 -­‐1.24
2 A-­‐100754 RNAi00699 IBTK 25998 3 99.87 41.06 -­‐0.76 2 A-­‐100755 RNAi00755 KCTD7 154881 3 93.53 -­‐0.73 -­‐0.40
1 A-­‐100717 RNAi00700 IKBKG 8517 3.25 87.12 -­‐24.39 -­‐0.50 1 A-­‐100718 RNAi00756 KCTD8 386617 3.25 81.90 35.43 -­‐1.45
2 A-­‐100754 RNAi00700 IKBKG 8517 3 85.87 -­‐11.92 -­‐0.47 2 A-­‐100755 RNAi00756 KCTD8 386617 3 98.93 22.12 -­‐0.52
1 A-­‐100717 RNAi00701 IMPACT 55364 3.25 83.18 -­‐19.13 -­‐0.55 1 A-­‐100718 RNAi00757 KCTD9 54793 3.25 70.71 -­‐48.72 -­‐0.74
2 A-­‐100754 RNAi00701 IMPACT 55364 3 93.33 29.12 -­‐0.70 2 A-­‐100755 RNAi00757 KCTD9 54793 3 92.25 -­‐9.13 -­‐0.35
1 A-­‐100717 RNAi00702 IPP 3652 3.25 93.29 -­‐17.50 -­‐0.57 1 A-­‐100718 RNAi00758 KEAP1 9817 3.25 37.62 -­‐13.99 -­‐1.03
2 A-­‐100754 RNAi00702 IPP 3652 3 102.11 5.83 -­‐0.57 2 A-­‐100755 RNAi00758 KEAP1 9817 3 61.70 68.51 -­‐0.76
1 A-­‐100717 RNAi00703 IVNS1ABP 10625 3.25 87.94 22.24 -­‐0.95 1 A-­‐100718 RNAi00759 KIAA0999 23387 3.25 53.69 -­‐35.19 -­‐0.85
2 A-­‐100754 RNAi00703 IVNS1ABP 10625 3 85.06 -­‐4.85 -­‐0.51 2 A-­‐100755 RNAi00759 KIAA0999 23387 3 61.04 -­‐25.74 -­‐0.26
1 A-­‐100717 RNAi00704 JOSD1 9929 3.25 78.42 -­‐3.73 -­‐0.70 1 A-­‐100718 RNAi00760 KLHDC5 57542 3.25 86.44 18.65 -­‐1.31
2 A-­‐100754 RNAi00704 JOSD1 9929 3 92.96 26.97 -­‐0.69 2 A-­‐100755 RNAi00760 KLHDC5 57542 3 98.62 30.78 -­‐0.56
1 A-­‐100717 RNAi00705 SBBI54 126119 3.25 90.17 22.91 -­‐0.95 1 A-­‐100718 RNAi00761 FLJ46299 166348 3.25 71.71 -­‐22.68 -­‐0.96
2 A-­‐100754 RNAi00705 SBBI54 126119 3 100.49 31.49 -­‐0.71 2 A-­‐100755 RNAi00761 FLJ46299 166348 3 86.73 24.74 -­‐0.53
1 A-­‐100717 RNAi00706 KBTBD10 10324 3.25 96.17 -­‐16.19 -­‐0.58 1 A-­‐100718 RNAi00762 KLHL1 57626 3.25 72.20 -­‐42.60 -­‐0.79
2 A-­‐100754 RNAi00706 KBTBD10 10324 3 95.94 -­‐7.66 -­‐0.49 2 A-­‐100755 RNAi00762 KLHL1 57626 3 86.22 -­‐9.67 -­‐0.35
1 A-­‐100717 RNAi00707 KBTBD11 9920 3.25 96.60 -­‐2.64 -­‐0.71 1 A-­‐100718 RNAi00763 KLHL10 317719 3.25 94.40 -­‐8.05 -­‐1.08
2 A-­‐100754 RNAi00707 KBTBD11 9920 3 91.93 3.56 -­‐0.55 2 A-­‐100755 RNAi00763 KLHL10 317719 3 92.03 -­‐16.40 -­‐0.31
1 A-­‐100717 RNAi00708 KBTBD2 25948 3.25 61.28 -­‐22.01 -­‐0.52 1 A-­‐100718 RNAi00764 KLHL11 55175 3.25 75.25 -­‐53.14 -­‐0.70
2 A-­‐100754 RNAi00708 KBTBD2 25948 3 65.52 21.39 -­‐0.65 2 A-­‐100755 RNAi00764 KLHL11 55175 3 89.48 9.06 -­‐0.45
1 A-­‐100717 RNAi00709 KBTBD3 143879 3.25 98.05 4.84 -­‐0.78 1 A-­‐100718 RNAi00765 KLHL12 59349 3.25 89.91 9.92 -­‐1.23
2 A-­‐100754 RNAi00709 KBTBD3 143879 3 101.93 -­‐12.74 -­‐0.46 2 A-­‐100755 RNAi00765 KLHL12 59349 3 92.89 -­‐5.79 -­‐0.37
1 A-­‐100717 RNAi00710 KBTBD4 55709 3.25 91.34 15.96 -­‐0.89 1 A-­‐100718 RNAi00766 KLHL13 90293 3.25 80.33 -­‐65.17 -­‐0.60
2 A-­‐100754 RNAi00710 KBTBD4 55709 3 99.37 22.78 -­‐0.66 2 A-­‐100755 RNAi00766 KLHL13 90293 3 92.42 -­‐3.15 -­‐0.38
1 A-­‐100717 RNAi00711 KBTBD5 131377 3.25 100.09 -­‐12.05 -­‐0.62 1 A-­‐100718 RNAi00767 KLHL14 57565 3.25 78.15 -­‐27.32 -­‐0.92
2 A-­‐100754 RNAi00711 KBTBD5 131377 3 98.52 8.40 -­‐0.58 2 A-­‐100755 RNAi00767 KLHL14 57565 3 101.88 37.08 -­‐0.59
1 A-­‐100717 RNAi00712 KBTBD6 89890 3.25 86.51 8.89 -­‐0.82 1 A-­‐100718 RNAi00768 KLHL15 80311 3.25 77.29 -­‐80.22 -­‐0.47
2 A-­‐100754 RNAi00712 KBTBD6 89890 3 91.30 -­‐20.29 -­‐0.42 2 A-­‐100755 RNAi00768 KLHL15 80311 3 84.94 0.43 -­‐0.40
1 A-­‐100717 RNAi00713 KBTBD7 84078 3.25 94.15 -­‐8.70 -­‐0.65 1 A-­‐100718 RNAi00769 LOC339451 339451 3.25 83.68 16.95 -­‐1.29
2 A-­‐100754 RNAi00713 KBTBD7 84078 3 88.98 -­‐5.41 -­‐0.50 2 A-­‐100755 RNAi00769 LOC339451 339451 3 86.75 59.03 -­‐0.71
1 A-­‐100717 RNAi00714 TA-­‐KRP 84541 3.25 90.13 15.68 -­‐0.88 1 A-­‐100718 RNAi00770 KIAA0795 23276 3.25 75.82 -­‐18.11 -­‐1.00
2 A-­‐100754 RNAi00714 TA-­‐KRP 84541 3 98.01 -­‐4.84 -­‐0.51 2 A-­‐100755 RNAi00770 KIAA0795 23276 3 72.95 -­‐14.37 -­‐0.32
1 A-­‐100717 RNAi00715 KCMF1 56888 3.25 64.48 60.58 -­‐1.31 1 A-­‐100718 RNAi00771 AB026190 27252 3.25 61.59 -­‐6.28 -­‐1.10
2 A-­‐100754 RNAi00715 KCMF1 56888 3 82.29 21.79 -­‐0.66 2 A-­‐100755 RNAi00771 AB026190 27252 3 62.61 -­‐5.43 -­‐0.37
1 A-­‐100717 RNAi00716 KCNA1 3736 3.25 79.18 8.63 -­‐0.82 1 A-­‐100718 RNAi00772 KLHL21 9903 3.25 82.35 -­‐39.49 -­‐0.81
2 A-­‐100754 RNAi00716 KCNA1 3736 3 84.67 2.47 -­‐0.55 2 A-­‐100755 RNAi00772 KLHL21 9903 3 98.80 12.94 -­‐0.47
1 A-­‐100717 RNAi00717 KCNA10 3744 3.25 90.04 30.62 -­‐1.03 1 A-­‐100718 RNAi00773 KLHL22 84861 3.25 81.63 -­‐40.81 -­‐0.80
2 A-­‐100754 RNAi00717 KCNA10 3744 3 94.45 9.41 -­‐0.59 2 A-­‐100755 RNAi00773 KLHL22 84861 3 84.81 -­‐34.14 -­‐0.22
1 A-­‐100717 RNAi00718 KCNA2 3737 3.25 71.82 -­‐34.30 -­‐0.41 1 A-­‐100718 RNAi00774 MGC22679 151230 3.25 58.94 -­‐25.66 -­‐0.93
2 A-­‐100754 RNAi00718 KCNA2 3737 3 97.02 12.96 -­‐0.61 2 A-­‐100755 RNAi00774 MGC22679 151230 3 83.10 14.25 -­‐0.47
1 A-­‐100717 RNAi00719 KCNA3 3738 3.25 76.51 -­‐5.76 -­‐0.68 1 A-­‐100718 RNAi00775 DRE1 54800 3.25 74.87 -­‐3.02 -­‐1.12
2 A-­‐100754 RNAi00719 KCNA3 3738 3 74.74 -­‐12.76 -­‐0.46 2 A-­‐100755 RNAi00775 DRE1 54800 3 92.54 14.97 -­‐0.48
1 A-­‐100717 RNAi00720 KCNA4 3739 3.25 90.84 101.49 -­‐1.71 1 A-­‐100718 RNAi00776 FLJ12587 64410 3.25 67.48 -­‐75.99 -­‐0.51
2 A-­‐100754 RNAi00720 KCNA4 3739 3 90.49 90.39 -­‐1.04 2 A-­‐100755 RNAi00776 FLJ12587 64410 3 63.77 -­‐41.15 -­‐0.18
1 A-­‐100717 RNAi00721 KCNA5 3741 3.25 96.18 31.57 -­‐1.04 1 A-­‐100718 RNAi00777 FLJ11078 55295 3.25 48.45 -­‐25.49 -­‐0.93
2 A-­‐100754 RNAi00721 KCNA5 3741 3 98.26 8.58 -­‐0.58 2 A-­‐100755 RNAi00777 FLJ11078 55295 3 72.81 -­‐1.53 -­‐0.39
Rep Plate ID Compound ID Target Gene Locus ID Cisplatin (µM) CGE PNSF SF Rep Plate ID Compound ID Target Gene Locus ID Cisplatin (µM) CGE PNSF SF
1 A-­‐100718 RNAi00778 BTBD5 54813 3.25 94.96 -­‐22.56 -­‐0.96 1 A-­‐100718 RNAi00834 NUP153 9972 3.25 51.89 37.98 -­‐1.47
2 A-­‐100755 RNAi00778 BTBD5 54813 3 102.74 1.16 -­‐0.41 2 A-­‐100755 RNAi00834 NUP153 9972 3 71.31 -­‐15.21 -­‐0.32
1 A-­‐100718 RNAi00779 KBTBD9 114818 3.25 86.47 -­‐21.83 -­‐0.96 1 A-­‐100719 RNAi00835 NXF1 10482 3.25 17.74 33.78 -­‐1.51
2 A-­‐100755 RNAi00779 KBTBD9 114818 3 97.03 32.25 -­‐0.57 2 A-­‐100756 RNAi00835 NXF1 10482 3 12.20 41.91 -­‐0.63
1 A-­‐100718 RNAi00780 KLHL3 26249 3.25 88.64 11.19 -­‐1.24 1 A-­‐100719 RNAi00836 NXF2 56001 3.25 93.62 13.52 -­‐1.36
2 A-­‐100755 RNAi00780 KLHL3 26249 3 102.51 20.31 -­‐0.51 2 A-­‐100756 RNAi00836 NXF2 56001 3 98.85 27.99 -­‐0.56
1 A-­‐100718 RNAi00781 FLJ43374 377007 3.25 52.76 -­‐71.18 -­‐0.55 1 A-­‐100719 RNAi00837 OPTN 10133 3.25 94.21 -­‐0.39 -­‐1.25
2 A-­‐100755 RNAi00781 FLJ43374 377007 3 62.88 -­‐37.37 -­‐0.20 2 A-­‐100756 RNAi00837 OPTN 10133 3 94.02 -­‐2.16 -­‐0.40
1 A-­‐100718 RNAi00782 KBTBD1 401265 3.25 77.54 -­‐6.92 -­‐1.09 1 A-­‐100719 RNAi00838 OSTM1 28962 3.25 80.86 -­‐26.63 -­‐1.05
2 A-­‐100755 RNAi00782 KBTBD1 401265 3 103.51 37.54 -­‐0.60 2 A-­‐100756 RNAi00838 OSTM1 28962 3 84.78 -­‐21.77 -­‐0.29
1 A-­‐100718 RNAi00783 KIAA1900 114792 3.25 63.92 -­‐58.97 -­‐0.65 1 A-­‐100719 RNAi00839 OTUB1 55611 3.25 65.93 41.46 -­‐1.57
2 A-­‐100755 RNAi00783 KIAA1900 114792 3 77.26 -­‐26.68 -­‐0.26 2 A-­‐100756 RNAi00839 OTUB1 55611 3 77.15 18.82 -­‐0.51
1 A-­‐100718 RNAi00784 LOC123103 123103 3.25 51.18 -­‐70.24 -­‐0.55 1 A-­‐100719 RNAi00840 OTUB2 78990 3.25 76.97 -­‐18.77 -­‐1.11
2 A-­‐100755 RNAi00784 LOC123103 123103 3 52.89 -­‐45.73 -­‐0.16 2 A-­‐100756 RNAi00840 OTUB2 78990 3 92.75 7.97 -­‐0.45
1 A-­‐100718 RNAi00785 FLJ34960 257240 3.25 95.54 -­‐2.45 -­‐1.13 1 A-­‐100719 RNAi00841 OTUD1 220213 3.25 75.10 -­‐36.35 -­‐0.97
2 A-­‐100755 RNAi00785 FLJ34960 257240 3 96.37 -­‐11.15 -­‐0.34 2 A-­‐100756 RNAi00841 OTUD1 220213 3 93.18 7.85 -­‐0.45
1 A-­‐100718 RNAi00786 C16ORF44 79786 3.25 69.27 -­‐67.60 -­‐0.58 1 A-­‐100719 RNAi00842 OTUD4 54726 3.25 91.79 -­‐30.98 -­‐1.01
2 A-­‐100755 RNAi00786 C16ORF44 79786 3 85.54 9.14 -­‐0.45 2 A-­‐100756 RNAi00842 OTUD4 54726 3 100.04 16.23 -­‐0.50
1 A-­‐100718 RNAi00787 LOC340359 340359 3.25 73.58 71.95 -­‐1.76 1 A-­‐100719 RNAi00843 OTUD5 55593 3.25 56.02 -­‐78.62 -­‐0.64
2 A-­‐100755 RNAi00787 LOC340359 340359 3 94.68 80.79 -­‐0.82 2 A-­‐100756 RNAi00843 OTUD5 55593 3 63.85 -­‐70.36 -­‐0.04
1 A-­‐100718 RNAi00788 KLHL4 56062 3.25 53.03 -­‐46.21 -­‐0.76 1 A-­‐100719 RNAi00844 HSHIN6 139562 3.25 76.17 -­‐17.96 -­‐1.11
2 A-­‐100755 RNAi00788 KLHL4 56062 3 69.59 6.54 -­‐0.43 2 A-­‐100756 RNAi00844 HSHIN6 139562 3 93.00 12.86 -­‐0.48
1 A-­‐100718 RNAi00789 KLHL5 51088 3.25 80.16 -­‐12.85 -­‐1.04 1 A-­‐100719 RNAi00845 OTUD6B 51633 3.25 86.09 10.17 -­‐1.33
2 A-­‐100755 RNAi00789 KLHL5 51088 3 87.69 7.19 -­‐0.44 2 A-­‐100756 RNAi00845 OTUD6B 51633 3 97.09 0.09 -­‐0.41
1 A-­‐100718 RNAi00790 KLHL6 89857 3.25 73.73 24.55 -­‐1.36 1 A-­‐100719 RNAi00846 OTUD7 161725 3.25 99.55 -­‐55.18 -­‐0.83
2 A-­‐100755 RNAi00790 KLHL6 89857 3 91.56 55.97 -­‐0.69 2 A-­‐100756 RNAi00846 OTUD7 161725 3 92.23 -­‐13.04 -­‐0.34
1 A-­‐100718 RNAi00791 KLHL7 55975 3.25 65.22 -­‐27.01 -­‐0.92 1 A-­‐100719 RNAi00847 USP52 9924 3.25 48.89 -­‐30.23 -­‐1.02
2 A-­‐100755 RNAi00791 KLHL7 55975 3 80.55 21.06 -­‐0.51 2 A-­‐100756 RNAi00847 USP52 9924 3 58.89 5.63 -­‐0.44
1 A-­‐100718 RNAi00792 KLHL8 57563 3.25 82.80 -­‐24.05 -­‐0.95 1 A-­‐100719 RNAi00848 PARP11 57097 3.25 77.59 -­‐1.43 -­‐1.24
2 A-­‐100755 RNAi00792 KLHL8 57563 3 92.07 -­‐22.42 -­‐0.28 2 A-­‐100756 RNAi00848 PARP11 57097 3 81.14 -­‐23.73 -­‐0.28
1 A-­‐100718 RNAi00793 KLHL9 55958 3.25 89.09 -­‐6.58 -­‐1.09 1 A-­‐100719 RNAi00849 PCF11 51585 3.25 23.67 28.06 -­‐1.47
2 A-­‐100755 RNAi00793 KLHL9 55958 3 95.48 14.71 -­‐0.48 2 A-­‐100756 RNAi00849 PCF11 51585 3 52.17 77.32 -­‐0.82
1 A-­‐100718 RNAi00794 LATS1 9113 3.25 63.76 -­‐34.56 -­‐0.86 1 A-­‐100719 RNAi00850 PEX12 5193 3.25 77.67 -­‐33.49 -­‐0.99
2 A-­‐100755 RNAi00794 LATS1 9113 3 77.62 21.31 -­‐0.51 2 A-­‐100756 RNAi00850 PEX12 5193 3 89.86 -­‐16.46 -­‐0.32
1 A-­‐100718 RNAi00795 LATS2 26524 3.25 40.99 48.12 -­‐1.56 1 A-­‐100719 RNAi00851 PIAS1 8554 3.25 53.90 -­‐1.79 -­‐1.24
2 A-­‐100755 RNAi00795 LATS2 26524 3 42.25 55.76 -­‐0.69 2 A-­‐100756 RNAi00851 PIAS1 8554 3 77.97 46.01 -­‐0.66
1 A-­‐100718 RNAi00796 LGALS3BP 3959 3.25 53.75 78.50 -­‐1.82 1 A-­‐100719 RNAi00852 PIAS2 9063 3.25 97.60 -­‐22.74 -­‐1.08
2 A-­‐100755 RNAi00796 LGALS3BP 3959 3 81.59 78.15 -­‐0.81 2 A-­‐100756 RNAi00852 PIAS2 9063 3 95.46 4.58 -­‐0.44
1 A-­‐100718 RNAi00797 LMX1B 4010 3.25 52.50 -­‐44.59 -­‐0.77 1 A-­‐100719 RNAi00853 PIAS3 10401 3.25 102.24 24.09 -­‐1.44
2 A-­‐100755 RNAi00797 LMX1B 4010 3 81.29 50.36 -­‐0.66 2 A-­‐100756 RNAi00853 PIAS3 10401 3 111.13 34.83 -­‐0.60
1 A-­‐100718 RNAi00798 LOC100134427 100134427 3.25 55.55 -­‐57.81 -­‐0.66 1 A-­‐100719 RNAi00854 PIAS4 51588 3.25 60.73 -­‐50.75 -­‐0.86
2 A-­‐100755 RNAi00798 LOC100134427 100134427 3 87.83 16.60 -­‐0.49 2 A-­‐100756 RNAi00854 PIAS4 51588 3 71.56 -­‐27.45 -­‐0.26
1 A-­‐100718 RNAi00799 LOC643596 643596 3.25 15.14 132.28 -­‐2.27 1 A-­‐100719 RNAi00855 POLH 5429 3.25 57.67 -­‐0.05 -­‐1.25
2 A-­‐100755 RNAi00799 LOC643596 643596 3 35.31 97.86 -­‐0.91 2 A-­‐100756 RNAi00855 POLH 5429 3 62.09 -­‐0.51 -­‐0.41
1 A-­‐100718 RNAi00800 LOC646862 646862 3.25 64.99 -­‐21.79 -­‐0.97 1 A-­‐100719 RNAi00856 POLI 11201 3.25 81.35 13.33 -­‐1.36
2 A-­‐100755 RNAi00800 LOC646862 646862 3 56.90 -­‐47.56 -­‐0.15 2 A-­‐100756 RNAi00856 POLI 11201 3 85.61 -­‐0.86 -­‐0.41
1 A-­‐100718 RNAi00801 LOC648245 648245 3.25 83.96 -­‐17.14 -­‐1.00 1 A-­‐100719 RNAi00857 POLK 51426 3.25 72.91 -­‐3.15 -­‐1.23
2 A-­‐100755 RNAi00801 LOC648245 648245 3 84.19 17.09 -­‐0.49 2 A-­‐100756 RNAi00857 POLK 51426 3 79.59 28.34 -­‐0.56
1 A-­‐100718 RNAi00802 LOC731049 731049 3.25 48.39 13.35 -­‐1.26 1 A-­‐100719 RNAi00858 PRPF8 10594 3.25 16.22 71.66 -­‐1.81
2 A-­‐100755 RNAi00802 LOC731049 731049 3 72.66 15.84 -­‐0.48 2 A-­‐100756 RNAi00858 PRPF8 10594 3 11.13 -­‐16.51 -­‐0.32
1 A-­‐100718 RNAi00803 LZTR1 8216 3.25 27.74 -­‐13.38 -­‐1.04 1 A-­‐100719 RNAi00859 PSMD14 10213 3.25 22.22 -­‐76.13 -­‐0.66
2 A-­‐100755 RNAi00803 LZTR1 8216 3 26.87 -­‐43.05 -­‐0.17 2 A-­‐100756 RNAi00859 PSMD14 10213 3 21.37 -­‐126.06 0.26
1 A-­‐100718 RNAi00804 MAP3K7IP2 23118 3.25 53.38 173.47 -­‐2.62 1 A-­‐100719 RNAi00860 PSMD4 5710 3.25 43.67 22.54 -­‐1.43
2 A-­‐100755 RNAi00804 MAP3K7IP2 23118 3 75.60 177.71 -­‐1.33 2 A-­‐100756 RNAi00860 PSMD4 5710 3 55.59 59.25 -­‐0.73
1 A-­‐100718 RNAi00805 TAB3 257397 3.25 71.11 11.31 -­‐1.25 1 A-­‐100719 RNAi00861 PSMD7 5713 3.25 21.20 -­‐99.81 -­‐0.48
2 A-­‐100755 RNAi00805 TAB3 257397 3 77.52 -­‐2.26 -­‐0.39 2 A-­‐100756 RNAi00861 PSMD7 5713 3 24.43 -­‐81.66 0.02
1 A-­‐100718 RNAi00806 MARK1 4139 3.25 73.91 -­‐65.15 -­‐0.60 1 A-­‐100719 RNAi00862 LL0XNC01-­‐237H1.1282808 3.25 81.30 -­‐12.32 -­‐1.16
2 A-­‐100755 RNAi00806 MARK1 4139 3 84.56 -­‐38.84 -­‐0.20 2 A-­‐100756 RNAi00862 LL0XNC01-­‐237H1.1282808 3 94.49 27.43 -­‐0.56
1 A-­‐100718 RNAi00807 MARK2 2011 3.25 76.96 -­‐33.51 -­‐0.87 1 A-­‐100719 RNAi00863 RABGEF1 27342 3.25 59.35 22.49 -­‐1.43
2 A-­‐100755 RNAi00807 MARK2 2011 3 85.23 -­‐30.37 -­‐0.24 2 A-­‐100756 RNAi00863 RABGEF1 27342 3 82.46 76.49 -­‐0.82
1 A-­‐100718 RNAi00808 MARK3 4140 3.25 46.15 58.14 -­‐1.64 1 A-­‐100719 RNAi00864 RAD23A 5886 3.25 92.08 -­‐5.05 -­‐1.21
2 A-­‐100755 RNAi00808 MARK3 4140 3 65.25 14.36 -­‐0.47 2 A-­‐100756 RNAi00864 RAD23A 5886 3 95.75 -­‐9.19 -­‐0.36
1 A-­‐100718 RNAi00809 MARK4 57787 3.25 44.80 7.75 -­‐1.22 1 A-­‐100719 RNAi00865 RAD23B 5887 3.25 72.60 -­‐7.39 -­‐1.20
2 A-­‐100755 RNAi00809 MARK4 57787 3 28.82 -­‐65.60 -­‐0.06 2 A-­‐100756 RNAi00865 RAD23B 5887 3 85.69 37.25 -­‐0.61
1 A-­‐100718 RNAi00810 TRFP 9477 3.25 72.38 -­‐4.52 -­‐1.11 1 A-­‐100719 RNAi00866 RANBP2 5903 3.25 92.87 -­‐25.28 -­‐1.06
2 A-­‐100755 RNAi00810 TRFP 9477 3 70.37 -­‐32.94 -­‐0.23 2 A-­‐100756 RNAi00866 RANBP2 5903 3 94.87 -­‐21.76 -­‐0.30
1 A-­‐100718 RNAi00811 MOCS3 27304 3.25 82.12 27.13 -­‐1.38 1 A-­‐100719 RNAi00867 RBM10 8241 3.25 84.04 47.13 -­‐1.62
2 A-­‐100755 RNAi00811 MOCS3 27304 3 81.99 -­‐45.22 -­‐0.16 2 A-­‐100756 RNAi00867 RBM10 8241 3 94.17 41.03 -­‐0.63
1 A-­‐100718 RNAi00812 FLJ14981 84954 3.25 76.57 -­‐6.80 -­‐1.09 1 A-­‐100719 RNAi00868 FLJ40411 375316 3.25 65.42 -­‐35.22 -­‐0.98
2 A-­‐100755 RNAi00812 FLJ14981 84954 3 98.65 23.31 -­‐0.52 2 A-­‐100756 RNAi00868 FLJ40411 375316 3 87.50 -­‐11.06 -­‐0.35
1 A-­‐100718 RNAi00813 KIAA1018 22909 3.25 65.94 -­‐28.01 -­‐0.91 1 A-­‐100719 RNAi00869 RBM6 10180 3.25 83.93 22.41 -­‐1.43
2 A-­‐100755 RNAi00813 KIAA1018 22909 3 72.60 -­‐5.91 -­‐0.37 2 A-­‐100756 RNAi00869 RBM6 10180 3 97.73 3.92 -­‐0.43
1 A-­‐100718 RNAi00814 MYNN 55892 3.25 95.30 7.32 -­‐1.21 1 A-­‐100719 RNAi00870 RCBTB1 55213 3.25 102.16 -­‐27.36 -­‐1.04
2 A-­‐100755 RNAi00814 MYNN 55892 3 93.75 -­‐13.90 -­‐0.33 2 A-­‐100756 RNAi00870 RCBTB1 55213 3 87.38 -­‐35.96 -­‐0.22
1 A-­‐100718 RNAi00815 MYO6 4646 3.25 56.69 68.66 -­‐1.73 1 A-­‐100719 RNAi00871 CHC1L 1102 3.25 102.80 -­‐11.64 -­‐1.16
2 A-­‐100755 RNAi00815 MYO6 4646 3 75.48 45.85 -­‐0.64 2 A-­‐100756 RNAi00871 CHC1L 1102 3 103.67 -­‐4.04 -­‐0.39
1 A-­‐100718 RNAi00816 MYSM1 114803 3.25 88.67 -­‐44.72 -­‐0.77 1 A-­‐100719 RNAi00872 REV1L 51455 3.25 71.08 48.50 -­‐1.63
2 A-­‐100755 RNAi00816 MYSM1 114803 3 99.91 1.47 -­‐0.41 2 A-­‐100756 RNAi00872 REV1L 51455 3 99.35 81.25 -­‐0.84
1 A-­‐100718 RNAi00817 N4BP2 55728 3.25 80.52 -­‐70.12 -­‐0.56 1 A-­‐100719 RNAi00873 RFC1 5981 3.25 88.25 71.04 -­‐1.80
2 A-­‐100755 RNAi00817 N4BP2 55728 3 89.23 -­‐15.37 -­‐0.32 2 A-­‐100756 RNAi00873 RFC1 5981 3 103.63 40.88 -­‐0.63
1 A-­‐100718 RNAi00818 NACA 4666 3.25 25.55 -­‐42.43 -­‐0.79 1 A-­‐100719 RNAi00874 LOC342931 342931 3.25 71.82 -­‐44.28 -­‐0.91
2 A-­‐100755 RNAi00818 NACA 4666 3 38.63 19.38 -­‐0.50 2 A-­‐100756 RNAi00874 LOC342931 342931 3 86.16 10.81 -­‐0.47
1 A-­‐100718 RNAi00819 MGC71999 342538 3.25 55.70 -­‐61.73 -­‐0.63 1 A-­‐100719 RNAi00875 C22ORF3 25807 3.25 65.12 27.21 -­‐1.46
2 A-­‐100755 RNAi00819 MGC71999 342538 3 87.12 46.30 -­‐0.64 2 A-­‐100756 RNAi00875 C22ORF3 25807 3 87.34 33.60 -­‐0.59
1 A-­‐100718 RNAi00820 KIAA0363 23148 3.25 33.72 61.57 -­‐1.67 1 A-­‐100719 RNAi00876 RHOBTB1 9886 3.25 71.75 147.13 -­‐2.39
2 A-­‐100755 RNAi00820 KIAA0363 23148 3 56.12 115.30 -­‐1.00 2 A-­‐100756 RNAi00876 RHOBTB1 9886 3 79.89 71.39 -­‐0.79
1 A-­‐100718 RNAi00821 BTBD14B 112939 3.25 41.91 43.68 -­‐1.52 1 A-­‐100719 RNAi00877 RHOBTB2 23221 3.25 45.99 4.96 -­‐1.29
2 A-­‐100755 RNAi00821 BTBD14B 112939 3 53.34 -­‐1.25 -­‐0.39 2 A-­‐100756 RNAi00877 RHOBTB2 23221 3 57.45 -­‐1.63 -­‐0.40
1 A-­‐100718 RNAi00822 BTBD14A 138151 3.25 70.53 20.87 -­‐1.33 1 A-­‐100719 RNAi00878 RHOBTB3 22836 3.25 86.52 75.92 -­‐1.84
2 A-­‐100755 RNAi00822 BTBD14A 138151 3 72.86 -­‐23.75 -­‐0.28 2 A-­‐100756 RNAi00878 RHOBTB3 22836 3 102.78 24.27 -­‐0.54
1 A-­‐100718 RNAi00823 APPBP1 8883 3.25 70.03 -­‐40.45 -­‐0.81 1 A-­‐100719 RNAi00879 LOC285498 285498 3.25 79.63 22.90 -­‐1.43
2 A-­‐100755 RNAi00823 APPBP1 8883 3 72.19 -­‐8.37 -­‐0.36 2 A-­‐100756 RNAi00879 LOC285498 285498 3 81.00 -­‐8.66 -­‐0.36
1 A-­‐100718 RNAi00824 M17S2 4077 3.25 75.06 -­‐36.40 -­‐0.84 1 A-­‐100719 RNAi00880 RWDD1 51389 3.25 96.24 21.45 -­‐1.42
2 A-­‐100755 RNAi00824 M17S2 4077 3 78.91 -­‐28.81 -­‐0.25 2 A-­‐100756 RNAi00880 RWDD1 51389 3 95.89 -­‐10.67 -­‐0.35
1 A-­‐100718 RNAi00825 NEIL3 55247 3.25 87.56 66.18 -­‐1.71 1 A-­‐100719 RNAi00881 RWDD2 112611 3.25 89.01 -­‐38.56 -­‐0.95
2 A-­‐100755 RNAi00825 NEIL3 55247 3 98.03 9.06 -­‐0.45 2 A-­‐100756 RNAi00881 RWDD2 112611 3 90.02 -­‐39.57 -­‐0.20
1 A-­‐100718 RNAi00826 NFX1 4799 3.25 70.84 41.64 -­‐1.50 1 A-­‐100719 RNAi00882 C21ORF6 10069 3.25 82.82 5.73 -­‐1.30
2 A-­‐100755 RNAi00826 NFX1 4799 3 82.19 18.35 -­‐0.50 2 A-­‐100756 RNAi00882 C21ORF6 10069 3 90.18 14.32 -­‐0.49
1 A-­‐100718 RNAi00827 HOZFP 152518 3.25 77.61 83.78 -­‐1.86 1 A-­‐100719 RNAi00883 RWDD3 25950 3.25 70.91 35.79 -­‐1.53
2 A-­‐100755 RNAi00827 HOZFP 152518 3 98.37 9.91 -­‐0.45 2 A-­‐100756 RNAi00883 RWDD3 25950 3 85.19 44.25 -­‐0.65
1 A-­‐100718 RNAi00828 NIPBL 25836 3.25 44.11 -­‐57.92 -­‐0.66 1 A-­‐100719 RNAi00884 MGC10198 201965 3.25 98.38 -­‐2.20 -­‐1.24
2 A-­‐100755 RNAi00828 NIPBL 25836 3 59.43 -­‐44.14 -­‐0.17 2 A-­‐100756 RNAi00884 MGC10198 201965 3 98.01 -­‐20.61 -­‐0.30
1 A-­‐100718 RNAi00829 NOSIP 51070 3.25 58.00 20.98 -­‐1.33 1 A-­‐100719 RNAi00885 RYBP 23429 3.25 37.36 28.99 -­‐1.48
2 A-­‐100755 RNAi00829 NOSIP 51070 3 88.04 13.31 -­‐0.47 2 A-­‐100756 RNAi00885 RYBP 23429 3 61.74 35.34 -­‐0.60
1 A-­‐100718 RNAi00830 NPL4 55666 3.25 77.22 60.24 -­‐1.66 1 A-­‐100719 RNAi00886 SAE1 10055 3.25 89.94 29.64 -­‐1.48
2 A-­‐100755 RNAi00830 NPL4 55666 3 93.82 3.02 -­‐0.42 2 A-­‐100756 RNAi00886 SAE1 10055 3 87.95 -­‐8.05 -­‐0.37
1 A-­‐100718 RNAi00831 NSFL1C 55968 3.25 64.32 143.21 -­‐2.36 1 A-­‐100719 RNAi00887 SENP1 29843 3.25 67.11 8.42 -­‐1.32
2 A-­‐100755 RNAi00831 NSFL1C 55968 3 82.29 35.23 -­‐0.58 2 A-­‐100756 RNAi00887 SENP1 29843 3 83.40 -­‐3.36 -­‐0.39
1 A-­‐100718 RNAi00832 NSMCE1 197370 3.25 56.41 72.41 -­‐1.76 1 A-­‐100719 RNAi00888 SENP2 59343 3.25 73.52 -­‐11.18 -­‐1.17
2 A-­‐100755 RNAi00832 NSMCE1 197370 3 69.73 -­‐14.31 -­‐0.32 2 A-­‐100756 RNAi00888 SENP2 59343 3 80.65 -­‐5.67 -­‐0.38
1 A-­‐100718 RNAi00833 NYREN18 51667 3.25 63.26 124.49 -­‐2.21 1 A-­‐100719 RNAi00889 SENP3 26168 3.25 101.64 40.28 -­‐1.56
2 A-­‐100755 RNAi00833 NYREN18 51667 3 89.26 -­‐9.35 -­‐0.35 2 A-­‐100756 RNAi00889 SENP3 26168 3 91.76 -­‐7.78 -­‐0.37
Rep Plate ID Compound ID Target Gene Locus ID Cisplatin (µM) CGE PNSF SF Rep Plate ID Compound ID Target Gene Locus ID Cisplatin (µM) CGE PNSF SF
1 A-­‐100719 RNAi00890 SENP5 205564 3.25 88.27 -­‐2.53 -­‐1.23 1 A-­‐100720 RNAi00946 RBAF600 23352 3.25 108.81 23.14 -­‐0.94
2 A-­‐100756 RNAi00890 SENP5 205564 3 96.88 8.58 -­‐0.46 2 A-­‐100741 RNAi00946 RBAF600 23352 3 99.39 -­‐18.69 -­‐0.06
1 A-­‐100719 RNAi00891 SENP6 26054 3.25 98.08 68.73 -­‐1.79 1 A-­‐100720 RNAi00947 UBTD1 80019 3.25 93.92 13.48 -­‐0.88
2 A-­‐100756 RNAi00891 SENP6 26054 3 95.02 18.87 -­‐0.51 2 A-­‐100741 RNAi00947 UBTD1 80019 3 88.51 -­‐15.80 -­‐0.08
1 A-­‐100719 RNAi00892 SENP7 57337 3.25 73.05 18.61 -­‐1.40 1 A-­‐100720 RNAi00948 LOC120126 120126 3.25 79.81 85.49 -­‐1.37
2 A-­‐100756 RNAi00892 SENP7 57337 3 91.07 -­‐5.62 -­‐0.38 2 A-­‐100741 RNAi00948 LOC120126 120126 3 97.61 34.11 -­‐0.37
1 A-­‐100719 RNAi00893 SENP8 123228 3.25 82.14 7.62 -­‐1.31 1 A-­‐100720 RNAi00949 LOC51035 51035 3.25 48.94 149.25 -­‐1.81
2 A-­‐100756 RNAi00893 SENP8 123228 3 98.15 29.94 -­‐0.57 2 A-­‐100741 RNAi00949 LOC51035 51035 3 77.65 168.56 -­‐1.17
1 A-­‐100719 RNAi00894 SF3B3 23450 3.25 24.09 -­‐55.31 -­‐0.83 1 A-­‐100720 RNAi00950 KIAA0794 26043 3.25 93.66 13.75 -­‐0.88
2 A-­‐100756 RNAi00894 SF3B3 23450 3 28.22 -­‐58.86 -­‐0.10 2 A-­‐100741 RNAi00950 KIAA0794 26043 3 89.49 -­‐20.45 -­‐0.05
1 A-­‐100719 RNAi00895 SHARPIN 81858 3.25 63.07 -­‐22.15 -­‐1.08 1 A-­‐100720 RNAi00951 UCHL1 7345 3.25 84.68 3.88 -­‐0.81
2 A-­‐100756 RNAi00895 SHARPIN 81858 3 81.02 26.00 -­‐0.55 2 A-­‐100741 RNAi00951 UCHL1 7345 3 84.92 -­‐16.31 -­‐0.07
1 A-­‐100719 RNAi00896 SHKBP1 92799 3.25 44.46 -­‐6.30 -­‐1.20 1 A-­‐100720 RNAi00952 UCHL3 7347 3.25 56.33 -­‐22.40 -­‐0.63
2 A-­‐100756 RNAi00896 SHKBP1 92799 3 61.37 59.90 -­‐0.73 2 A-­‐100741 RNAi00952 UCHL3 7347 3 61.32 -­‐30.11 0.01
1 A-­‐100719 RNAi00897 SIAH1 6477 3.25 54.14 7.85 -­‐1.31 1 A-­‐100720 RNAi00953 UCHL5 51377 3.25 82.35 16.92 -­‐0.90
2 A-­‐100756 RNAi00897 SIAH1 6477 3 59.43 -­‐9.07 -­‐0.36 2 A-­‐100741 RNAi00953 UCHL5 51377 3 92.46 27.47 -­‐0.33
1 A-­‐100719 RNAi00898 SNF1LK 150094 3.25 65.71 1.17 -­‐1.26 1 A-­‐100720 RNAi00954 UFD1L 7353 3.25 80.70 3.89 -­‐0.81
2 A-­‐100756 RNAi00898 SNF1LK 150094 3 91.67 46.24 -­‐0.66 2 A-­‐100741 RNAi00954 UFD1L 7353 3 83.25 -­‐0.96 -­‐0.16
1 A-­‐100719 RNAi00899 SIK2 23235 3.25 65.74 -­‐7.77 -­‐1.19 1 A-­‐100720 RNAi00955 RAP80 51720 3.25 96.53 1.75 -­‐0.80
2 A-­‐100756 RNAi00899 SIK2 23235 3 97.48 30.52 -­‐0.57 2 A-­‐100741 RNAi00955 RAP80 51720 3 90.40 -­‐27.56 -­‐0.01
1 A-­‐100719 RNAi00900 SMARCAD1 56916 3.25 91.63 -­‐21.76 -­‐1.08 1 A-­‐100720 RNAi00956 UNKL 64718 3.25 85.25 34.87 -­‐1.02
2 A-­‐100756 RNAi00900 SMARCAD1 56916 3 93.82 -­‐31.78 -­‐0.24 2 A-­‐100741 RNAi00956 UNKL 64718 3 85.49 9.19 -­‐0.22
1 A-­‐100719 RNAi00901 SNRK 54861 3.25 91.28 -­‐37.19 -­‐0.97 1 A-­‐100720 RNAi00957 USP1 7398 3.25 73.76 -­‐5.19 -­‐0.75
2 A-­‐100756 RNAi00901 SNRK 54861 3 93.07 20.01 -­‐0.52 2 A-­‐100741 RNAi00957 USP1 7398 3 70.61 -­‐36.12 0.04
1 A-­‐100719 RNAi00902 SOLH 6650 3.25 91.24 1.38 -­‐1.26 1 A-­‐100720 RNAi00958 USP10 9100 3.25 43.56 122.93 -­‐1.63
2 A-­‐100756 RNAi00902 SOLH 6650 3 92.93 -­‐1.55 -­‐0.40 2 A-­‐100741 RNAi00958 USP10 9100 3 69.27 98.39 -­‐0.75
1 A-­‐100719 RNAi00903 SPOP 8405 3.25 92.61 5.71 -­‐1.30 1 A-­‐100720 RNAi00959 USP11 8237 3.25 94.83 15.18 -­‐0.89
2 A-­‐100756 RNAi00903 SPOP 8405 3 92.69 -­‐24.60 -­‐0.28 2 A-­‐100741 RNAi00959 USP11 8237 3 82.19 -­‐27.66 -­‐0.01
1 A-­‐100719 RNAi00904 LOC339745 339745 3.25 102.81 11.86 -­‐1.35 1 A-­‐100720 RNAi00960 USP12 219333 3.25 103.09 -­‐8.63 -­‐0.73
2 A-­‐100756 RNAi00904 LOC339745 339745 3 100.66 15.74 -­‐0.49 2 A-­‐100741 RNAi00960 USP12 219333 3 87.81 -­‐31.30 0.01
1 A-­‐100719 RNAi00905 SQSTM1 8878 3.25 94.72 78.67 -­‐1.86 1 A-­‐100720 RNAi00961 USP13 8975 3.25 99.04 47.08 -­‐1.11
2 A-­‐100756 RNAi00905 SQSTM1 8878 3 95.90 8.06 -­‐0.45 2 A-­‐100741 RNAi00961 USP13 8975 3 87.16 -­‐32.68 0.02
1 A-­‐100719 RNAi00906 STAM 8027 3.25 6.05 167.81 -­‐2.55 1 A-­‐100720 RNAi00962 USP14 9097 3.25 92.28 -­‐7.97 -­‐0.73
2 A-­‐100756 RNAi00906 STAM 8027 3 10.48 171.31 -­‐1.32 2 A-­‐100741 RNAi00962 USP14 9097 3 90.96 -­‐16.75 -­‐0.07
1 A-­‐100719 RNAi00907 STAM2 10254 3.25 83.64 89.54 -­‐1.95 1 A-­‐100720 RNAi00963 USP15 9958 3.25 99.94 13.54 -­‐0.88
2 A-­‐100756 RNAi00907 STAM2 10254 3 93.60 -­‐8.18 -­‐0.37 2 A-­‐100741 RNAi00963 USP15 9958 3 102.53 -­‐6.85 -­‐0.13
1 A-­‐100719 RNAi00908 STAMBP 10617 3.25 85.43 166.24 -­‐2.54 1 A-­‐100720 RNAi00964 USP16 10600 3.25 98.23 19.98 -­‐0.92
2 A-­‐100756 RNAi00908 STAMBP 10617 3 98.06 25.90 -­‐0.55 2 A-­‐100741 RNAi00964 USP16 10600 3 90.88 -­‐8.38 -­‐0.12
1 A-­‐100719 RNAi00909 STAMBPL1 57559 3.25 27.60 152.13 -­‐2.43 1 A-­‐100720 RNAi00965 LOC645836 645836 3.25 50.00 77.37 -­‐1.31
2 A-­‐100756 RNAi00909 STAMBPL1 57559 3 65.25 149.33 -­‐1.21 2 A-­‐100741 RNAi00965 LOC645836 645836 3 73.10 49.73 -­‐0.46
1 A-­‐100719 RNAi00910 MGC5306 79101 3.25 71.12 42.60 -­‐1.58 1 A-­‐100720 RNAi00966 USP18 11274 3.25 70.84 -­‐23.67 -­‐0.62
2 A-­‐100756 RNAi00910 MGC5306 79101 3 97.76 9.09 -­‐0.46 2 A-­‐100741 RNAi00966 USP18 11274 3 67.62 -­‐35.41 0.04
1 A-­‐100719 RNAi00911 TANK 10010 3.25 68.84 10.22 -­‐1.33 1 A-­‐100720 RNAi00967 USP19 10869 3.25 97.85 65.46 -­‐1.23
2 A-­‐100756 RNAi00911 TANK 10010 3 72.40 22.64 -­‐0.53 2 A-­‐100741 RNAi00967 USP19 10869 3 84.83 -­‐18.58 -­‐0.06
1 A-­‐100719 RNAi00912 TAX1BP1 8887 3.25 61.11 -­‐30.90 -­‐1.01 1 A-­‐100720 RNAi00968 USP2 9099 3.25 84.03 66.31 -­‐1.24
2 A-­‐100756 RNAi00912 TAX1BP1 8887 3 89.35 -­‐27.71 -­‐0.26 2 A-­‐100741 RNAi00968 USP2 9099 3 88.83 4.68 -­‐0.20
1 A-­‐100719 RNAi00913 PROSAPIP2 9755 3.25 90.86 109.43 -­‐2.10 1 A-­‐100720 RNAi00969 USP20 10868 3.25 51.61 3.99 -­‐0.81
2 A-­‐100756 RNAi00913 PROSAPIP2 9755 3 101.27 10.68 -­‐0.47 2 A-­‐100741 RNAi00969 USP20 10868 3 59.26 16.21 -­‐0.27
1 A-­‐100719 RNAi00914 TCEB3 6924 3.25 44.73 -­‐15.06 -­‐1.14 1 A-­‐100720 RNAi00970 USP21 27005 3.25 88.63 12.95 -­‐0.87
2 A-­‐100756 RNAi00914 TCEB3 6924 3 64.85 4.84 -­‐0.44 2 A-­‐100741 RNAi00970 USP21 27005 3 90.11 0.79 -­‐0.18
1 A-­‐100720 RNAi00915 TDRD3 81550 3.25 97.09 40.77 -­‐1.06 1 A-­‐100720 RNAi00971 USP22 23326 3.25 72.08 63.08 -­‐1.22
2 A-­‐100741 RNAi00915 TDRD3 81550 3 92.01 -­‐7.26 -­‐0.13 2 A-­‐100741 RNAi00971 USP22 23326 3 84.90 24.84 -­‐0.32
1 A-­‐100720 RNAi00916 TNFAIP1 7126 3.25 85.25 44.01 -­‐1.09 1 A-­‐100720 RNAi00972 USP24 23358 3.25 76.27 20.29 -­‐0.92
2 A-­‐100741 RNAi00916 TNFAIP1 7126 3 95.00 3.29 -­‐0.19 2 A-­‐100741 RNAi00972 USP24 23358 3 86.67 -­‐0.89 -­‐0.17
1 A-­‐100720 RNAi00917 TNIP1 10318 3.25 57.70 199.08 -­‐2.15 1 A-­‐100720 RNAi00973 USP25 29761 3.25 92.33 7.76 -­‐0.84
2 A-­‐100741 RNAi00917 TNIP1 10318 3 79.24 128.31 -­‐0.93 2 A-­‐100741 RNAi00973 USP25 29761 3 98.45 -­‐0.10 -­‐0.17
1 A-­‐100720 RNAi00918 TNIP2 79155 3.25 89.76 27.26 -­‐0.97 1 A-­‐100720 RNAi00974 USP26 83844 3.25 99.39 36.56 -­‐1.04
2 A-­‐100741 RNAi00918 TNIP2 79155 3 95.18 -­‐0.40 -­‐0.17 2 A-­‐100741 RNAi00974 USP26 83844 3 94.34 0.44 -­‐0.17
1 A-­‐100720 RNAi00919 TNIP3 79931 3.25 80.87 92.88 -­‐1.42 1 A-­‐100720 RNAi00975 USP28 57646 3.25 100.70 17.22 -­‐0.90
2 A-­‐100741 RNAi00919 TNIP3 79931 3 80.60 18.47 -­‐0.28 2 A-­‐100741 RNAi00975 USP28 57646 3 96.92 16.93 -­‐0.27
1 A-­‐100720 RNAi00920 TNK2 10188 3.25 36.71 21.55 -­‐0.93 1 A-­‐100720 RNAi00976 USP29 57663 3.25 99.17 28.88 -­‐0.98
2 A-­‐100741 RNAi00920 TNK2 10188 3 66.16 60.95 -­‐0.53 2 A-­‐100741 RNAi00976 USP29 57663 3 90.73 2.54 -­‐0.19
1 A-­‐100720 RNAi00921 KIAA1582 57690 3.25 71.82 34.96 -­‐1.02 1 A-­‐100720 RNAi00977 USP3 9960 3.25 75.41 82.65 -­‐1.35
2 A-­‐100741 RNAi00921 KIAA1582 57690 3 77.57 14.89 -­‐0.26 2 A-­‐100741 RNAi00977 USP3 9960 3 100.43 79.50 -­‐0.64
1 A-­‐100720 RNAi00922 TOLLIP 54472 3.25 70.17 15.42 -­‐0.89 1 A-­‐100720 RNAi00978 USP30 84749 3.25 99.54 46.07 -­‐1.10
2 A-­‐100741 RNAi00922 TOLLIP 54472 3 86.39 51.44 -­‐0.47 2 A-­‐100741 RNAi00978 USP30 84749 3 91.04 -­‐4.46 -­‐0.14
1 A-­‐100720 RNAi00923 TOM1 10043 3.25 44.91 -­‐22.27 -­‐0.63 1 A-­‐100720 RNAi00979 USP31 57478 3.25 100.55 52.98 -­‐1.15
2 A-­‐100741 RNAi00923 TOM1 10043 3 53.03 12.26 -­‐0.24 2 A-­‐100741 RNAi00979 USP31 57478 3 92.34 7.35 -­‐0.21
1 A-­‐100720 RNAi00924 TOM1L1 10040 3.25 81.86 16.49 -­‐0.90 1 A-­‐100720 RNAi00980 USP32 84669 3.25 86.00 -­‐10.08 -­‐0.72
2 A-­‐100741 RNAi00924 TOM1L1 10040 3 83.31 0.92 -­‐0.18 2 A-­‐100741 RNAi00980 USP32 84669 3 89.33 2.14 -­‐0.18
1 A-­‐100720 RNAi00925 TOM1L2 146691 3.25 75.83 -­‐15.75 -­‐0.68 1 A-­‐100720 RNAi00981 USP33 23032 3.25 61.75 89.14 -­‐1.40
2 A-­‐100741 RNAi00925 TOM1L2 146691 3 86.37 0.38 -­‐0.17 2 A-­‐100741 RNAi00981 USP33 23032 3 103.87 74.30 -­‐0.61
1 A-­‐100720 RNAi00926 TRAF2 7186 3.25 36.90 94.40 -­‐1.43 1 A-­‐100720 RNAi00982 USP34 9736 3.25 109.71 42.57 -­‐1.08
2 A-­‐100741 RNAi00926 TRAF2 7186 3 53.49 129.23 -­‐0.93 2 A-­‐100741 RNAi00982 USP34 9736 3 108.90 23.98 -­‐0.31
1 A-­‐100720 RNAi00927 TRIM9 114088 3.25 87.27 8.16 -­‐0.84 1 A-­‐100720 RNAi00983 USP35 57558 3.25 86.69 -­‐3.88 -­‐0.76
2 A-­‐100741 RNAi00927 TRIM9 114088 3 89.58 0.96 -­‐0.18 2 A-­‐100741 RNAi00983 USP35 57558 3 90.89 -­‐2.67 -­‐0.15
1 A-­‐100720 RNAi00928 TTRAP 51567 3.25 46.77 -­‐6.77 -­‐0.74 1 A-­‐100720 RNAi00984 USP36 57602 3.25 77.97 47.44 -­‐1.11
2 A-­‐100741 RNAi00928 TTRAP 51567 3 69.27 5.18 -­‐0.20 2 A-­‐100741 RNAi00984 USP36 57602 3 89.69 45.52 -­‐0.44
1 A-­‐100720 RNAi00929 UBA2 10054 3.25 80.78 34.41 -­‐1.02 1 A-­‐100720 RNAi00985 USP37 57695 3.25 66.71 132.65 -­‐1.69
2 A-­‐100741 RNAi00929 UBA2 10054 3 83.80 9.43 -­‐0.23 2 A-­‐100741 RNAi00985 USP37 57695 3 91.21 97.69 -­‐0.75
1 A-­‐100720 RNAi00930 UBADC1 10422 3.25 105.62 8.02 -­‐0.84 1 A-­‐100720 RNAi00986 USP38 84640 3.25 47.31 148.34 -­‐1.80
2 A-­‐100741 RNAi00930 UBADC1 10422 3 96.71 -­‐7.54 -­‐0.13 2 A-­‐100741 RNAi00986 USP38 84640 3 62.70 44.73 -­‐0.43
1 A-­‐100720 RNAi00931 PHGDHL1 337867 3.25 86.20 -­‐13.08 -­‐0.70 1 A-­‐100720 RNAi00987 USP39 10713 3.25 43.53 81.37 -­‐1.34
2 A-­‐100741 RNAi00931 PHGDHL1 337867 3 96.66 -­‐15.07 -­‐0.08 2 A-­‐100741 RNAi00987 USP39 10713 3 54.16 114.81 -­‐0.85
1 A-­‐100720 RNAi00932 UBAP1 51271 3.25 83.27 13.07 -­‐0.87 1 A-­‐100720 RNAi00988 USP4 7375 3.25 83.36 54.81 -­‐1.16
2 A-­‐100741 RNAi00932 UBAP1 51271 3 90.36 22.53 -­‐0.30 2 A-­‐100741 RNAi00988 USP4 7375 3 82.66 16.61 -­‐0.27
1 A-­‐100720 RNAi00933 UBAP2 55833 3.25 87.63 18.34 -­‐0.91 1 A-­‐100720 RNAi00989 USP40 55230 3.25 90.51 55.55 -­‐1.17
2 A-­‐100741 RNAi00933 UBAP2 55833 3 86.60 -­‐12.11 -­‐0.10 2 A-­‐100741 RNAi00989 USP40 55230 3 89.92 21.25 -­‐0.30
1 A-­‐100720 RNAi00934 NICE-­‐4 9898 3.25 90.18 -­‐16.70 -­‐0.67 1 A-­‐100720 RNAi00990 USP41 373856 3.25 54.84 34.35 -­‐1.02
2 A-­‐100741 RNAi00934 NICE-­‐4 9898 3 84.21 -­‐16.53 -­‐0.07 2 A-­‐100741 RNAi00990 USP41 373856 3 71.17 1.23 -­‐0.18
1 A-­‐100720 RNAi00935 UBASH3A 53347 3.25 79.52 14.43 -­‐0.88 1 A-­‐100720 RNAi00991 USP42 84132 3.25 75.93 87.12 -­‐1.38
2 A-­‐100741 RNAi00935 UBASH3A 53347 3 85.22 -­‐0.67 -­‐0.17 2 A-­‐100741 RNAi00991 USP42 84132 3 84.09 36.35 -­‐0.39
1 A-­‐100720 RNAi00936 KIAA1959 84959 3.25 91.93 3.66 -­‐0.81 1 A-­‐100720 RNAi00992 USP43 124739 3.25 63.79 88.54 -­‐1.39
2 A-­‐100741 RNAi00936 KIAA1959 84959 3 96.90 6.22 -­‐0.21 2 A-­‐100741 RNAi00992 USP43 124739 3 74.12 4.26 -­‐0.20
1 A-­‐100720 RNAi00937 LOC646463 646463 3.25 84.63 134.55 -­‐1.71 1 A-­‐100720 RNAi00993 USP44 84101 3.25 95.74 34.75 -­‐1.02
2 A-­‐100741 RNAi00937 LOC646463 646463 3 87.11 31.10 -­‐0.35 2 A-­‐100741 RNAi00993 USP44 84101 3 92.89 -­‐1.51 -­‐0.16
1 A-­‐100720 RNAi00938 UBL3 5412 3.25 102.68 -­‐0.94 -­‐0.78 1 A-­‐100720 RNAi00994 USP45 85015 3.25 98.94 34.25 -­‐1.02
2 A-­‐100741 RNAi00938 UBL3 5412 3 100.48 -­‐8.13 -­‐0.12 2 A-­‐100741 RNAi00994 USP45 85015 3 95.73 18.32 -­‐0.28
1 A-­‐100720 RNAi00939 UBL4 8266 3.25 83.63 7.14 -­‐0.83 1 A-­‐100769 RNAi00995 USP46 64854 3.25 91.48 8.78 -­‐0.30
2 A-­‐100741 RNAi00939 UBL4 8266 3 88.68 -­‐15.01 -­‐0.08 2 A-­‐100758 RNAi00995 USP46 64854 3 88.82 8.62 -­‐0.23
1 A-­‐100720 RNAi00940 UBL5 59286 3.25 24.71 -­‐12.71 -­‐0.70 1 A-­‐100769 RNAi00996 USP47 55031 3.25 95.32 -­‐5.67 -­‐0.23
2 A-­‐100741 RNAi00940 UBL5 59286 3 32.45 20.88 -­‐0.29 2 A-­‐100758 RNAi00996 USP47 55031 3 100.93 3.02 -­‐0.20
1 A-­‐100720 RNAi00941 BMSC-­‐UBP 84993 3.25 91.89 25.62 -­‐0.96 1 A-­‐100769 RNAi00997 USP48 84196 3.25 97.24 14.69 -­‐0.33
2 A-­‐100741 RNAi00941 BMSC-­‐UBP 84993 3 85.50 -­‐25.40 -­‐0.02 2 A-­‐100758 RNAi00997 USP48 84196 3 94.99 -­‐1.89 -­‐0.17
1 A-­‐100720 RNAi00942 UBQLN1 29979 3.25 82.29 -­‐52.48 -­‐0.43 1 A-­‐100769 RNAi00998 USP49 25862 3.25 104.51 25.13 -­‐0.38
2 A-­‐100741 RNAi00942 UBQLN1 29979 3 78.12 -­‐12.52 -­‐0.10 2 A-­‐100758 RNAi00998 USP49 25862 3 104.92 24.79 -­‐0.32
1 A-­‐100720 RNAi00943 UBQLN2 29978 3.25 48.03 -­‐5.92 -­‐0.74 1 A-­‐100769 RNAi00999 USP5 8078 3.25 82.71 -­‐12.35 -­‐0.19
2 A-­‐100741 RNAi00943 UBQLN2 29978 3 72.90 56.16 -­‐0.50 2 A-­‐100758 RNAi00999 USP5 8078 3 85.47 -­‐15.34 -­‐0.10
1 A-­‐100720 RNAi00944 UBQLN3 50613 3.25 103.94 -­‐14.50 -­‐0.69 1 A-­‐100769 RNAi01000 USP50 373509 3.25 90.76 98.93 -­‐0.74
2 A-­‐100741 RNAi00944 UBQLN3 50613 3 93.06 -­‐27.62 -­‐0.01 2 A-­‐100758 RNAi01000 USP50 373509 3 93.40 90.22 -­‐0.68
1 A-­‐100720 RNAi00945 C1ORF6 56893 3.25 80.56 61.73 -­‐1.21 1 A-­‐100769 RNAi01001 USP51 158880 3.25 83.26 24.55 -­‐0.37
2 A-­‐100741 RNAi00945 C1ORF6 56893 3 100.01 27.10 -­‐0.33 2 A-­‐100758 RNAi01001 USP51 158880 3 87.77 36.72 -­‐0.39
Rep Plate ID Compound ID Target Gene Locus ID Cisplatin (µM) CGE PNSF SF Rep Plate ID Compound ID Target Gene Locus ID Cisplatin (µM) CGE PNSF SF
1 A-­‐100769 RNAi01002 USP53 54532 3.25 91.33 -­‐18.96 -­‐0.16 1 A-­‐100769 RNAi01058 DKFZP761I212383637 3.25 77.70 25.84 -­‐0.38
2 A-­‐100758 RNAi01002 USP53 54532 3 96.37 -­‐11.07 -­‐0.12 2 A-­‐100758 RNAi01058 DKFZP761I212383637 3 78.49 34.53 -­‐0.37
1 A-­‐100769 RNAi01003 USP54 159195 3.25 72.36 125.36 -­‐0.87 1 A-­‐100769 RNAi01059 ZNF131 7690 3.25 84.41 -­‐5.44 -­‐0.23
2 A-­‐100758 RNAi01003 USP54 159195 3 78.48 117.66 -­‐0.84 2 A-­‐100758 RNAi01059 ZNF131 7690 3 85.01 5.75 -­‐0.21
1 A-­‐100769 RNAi01004 USP6 9098 3.25 58.26 39.89 -­‐0.45 1 A-­‐100769 RNAi01060 ZNF238 10472 3.25 82.11 3.88 -­‐0.27
2 A-­‐100758 RNAi01004 USP6 9098 3 63.25 40.31 -­‐0.41 2 A-­‐100758 RNAi01060 ZNF238 10472 3 86.54 40.86 -­‐0.41
1 A-­‐100769 RNAi01005 USP7 7874 3.25 73.19 -­‐27.07 -­‐0.12 1 A-­‐100769 RNAi01061 ZNF295 49854 3.25 83.92 -­‐24.40 -­‐0.13
2 A-­‐100758 RNAi01005 USP7 7874 3 70.58 -­‐26.26 -­‐0.04 2 A-­‐100758 RNAi01061 ZNF295 49854 3 85.04 -­‐16.25 -­‐0.09
1 A-­‐100769 RNAi01006 USP8 9101 3.25 77.25 5.14 -­‐0.28 1 A-­‐100769 RNAi01062 ZNF509 166793 3.25 82.77 -­‐3.42 -­‐0.24
2 A-­‐100758 RNAi01006 USP8 9101 3 75.09 -­‐4.95 -­‐0.16 2 A-­‐100758 RNAi01062 ZNF509 166793 3 87.44 6.01 -­‐0.22
1 A-­‐100769 RNAi01007 USP9X 8239 3.25 82.94 0.50 -­‐0.26 1 A-­‐100769 RNAi01063 ZNF598 90850 3.25 88.69 32.53 -­‐0.41
2 A-­‐100758 RNAi01007 USP9X 8239 3 84.66 12.40 -­‐0.25 2 A-­‐100758 RNAi01063 ZNF598 90850 3 90.59 9.54 -­‐0.24
1 A-­‐100769 RNAi01008 USP9Y 8287 3.25 83.36 38.41 -­‐0.44 1 A-­‐100769 RNAi01064 ZRANB1 54764 3.25 61.93 33.46 -­‐0.42
2 A-­‐100758 RNAi01008 USP9Y 8287 3 85.13 19.08 -­‐0.29 2 A-­‐100758 RNAi01064 ZRANB1 54764 3 68.73 38.98 -­‐0.40
1 A-­‐100769 RNAi01009 C13ORF22 10208 3.25 38.78 67.66 -­‐0.58 1 A-­‐100769 RNAi01065 ZNF265 9406 3.25 78.45 -­‐3.25 -­‐0.24
2 A-­‐100758 RNAi01009 C13ORF22 10208 3 39.05 91.60 -­‐0.69 2 A-­‐100758 RNAi01065 ZNF265 9406 3 82.77 41.83 -­‐0.41
1 A-­‐100769 RNAi01010 VCPIP1 80124 3.25 88.58 -­‐3.92 -­‐0.23 1 A-­‐100769 RNAi01066 ZRANB3 84083 3.25 93.63 -­‐9.45 -­‐0.21
2 A-­‐100758 RNAi01010 VCPIP1 80124 3 91.65 -­‐6.95 -­‐0.14 2 A-­‐100758 RNAi01066 ZRANB3 84083 3 94.29 -­‐9.97 -­‐0.13
1 A-­‐100769 RNAi01011 VHL 7428 3.25 89.73 120.13 -­‐0.84 1 A-­‐100769 RNAi01067 C6ORF113 221302 3.25 80.19 -­‐14.94 -­‐0.18
2 A-­‐100758 RNAi01011 VHL 7428 3 92.64 85.39 -­‐0.66 2 A-­‐100758 RNAi01067 C6ORF113 221302 3 84.24 -­‐4.63 -­‐0.16
1 A-­‐100769 RNAi01012 VPS13D 55187 3.25 93.96 -­‐7.80 -­‐0.22
2 A-­‐100758 RNAi01012 VPS13D 55187 3 97.86 -­‐9.76 -­‐0.13
1 A-­‐100769 RNAi01013 FLJ32642 137492 3.25 91.41 15.70 -­‐0.33
2 A-­‐100758 RNAi01013 FLJ32642 137492 3 96.09 2.07 -­‐0.19
1 A-­‐100769 RNAi01014 WRNIP1 56897 3.25 91.32 2.33 -­‐0.27
2 A-­‐100758 RNAi01014 WRNIP1 56897 3 97.95 8.14 -­‐0.23
1 A-­‐100769 RNAi01015 XPA 7507 3.25 89.36 18.23 -­‐0.34
2 A-­‐100758 RNAi01015 XPA 7507 3 87.83 5.52 -­‐0.21
1 A-­‐100769 RNAi01016 YAF2 10138 3.25 68.62 1.05 -­‐0.26
2 A-­‐100758 RNAi01016 YAF2 10138 3 69.71 2.92 -­‐0.20
1 A-­‐100769 RNAi01017 YOD1 55432 3.25 97.73 -­‐10.04 -­‐0.20
2 A-­‐100758 RNAi01017 YOD1 55432 3 97.42 -­‐13.37 -­‐0.11
1 A-­‐100769 RNAi01018 ZBTB1 22890 3.25 87.99 6.32 -­‐0.28
2 A-­‐100758 RNAi01018 ZBTB1 22890 3 88.35 9.71 -­‐0.24
1 A-­‐100769 RNAi01019 ZBTB10 65986 3.25 85.07 -­‐16.16 -­‐0.17
2 A-­‐100758 RNAi01019 ZBTB10 65986 3 87.94 0.12 -­‐0.18
1 A-­‐100769 RNAi01020 ZBTB11 27107 3.25 92.93 21.66 -­‐0.36
2 A-­‐100758 RNAi01020 ZBTB11 27107 3 95.90 5.21 -­‐0.21
1 A-­‐100769 RNAi01021 ZBTB12 221527 3.25 47.68 -­‐11.11 -­‐0.20
2 A-­‐100758 RNAi01021 ZBTB12 221527 3 54.45 -­‐24.40 -­‐0.05
1 A-­‐100769 RNAi01022 ZBTB16 7704 3.25 63.25 -­‐26.75 -­‐0.12
2 A-­‐100758 RNAi01022 ZBTB16 7704 3 67.97 -­‐17.06 -­‐0.09
1 A-­‐100769 RNAi01023 ZNF151 7709 3.25 75.79 -­‐14.32 -­‐0.18
2 A-­‐100758 RNAi01023 ZNF151 7709 3 81.26 -­‐7.47 -­‐0.14
1 A-­‐100769 RNAi01024 ZBTB2 57621 3.25 100.42 21.90 -­‐0.36
2 A-­‐100758 RNAi01024 ZBTB2 57621 3 106.45 21.54 -­‐0.30
1 A-­‐100769 RNAi01025 ZNF288 26137 3.25 95.83 85.62 -­‐0.67
2 A-­‐100758 RNAi01025 ZNF288 26137 3 97.76 78.92 -­‐0.62
1 A-­‐100769 RNAi01026 ZNF297 9278 3.25 96.82 -­‐4.94 -­‐0.23
2 A-­‐100758 RNAi01026 ZNF297 9278 3 95.85 -­‐18.72 -­‐0.08
1 A-­‐100769 RNAi01027 ZBTB24 9841 3.25 87.91 7.59 -­‐0.29
2 A-­‐100758 RNAi01027 ZBTB24 9841 3 90.37 5.90 -­‐0.22
1 A-­‐100769 RNAi01028 ZNF46 7597 3.25 100.31 23.57 -­‐0.37
2 A-­‐100758 RNAi01028 ZNF46 7597 3 103.61 34.62 -­‐0.37
1 A-­‐100769 RNAi01029 ZBTB26 57684 3.25 94.33 5.47 -­‐0.28
2 A-­‐100758 RNAi01029 ZBTB26 57684 3 97.03 4.66 -­‐0.21
1 A-­‐100769 RNAi01030 ZBTB3 79842 3.25 92.94 5.41 -­‐0.28
2 A-­‐100758 RNAi01030 ZBTB3 79842 3 98.53 7.26 -­‐0.22
1 A-­‐100769 RNAi01031 TZFP 27033 3.25 82.36 8.52 -­‐0.30
2 A-­‐100758 RNAi01031 TZFP 27033 3 89.08 9.48 -­‐0.24
1 A-­‐100769 RNAi01032 ZBTB33 10009 3.25 79.77 -­‐0.05 -­‐0.25
2 A-­‐100758 RNAi01032 ZBTB33 10009 3 84.46 -­‐5.63 -­‐0.15
1 A-­‐100769 RNAi01033 MGC2629 84614 3.25 90.00 40.61 -­‐0.45
2 A-­‐100758 RNAi01033 MGC2629 84614 3 95.88 6.80 -­‐0.22
1 A-­‐100769 RNAi01034 ZBTB38 253461 3.25 74.61 131.70 -­‐0.90
2 A-­‐100758 RNAi01034 ZBTB38 253461 3 81.79 106.67 -­‐0.77
1 A-­‐100769 RNAi01035 ZBTB39 9880 3.25 78.44 -­‐23.59 -­‐0.14
2 A-­‐100758 RNAi01035 ZBTB39 9880 3 78.87 -­‐33.70 0.00
1 A-­‐100769 RNAi01036 ZBTB4 57659 3.25 84.39 15.94 -­‐0.33
2 A-­‐100758 RNAi01036 ZBTB4 57659 3 86.18 3.87 -­‐0.20
1 A-­‐100769 RNAi01037 KIAA0478 9923 3.25 90.07 6.72 -­‐0.29
2 A-­‐100758 RNAi01037 KIAA0478 9923 3 93.45 13.88 -­‐0.26
1 A-­‐100769 RNAi01038 FRBZ1 360023 3.25 69.32 -­‐43.37 -­‐0.04
2 A-­‐100758 RNAi01038 FRBZ1 360023 3 72.86 -­‐29.01 -­‐0.02
1 A-­‐100769 RNAi01039 ZNF297B 23099 3.25 64.57 57.04 -­‐0.53
2 A-­‐100758 RNAi01039 ZNF297B 23099 3 69.75 96.08 -­‐0.72
1 A-­‐100769 RNAi01040 HSPC063 29068 3.25 100.98 16.36 -­‐0.33
2 A-­‐100758 RNAi01040 HSPC063 29068 3 107.92 24.37 -­‐0.32
1 A-­‐100769 RNAi01041 ZNF499 84878 3.25 96.36 12.39 -­‐0.31
2 A-­‐100758 RNAi01041 ZNF499 84878 3 104.58 16.71 -­‐0.28
1 A-­‐100769 RNAi01042 BTBD4 140685 3.25 95.12 -­‐3.59 -­‐0.24
2 A-­‐100758 RNAi01042 BTBD4 140685 3 101.66 -­‐2.34 -­‐0.17
1 A-­‐100769 RNAi01043 HKR3 3104 3.25 79.68 127.49 -­‐0.88
2 A-­‐100758 RNAi01043 HKR3 3104 3 89.31 78.48 -­‐0.62
1 A-­‐100769 RNAi01044 ZBTB5 9925 3.25 79.23 -­‐13.73 -­‐0.19
2 A-­‐100758 RNAi01044 ZBTB5 9925 3 81.65 -­‐28.98 -­‐0.02
1 A-­‐100769 RNAi01045 ZNF482 10773 3.25 88.53 -­‐7.74 -­‐0.22
2 A-­‐100758 RNAi01045 ZNF482 10773 3 86.77 -­‐1.09 -­‐0.18
1 A-­‐100769 RNAi01046 ZBTB7 51341 3.25 96.19 -­‐0.93 -­‐0.25
2 A-­‐100758 RNAi01046 ZBTB7 51341 3 95.74 -­‐3.44 -­‐0.16
1 A-­‐100769 RNAi01047 ZFP67 51043 3.25 87.90 -­‐13.67 -­‐0.19
2 A-­‐100758 RNAi01047 ZFP67 51043 3 89.85 -­‐1.48 -­‐0.17
1 A-­‐100769 RNAi01048 APM-­‐1 201501 3.25 90.17 29.38 -­‐0.40
2 A-­‐100758 RNAi01048 APM-­‐1 201501 3 96.53 53.85 -­‐0.48
1 A-­‐100769 RNAi01049 LOC653121 653121 3.25 82.05 6.61 -­‐0.29
2 A-­‐100758 RNAi01049 LOC653121 653121 3 88.41 32.19 -­‐0.36
1 A-­‐100769 RNAi01050 ZBTB9 221504 3.25 77.09 -­‐39.03 -­‐0.06
2 A-­‐100758 RNAi01050 ZBTB9 221504 3 80.92 -­‐15.36 -­‐0.10
1 A-­‐100769 RNAi01051 LOC90637 90637 3.25 85.34 30.97 -­‐0.41
2 A-­‐100758 RNAi01051 LOC90637 90637 3 88.73 23.64 -­‐0.31
1 A-­‐100769 RNAi01052 LOC130617 130617 3.25 87.05 -­‐7.08 -­‐0.22
2 A-­‐100758 RNAi01052 LOC130617 130617 3 95.11 -­‐0.36 -­‐0.18
1 A-­‐100769 RNAi01053 TEX27 60685 3.25 90.58 6.29 -­‐0.28
2 A-­‐100758 RNAi01053 TEX27 60685 3 95.50 -­‐4.00 -­‐0.16
1 A-­‐100769 RNAi01054 ZFP161 7541 3.25 93.85 -­‐0.15 -­‐0.25
2 A-­‐100758 RNAi01054 ZFP161 7541 3 102.42 4.74 -­‐0.21
1 A-­‐100769 RNAi01055 ZFPL1 7542 3.25 78.71 -­‐14.35 -­‐0.18
2 A-­‐100758 RNAi01055 ZFPL1 7542 3 76.23 -­‐14.77 -­‐0.10
1 A-­‐100769 RNAi01056 ZFYVE20 64145 3.25 82.66 7.74 -­‐0.29
2 A-­‐100758 RNAi01056 ZFYVE20 64145 3 82.67 -­‐2.97 -­‐0.17
1 A-­‐100769 RNAi01057 RAI17 57178 3.25 87.34 -­‐27.67 -­‐0.12
2 A-­‐100758 RNAi01057 RAI17 57178 3 91.16 -­‐4.54 -­‐0.16
Appendix	  3
Secondary	  screen	  with	  cisplatin
SF	  and	  CGE	  graphs:	  X	  axis	  represents	  cisplatin	  concentration	  (0	  -­‐	  6	  µM)
Compound ID Plate ID Target gene Locus ID IC50 Graphical Result (SF) Graphical Result (CGE) Effect Compound ID Plate ID Target gene Locus ID IC50 Graphical Result (SF) Graphical Result (CGE) Effect
NonTargeted A-­‐100924 Non	  targeting >6.00 Reject NonTargeted A-­‐100956 Non	  targeting >6.00 Reject
NonTargeted A-­‐100925 Non	  targeting >6.00 Reject NonTargeted A-­‐100957 Non	  targeting >6.00 Reject
NonTargeted A-­‐100926 Non	  targeting >6.00 Reject NonTargeted A-­‐100958 Non	  targeting >6.00 Reject
NonTargeted A-­‐100927 Non	  targeting >6.00 Reject NonTargeted A-­‐100959 Non	  targeting >6.00 Reject
NonTargeted A-­‐100928 Non	  targeting >6.00 Reject NonTargeted A-­‐100960 Non	  targeting >6.00 Reject
NonTargeted A-­‐100929 Non	  targeting >6.00 Reject RNAi00016 A-­‐100924 DCUN1D1 54165 >6.00 Reject
NonTargeted A-­‐100930 Non	  targeting >6.00 Reject RNAi00016 A-­‐100944 DCUN1D1 54165 >6.00 Low
NonTargeted A-­‐100931 Non	  targeting >6.00 Reject RNAi00016 A-­‐100953 DCUN1D1 54165 >6.00 Reject
NonTargeted A-­‐100944 Non	  targeting >6.00 Reject RNAi00018 A-­‐100924 DCUN1D3 123879 >6.00 Reject
NonTargeted A-­‐100945 Non	  targeting >6.00 Reject RNAi00018 A-­‐100944 DCUN1D3 123879 5.33 Low
NonTargeted A-­‐100946 Non	  targeting >6.00 Reject RNAi00018 A-­‐100953 DCUN1D3 123879 5.25 High
NonTargeted A-­‐100947 Non	  targeting >6.00 Reject RNAi00030 A-­‐100924 HERC2 8924 >6.00 Reject
NonTargeted A-­‐100948 Non	  targeting >6.00 Reject RNAi00030 A-­‐100944 HERC2 8924 >6.00 Low
NonTargeted A-­‐100949 Non	  targeting >6.00 Reject RNAi00030 A-­‐100953 HERC2 8924 6.01 Low
NonTargeted A-­‐100950 Non	  targeting >6.00 Reject RNAi00033 A-­‐100924 HERC5 51191 >6.00 Reject
NonTargeted A-­‐100951 Non	  targeting >6.00 Reject RNAi00033 A-­‐100944 HERC5 51191 >6.00 Low
NonTargeted A-­‐100953 Non	  targeting >6.00 Reject RNAi00033 A-­‐100953 HERC5 51191 >6.00 Low
NonTargeted A-­‐100954 Non	  targeting >6.00 Reject RNAi00055 A-­‐100924 UBE2D2 7322 0.08 Reject
NonTargeted A-­‐100955 Non	  targeting >6.00 Reject RNAi00055 A-­‐100944 UBE2D2 7322 2.27 High
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Compound ID Plate ID Target gene Locus ID IC50 Graphical Result (SF) Graphical Result (CGE) Effect rating Compound ID Plate ID Target gene Locus ID IC50 Graphical Result (SF) Graphical Result (CGE) Effect rating
RNAi00055 A-­‐100953 UBE2D2 7322 2.80 High RNAi00139 A-­‐100944 FBXO2 26232 5.81 Low
RNAi00070 A-­‐100924 UBE2M 9040 >6.00 Reject RNAi00139 A-­‐100953 FBXO2 26232 >6.00 Reject
RNAi00070 A-­‐100944 UBE2M 9040 >6.00 Reject RNAi00169 A-­‐100924 FBXW10 10517 >6.00 Low
RNAi00070 A-­‐100953 UBE2M 9040 >6.00 Low RNAi00169 A-­‐100944 FBXW10 10517 5.36 Low
RNAi00071 A-­‐100924 UBE2N 7334 <0.00 Reject RNAi00169 A-­‐100953 FBXW10 10517 5.88 Low
RNAi00071 A-­‐100944 UBE2N 7334 0.24 High RNAi00170 A-­‐100924 FBXW11 23291 4.84 High
RNAi00071 A-­‐100953 UBE2N 7334 0.91 High RNAi00170 A-­‐100944 FBXW11 23291 4.38 High
RNAi00078 A-­‐100924 UBE2T 29089 >6.00 Low RNAi00170 A-­‐100953 FBXW11 23291 4.48 High
RNAi00078 A-­‐100944 UBE2T 29089 0.71 High RNAi00207 A-­‐100925 MARCH-­‐III 115123 4.09 Low
RNAi00078 A-­‐100953 UBE2T 29089 0.52 Reject RNAi00207 A-­‐100945 MARCH-­‐III 115123 1.32 Low
RNAi00082 A-­‐100924 UBE2W 55284 4.16 High RNAi00207 A-­‐100954 MARCH-­‐III 115123 5.22 Reject
RNAi00082 A-­‐100944 UBE2W 55284 1.10 High RNAi00215 A-­‐100925 AMFR 267 4.75 High
RNAi00082 A-­‐100953 UBE2W 55284 3.59 Reject RNAi00215 A-­‐100945 AMFR 267 1.08 Reject
RNAi00099 A-­‐100924 ASB16 92591 >6.00 Reject RNAi00215 A-­‐100954 AMFR 267 5.63 Low
RNAi00099 A-­‐100944 ASB16 92591 >6.00 Reject RNAi00219 A-­‐100925 ARIH1 25820 >6.00 Reject
RNAi00099 A-­‐100953 ASB16 92591 >6.00 Reject RNAi00219 A-­‐100945 ARIH1 25820 >6.00 Reject
RNAi00101 A-­‐100924 ASB18 401036 >6.00 Low RNAi00219 A-­‐100954 ARIH1 25820 >6.00 Reject
RNAi00101 A-­‐100944 ASB18 401036 5.78 Low RNAi00222 A-­‐100925 BARD1 580 >6.00 Reject
RNAi00101 A-­‐100953 ASB18 401036 >6.00 Low RNAi00222 A-­‐100945 BARD1 580 5.57 Reject
RNAi00139 A-­‐100924 FBXO2 26232 >6.00 Low RNAi00222 A-­‐100954 BARD1 580 >6.00 Reject
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Compound ID Plate ID Target gene Locus ID IC50 Graphical Result (SF) Graphical Result (CGE) Effect rating Compound ID Plate ID Target gene Locus ID IC50 Graphical Result (SF) Graphical Result (CGE) Effect rating
RNAi00226 A-­‐100925 BIRC2 329 >6.00 Low RNAi00281 A-­‐100954 KRTAP5-­‐9 3846 1.37 High
RNAi00226 A-­‐100945 BIRC2 329 4.62 High RNAi00293 A-­‐100925 LOC51136 51136 3.89 High
RNAi00226 A-­‐100954 BIRC2 329 5.38 Low RNAi00293 A-­‐100945 LOC51136 51136 2.74 Reject
RNAi00232 A-­‐100925 BRCA1 672 >6.00 Reject RNAi00293 A-­‐100954 LOC51136 51136 3.75 Low
RNAi00232 A-­‐100945 BRCA1 672 4.02 Reject RNAi00296 A-­‐100925 LOC643596 643596 0.97 Low
RNAi00232 A-­‐100954 BRCA1 672 >6.00 Reject RNAi00296 A-­‐100945 LOC643596 643596 <0.00 Reject
RNAi00240 A-­‐100925 C20ORF18 10616 >6.00 Reject RNAi00296 A-­‐100954 LOC643596 643596 <0.00 Low
RNAi00240 A-­‐100945 C20ORF18 10616 5.67 Low RNAi00297 A-­‐100925 LOC643904 643904 3.36 High
RNAi00240 A-­‐100954 C20ORF18 10616 >6.00 Low RNAi00297 A-­‐100945 LOC643904 643904 <0.00 Reject
RNAi00244 A-­‐100925 CBLC 23624 3.02 Low RNAi00297 A-­‐100954 LOC643904 643904 <0.00 Reject
RNAi00244 A-­‐100945 CBLC 23624 2.06 Low RNAi00301 A-­‐100926 LOC652557 652557 1.35 Reject
RNAi00244 A-­‐100954 CBLC 23624 4.52 Low RNAi00301 A-­‐100946 LOC652557 652557 <0.00 Low
RNAi00250 A-­‐100925 CHFR 55743 >6.00 Reject RNAi00301 A-­‐100955 LOC652557 652557 4.95 Reject
RNAi00250 A-­‐100945 CHFR 55743 >6.00 Reject RNAi00310 A-­‐100926 MDM2 4193 >6.00 Reject
RNAi00250 A-­‐100954 CHFR 55743 >6.00 Reject RNAi00310 A-­‐100946 MDM2 4193 5.80 Reject
RNAi00259 A-­‐100925 DTX3 196403 3.07 Low RNAi00310 A-­‐100955 MDM2 4193 >6.00 Reject
RNAi00259 A-­‐100945 DTX3 196403 <0.00 Reject RNAi00324 A-­‐100926 MLL4 9757 3.52 Reject
RNAi00259 A-­‐100954 DTX3 196403 0.85 Low RNAi00324 A-­‐100946 MLL4 9757 4.05 Reject
RNAi00281 A-­‐100925 KRTAP5-­‐9 3846 1.68 High RNAi00324 A-­‐100955 MLL4 9757 >6.00 Reject
RNAi00281 A-­‐100945 KRTAP5-­‐9 3846 0.21 Low RNAi00326 A-­‐100926 MLLT6 4302 4.08 Low
A-100925 : RNAi00226
Conc
0 1.5 3 4.5 6
S
F
-2
-1.6
-1.2
-0.8
-0.4
0
0.4
0.8
A-100925 : RNAi00226
Conc
0 3 6
C
G
E
0
10
20
30
40
50
60
70
80
90
100
IC50 = >6
A-100945 : RNAi00226
Conc
0 1.5 3 4.5 6
S
F
-2
-1.6
-1.2
-0.8
-0.4
0
0.4
0.8
A-100945 : RNAi00226
Conc
0 3 6
C
G
E
0
10
20
30
40
50
60
70
80
90
100
IC50 = 4.62
A-100954 : RNAi00226
Conc
0 1.5 3 4.5 6
S
F
-2
-1.6
-1.2
-0.8
-0.4
0
0.4
0.8
A-100954 : RNAi00226
Conc
0 3 6
C
G
E
0
10
20
30
40
50
60
70
80
90
100
IC50 = 5.38
A-100925 : RNAi00232
Conc
0 1.5 3 4.5 6
S
F
-2
-1.6
-1.2
-0.8
-0.4
0
0.4
0.8
A-100925 : RNAi00232
Conc
0 3 6
C
G
E
0
10
20
30
40
50
60
70
80
90
100
IC50 = >6
A-100945 : RNAi00232
Conc
0 1.5 3 4.5 6
S
F
-2
-1.6
-1.2
-0.8
-0.4
0
0.4
0.8
A-100945 : RNAi00232
Conc
0 3 6
C
G
E
0
10
20
30
40
50
60
70
80
90
100
IC50 = 4.02
A-100954 : RNAi00232
Conc
0 1.5 3 4.5 6
S
F
-2
-1.6
-1.2
-0.8
-0.4
0
0.4
0.8
A-100954 : RNAi00232
Conc
0 3 6
C
G
E
0
10
20
30
40
50
60
70
80
90
100
IC50 = >6
A-100925 : RNAi00240
Conc
0 1.5 3 4.5 6
S
F
-2
-1.6
-1.2
-0.8
-0.4
0
0.4
0.8
A-100925 : RNAi00240
Conc
0 3 6
C
G
E
0
10
20
30
40
50
60
70
80
90
100
IC50 = >6
A-100945 : RNAi00240
Conc
0 1.5 3 4.5 6
S
F
-2
-1.6
-1.2
-0.8
-0.4
0
0.4
0.8
A-100945 : RNAi00240
Conc
0 3 6
C
G
E
0
10
20
30
40
50
60
70
80
90
100
IC50 = 5.67
A-100954 : RNAi00240
Conc
0 1.5 3 4.5 6
S
F
-2
-1.6
-1.2
-0.8
-0.4
0
0.4
0.8
A-100954 : RNAi00240
Conc
0 3 6
C
G
E
0
10
20
30
40
50
60
70
80
90
100
IC50 = >6
A-100925 : RNAi00244
Conc
0 1.5 3 4.5 6
S
F
-2
-1.6
-1.2
-0.8
-0.4
0
0.4
0.8
A-100925 : RNAi00244
Conc
0 3 6
C
G
E
0
10
20
30
40
50
60
70
80
90
100
IC50 = 3.02
A-100945 : RNAi00244
Conc
0 1.5 3 4.5 6
S
F
-2
-1.6
-1.2
-0.8
-0.4
0
0.4
0.8
A-100945 : RNAi00244
Conc
0 3 6
C
G
E
0
10
20
30
40
50
60
70
80
90
100
IC50 = 2.06
A-100954 : RNAi00244
Conc
0 1.5 3 4.5 6
S
F
-2
-1.6
-1.2
-0.8
-0.4
0
0.4
0.8
A-100954 : RNAi00244
Conc
0 3 6
C
G
E
0
10
20
30
40
50
60
70
80
90
100
IC50 = 4.52
A-100925 : RNAi00250
Conc
0 1.5 3 4.5 6
S
F
-2
-1.6
-1.2
-0.8
-0.4
0
0.4
0.8
A-100925 : RNAi00250
Conc
0 3 6
C
G
E
0
20
40
60
80
100 IC50 = >6
A-100945 : RNAi00250
Conc
0 1.5 3 4.5 6
S
F
-2
-1.6
-1.2
-0.8
-0.4
0
0.4
0.8
A-100945 : RNAi00250
Conc
0 3 6
C
G
E
0
10
20
30
40
50
60
70
80
90
100
IC50 = >6
A-100954 : RNAi00250
Conc
0 1.5 3 4.5 6
S
F
-2
-1.6
-1.2
-0.8
-0.4
0
0.4
0.8
A-100954 : RNAi00250
Conc
0 3 6
C
G
E
0
10
20
30
40
50
60
70
80
90
100
IC50 = >6
A-100925 : RNAi00259
Conc
0 1.5 3 4.5 6
S
F
-2
-1.6
-1.2
-0.8
-0.4
0
0.4
0.8
A-100925 : RNAi00259
Conc
0 3 6
C
G
E
0
10
20
30
40
50
60
70
80
90
100
IC50 = 3.07
A-100945 : RNAi00259
Conc
0 1.5 3 4.5 6
S
F
-2
-1.6
-1.2
-0.8
-0.4
0
0.4
0.8
A-100945 : RNAi00259
Conc
0 3 6
C
G
E
0
10
20
30
40
50
60
70
80
90
100
IC50 = <0
A-100954 : RNAi00259
Conc
0 1.5 3 4.5 6
S
F
-2
-1.6
-1.2
-0.8
-0.4
0
0.4
0.8
A-100954 : RNAi00259
Conc
0 3 6
C
G
E
0
10
20
30
40
50
60
70
80
90
100
IC50 = 0.85
A-100925 : RNAi00281
Conc
0 1.5 3 4.5 6
S
F
-2
-1.6
-1.2
-0.8
-0.4
0
0.4
0.8
A-100925 : RNAi00281
Conc
0 3 6
C
G
E
0
10
20
30
40
50
60
70
80
90
100
IC50 = 1.68
A-100945 : RNAi00281
Conc
0 1.5 3 4.5 6
S
F
-2.2
-1.8
-1.4
-1
-0.6
-0.2
0.2
0.6
1
A-100945 : RNAi00281
Conc
0 3 6
C
G
E
0
10
20
30
40
50
60
70
80
90
100
IC50 = 0.21
A-100954 : RNAi00281
Conc
0 1.5 3 4.5 6
S
F
-2
-1.6
-1.2
-0.8
-0.4
0
0.4
0.8
A-100954 : RNAi00281
Conc
0 3 6
C
G
E
0
10
20
30
40
50
60
70
80
90
100
IC50 = 1.37
A-100925 : RNAi00293
Conc
0 1.5 3 4.5 6
S
F
-2
-1.6
-1.2
-0.8
-0.4
0
0.4
0.8
A-100925 : RNAi00293
Conc
0 3 6
C
G
E
0
10
20
30
40
50
60
70
80
90
100
IC50 = 3.89
A-100945 : RNAi00293
Conc
0 1.5 3 4.5 6
S
F
-2
-1.6
-1.2
-0.8
-0.4
0
0.4
0.8
A-100945 : RNAi00293
Conc
0 3 6
C
G
E
0
10
20
30
40
50
60
70
80
90
100
IC50 = 2.74
A-100954 : RNAi00293
Conc
0 1.5 3 4.5 6
S
F
-2
-1.6
-1.2
-0.8
-0.4
0
0.4
0.8
A-100954 : RNAi00293
Conc
0 3 6
C
G
E
0
10
20
30
40
50
60
70
80
90
100
IC50 = 3.75
A-100925 : RNAi00296
Conc
0 1.5 3 4.5 6
S
F
-2
-1.6
-1.2
-0.8
-0.4
0
0.4
0.8
A-100925 : RNAi00296
Conc
0 3 6
C
G
E
0
10
20
30
40
50
60
70
80
90
100
IC50 = 0.97
A-100945 : RNAi00296
Conc
0 1.5 3 4.5 6
S
F
-2
-1.6
-1.2
-0.8
-0.4
0
0.4
0.8
A-100945 : RNAi00296
Conc
0 3 6
C
G
E
0
10
20
30
40
50
60
70
80
90
100
IC50 = <0
A-100954 : RNAi00296
Conc
0 1.5 3 4.5 6
S
F
-2
-1.6
-1.2
-0.8
-0.4
0
0.4
0.8
A-100954 : RNAi00296
Conc
0 3 6
C
G
E
0
10
20
30
40
50
60
70
80
90
100
IC50 = <0
A-100925 : RNAi00297
Conc
0 1.5 3 4.5 6
S
F
-2
-1.6
-1.2
-0.8
-0.4
0
0.4
0.8
A-100925 : RNAi00297
Conc
0 3 6
C
G
E
0
10
20
30
40
50
60
70
80
90
100
IC50 = 3.36
A-100945 : RNAi00297
Conc
0 1.5 3 4.5 6
S
F
-2
-1.6
-1.2
-0.8
-0.4
0
0.4
0.8
A-100945 : RNAi00297
Conc
0 3 6
C
G
E
0
10
20
30
40
50
60
70
80
90
100
IC50 = <0
A-100954 : RNAi00297
Conc
0 1.5 3 4.5 6
S
F
-2
-1.6
-1.2
-0.8
-0.4
0
0.4
0.8
A-100954 : RNAi00297
Conc
0 3 6
C
G
E
0
10
20
30
40
50
60
70
80
90
100
IC50 = <0
A-100926 : RNAi00301
Conc
0 1.5 3 4.5 6
S
F
-2
-1.6
-1.2
-0.8
-0.4
0
0.4
0.8
A-100926 : RNAi00301
Conc
0 3 6
C
G
E
0
10
20
30
40
50
60
70
80
90
100
IC50 = 1.35
A-100946 : RNAi00301
Conc
0 1.5 3 4.5 6
S
F
-2
-1.6
-1.2
-0.8
-0.4
0
0.4
0.8
A-100946 : RNAi00301
Conc
0 3 6
C
G
E
0
10
20
30
40
50
60
70
80
90
100
IC50 = <0
A-100955 : RNAi00301
Conc
0 1.5 3 4.5 6
S
F
-2
-1.6
-1.2
-0.8
-0.4
0
0.4
0.8
A-100955 : RNAi00301
Conc
0 3 6
C
G
E
0
10
20
30
40
50
60
70
80
90
100
IC50 = 4.95
A-100926 : RNAi00310
Conc
0 1.5 3 4.5 6
S
F
-2
-1.6
-1.2
-0.8
-0.4
0
0.4
0.8
A-100926 : RNAi00310
Conc
0 3 6
C
G
E
0
20
40
60
80
100
120
IC50 = >6
A-100946 : RNAi00310
Conc
0 1.5 3 4.5 6
S
F
-2
-1.6
-1.2
-0.8
-0.4
0
0.4
0.8
A-100946 : RNAi00310
Conc
0 3 6
C
G
E
0
10
20
30
40
50
60
70
80
90
100
IC50 = 5.80
A-100955 : RNAi00310
Conc
0 1.5 3 4.5 6
S
F
-2
-1.6
-1.2
-0.8
-0.4
0
0.4
0.8
A-100955 : RNAi00310
Conc
0 3 6
C
G
E
0
10
20
30
40
50
60
70
80
90
100
IC50 = >6
A-100926 : RNAi00324
Conc
0 1.5 3 4.5 6
S
F
-2
-1.6
-1.2
-0.8
-0.4
0
0.4
0.8
A-100926 : RNAi00324
Conc
0 3 6
C
G
E
0
10
20
30
40
50
60
70
80
90
100
IC50 = 3.52
A-100946 : RNAi00324
Conc
0 1.5 3 4.5 6
S
F
-2
-1.6
-1.2
-0.8
-0.4
0
0.4
0.8
A-100946 : RNAi00324
Conc
0 3 6
C
G
E
0
10
20
30
40
50
60
70
80
90
100
IC50 = 4.05
A-100955 : RNAi00324
Conc
0 1.5 3 4.5 6
S
F
-2
-1.6
-1.2
-0.8
-0.4
0
0.4
0.8
A-100955 : RNAi00324
Conc
0 3 6
C
G
E
0
10
20
30
40
50
60
70
80
90
100
IC50 = >6
A-100926 : RNAi00326
Conc
0 1.5 3 4.5 6
S
F
-2
-1.6
-1.2
-0.8
-0.4
0
0.4
0.8
A-100926 : RNAi00326
Conc
0 3 6
C
G
E
0
10
20
30
40
50
60
70
80
90
100
IC50 = 4.08
Compound ID Plate ID Target gene Locus ID IC50 Graphical Result (SF) Graphical Result (CGE) Effect rating Compound ID Plate ID Target gene Locus ID IC50 Graphical Result (SF) Graphical Result (CGE) Effect rating
RNAi00326 A-­‐100946 MLLT6 4302 3.71 Low RNAi00344 A-­‐100926 PCGF5 84333 >6.00 Reject
RNAi00326 A-­‐100955 MLLT6 4302 4.98 Low RNAi00344 A-­‐100946 PCGF5 84333 >6.00 Reject
RNAi00327 A-­‐100926 MNAT1 4331 >6.00 Reject RNAi00344 A-­‐100955 PCGF5 84333 >6.00 Reject
RNAi00327 A-­‐100946 MNAT1 4331 >6.00 Reject RNAi00353 A-­‐100926 PHF12 57649 4.89 Low
RNAi00327 A-­‐100955 MNAT1 4331 >6.00 Reject RNAi00353 A-­‐100946 PHF12 57649 3.78 Low
RNAi00328 A-­‐100926 MSL2L1 55167 >6.00 Reject RNAi00353 A-­‐100955 PHF12 57649 >6.00 Reject
RNAi00328 A-­‐100946 MSL2L1 55167 >6.00 Reject RNAi00363 A-­‐100926 PHF21A 51317 0.63 Reject
RNAi00328 A-­‐100955 MSL2L1 55167 >6.00 Reject RNAi00363 A-­‐100946 PHF21A 51317 0.43 Low
RNAi00329 A-­‐100926 M96 22823 5.71 Low RNAi00363 A-­‐100955 PHF21A 51317 1.68 Low
RNAi00329 A-­‐100946 M96 22823 >6.00 Reject RNAi00364 A-­‐100926 PHF21B 112885 5.82 Low
RNAi00329 A-­‐100955 M96 22823 >6.00 Reject RNAi00364 A-­‐100946 PHF21B 112885 >6.00 Reject
RNAi00333 A-­‐100926 NEURL 9148 <0.00 Reject RNAi00364 A-­‐100955 PHF21B 112885 >6.00 Low
RNAi00333 A-­‐100946 NEURL 9148 <0.00 Reject RNAi00391 A-­‐100927 RFPL2 10739 2.21 Low
RNAi00333 A-­‐100955 NEURL 9148 4.20 Reject RNAi00391 A-­‐100947 RFPL2 10739 0.50 High
RNAi00337 A-­‐100926 PARC 23113 5.67 Low RNAi00391 A-­‐100956 RFPL2 10739 3.07 High
RNAi00337 A-­‐100946 PARC 23113 5.55 Reject RNAi00406 A-­‐100927 RNF113B 140432 4.85 Low
RNAi00337 A-­‐100955 PARC 23113 >6.00 Reject RNAi00406 A-­‐100947 RNF113B 140432 4.63 High
RNAi00338 A-­‐100926 PARK2 5071 >6.00 Reject RNAi00406 A-­‐100956 RNF113B 140432 5.91 High
RNAi00338 A-­‐100946 PARK2 5071 >6.00 Reject RNAi00426 A-­‐100927 RNF150 57484 4.24 Low
RNAi00338 A-­‐100955 PARK2 5071 >6.00 Reject RNAi00426 A-­‐100947 RNF150 57484 3.19 High
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Compound ID Plate ID Target gene Locus ID IC50 Graphical Result (SF) Graphical Result (CGE) Effect rating Compound ID Plate ID Target gene Locus ID IC50 Graphical Result (SF) Graphical Result (CGE) Effect rating
RNAi00426 A-­‐100956 RNF150 57484 5.25 Low RNAi00517 A-­‐100947 TRIM36 55521 >6.00 Reject
RNAi00433 A-­‐100927 RNF168 165918 >6.00 Low RNAi00517 A-­‐100956 TRIM36 55521 >6.00 Reject
RNAi00433 A-­‐100947 RNF168 165918 >6.00 Reject RNAi00530 A-­‐100927 TRIM49 57093 4.95 Low
RNAi00433 A-­‐100956 RNF168 165918 >6.00 Reject RNAi00530 A-­‐100947 TRIM49 57093 3.68 Low
RNAi00447 A-­‐100927 RNF20 56254 >6.00 Reject RNAi00530 A-­‐100956 TRIM49 57093 >6.00 Reject
RNAi00447 A-­‐100947 RNF20 56254 >6.00 Reject RNAi00551 A-­‐100927 TRIM71 131405 5.54 Low
RNAi00447 A-­‐100956 RNF20 56254 >6.00 Reject RNAi00551 A-­‐100947 TRIM71 131405 5.27 High
RNAi00454 A-­‐100927 RNF31 55072 3.77 High RNAi00551 A-­‐100956 TRIM71 131405 >6.00 Reject
RNAi00454 A-­‐100947 RNF31 55072 4.18 High RNAi00556 A-­‐100927 TRIM8 81603 4.18 High
RNAi00454 A-­‐100956 RNF31 55072 4.23 High RNAi00556 A-­‐100947 TRIM8 81603 3.73 High
RNAi00456 A-­‐100927 RNF34 80196 >6.00 Reject RNAi00556 A-­‐100956 TRIM8 81603 >6.00 Reject
RNAi00456 A-­‐100947 RNF34 80196 >6.00 Reject RNAi00594 A-­‐100927 ZSWIM2 151112 >6.00 Reject
RNAi00456 A-­‐100956 RNF34 80196 >6.00 Reject RNAi00594 A-­‐100947 ZSWIM2 151112 4.60 High
RNAi00478 A-­‐100927 JARID1C 8242 5.84 Low RNAi00594 A-­‐100956 ZSWIM2 151112 >6.00 Reject
RNAi00478 A-­‐100947 JARID1C 8242 >6.00 Low RNAi00606 A-­‐100928 FLJ25555 124930 >6.00 Reject
RNAi00478 A-­‐100956 JARID1C 8242 >6.00 Reject RNAi00606 A-­‐100948 FLJ25555 124930 >6.00 Reject
RNAi00479 A-­‐100927 JARID1D 8284 6.06 Low RNAi00606 A-­‐100957 FLJ25555 124930 >6.00 Reject
RNAi00479 A-­‐100947 JARID1D 8284 >6.00 Low RNAi00623 A-­‐100928 BCL6B 255877 >6.00 Low
RNAi00479 A-­‐100956 JARID1D 8284 >6.00 Reject RNAi00623 A-­‐100948 BCL6B 255877 >6.00 Reject
RNAi00517 A-­‐100927 TRIM36 55521 5.68 Reject RNAi00623 A-­‐100957 BCL6B 255877 >6.00 Low
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Compound ID Plate ID Target gene Locus ID IC50 Graphical Result (SF) Graphical Result (CGE) Effect rating Compound ID Plate ID Target gene Locus ID IC50 Graphical Result (SF) Graphical Result (CGE) Effect rating
RNAi00656 A-­‐100928 CUEDC1 404093 >6.00 Reject RNAi00736 A-­‐100957 KCNS1 3787 >6.00 Reject
RNAi00656 A-­‐100948 CUEDC1 404093 >6.00 Low RNAi00740 A-­‐100928 KCTD1 284252 >6.00 Reject
RNAi00656 A-­‐100957 CUEDC1 404093 >6.00 Reject RNAi00740 A-­‐100948 KCTD1 284252 >6.00 Reject
RNAi00720 A-­‐100928 KCNA4 3739 5.06 High RNAi00740 A-­‐100957 KCTD1 284252 >6.00 Reject
RNAi00720 A-­‐100948 KCNA4 3739 5.42 Reject RNAi00748 A-­‐100928 KCTD2 23510 >6.00 Reject
RNAi00720 A-­‐100957 KCNA4 3739 5.89 Low RNAi00748 A-­‐100948 KCTD2 23510 >6.00 Reject
RNAi00725 A-­‐100928 KCNB2 9312 5.88 Low RNAi00748 A-­‐100957 KCTD2 23510 >6.00 Reject
RNAi00725 A-­‐100948 KCNB2 9312 4.96 Reject RNAi00751 A-­‐100928 KCTD3 51133 3.83 Low
RNAi00725 A-­‐100957 KCNB2 9312 >6.00 Low RNAi00751 A-­‐100948 KCTD3 51133 2.04 High
RNAi00726 A-­‐100928 KCNC1 3746 >6.00 Reject RNAi00751 A-­‐100957 KCTD3 51133 5.13 High
RNAi00726 A-­‐100948 KCNC1 3746 4.95 Low RNAi00787 A-­‐100928 LOC340359 340359 >6.00 Low
RNAi00726 A-­‐100957 KCNC1 3746 >6.00 Low RNAi00787 A-­‐100948 LOC340359 340359 >6.00 Low
RNAi00730 A-­‐100928 KCND1 3750 >6.00 Reject RNAi00787 A-­‐100957 LOC340359 340359 >6.00 Reject
RNAi00730 A-­‐100948 KCND1 3750 4.91 High RNAi00796 A-­‐100928 LGALS3BP 3959 3.46 Low
RNAi00730 A-­‐100957 KCND1 3750 >6.00 Low RNAi00796 A-­‐100948 LGALS3BP 3959 1.61 Low
RNAi00732 A-­‐100928 KCND3 3752 3.15 Low RNAi00796 A-­‐100957 LGALS3BP 3959 4.10 High
RNAi00732 A-­‐100948 KCND3 3752 1.62 Low RNAi00804 A-­‐100929 MAP3K7IP2 23118 3.26 High
RNAi00732 A-­‐100957 KCND3 3752 5.59 Low RNAi00804 A-­‐100949 MAP3K7IP2 23118 3.63 Low
RNAi00736 A-­‐100928 KCNS1 3787 >6.00 Reject RNAi00804 A-­‐100958 MAP3K7IP2 23118 >6.00 Reject
RNAi00736 A-­‐100948 KCNS1 3787 4.95 Low RNAi00815 A-­‐100929 MYO6 4646 >6.00 Reject
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Compound ID Plate ID Target gene Locus ID IC50 Graphical Result (SF) Graphical Result (CGE) Effect rating Compound ID Plate ID Target gene Locus ID IC50 Graphical Result (SF) Graphical Result (CGE) Effect rating
RNAi00815 A-­‐100949 MYO6 4646 4.31 Reject RNAi00833 A-­‐100929 NYREN18 51667 5.69 Low
RNAi00815 A-­‐100958 MYO6 4646 >6.00 Reject RNAi00833 A-­‐100949 NYREN18 51667 >6.00 Reject
RNAi00825 A-­‐100929 NEIL3 55247 >6.00 Reject RNAi00833 A-­‐100958 NYREN18 51667 >6.00 Reject
RNAi00825 A-­‐100949 NEIL3 55247 >6.00 Reject RNAi00834 A-­‐100929 NUP153 9972 4.42 Low
RNAi00825 A-­‐100958 NEIL3 55247 >6.00 Reject RNAi00834 A-­‐100949 NUP153 9972 >6.00 Reject
RNAi00826 A-­‐100929 NFX1 4799 >6.00 Reject RNAi00834 A-­‐100958 NUP153 9972 >6.00 Reject
RNAi00826 A-­‐100949 NFX1 4799 >6.00 Reject RNAi00839 A-­‐100929 OTUB1 55611 5.03 High
RNAi00826 A-­‐100958 NFX1 4799 >6.00 Reject RNAi00839 A-­‐100949 OTUB1 55611 >6.00 Reject
RNAi00827 A-­‐100929 HOZFP 152518 >6.00 Reject RNAi00839 A-­‐100958 OTUB1 55611 >6.00 Reject
RNAi00827 A-­‐100949 HOZFP 152518 >6.00 Reject RNAi00863 A-­‐100929 RABGEF1 27342 3.46 Low
RNAi00827 A-­‐100958 HOZFP 152518 >6.00 Reject RNAi00863 A-­‐100949 RABGEF1 27342 3.77 High
RNAi00830 A-­‐100929 NPL4 55666 >6.00 Reject RNAi00863 A-­‐100958 RABGEF1 27342 >6.00 Reject
RNAi00830 A-­‐100949 NPL4 55666 >6.00 Reject RNAi00867 A-­‐100929 RBM10 8241 4.85 High
RNAi00830 A-­‐100958 NPL4 55666 >6.00 Reject RNAi00867 A-­‐100949 RBM10 8241 >6.00 Reject
RNAi00831 A-­‐100929 NSFL1C 55968 2.94 Low RNAi00867 A-­‐100958 RBM10 8241 >6.00 Reject
RNAi00831 A-­‐100949 NSFL1C 55968 >6.00 Reject RNAi00872 A-­‐100929 REV1L 51455 1.20 Low
RNAi00831 A-­‐100958 NSFL1C 55968 >6.00 Reject RNAi00872 A-­‐100949 REV1L 51455 4.56 High
RNAi00832 A-­‐100929 NSMCE1 197370 4.67 Low RNAi00872 A-­‐100958 REV1L 51455 >6.00 Low
RNAi00832 A-­‐100949 NSMCE1 197370 >6.00 Reject RNAi00873 A-­‐100930 RFC1 5981 >6.00 Reject
RNAi00832 A-­‐100958 NSMCE1 197370 >6.00 Reject RNAi00873 A-­‐100950 RFC1 5981 >6.00 Reject
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Compound ID Plate ID Target gene Locus ID IC50 Graphical Result (SF) Graphical Result (CGE) Effect rating Compound ID Plate ID Target gene Locus ID IC50 Graphical Result (SF) Graphical Result (CGE) Effect rating
RNAi00873 A-­‐100959 RFC1 5981 >6.00 Reject RNAi00905 A-­‐100950 SQSTM1 8878 >6.00 Reject
RNAi00876 A-­‐100930 RHOBTB1 9886 >6.00 Reject RNAi00905 A-­‐100959 SQSTM1 8878 >6.00 Reject
RNAi00876 A-­‐100950 RHOBTB1 9886 >6.00 Reject RNAi00907 A-­‐100930 STAM2 10254 >6.00 Reject
RNAi00876 A-­‐100959 RHOBTB1 9886 >6.00 Reject RNAi00907 A-­‐100950 STAM2 10254 >6.00 Reject
RNAi00878 A-­‐100930 RHOBTB3 22836 >6.00 Reject RNAi00907 A-­‐100959 STAM2 10254 >6.00 Reject
RNAi00878 A-­‐100950 RHOBTB3 22836 >6.00 Reject RNAi00908 A-­‐100930 STAMBP 10617 >6.00 Reject
RNAi00878 A-­‐100959 RHOBTB3 22836 >6.00 Reject RNAi00908 A-­‐100950 STAMBP 10617 >6.00 Reject
RNAi00883 A-­‐100930 RWDD3 25950 >6.00 Reject RNAi00908 A-­‐100959 STAMBP 10617 >6.00 Reject
RNAi00883 A-­‐100950 RWDD3 25950 >6.00 Reject RNAi00909 A-­‐100930 STAMBPL1 57559 2.04 Low
RNAi00883 A-­‐100959 RWDD3 25950 >6.00 Reject RNAi00909 A-­‐100950 STAMBPL1 57559 5.67 Reject
RNAi00886 A-­‐100930 SAE1 10055 >6.00 Reject RNAi00909 A-­‐100959 STAMBPL1 57559 1.68 Low
RNAi00886 A-­‐100950 SAE1 10055 >6.00 Reject RNAi00910 A-­‐100930 MGC5306 79101 >6.00 Reject
RNAi00886 A-­‐100959 SAE1 10055 >6.00 Reject RNAi00910 A-­‐100950 MGC5306 79101 >6.00 Reject
RNAi00889 A-­‐100930 SENP3 26168 >6.00 Reject RNAi00910 A-­‐100959 MGC5306 79101 >6.00 Reject
RNAi00889 A-­‐100950 SENP3 26168 >6.00 Reject RNAi00913 A-­‐100930 PROSAPIP2 9755 >6.00 Reject
RNAi00889 A-­‐100959 SENP3 26168 >6.00 Reject RNAi00913 A-­‐100950 PROSAPIP2 9755 >6.00 Reject
RNAi00891 A-­‐100930 SENP6 26054 >6.00 Low RNAi00913 A-­‐100959 PROSAPIP2 9755 >6.00 Reject
RNAi00891 A-­‐100950 SENP6 26054 >6.00 Reject RNAi00917 A-­‐100930 TNIP1 10318 2.24 High
RNAi00891 A-­‐100959 SENP6 26054 >6.00 Reject RNAi00917 A-­‐100950 TNIP1 10318 1.21 High
RNAi00905 A-­‐100930 SQSTM1 8878 >6.00 Reject RNAi00917 A-­‐100959 TNIP1 10318 3.33 High
A-100959 : RNAi00873
Conc
0 1.5 3 4.5 6
S
F
-2
-1.6
-1.2
-0.8
-0.4
0
0.4
0.8
A-100959 : RNAi00873
Conc
0 3 6
C
G
E
0
20
40
60
80
100
IC50 = >6
A-100930 : RNAi00876
Conc
0 1.5 3 4.5 6
S
F
-2
-1.6
-1.2
-0.8
-0.4
0
0.4
0.8
A-100930 : RNAi00876
Conc
0 3 6
C
G
E
0
10
20
30
40
50
60
70
80
90
100
IC50 = >6
A-100950 : RNAi00876
Conc
0 1.5 3 4.5 6
S
F
-2
-1.6
-1.2
-0.8
-0.4
0
0.4
0.8
A-100950 : RNAi00876
Conc
0 3 6
C
G
E
0
10
20
30
40
50
60
70
80
90
100
IC50 = >6
A-100959 : RNAi00876
Conc
0 1.5 3 4.5 6
S
F
-2
-1.6
-1.2
-0.8
-0.4
0
0.4
0.8
A-100959 : RNAi00876
Conc
0 3 6
C
G
E
0
10
20
30
40
50
60
70
80
90
100
IC50 = >6
A-100930 : RNAi00878
Conc
0 1.5 3 4.5 6
S
F
-2
-1.6
-1.2
-0.8
-0.4
0
0.4
0.8
A-100930 : RNAi00878
Conc
0 3 6
C
G
E
0
20
40
60
80
100
120 IC50 = >6
A-100950 : RNAi00878
Conc
0 1.5 3 4.5 6
S
F
-2
-1.6
-1.2
-0.8
-0.4
0
0.4
0.8
A-100950 : RNAi00878
Conc
0 3 6
C
G
E
0
20
40
60
80
100
IC50 = >6
A-100959 : RNAi00878
Conc
0 1.5 3 4.5 6
S
F
-2
-1.6
-1.2
-0.8
-0.4
0
0.4
0.8
A-100959 : RNAi00878
Conc
0 3 6
C
G
E
0
20
40
60
80
100 IC50 = >6
A-100930 : RNAi00883
Conc
0 1.5 3 4.5 6
S
F
-2
-1.6
-1.2
-0.8
-0.4
0
0.4
0.8
A-100930 : RNAi00883
Conc
0 3 6
C
G
E
0
10
20
30
40
50
60
70
80
90
100
IC50 = >6
A-100950 : RNAi00883
Conc
0 1.5 3 4.5 6
S
F
-2
-1.6
-1.2
-0.8
-0.4
0
0.4
0.8
A-100950 : RNAi00883
Conc
0 3 6
C
G
E
0
10
20
30
40
50
60
70
80
90
100
IC50 = >6
A-100959 : RNAi00883
Conc
0 1.5 3 4.5 6
S
F
-2
-1.6
-1.2
-0.8
-0.4
0
0.4
0.8
A-100959 : RNAi00883
Conc
0 3 6
C
G
E
0
10
20
30
40
50
60
70
80
90
100
IC50 = >6
A-100930 : RNAi00886
Conc
0 1.5 3 4.5 6
S
F
-2
-1.6
-1.2
-0.8
-0.4
0
0.4
0.8
A-100930 : RNAi00886
Conc
0 3 6
C
G
E
0
10
20
30
40
50
60
70
80
90
100
IC50 = >6
A-100950 : RNAi00886
Conc
0 1.5 3 4.5 6
S
F
-2
-1.6
-1.2
-0.8
-0.4
0
0.4
0.8
A-100950 : RNAi00886
Conc
0 3 6
C
G
E
0
10
20
30
40
50
60
70
80
90
100
IC50 = >6
A-100959 : RNAi00886
Conc
0 1.5 3 4.5 6
S
F
-2
-1.6
-1.2
-0.8
-0.4
0
0.4
0.8
A-100959 : RNAi00886
Conc
0 3 6
C
G
E
0
10
20
30
40
50
60
70
80
90
100
IC50 = >6
A-100930 : RNAi00889
Conc
0 1.5 3 4.5 6
S
F
-2
-1.6
-1.2
-0.8
-0.4
0
0.4
0.8
A-100930 : RNAi00889
Conc
0 3 6
C
G
E
0
20
40
60
80
100 IC50 = >6
A-100950 : RNAi00889
Conc
0 1.5 3 4.5 6
S
F
-2
-1.6
-1.2
-0.8
-0.4
0
0.4
0.8
A-100950 : RNAi00889
Conc
0 3 6
C
G
E
0
10
20
30
40
50
60
70
80
90
100
IC50 = >6
A-100959 : RNAi00889
Conc
0 1.5 3 4.5 6
S
F
-2
-1.6
-1.2
-0.8
-0.4
0
0.4
0.8
A-100959 : RNAi00889
Conc
0 3 6
C
G
E
0
10
20
30
40
50
60
70
80
90
100
IC50 = >6
A-100930 : RNAi00891
Conc
0 1.5 3 4.5 6
S
F
-2
-1.6
-1.2
-0.8
-0.4
0
0.4
0.8
A-100930 : RNAi00891
Conc
0 3 6
C
G
E
0
10
20
30
40
50
60
70
80
90
100
IC50 = >6
A-100950 : RNAi00891
Conc
0 1.5 3 4.5 6
S
F
-2
-1.6
-1.2
-0.8
-0.4
0
0.4
0.8
A-100950 : RNAi00891
Conc
0 3 6
C
G
E
0
10
20
30
40
50
60
70
80
90
100
IC50 = >6
A-100959 : RNAi00891
Conc
0 1.5 3 4.5 6
S
F
-2
-1.6
-1.2
-0.8
-0.4
0
0.4
0.8
A-100959 : RNAi00891
Conc
0 3 6
C
G
E
0
10
20
30
40
50
60
70
80
90
100
IC50 = >6
A-100930 : RNAi00905
Conc
0 1.5 3 4.5 6
S
F
-2
-1.6
-1.2
-0.8
-0.4
0
0.4
0.8
A-100930 : RNAi00905
Conc
0 3 6
C
G
E
0
20
40
60
80
100
120 IC50 = >6
A-100950 : RNAi00905
Conc
0 1.5 3 4.5 6
S
F
-2
-1.6
-1.2
-0.8
-0.4
0
0.4
0.8
A-100950 : RNAi00905
Conc
0 3 6
C
G
E
0
10
20
30
40
50
60
70
80
90
100
IC50 = >6
A-100959 : RNAi00905
Conc
0 1.5 3 4.5 6
S
F
-2
-1.6
-1.2
-0.8
-0.4
0
0.4
0.8
A-100959 : RNAi00905
Conc
0 3 6
C
G
E
0
20
40
60
80
100
IC50 = >6
A-100930 : RNAi00907
Conc
0 1.5 3 4.5 6
S
F
-2
-1.6
-1.2
-0.8
-0.4
0
0.4
0.8
A-100930 : RNAi00907
Conc
0 3 6
C
G
E
0
20
40
60
80
100
120
IC50 = >6
A-100950 : RNAi00907
Conc
0 1.5 3 4.5 6
S
F
-2
-1.6
-1.2
-0.8
-0.4
0
0.4
0.8
A-100950 : RNAi00907
Conc
0 3 6
C
G
E
0
20
40
60
80
100
IC50 = >6
A-100959 : RNAi00907
Conc
0 1.5 3 4.5 6
S
F
-2
-1.6
-1.2
-0.8
-0.4
0
0.4
0.8
A-100959 : RNAi00907
Conc
0 3 6
C
G
E
0
20
40
60
80
100
IC50 = >6
A-100930 : RNAi00908
Conc
0 1.5 3 4.5 6
S
F
-2
-1.6
-1.2
-0.8
-0.4
0
0.4
0.8
A-100930 : RNAi00908
Conc
0 3 6
C
G
E
0
20
40
60
80
100 IC50 = >6
A-100950 : RNAi00908
Conc
0 1.5 3 4.5 6
S
F
-2
-1.6
-1.2
-0.8
-0.4
0
0.4
0.8
A-100950 : RNAi00908
Conc
0 3 6
C
G
E
0
20
40
60
80
100
IC50 = >6
A-100959 : RNAi00908
Conc
0 1.5 3 4.5 6
S
F
-2
-1.6
-1.2
-0.8
-0.4
0
0.4
0.8
A-100959 : RNAi00908
Conc
0 3 6
C
G
E
0
10
20
30
40
50
60
70
80
90
100
IC50 = >6
A-100930 : RNAi00909
Conc
0 1.5 3 4.5 6
S
F
-2
-1.6
-1.2
-0.8
-0.4
0
0.4
0.8
A-100930 : RNAi00909
Conc
0 3 6
C
G
E
0
10
20
30
40
50
60
70
80
90
100
IC50 = 2.04
A-100950 : RNAi00909
Conc
0 1.5 3 4.5 6
S
F
-2
-1.6
-1.2
-0.8
-0.4
0
0.4
0.8
A-100950 : RNAi00909
Conc
0 3 6
C
G
E
0
10
20
30
40
50
60
70
80
90
100
IC50 = 5.67
A-100959 : RNAi00909
Conc
0 1.5 3 4.5 6
S
F
-2
-1.6
-1.2
-0.8
-0.4
0
0.4
0.8
A-100959 : RNAi00909
Conc
0 3 6
C
G
E
0
10
20
30
40
50
60
70
80
90
100
IC50 = 1.68
A-100930 : RNAi00910
Conc
0 1.5 3 4.5 6
S
F
-2
-1.6
-1.2
-0.8
-0.4
0
0.4
0.8
A-100930 : RNAi00910
Conc
0 3 6
C
G
E
0
20
40
60
80
100
IC50 = >6
A-100950 : RNAi00910
Conc
0 1.5 3 4.5 6
S
F
-2
-1.6
-1.2
-0.8
-0.4
0
0.4
0.8
A-100950 : RNAi00910
Conc
0 3 6
C
G
E
0
10
20
30
40
50
60
70
80
90
100
IC50 = >6
A-100959 : RNAi00910
Conc
0 1.5 3 4.5 6
S
F
-2
-1.6
-1.2
-0.8
-0.4
0
0.4
0.8
A-100959 : RNAi00910
Conc
0 3 6
C
G
E
0
10
20
30
40
50
60
70
80
90
100
IC50 = >6
A-100930 : RNAi00913
Conc
0 1.5 3 4.5 6
S
F
-2
-1.6
-1.2
-0.8
-0.4
0
0.4
0.8
A-100930 : RNAi00913
Conc
0 3 6
C
G
E
0
20
40
60
80
100
IC50 = >6
A-100950 : RNAi00913
Conc
0 1.5 3 4.5 6
S
F
-2
-1.6
-1.2
-0.8
-0.4
0
0.4
0.8
A-100950 : RNAi00913
Conc
0 3 6
C
G
E
0
20
40
60
80
100 IC50 = >6
A-100959 : RNAi00913
Conc
0 1.5 3 4.5 6
S
F
-2
-1.6
-1.2
-0.8
-0.4
0
0.4
0.8
A-100959 : RNAi00913
Conc
0 3 6
C
G
E
0
20
40
60
80
100 IC50 = >6
A-100930 : RNAi00917
Conc
0 1.5 3 4.5 6
S
F
-2
-1.6
-1.2
-0.8
-0.4
0
0.4
0.8
A-100930 : RNAi00917
Conc
0 3 6
C
G
E
0
10
20
30
40
50
60
70
80
90
100
IC50 = 2.24
A-100950 : RNAi00917
Conc
0 1.5 3 4.5 6
S
F
-2
-1.6
-1.2
-0.8
-0.4
0
0.4
0.8
A-100950 : RNAi00917
Conc
0 3 6
C
G
E
0
10
20
30
40
50
60
70
80
90
100
IC50 = 1.21
A-100959 : RNAi00917
Conc
0 1.5 3 4.5 6
S
F
-2
-1.6
-1.2
-0.8
-0.4
0
0.4
0.8
A-100959 : RNAi00917
Conc
0 3 6
C
G
E
0
10
20
30
40
50
60
70
80
90
100
IC50 = 3.33
Compound ID Plate ID Target gene Locus ID IC50 Graphical Result (SF) Graphical Result (CGE) Effect rating Compound ID Plate ID Target gene Locus ID IC50 Graphical Result (SF) Graphical Result (CGE) Effect rating
RNAi00919 A-­‐100931 TNIP3 79931 >6.00 Reject RNAi00991 A-­‐100960 USP42 84132 >6.00 Low
RNAi00919 A-­‐100951 TNIP3 79931 5.45 High RNAi00992 A-­‐100931 USP43 124739 >6.00 Reject
RNAi00919 A-­‐100960 TNIP3 79931 >6.00 Low RNAi00992 A-­‐100951 USP43 124739 4.63 Low
RNAi00937 A-­‐100931 LOC646463 646463 >6.00 Low RNAi00992 A-­‐100960 USP43 124739 >6.00 Reject
RNAi00937 A-­‐100951 LOC646463 646463 4.48 High RNAi01000 A-­‐100931 USP50 373509 >6.00 Low
RNAi00937 A-­‐100960 LOC646463 646463 >6.00 Low RNAi01000 A-­‐100951 USP50 373509 2.54 High
RNAi00949 A-­‐100931 LOC51035 51035 3.53 High RNAi01000 A-­‐100960 USP50 373509 >6.00 Low
RNAi00949 A-­‐100951 LOC51035 51035 1.55 Low RNAi01003 A-­‐100931 USP54 159195 3.45 Low
RNAi00949 A-­‐100960 LOC51035 51035 >6.00 Low RNAi01003 A-­‐100951 USP54 159195 0.72 High
RNAi00958 A-­‐100931 USP10 9100 0.18 Reject RNAi01003 A-­‐100960 USP54 159195 4.57 High
RNAi00958 A-­‐100951 USP10 9100 <0.00 Reject RNAi01011 A-­‐100931 VHL 7428 4.44 High
RNAi00958 A-­‐100960 USP10 9100 3.30 Low RNAi01011 A-­‐100951 VHL 7428 0.14 Low
RNAi00981 A-­‐100931 USP33 23032 >6.00 Reject RNAi01011 A-­‐100960 VHL 7428 4.46 High
RNAi00981 A-­‐100951 USP33 23032 3.97 High RNAi01034 A-­‐100931 ZBTB38 253461 2.70 Low
RNAi00981 A-­‐100960 USP33 23032 >6.00 Low RNAi01034 A-­‐100951 ZBTB38 253461 4.03 Low
RNAi00985 A-­‐100931 USP37 57695 >6.00 Low RNAi01034 A-­‐100960 ZBTB38 253461 >6.00 Reject
RNAi00985 A-­‐100951 USP37 57695 2.97 High RNAi01039 A-­‐100931 ZNF297B 23099 4.84 Low
RNAi00985 A-­‐100960 USP37 57695 >6.00 Low RNAi01039 A-­‐100951 ZNF297B 23099 1.96 Low
RNAi00991 A-­‐100931 USP42 84132 >6.00 Reject RNAi01039 A-­‐100960 ZNF297B 23099 >6.00 Reject
RNAi00991 A-­‐100951 USP42 84132 4.52 High RNAi01043 A-­‐100931 HKR3 3104 3.89 Low
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Compound ID Plate ID Target gene Locus ID IC50 Graphical Result (SF) Graphical Result (CGE) Effect rating Compound ID Plate ID Target gene Locus ID IC50 Graphical Result (SF) Graphical Result (CGE) Effect rating
RNAi01043 A-­‐100951 HKR3 3104 1.18 Low RNALowControl A-­‐100955 REV1L 51455 >6.00 High
RNAi01043 A-­‐100960 HKR3 3104 >6.00 Low RNALowControl A-­‐100956 REV1L 51455 >6.00 Low
RNALowControl A-­‐100924 REV1L 51455 5.51 High RNALowControl A-­‐100957 REV1L 51455 4.75 High
RNALowControl A-­‐100925 REV1L 51455 4.99 High RNALowControl A-­‐100958 REV1L 51455 5.87 High
RNALowControl A-­‐100926 REV1L 51455 4.51 High RNALowControl A-­‐100959 REV1L 51455 5.09 High
RNALowControl A-­‐100927 REV1L 51455 3.96 High RNALowControl A-­‐100960 REV1L 51455 >6.00 High
RNALowControl A-­‐100928 REV1L 51455 4.41 High
RNALowControl A-­‐100929 REV1L 51455 2.64 High
RNALowControl A-­‐100930 REV1L 51455 5.09 High
RNALowControl A-­‐100931 REV1L 51455 5.29 High
RNALowControl A-­‐100944 REV1L 51455 5.17 High
RNALowControl A-­‐100945 REV1L 51455 4.29 High
RNALowControl A-­‐100946 REV1L 51455 5.01 High
RNALowControl A-­‐100947 REV1L 51455 4.62 High
RNALowControl A-­‐100948 REV1L 51455 3.80 High
RNALowControl A-­‐100949 REV1L 51455 5.22 High
RNALowControl A-­‐100950 REV1L 51455 4.92 High
RNALowControl A-­‐100951 REV1L 51455 4.29 High
RNALowControl A-­‐100953 REV1L 51455 4.35 High
RNALowControl A-­‐100954 REV1L 51455 5.78 High
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Appendix	  4
Secondary	  screen	  with	  MMC
SF	  and	  CGE	  graphs:	  X	  axis	  represents	  MMC	  concentration	  (0	  -­‐	  1	  µM)
Compound ID Plate ID Target gene  Locus ID IC50 Graphical Result (SF) Graphical Result(CGE) Effect Compound ID Plate ID Target gene  Locus ID IC50 Graphical Result (SF) Graphical Result(CGE) Effect
NonTargeted A-­‐100972 Non	  targeting >1.00 Reject RNAi00281 A-­‐100975 KRTAP5-­‐9 3846 0.15 High
NonTargeted A-­‐100973 Non	  targeting 0.98 Reject RNAi00281 A-­‐100978 KRTAP5-­‐9 3846 0.33 Low
NonTargeted A-­‐100975 Non	  targeting 0.87 Reject RNAi00391 A-­‐100972 RFPL2 10739 0.14 High
NonTargeted A-­‐100976 Non	  targeting 0.96 Reject RNAi00391 A-­‐100975 RFPL2 10739 0.04 High
NonTargeted A-­‐100978 Non	  targeting >1.00 Reject RNAi00391 A-­‐100978 RFPL2 10739 0.42 High
NonTargeted A-­‐100979 Non	  targeting >1.00 Reject RNAi00406 A-­‐100972 RNF113B 140432 0.36 High
RNAi00055 A-­‐100972 UBE2D2 7322 0.12 High RNAi00406 A-­‐100975 RNF113B 140432 0.33 Low
RNAi00055 A-­‐100975 UBE2D2 7322 0.12 High RNAi00406 A-­‐100978 RNF113B 140432 0.63 High
RNAi00055 A-­‐100978 UBE2D2 7322 0.62 High RNAi00426 A-­‐100972 RNF150 57484 0.23 High
RNAi00071 A-­‐100972 UBE2N 7334 0.03 High RNAi00426 A-­‐100975 RNF150 57484 0.20 Low
RNAi00071 A-­‐100975 UBE2N 7334 0.14 High RNAi00426 A-­‐100978 RNF150 57484 0.67 Low
RNAi00071 A-­‐100978 UBE2N 7334 0.94 Low RNAi00454 A-­‐100972 RNF31 55072 0.21 High
RNAi00082 A-­‐100972 UBE2W 55284 0.14 High RNAi00454 A-­‐100975 RNF31 55072 0.26 High
RNAi00082 A-­‐100975 UBE2W 55284 0.07 High RNAi00454 A-­‐100978 RNF31 55072 0.50 High
RNAi00082 A-­‐100978 UBE2W 55284 0.76 Low RNAi00556 A-­‐100972 TRIM8 81603 0.39 Low
RNAi00170 A-­‐100972 FBXW11 23291 0.24 High RNAi00556 A-­‐100975 TRIM8 81603 0.42 Low
RNAi00170 A-­‐100975 FBXW11 23291 0.25 High RNAi00556 A-­‐100978 TRIM8 81603 0.87 Low
RNAi00170 A-­‐100978 FBXW11 23291 0.89 Low RNAi00751 A-­‐100972 KCTD3 51133 0.37 Low
RNAi00226 A-­‐100972 BIRC2 329 0.38 High RNAi00751 A-­‐100975 KCTD3 51133 0.38 Reject
RNAi00226 A-­‐100975 BIRC2 329 0.29 High RNAi00751 A-­‐100978 KCTD3 51133 0.86 Low
RNAi00226 A-­‐100978 BIRC2 329 0.61 High RNAi00796 A-­‐100972 LGALS3BP 3959 0.71 Low
RNAi00281 A-­‐100972 KRTAP5-­‐9 3846 <0.00 High RNAi00796 A-­‐100975 LGALS3BP 3959 0.62 Low
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Compound ID Plate ID Target gene  Locus ID IC50 Graphical Result (SF) Graphical Result(CGE) Effect Compound ID Plate ID Target gene  Locus ID IC50 Graphical Result (SF) Graphical Result(CGE) Effect
RNAi00796 A-­‐100978 LGALS3BP 3959 >1.00 Reject RNAi01011 A-­‐100976 VHL 7428 0.06 High
RNAi00872 A-­‐100972 REV1L 51455 0.44 High RNAi01011 A-­‐100979 VHL 7428 0.39 High
RNAi00872 A-­‐100975 REV1L 51455 0.33 High RNALowControl A-­‐100972 REV1L 51455 0.42 High
RNAi00872 A-­‐100978 REV1L 51455 0.71 High RNALowControl A-­‐100973 REV1L 51455 0.35 High
RNAi00917 A-­‐100973 TNIP1 10318 0.12 High RNALowControl A-­‐100975 REV1L 51455 0.29 High
RNAi00917 A-­‐100976 TNIP1 10318 0.16 High RNALowControl A-­‐100976 REV1L 51455 0.36 High
RNAi00917 A-­‐100979 TNIP1 10318 0.25 High RNALowControl A-­‐100978 REV1L 51455 0.75 High
RNAi00937 A-­‐100973 LOC646463 646463 0.24 High RNALowControl A-­‐100979 REV1L 51455 0.57 Low
RNAi00937 A-­‐100976 LOC646463 646463 0.42 High
RNAi00937 A-­‐100979 LOC646463 646463 0.91 Low
RNAi00949 A-­‐100973 LOC51035 51035 0.40 Low
RNAi00949 A-­‐100976 LOC51035 51035 0.31 Low
RNAi00949 A-­‐100979 LOC51035 51035 0.95 Low
RNAi00985 A-­‐100973 USP37 57695 0.30 High
RNAi00985 A-­‐100976 USP37 57695 0.25 High
RNAi00985 A-­‐100979 USP37 57695 0.67 High
RNAi01000 A-­‐100973 USP50 373509 0.37 High
RNAi01000 A-­‐100976 USP50 373509 0.47 Low
RNAi01000 A-­‐100979 USP50 373509 0.94 High
RNAi01003 A-­‐100973 USP54 159195 0.16 High
RNAi01003 A-­‐100976 USP54 159195 0.14 High
RNAi01003 A-­‐100979 USP54 159195 0.74 Low
RNAi01011 A-­‐100973 VHL 7428 0.09 High
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Appendix	  5
Deconvolution	  with	  cisplatin
SF	  and	  CGE	  graphs:	  X	  axis	  represents	  cisplatin	  concentration	  (0	  -­‐	  6	  µM)
Compound ID Plate ID Target gene Locus ID IC50 Graphical Result (SF) Graphical Result(CGE) Effect Compound ID Plate ID Target gene Locus ID IC50 Graphical Result (SF) Graphical Result(CGE) Effect
NonTargeted A-­‐100984 Non	  targeting >6.00 Reject NonTrasfected A-­‐100986 NonTransfected >6.00 Reject
NonTargeted A-­‐100985 Non	  targeting >6.00 Reject NonTrasfected A-­‐100987 NonTransfected >6.00 Reject
NonTargeted A-­‐100986 Non	  targeting >6.00 Reject NonTrasfected A-­‐100988 NonTransfected >6.00 Reject
NonTargeted A-­‐100987 Non	  targeting >6.00 Reject NonTrasfected A-­‐100990 NonTransfected >6.00 Reject
NonTargeted A-­‐100988 Non	  targeting >6.00 Reject NonTrasfected A-­‐100991 NonTransfected >6.00 Reject
NonTargeted A-­‐100990 Non	  targeting >6.00 Reject NonTrasfected A-­‐100992 NonTransfected >6.00 Reject
NonTargeted A-­‐100991 Non	  targeting >6.00 Reject NonTrasfected A-­‐100993 NonTransfected >6.00 Reject
NonTargeted A-­‐100992 Non	  targeting >6.00 Reject NonTrasfected A-­‐100994 NonTransfected >6.00 Reject
NonTargeted A-­‐100993 Non	  targeting >6.00 Reject NonTrasfected A-­‐100996 NonTransfected >6.00 Reject
NonTargeted A-­‐100994 Non	  targeting >6.00 Reject NonTrasfected A-­‐100997 NonTransfected >6.00 Reject
NonTargeted A-­‐100996 Non	  targeting >6.00 Reject NonTrasfected A-­‐100999 NonTransfected >6.00 Reject
NonTargeted A-­‐100997 Non	  targeting >6.00 Reject NonTrasfected A-­‐101000 NonTransfected >6.00 Reject
NonTargeted A-­‐100999 Non	  targeting >6.00 Reject NonTrasfected A-­‐101010 NonTransfected >6.00 Reject
NonTargeted A-­‐101000 Non	  targeting >6.00 Reject OS00055-­‐06 A-­‐100987 UBE2D2 7322 >6.00 Reject
NonTargeted A-­‐101010 Non	  targeting >6.00 Reject OS00055-­‐06 A-­‐100993 UBE2D2 7322 >6.00 Reject
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Compound ID Plate ID Target gene Locus ID IC50 Graphical Result (SF) Graphical Result(CGE) Effect Compound ID Plate ID Target gene Locus ID IC50 Graphical Result (SF) Graphical Result(CGE) Effect
OS00055-­‐07 A-­‐100993 UBE2D2 7322 1.40 High OS00071-­‐09 A-­‐100992 UBE2N 7334 >6.00 Reject
OS00055-­‐07 A-­‐100999 UBE2D2 7322 0.37 High OS00071-­‐09 A-­‐101010 UBE2N 7334 >6.00 Reject
OS00055-­‐08 A-­‐100987 UBE2D2 7322 >6.00 Low OS00082-­‐07 A-­‐100986 UBE2W 55284 >6.00 Low
OS00055-­‐08 A-­‐100993 UBE2D2 7322 >6.00 Low OS00082-­‐07 A-­‐100992 UBE2W 55284 >6.00 Reject
OS00055-­‐08 A-­‐100999 UBE2D2 7322 0.13 High OS00082-­‐07 A-­‐101010 UBE2W 55284 >6.00 Reject
OS00055-­‐09 A-­‐100987 UBE2D2 7322 >6.00 Reject OS00082-­‐08 A-­‐100986 UBE2W 55284 2.92 High
OS00055-­‐09 A-­‐100993 UBE2D2 7322 >6.00 Reject OS00082-­‐08 A-­‐100992 UBE2W 55284 <0.00 High
OS00055-­‐09 A-­‐100999 UBE2D2 7322 4.82 Low OS00082-­‐08 A-­‐101010 UBE2W 55284 <0.00 High
OS00071-­‐06 A-­‐100986 UBE2N 7334 >6.00 Reject OS00082-­‐09 A-­‐100986 UBE2W 55284 >6.00 Reject
OS00071-­‐06 A-­‐100992 UBE2N 7334 >6.00 Reject OS00082-­‐09 A-­‐100992 UBE2W 55284 >6.00 Reject
OS00071-­‐06 A-­‐101010 UBE2N 7334 >6.00 Reject OS00082-­‐09 A-­‐101010 UBE2W 55284 >6.00 Reject
OS00071-­‐07 A-­‐100986 UBE2N 7334 >6.00 Reject OS00082-­‐10 A-­‐100986 UBE2W 55284 >6.00 Reject
OS00071-­‐07 A-­‐100992 UBE2N 7334 5.87 Reject OS00082-­‐10 A-­‐100992 UBE2W 55284 >6.00 Reject
OS00071-­‐07 A-­‐101010 UBE2N 7334 >6.00 Reject OS00082-­‐10 A-­‐101010 UBE2W 55284 >6.00 Reject
OS00071-­‐08 A-­‐100986 UBE2N 7334 >6.00 Reject OS00226-­‐12 A-­‐100985 BIRC2 329 >6.00 Reject
OS00071-­‐08 A-­‐100992 UBE2N 7334 >6.00 Reject OS00226-­‐12 A-­‐100991 BIRC2 329 >6.00 Reject
OS00071-­‐08 A-­‐101010 UBE2N 7334 >6.00 Reject OS00226-­‐12 A-­‐100997 BIRC2 329 >6.00 Reject
OS00071-­‐09 A-­‐100986 UBE2N 7334 >6.00 Reject OS00226-­‐13 A-­‐100985 BIRC2 329 >6.00 Low
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Compound ID Plate ID Target gene Locus ID IC50 Graphical Result (SF) Graphical Result(CGE) Effect Compound ID Plate ID Target gene Locus ID IC50 Graphical Result (SF) Graphical Result(CGE) Effect
OS00226-­‐13 A-­‐100991 BIRC2 329 >6.00 Low OS00406-­‐08 A-­‐100990 RNF113B 140432 >6.00 Reject
OS00226-­‐13 A-­‐100997 BIRC2 329 5.91 Low OS00406-­‐08 A-­‐100996 RNF113B 140432 >6.00 Reject
OS00226-­‐14 A-­‐100985 BIRC2 329 3.51 High OS00426-­‐07 A-­‐100985 RNF150 57484 <0.00 High
OS00226-­‐14 A-­‐100991 BIRC2 329 >6.00 High OS00426-­‐07 A-­‐100991 RNF150 57484 <0.00 High
OS00226-­‐14 A-­‐100997 BIRC2 329 2.09 High OS00426-­‐07 A-­‐100997 RNF150 57484 <0.00 Low
OS00226-­‐15 A-­‐100985 BIRC2 329 >6.00 Reject OS00426-­‐08 A-­‐100985 RNF150 57484 >6.00 Reject
OS00226-­‐15 A-­‐100991 BIRC2 329 >6.00 Reject OS00426-­‐08 A-­‐100991 RNF150 57484 >6.00 Reject
OS00226-­‐15 A-­‐100997 BIRC2 329 >6.00 Reject OS00426-­‐08 A-­‐100997 RNF150 57484 >6.00 Reject
OS00406-­‐05 A-­‐100984 RNF113B 140432 >6.00 High OS00426-­‐09 A-­‐100985 RNF150 57484 >6.00 Reject
OS00406-­‐05 A-­‐100990 RNF113B 140432 4.13 High OS00426-­‐09 A-­‐100991 RNF150 57484 >6.00 Reject
OS00406-­‐05 A-­‐100996 RNF113B 140432 <0.00 High OS00426-­‐09 A-­‐100997 RNF150 57484 >6.00 Reject
OS00406-­‐06 A-­‐100984 RNF113B 140432 >6.00 Reject OS00426-­‐10 A-­‐100985 RNF150 57484 >6.00 Reject
OS00406-­‐06 A-­‐100990 RNF113B 140432 >6.00 Reject OS00426-­‐10 A-­‐100991 RNF150 57484 >6.00 Reject
OS00406-­‐06 A-­‐100996 RNF113B 140432 >6.00 Reject OS00426-­‐10 A-­‐100997 RNF150 57484 >6.00 Reject
OS00406-­‐07 A-­‐100984 RNF113B 140432 >6.00 Reject OS00454-­‐05 A-­‐100984 RNF31 55072 >6.00 High
OS00406-­‐07 A-­‐100990 RNF113B 140432 >6.00 Reject OS00454-­‐05 A-­‐100990 RNF31 55072 >6.00 Low
OS00406-­‐07 A-­‐100996 RNF113B 140432 >6.00 Reject OS00454-­‐05 A-­‐100996 RNF31 55072 3.49 High
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Compound ID Plate ID Target gene Locus ID IC50 Graphical Result (SF) Graphical Result(CGE) Effect Compound ID Plate ID Target gene Locus ID IC50 Graphical Result (SF) Graphical Result(CGE) Effect
OS00454-­‐06 A-­‐100990 RNF31 55072 >6.00 Reject OS00556-­‐08 A-­‐100991 TRIM8 81603 >6.00 Reject
OS00454-­‐06 A-­‐100996 RNF31 55072 4.82 High OS00556-­‐08 A-­‐100997 TRIM8 81603 >6.00 Reject
OS00454-­‐07 A-­‐100984 RNF31 55072 1.55 High OS00872-­‐05 A-­‐100988 REV1L 51455 >6.00 High
OS00454-­‐07 A-­‐100990 RNF31 55072 1.48 High OS00872-­‐05 A-­‐100994 REV1L 51455 >6.00 High
OS00454-­‐07 A-­‐100996 RNF31 55072 <0.00 High OS00872-­‐05 A-­‐101000 REV1L 51455 5.84 High
OS00454-­‐08 A-­‐100984 RNF31 55072 >6.00 High OS00872-­‐06 A-­‐100988 REV1L 51455 >6.00 Low
OS00454-­‐08 A-­‐100990 RNF31 55072 >6.00 High OS00872-­‐06 A-­‐100994 REV1L 51455 >6.00 Low
OS00454-­‐08 A-­‐100996 RNF31 55072 2.36 High OS00872-­‐06 A-­‐101000 REV1L 51455 3.20 High
OS00556-­‐05 A-­‐100985 TRIM8 81603 2.19 High OS00872-­‐07 A-­‐100988 REV1L 51455 >6.00 High
OS00556-­‐05 A-­‐100991 TRIM8 81603 4.04 High OS00872-­‐07 A-­‐100994 REV1L 51455 >6.00 High
OS00556-­‐05 A-­‐100997 TRIM8 81603 <0.00 High OS00872-­‐07 A-­‐101000 REV1L 51455 4.34 High
OS00556-­‐06 A-­‐100985 TRIM8 81603 >6.00 Reject OS00872-­‐08 A-­‐100988 REV1L 51455 >6.00 High
OS00556-­‐06 A-­‐100991 TRIM8 81603 >6.00 Reject OS00872-­‐08 A-­‐100994 REV1L 51455 >6.00 High
OS00556-­‐06 A-­‐100997 TRIM8 81603 >6.00 Reject OS00872-­‐08 A-­‐101000 REV1L 51455 5.24 High
OS00556-­‐07 A-­‐100985 TRIM8 81603 >6.00 Reject OS00917-­‐05 A-­‐100988 TNIP1 10318 >6.00 High
OS00556-­‐07 A-­‐100991 TRIM8 81603 >6.00 Reject OS00917-­‐05 A-­‐100994 TNIP1 10318 >6.00 High
OS00556-­‐07 A-­‐100997 TRIM8 81603 >6.00 Reject OS00917-­‐05 A-­‐101000 TNIP1 10318 3.52 High
OS00556-­‐08 A-­‐100985 TRIM8 81603 >6.00 Reject OS00917-­‐06 A-­‐100988 TNIP1 10318 >6.00 Reject
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Compound ID Plate ID Target gene Locus ID IC50 Graphical Result (SF) Graphical Result(CGE) Effect Compound ID Plate ID Target gene Locus ID IC50 Graphical Result (SF) Graphical Result(CGE) Effect
OS00917-­‐06 A-­‐100994 TNIP1 10318 >6.00 Reject OS00981-­‐08 A-­‐100993 USP33 23032 >6.00 Reject
OS00917-­‐06 A-­‐101000 TNIP1 10318 >6.00 Reject OS00981-­‐08 A-­‐100999 USP33 23032 >6.00 Reject
OS00917-­‐07 A-­‐100988 TNIP1 10318 >6.00 Reject OS00985-­‐06 A-­‐100988 USP37 57695 >6.00 Reject
OS00917-­‐07 A-­‐100994 TNIP1 10318 >6.00 Reject OS00985-­‐06 A-­‐100994 USP37 57695 >6.00 Reject
OS00917-­‐07 A-­‐101000 TNIP1 10318 <0.00 Reject OS00985-­‐06 A-­‐101000 USP37 57695 >6.00 Reject
OS00917-­‐08 A-­‐100988 TNIP1 10318 1.38 High OS00985-­‐07 A-­‐100988 USP37 57695 >6.00 Reject
OS00917-­‐08 A-­‐100994 TNIP1 10318 2.00 High OS00985-­‐07 A-­‐100994 USP37 57695 >6.00 Reject
OS00917-­‐08 A-­‐101000 TNIP1 10318 <0.00 High OS00985-­‐07 A-­‐101000 USP37 57695 >6.00 Reject
OS00981-­‐05 A-­‐100987 USP33 23032 >6.00 Reject OS00985-­‐08 A-­‐100988 USP37 57695 1.12 High
OS00981-­‐05 A-­‐100993 USP33 23032 >6.00 Low OS00985-­‐08 A-­‐100994 USP37 57695 1.38 High
OS00981-­‐05 A-­‐100999 USP33 23032 5.52 Low OS00985-­‐08 A-­‐101000 USP37 57695 1.74 High
OS00981-­‐06 A-­‐100987 USP33 23032 >6.00 Low OS00985-­‐09 A-­‐100988 USP37 57695 >6.00 Low
OS00981-­‐06 A-­‐100993 USP33 23032 2.85 Low OS00985-­‐09 A-­‐100994 USP37 57695 >6.00 Low
OS00981-­‐06 A-­‐100999 USP33 23032 <0.00 Low OS00985-­‐09 A-­‐101000 USP37 57695 2.92 Low
OS00981-­‐07 A-­‐100987 USP33 23032 >6.00 Reject OS00991-­‐05 A-­‐100987 USP42 84132 5.50 Reject
OS00981-­‐07 A-­‐100993 USP33 23032 >6.00 Reject OS00991-­‐05 A-­‐100993 USP42 84132 >6.00 Reject
OS00981-­‐07 A-­‐100999 USP33 23032 >6.00 Reject OS00991-­‐05 A-­‐100999 USP42 84132 >6.00 Reject
OS00981-­‐08 A-­‐100987 USP33 23032 >6.00 Reject OS00991-­‐06 A-­‐100987 USP42 84132 >6.00 Low
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Compound ID Plate ID Target gene Locus ID IC50 Graphical Result (SF) Graphical Result(CGE) Effect Compound ID Plate ID Target gene Locus ID IC50 Graphical Result (SF) Graphical Result(CGE) Effect
OS00991-­‐06 A-­‐100993 USP42 84132 >6.00 Low OS01000-­‐08 A-­‐100992 USP50 373509 >6.00 Reject
OS00991-­‐06 A-­‐100999 USP42 84132 >6.00 Low OS01000-­‐08 A-­‐101010 USP50 373509 >6.00 Reject
OS00991-­‐07 A-­‐100987 USP42 84132 >6.00 Low OS01003-­‐05 A-­‐100984 USP54 159195 >6.00 Reject
OS00991-­‐07 A-­‐100993 USP42 84132 >6.00 Low OS01003-­‐05 A-­‐100990 USP54 159195 >6.00 Reject
OS00991-­‐07 A-­‐100999 USP42 84132 1.19 High OS01003-­‐05 A-­‐100996 USP54 159195 5.69 Reject
OS00991-­‐08 A-­‐100987 USP42 84132 >6.00 Reject OS01003-­‐06 A-­‐100984 USP54 159195 >6.00 Reject
OS00991-­‐08 A-­‐100993 USP42 84132 >6.00 Reject OS01003-­‐06 A-­‐100990 USP54 159195 >6.00 Reject
OS00991-­‐08 A-­‐100999 USP42 84132 >6.00 Reject OS01003-­‐06 A-­‐100996 USP54 159195 0.46 Low
OS01000-­‐05 A-­‐100986 USP50 373509 5.74 High OS01003-­‐07 A-­‐100984 USP54 159195 >6.00 Reject
OS01000-­‐05 A-­‐100992 USP50 373509 2.14 High OS01003-­‐07 A-­‐100990 USP54 159195 >6.00 Reject
OS01000-­‐05 A-­‐101010 USP50 373509 1.68 High OS01003-­‐07 A-­‐100996 USP54 159195 >6.00 Reject
OS01000-­‐06 A-­‐100986 USP50 373509 >6.00 Reject OS01003-­‐08 A-­‐100984 USP54 159195 5.77 High
OS01000-­‐06 A-­‐100992 USP50 373509 >6.00 Reject OS01003-­‐08 A-­‐100990 USP54 159195 4.66 High
OS01000-­‐06 A-­‐101010 USP50 373509 >6.00 Reject OS01003-­‐08 A-­‐100996 USP54 159195 0.66 High
OS01000-­‐07 A-­‐100986 USP50 373509 >6.00 Reject RNALowControl A-­‐100984 REV1L 51455 >6.00 High
OS01000-­‐07 A-­‐100992 USP50 373509 >6.00 Reject RNALowControl A-­‐100985 REV1L 51455 >6.00 High
OS01000-­‐07 A-­‐101010 USP50 373509 >6.00 Reject RNALowControl A-­‐100986 REV1L 51455 >6.00 High
OS01000-­‐08 A-­‐100986 USP50 373509 >6.00 Reject RNALowControl A-­‐100987 REV1L 51455 >6.00 High
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Compound ID Plate ID Target gene Locus ID IC50 Graphical Result (SF) Graphical Result(CGE) Effect
RNALowControl A-­‐100988 REV1L 51455 >6.00 High
RNALowControl A-­‐100990 REV1L 51455 >6.00 High
RNALowControl A-­‐100991 REV1L 51455 >6.00 High
RNALowControl A-­‐100992 REV1L 51455 >6.00 High
RNALowControl A-­‐100993 REV1L 51455 >6.00 High
RNALowControl A-­‐100994 REV1L 51455 >6.00 High
RNALowControl A-­‐100996 REV1L 51455 3.32 High
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E3 Ubiquitin Ligase HOIP Attenuates Apoptotic Cell Death
Induced by Cisplatin
Craig MacKay1, Eilís Carroll1, Adel F.M. Ibrahim1, Amit Garg1, Gareth J. Inman2, Ronald T. Hay3, and
Arno F. Alpi1
Abstract
The genotoxin cisplatin is commonly used in chemotherapy to treat solid tumors, yet our understanding of
the mechanism underlying the drug response is limited. In a focused siRNA screen, using an siRNA library
targeting genes involved in ubiquitin and ubiquitin-like signaling, we identiﬁed the E3 ubiquitin ligase HOIP as a
key regulator of cisplatin-induced genotoxicity. HOIP forms, with SHARPIN and HOIL-1L, the linear ubiquitin
assembly complex (LUBAC). We show that cells deﬁcient in the HOIP ligase complex exhibit hypersensitivity
to cisplatin. This is due to a dramatic increase in caspase-8/caspase-3–mediated apoptosis that is strictly
dependent on ATM-, but not ATR-mediated DNA damage checkpoint activation. Moreover, basal and cisplatin-
induced activity of the stress response kinase JNK is enhanced in HOIP-depleted cells and, conversely, JNK
inhibition can increase cellular resistance to cisplatin and reverse the apoptotic hyperactivation inHOIP-depleted
cells. Furthermore, we show that HOIP depletion sensitizes cancer cells, derived from carcinomas of various
origins, through an enhanced apoptotic cell death response. We also provide evidence that ovarian cancer cells
classiﬁed as cisplatin-resistant can regain sensitivity following HOIP downregulation. Cumulatively, our study
identiﬁes a HOIP-regulated antiapoptotic signaling pathway, and we envisage HOIP as a potential target for the
development of combinatorial chemotherapies to potentiate the efﬁcacy of platinum-based anticancer drugs.
Cancer Res; 74(8); 1–12. 2014 AACR.
Introduction
Platinum-based agents such as cisplatin and carboplatin are
commonly used in chemotherapy. They display therapeutic
activity against awide variety of solid tumors such as testicular,
ovarian, and non–small cell lung cancers (1). Cisplatin is a
potent genotoxin that initially interferes with proliferation of
the tumor cell (antiproliferative activity) but ultimately
induces apoptosis in the tumor cell (cytotoxic activity). Despite
the successful application of this drug over the last 30 years,
side effects, in particular myelosuppression, nephrotoxicity,
and neurotoxicity, remain the limiting factors for its thera-
peutic efﬁcacy. Furthermore, efﬁcient therapy is frequently
challenging because tumor cells are either intrinsically resis-
tant or acquire resistance to platinum drugs (2). In particular,
resistance to platinum-based drugs remains a major problem
in the management of advanced ovarian cancer. High-grade
serous ovarian cancers frequently exhibit a complete clinical
response to platinum-based drugs after initial chemotherapy.
However, the majority of these patients will relapse with a
progressive development of platinum drug resistance, result-
ing in overall poor prognosis. Hence, the underlying resistance
mechanisms to these chemotherapeutic drugs are subject to
intense studies (3).
Cisplatin reacts directly with DNA, inducing DNA inter- and
intrastrand cross-link lesions (ICL) in proliferating tissues, and
thereby triggering a DNA damage response (1). ICL repair is
complex, involving multiple DNA-repair pathways, and their
coordination and regulation relies heavily upon the interplay
between phosphorylation and ubiquitin signaling (4–6). Initial
recognition and removal of the ICL is coordinated by the
Fanconi anemia tumor suppressor pathway (7), which targets
the FANCI/FANCD2 complex for mono-ubiquitylation (8).
Subsequently, the mono-ubiquitylated FANCI/FANCD2 com-
plex promotes the removal of ICL lesions by translesion
synthesis (TLS), as well as homologous recombination–depen-
dent repair mechanisms (7). Moreover, DNA double-strand
breaks (DSB) have been identiﬁed as intermediates in ICL
repair during S phase, and their formation involves the activity
of theMus81–Eme1 endonuclease (9). DSB repair is initiated by
the ATM (ataxia-telangiectasia mutated) checkpoint kinase-
dependent phosphorylation of MDC1 (mediator of DNA dam-
age checkpoint), and the subsequent assembly of an ubiquitin-
signaling complex, consisting of the E3 ubiquitin ligases RNF8
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and RNF168 (4, 10). RNF168 and RNF8 cooperate with BRCA1
to promote repair of DNA lesions (4, 11). Cancers with defects
in the ICL-repair pathway, which are frequently associated
with BRCA1 and BRCA2/FANCD1 deﬁciency, are hypersensi-
tive to DNA cross-linking agents, including cisplatin. Hence,
this provides a strong rationale to use cisplatin for the treat-
ment of BRCA1/2 mutated tumors.
Less is known about the determinants and pathways that
sense excessive DNA cross-link damage, and that activate the
apoptotic cell death pathway that eliminates irreversibly dam-
aged cells. The tumor suppressor p53, a transcription factor, is
stabilized and activated by genotoxic stress and triggers mul-
tiple effector pathways, including the intrinsic (also known as
mitochondrial) apoptotic pathway (reviewed in ref. 12). To
induce apoptosis, activated homotetrameric p53 directly tran-
scriptionally upregulates the expression of several proapopto-
tic BCL-2 family members such as PUMA, NOXA, and BAX.
There is increasing evidence that excessive DNA damage,
including cisplatin-induced lesions, can also activate the
extrinsic death receptor apoptosis pathway (reviewed in refs.
13, 14). This pathway is triggered by the binding of death
ligands of the TNF family to their cognate receptors, and the
subsequent assembly of the receptor-associated death-induc-
ing signaling complex (DISC). Initiator caspases 8 and 10 are
activated within the DISC, and the death signal is ampliﬁed by
the subsequent proteolytic activation of downstream effector
caspases 3 and 7. Cisplatin treatment can also induce sustained
activation of JNK (c-JunN-terminal kinase), which triggers high
levels of the transcription factor AP-1 (15). This leads to the
expression of the FAS-L (FAS ligand) and consequently results
in FAS receptor-mediated apoptosis.
The identiﬁcation of novel determinants of the cellular
response to cisplatin and other platinum-based cancer drugs
might extend their clinical application, as well as provide
potential insight into drug resistance mechanisms. The use
of RNA interference (RNAi) as a tool for speciﬁcally silencing
genes has opened up the possibility of performing high
throughput loss-of-function and synthetic lethality screens.
We have used a collection of siRNA pools targeting the
expression of genes involved in ubiquitin and ubiquitin-like
(UBL) signaling to address whether ablation of expression of
these proteins can cause cisplatin hypersensitivity. The screen
was carried out using human osteosarcoma U2OS cells, which
are p53 proﬁcient and exhibit a robust DNA damage response
(16). We identiﬁed the RING-in-between-RING E3 ubiquitin
ligase HOIP as a novel antiapoptotic regulator in response to
cisplatin-induced genotoxicity.
Materials and Methods
U2OS cells used in the siRNA screen were grown in phenol
red–free Dulbecco's Modiﬁed Eagle Medium (DMEM) supple-
mented with 10% fetal calf serum and 2 mmol/L L-glutamine.
The cell lines A2780, ZR.75.1, MDA-MB-231, PEA1, PEA2, PEO14,
and PEO23 were maintained in RPMI-1640 supplemented with
10% fetal calf serum, 2 mmol/L L-glutamine, 100 U/mL peni-
cillin, and 100 mg/mL streptomycin. Cisplatin-resistant A2780
cells were maintained as A2780 cells but supplemented with
1 mmol/L cisplatin. HEK293, HeLa, HCT116, PC3, and U2OS
cells were maintained in DMEM supplemented with 10% fetal
calf serum, 2 mmol/L L-glutamine, 100 U/mL penicillin, and
100 mg/mL streptomycin. Mouse embryonic ﬁbroblasts (MEF)
were obtained from Prof. Philip Cohen (University of Dundee,
Dundee, United Kingdom) and maintained as for HEK293 cells,
with the addition of 1% sodium pyruvate and 1% nonessential
amino acids. Stably transfected Flp-In T-Rex-293 cells were
generated according to the manufacturer's instructions (Invi-
trogen). A2780 and A2780 cisplatin-resistant cell lines were a
kind gift from Dr. Gillian Smith (University of Dundee, Dundee,
United Kingdom). PEA1, PEA2, PEO14, and PEO23 cell lines
were a kind gift from Dr. Simon Langdon (University of
Edinburgh, Edinburgh, United Kingdom). These cell lines were
regularly examined for morphology and tested for cisplatin
sensitivity status. All other cell lines were obtained from the
American Type Culture Collection, where they were authenti-
cated using short tandem repeat analysis, and passaged for a
maximum of 2 months post resuscitation. All cell lines used
were tested regularly for mycoplasma contamination.
Cell proliferation assay
HEK293 cells were seeded at 25% to 30% conﬂuence in
10-cm2 dishes and treated with the indicated siRNA for 48
hours before being seeded at 5,000 cells per well in a 96-well
plate; ﬁve wells seeded for each dose of cisplatin. Cells were
allowed to adhere for a minimum of 8 hours before addition of
0 to 5 mg/mL cisplatin. Cells were grown for 72 to 96 hours
before MTS assays (Promega) were performed according to
manufacturer's instructions. Proliferation assays for all other
cells were carried out as for HEK293 cells, except that siRNA
treatments were performed on cells seeded in a 96-well plate.
Clonogenic survival assays
Clonogenic survival assays were performed in triplicate.
Cells were seeded at 25% conﬂuence and allowed to adhere
before being transfected with the indicated siRNA for 48 hours.
Cells were then seeded in 10-cm2 dishes at 5,000 cells per dish
and allowed to adhere before being treated with the indicated
concentrations of genotoxin for 24 hours. Cells were incubated
in freshmedium for 10 days and colonies containingmore than
50 cells were counted.
Cell lysis and immunoblot analysis
Whole-cell extracts were prepared frommammalian cells by
lysis in 40 mmol/L HEPES pH 7.4, 120 mmol/L NaCl, 1 mmol/L
EDTA, 1% Triton X-100, and HALT protease and phosphatase
inhibitor cocktail (Pierce Biotechnology). Clariﬁed protein
lysates were separated by SDS-PAGE and transferred to a
nitrocellulose membrane. ImageJ software was used to quan-
tify immunoblots, and at least three independent experiments
were used to obtain results.
Caspase activity in vitro assay
Cells were seeded at 25% to 30% conﬂuence in 10-cm2 dishes
and treated with the indicated siRNA for 48 hours before
plating 10,000 cells per well of a 96-well plate, in triplicate for
each condition. Cells were grown in phenol red–free DMEM
and were replica plated on a 96-well plate for MTS assays.
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Caspase activity was measured 48 hours after treatment with
the indicated dose of cisplatin, using the Caspase-Glo 3/7 or
Caspase-Glo 8 assays (Promega), according to the manufac-
turer's instructions. Caspase activity was normalized with
respect to cell number per well, as calculated by an MTS assay
(Promega).
Immunoﬂuorescence analysis
Cells were treated with the indicated dose of genotoxin for
the times indicated in the ﬁgure legends, and processed as
described previously (17).
JNK in vitro kinase assay
JNK kinases were immunoprecipitated from 100 mg of
HEK293 cell whole-cell lysate, treated as indicated in the ﬁgure
legend, using 3 mg of anti-JNK1 antibody coupled to 10 mL
protein G Sepharose. Immunoprecipitates were washed thor-
oughly in cell lysis buffer and then equilibrated in kinase assay
buffer (50mmol/L Tris/HCl pH 7.5, 0.1mmol/L EGTA and 0.1%
2-mercaptoethanol). Assays were performed as described pre-
viously (18) using a peptide corresponding to GST-ATF2 amino
acids 19 to 96, at a concentration of 0.2 mg/mL as a substrate.
NF-kB luciferase reporter assay
Cells to be analyzed for NF-kB activation were seeded at
25% to 30% conﬂuence in 6-well plates and treated with the
indicated siRNA for 24 hours, or induced with tetracycline
for 24 hours, before transfection with 3  NF-kB ConA
luciferase reporter plasmid. After 24 hours, the indicated
concentrations of cisplatin were added to cells and lucifer-
ase activity was measured 24 or 48 hours later, as indicated.
Luciferase activity was measured using the Dual-Luciferase
Reporter Assay System (Promega) according to the manu-
facturer's instructions. Assays were performed in triplicate
and luciferase signals were normalized with respect to the
cell lysate protein concentration.
Results
siRNA screen identiﬁesHOIP as an enhancer of cisplatin-
induced cytotoxicity
We designed a robust, high-throughput RNAi platform to
screen for enhancement of cisplatin-induced cell death in the
human osteosarcoma cell line U2OS. We used an siRNA library
targeting 1,067 human genes, which are either validated or
computationally predicted components related to the ubiqui-
tin- and UBL signaling machinery (Supplementary Data).
These include ubiquitin, SUMO, NEDD8, E1s, E2s, E3s, UBL-
speciﬁc proteases, and UBL-binding domain-containing pro-
teins (siRNA "ubiquitome" library). The design of our enhancer
screen is outlined in Fig. 1A. Brieﬂy, U2OS cells were reverse
transfected in replicas with a library of siRNA pools (SMART-
Pools). Each plate contained nontransfected cells, negative
control (siCON, nontarget), and cells transfected with siRNA
against the positive control REV1L (siREV1L), a TLS polymer-
ase required for ICL repair (19). Sixteen hours after transfec-
tion, one replica was treated with 3 mmol/L cisplatin and the
other replicawith the vehicle, dimethyl sulfoxide (DMSO). Cells
were incubated for further 72 hours and viability of cells was
assayed using an ATP-dependent cell viability assay. To quan-
tify the robustness of this assay system, we calculated the Z0
factor. The average factor for our entire screen was Z0 ¼ 0.58,
indicating an excellent assay performance. The screen was
completed in duplicate. First, data were ﬁltered for lethal
siRNA by calculating cell growth (CGE) and rejecting siRNAs
causing CGE  50%. Second, we used a log2 surviving fraction
(log2SF) threshold of 1.47 or less to identify 112 siRNAs that
signiﬁcantly sensitized cells to cisplatin (Supplementary Data).
siRNAs from the primary screen were subjected to a sec-
ondary screen in which cells were treated with 0 to 6 mmol/L of
cisplatin (Supplementary Fig. S1A). This was performed in
triplicate, and dose-dependent log2SF functions were plotted
to determine the maximum log2SF for each siRNA (Fig. 1B).
Setting the threshold of the maximum log2SF values to 1.07,
we identiﬁed, with high conﬁdence, 14 siRNAs that sensitized
U2OS cells to cisplatin.
To test for off-target effects, the 14 siRNAs were assayed
separately with each of the four different siRNA species from
the SMARTPool that target the same gene. Such siRNAs were
considered to function on-target when at least three of the four
individual siRNAs caused enhanced cisplatin sensitivity. By
applying these strict criteria, we identiﬁed the E3 ubiquitin
ligase HOIP (RNF31) as being required for cellular resistance to
cisplatin (Supplementary Fig. S1B). HOIP is the catalytic sub-
unit of the E3 ubiquitin ligase linear ubiquitin assembly
complex (LUBAC), which also consists of the components
HOIL-1L and SHARPIN (20, 21). LUBAC is a critical regulator
of the canonical NF-kB signaling pathway, and has been
implicated in inﬂammatory diseases and immune regulation
(22). No role, however, has been suggested forHOIP in response
to cisplatin. We therefore chose to examine the biological
signiﬁcance ofHOIP depletion, and themechanisms impacting
cisplatin hypersensitivity.
As further validation, we analyzed cisplatin sensitivity in
mouse embryonic ﬁbroblast (MEF) cell lines obtained from
paired wild-type and HOIPC879S/C879S E3 ligase-dead knockin
mice, in which there is no LUBAC activity and no detectable
linear ubiquitin chain formation (21). The HOIPC879S/C879S
MEFs exhibited cisplatin hypersensitivity, indicating that
HOIP ligase activity is required for cellular resistance to
cisplatin (Fig. 1C). In addition, we repeated cisplatin sensitivity
assays using transformed human embryonic kidney 293
(HEK293) cells. HOIP depletion (siHOIP) was conﬁrmed by
immunoblot analysis and resulted in enhanced cisplatin sen-
sitivity when compared with cells transfected with vehicle only
(siCON; Fig. 1D and Supplementary Fig. S1C). Consistent with
published data, we noted that depletion of HOIP in HEK293
and U2OS cells resulted in destabilization of the LUBAC
complex members HOIL-1L and SHARPIN (Supplementary
Fig. S1D and S1E; refs. 23–25). siRNA targeting FAN1, a struc-
ture-speciﬁc nuclease required for interstrand cross-link
repair, was used as control for cisplatin hypersensitivity (26).
HOIP is not required for DNA damage checkpoint
activation
To uncover the mechanisms underlying cisplatin hypersen-
sitivity of HOIP-depleted cells, we ﬁrst analyzed the integrity of
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early DNA damage signaling mediated by the checkpoint
kinases ATM and ATR. Cisplatin-induced phosphorylation of
SMC1 on serine 966, a target of ATM, and phosphorylation of
CHK1 kinase on serine 345, a substrate of ATR, were unaffected
by HOIP depletion (siHOIP) in HEK293 cells (Fig. 2A). These
results indicate a robust and timely DNA damage checkpoint
activation. The presence of cisplatin-induced DNA lesions
triggers the checkpoint kinase-dependent phosphorylation of
the histone variant H2AX (g-H2AX). Distinct nuclear foci of
gH2AX can be visualized at sites of damage, allowing moni-
toring of DNA repair (27, 28). To test the possibility that
accumulation of persistent DNA damage is the cause of
cisplatin hypersensitivity, wemonitored gH2AX foci formation
in mock (siCON) and HOIP-depleted (siHOIP) HEK293 cells,
following cisplatin exposure and recovery over 72 hours (Fig.
2B and C). HOIP-depleted cells show kinetics of accumulation
and resolution of gH2AX foci similar to those of mock trans-
fected cells, suggesting that cisplatin hypersensitivity after
HOIP depletion is unlikely to be caused by an accumulation
of persistent cisplatin-induced DNA lesions.
Figure 1. siRNA screen identiﬁesHOIP as an enhancer of cisplatin-induced genotoxicity. A, schematic illustration of the primary siRNA screen using the siRNA
"ubiquitome" library in U2OS cells. B, maximum log2SF is plotted for each gene that was classed as cisplatin hypersensitive in the primary screen. C,
paired wild-type HOIPþ/þ and HOIPC879S/C879S knockin MEFs; cell viability was assayed 72 hours after cisplatin treatment by MTS cell proliferation assay. D,
HEK293 cells were transfected with the indicated siRNAs and cell lysates were assayed for efﬁcient knockdown by immunoblotting with the indicated
antibodies (top). Cell viability was assayed as in C. Data in C and D are represented as mean  SEM from three independent experiments.
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HOIP depletion sensitizes cells to genotoxin-induced
apoptotic cell death
Cells trigger apoptotic cell death when genotoxic stress
exceeds a certain threshold or upon the accumulation of
persistent DNA lesions. It was recently shown that loss of
the LUBAC component SHARPIN increased susceptibility to
TNF-a–induced caspase-8/caspase-3–mediated apoptosis
(24). Given this, we hypothesized that HOIP depletion might
sensitize cells to apoptotic cell death following cisplatin-
induced damage. We treated U2OS and HEK293 cells with 5
mmol/L cisplatin and observed, in both cell lines, that after 48
hours the proteolytic cleavage of the effector caspase, caspase-
3, was almost undetectable in siCON control cells but greatly
increased when HOIP was depleted (Fig. 3A). Similar results
were obtained following treatment of cells with other geno-
toxins such as etoposide, hydroxyurea and ionizing radiation,
or stress stimuli, including the broad-spectrum kinase inhib-
itor staurosporine and the mitotic inhibitor taxol (Supplemen-
tary Fig. S2A–S2E). We assayed caspase-3 activity in lysates of
either siCON- or siHOIP-depleted cells treated with cisplatin
and noted amodest elevation of caspase-3 activity in untreated
siHOIP cells. However, 48 hours after cisplatin exposure,
caspase-3 activity was signiﬁcantly enhanced in siHOIP cells,
compared with siCON cells (Fig. 3B and C). Importantly, we
also observe increased cisplatin-induced caspase-3 cleavage in
HOIPC879S/C879S MEFs when compared with control wild-type
MEFs (Fig. 3D). We tested whether the phenotype of HOIP
depletion could be mimicked by siRNA silencing of the LUBAC
subunits SHARPIN and HOIL-1L. Indeed, SHARPIN, but not
HOIL-1L, depletion causes a cisplatin-induced accumulation of
cleaved caspase-3, suggesting that HOIP and SHARPIN coop-
erate in an antiapoptotic cell death response (Fig. 3E and F).
Caspase-8 is one of the critical caspases upstream of caspase-3
and has been previously implicated in genotoxin-induced
apoptosis (29–31). To test whether caspase-8 mediates the
observed cisplatin-induced caspase-3 activation, cells were
pretreated with the speciﬁc caspase-8 inhibitor Z-IETD-FMK
before cisplatin treatment. Caspase-8 inhibition completely
abolished siHOIP-enhanced caspase-3 activation (Fig. 3G and
Supplementary Fig. S2F). In agreement with this, we observed a
signiﬁcant elevation of caspase-8 activity in HOIP-depleted
U2OS, aswell asHEK293, cells after cisplatin treatment (Fig. 3H
and I). These data suggest that HOIP protects cells from
cisplatin-induced caspase-8–mediated apoptotic cell death.
Apoptotic sensitization of HOIP-depleted cells requires
ATM but occurs in the absence of NF-kB activation
Recent evidence indicates that ATM drives LUBAC-depen-
dent linear ubiquitin chain formation on NEMO, which pro-
motes NF-kB activation in cells exposed to topoisomerase
inhibitors, such as etoposide (32). We show that the highly
speciﬁc ATM kinase inhibitor KU55933 (Fig. 4A, B, and E;
ref. 33), but not the ATR kinase inhibitor ETP-46464 (Fig. 4C
and D; ref. 34) blocks enhanced proteolytic caspase-3 cleavage
in HOIP-depleted HEK293 and U2OS cells. Next, we analyzed
whether NF-kB signaling is implicated in the hyperapoptotic
cisplatin response observed in HOIP-depleted cells. We gen-
erated a HEK293 cell overexpressing a dominant mutant
version of the NF-kB inhibitory protein IkBa (IkBa S32A/
S36A), which cannot be phosphorylated by IkB kinase (IKK)
and thus cannot be targeted for proteasomal degradation (35).
Overexpression of IkBa S32A/S36A inHEK293 cells completely
abolished cisplatin-induced NF-kB activation (Supplementary
Fig. S3). We then transfected IkBa S32A/S36A expressing
HEK293 cells with either siCON or siHOIP followed by cisplatin
treatment for 48 hours. HOIP depletion in IkBa S32A/S36A
cells resulted in an elevation of caspase-3 activation in untreat-
ed cells (t¼ 0 hours), and this was enhanced following cisplatin
exposure (t ¼ 48 hours; Fig. 4F). No signiﬁcant caspase-3
Figure 2. HOIP is not required for DNA damage checkpoint activation. A,
HEK293 cells were transfected with siCON or siHOIP and treated with 5
mmol/L cisplatin for the indicated times. Cell lysates were analyzed by
immunoblotting with the antibodies indicated. B, siCON- or siHOIP-
transfected HEK293 cells were treated with 8 mmol/L cisplatin for 2 hours
before being allowed to recover for the times indicated. Cells were then
ﬁxed and stained with 40,6-diamidino-2-phenylindole (DAPI) to visualize
nuclei and g-H2AX antibody to visualize g-H2AX foci. C, quantitation of
the data in B: cells with more than six foci were classed as g-H2AX
positive. Data in C are presented asmeanSEM from three independent
experiments.
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activation was detected in siCON-silenced IkBa S32A/S36A
cells following cisplatin exposure. Cumulatively, this suggests
that cisplatin-induced apoptotic cell death in HOIP-depleted
cells occurs independently of NF-kB activation.
JNK activity is elevated in HOIP-depleted cells
In addition to NF-kB activation, extensive DNA damage
triggers activation of the stress-responsive JNK and induces
Fas-Associated Death Domain (FADD)-mediated pro-caspase-
8 activation (36). We, therefore, assayed JNK activity by mon-
itoring JNK-targeted phosphorylation of c-Jun (P-c-Jun) in
response to cisplatin. We observed that HOIP-depleted cells
respond with enhanced c-Jun phosphorylation, suggesting
increased JNK activity (Fig. 5A). To assess JNK kinase activity
directly, we immunoprecipitated JNK from cell lysates of mock
() or cisplatin (þ)-treated cells that were either siCON or
siHOIP transfected, and assayed the kinase in vitro. In agree-
ment with increased P-c-JUN, we observed a signiﬁcantly
enhanced basal, as well as cisplatin-induced, JNK activity in
HOIP-depleted cells (Fig. 5B). To test whether ATM is required
for cisplatin-induced JNK activation, we pretreated cells with
ATM kinase inhibitor KU55933 (ATMi) following cisplatin
treatment. ATM inhibition had no effect on JNK activation,
suggesting that ATM checkpoint activation is not regulating
JNK activity in response to cisplatin (Fig. 5B). Using the highly
speciﬁc JNK inhibitor JNK-IN-8 (37), we next showed that
caspase-3 processing in HOIP-depleted HEK293 cells was
signiﬁcantly suppressed (Fig. 5C), and cisplatin hypersensitiv-
ity reversed (Fig. 5D), following JNK inhibition. Consistent with
HEK293 cells, HOIP depletion in U2OS cells triggered elevation
of both basal and cisplatin-induced JNK activity (Fig. 5E).
However, JNK inhibition did not alleviate caspase-3 hyperac-
tivation in HOIP-depleted U2OS cells, suggesting a cell type–
speciﬁc requirement of JNK in apoptotic cell death.
Figure 3. HOIP depletion sensitizes cells to cisplatin-induced apoptotic cell death. A, U2OS (left) or HEK293 (right) cells were transfected with mock siRNA
(siCON) or siRNA targeting HOIP (siHOIP) and treated with 5 mmol/L cisplatin for the indicated time. Cell lysates were analyzed by immunoblotting with the
antibodies indicated. B, siCON- or siHOIP-transfected U2OS cells were treated with 5 mmol/L cisplatin for 48 hours before caspase-3 activity was
measured using a caspase-3 Glo assay; , P ¼ 0.0028. C, HEK293 cells were treated as described in B; , P ¼ 0.0222. D, paired wild-type HOIPþ/þ and
HOIPC879S/C879S knockin MEFs were treated with 3 mmol/L cisplatin for the indicated time. Cell lysates were analyzed by immunoblotting. E and F, as in A,
except that cells were transfectedwith siSHARPIN or siHOIL-1L. G, siCON- or siHOIP-transfected HEK293 cells were treatedwith vehicle only () or 20 mmol/L
Z-IETD-FMK caspase-8 inhibitor (þ) 1 hour before treatment with 5 mmol/L cisplatin for the indicated times. Cell lysates were analyzed by immunoblotting.
H, as inB, except that a caspase-8Glo assaywasused tomeasure caspase-8 activity; ,P¼0.0076. I, HEK293cellswere treatedasdescribed inH. ,P¼0.014.
Data in B, C, H, and I are represented as mean  SEM from three independent experiments and the Student t test was used to calculate signiﬁcance.
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HOIP depletion induces cisplatin hypersensitivity in
different types of cancer cells
We demonstrate here that HOIP depletion sensitizes U2OS
osteosarcoma cells to cisplatin-induced apoptotic cell death.
These ﬁndings suggest potential strategies to sensitize cancer
cells or, even more relevantly, to resensitize cancer cells that
have become resistant following prolonged cisplatin exposure.
To test this concept, we studied the effect of HOIP depletion in
a panel of cancer cell lines derived from different tissues.
HCT116 (colon), HeLa (cervix), PC3 (prostate), ZR.75.1 (breast),
MDA-MB-231 (breast), and PEA1 (ovary) were transfectedwith
either siCON or siHOIP and analyzed for cisplatin-induced
caspase-3 activation. In addition, cell viability was determined
following exposure to a dose range of cisplatin (Fig. 6). Con-
sistently, all siHOIP-transfected cancer cell lines exhibited, to
varying degrees, elevated cleaved caspase-3 after cisplatin
exposure, which coincided with increased cisplatin sensitivity.
The PEA1 ovarian cancer cell line exhibits particularly
striking cisplatin hypersensitivity upon HOIP depletion. Dur-
ing platinum drug chemotherapy, ovarian cancers frequently
develop drug resistance. Hence, we next addressed whether
cisplatin-resistant ovarian cancer cells can be resensitized by
HOIP-depletion. We analyzed paired platinum sensitive
(A2780CisS) and resistant (A2780CisR) ovarian tumor cell lines.
A2780CisR cells are in vitro derivatives of the sensitive
A2780CisS cells that have acquired resistance through con-
tinuous treatment with cisplatin (38). A2780CisS and
A2780CisR cells were transfected with either siCON or siHOIP
and cellular viability was determined following exposure to
cisplatin. HOIP depletion modestly sensitized A2780CisS cells
(Fig. 7A); however, depletion resulted in a signiﬁcant resen-
sitization of A2780CisR cells (Fig. 7B). Importantly, A2780CisS
and A2780CisR cells also showed increased apoptosis follow-
ing HOIP depletion (Fig. 7A and B). Next, we investigated
high-grade serous ovarian cancers (HGS) derived from cases
of HGS carcinomas before and after the development of
platinum resistance (39). HOIP depletion in the matched
pair of PEA1CisS and PEA2CisR triggered enhanced cisplatin
Figure 4. Apoptotic sensitization of
HOIP-depleted cells requires ATM
but is independent of ATR activity.
A, siRNA-transfectedHEK293cells
were treatedwith vehicle only () or
10 mmol/L KU-55933 ATM inhibitor
(þ) 1 hour before treatment with 5
mmol/L cisplatin for the indicated
times. Cell lysates were analyzed
by immunoblotting. B, quantitation
of the data shown in A. ImageJ
software was used to quantify
immunoblots; , P ¼ 0.0078. C, as
in A, except that 5 mmol/L ETP-
46464 ATR inhibitor was used. D,
quantitation of the data shown inC.
E, as in A, except that U2OS cells
were used. F, human inﬂuenza
haemagglutinin (HA)-IkBa (S32A,
S36A)–expressing HEK293 cells
were transfected either with siCON
or siHOIP and treatedwith 5mmol/L
cisplatin for the indicated times.
Cell lysates were subjected to
immunoblot analyses. Data in B
and D are represented as mean 
SEM from three independent
experiments and the Student t test
was used to calculate signiﬁcance.
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sensitivity in both cell lines (Fig. 7C and D). Similar results
were obtained from the matching pair of PEO14CisS and
PEO23CisR, suggesting that HOIP protects these cells from
cisplatin genotoxicity (Fig. 7E and F).
Discussion
Managing resistance that occurs during platinum-based
drug chemotherapy remains a major challenge in the treat-
ment of ovarian and other cancers, and results in poor prog-
nosis for successful eradication of the cancer. Cells respond to
platinum drugs in several ways and the resistancemechanisms
modulating these responses, to protect cells from platinum
genotoxicity, are equally complex. Typically for platinum-
based drugs, cancer cells frequently gain resistance by reduced
cellular drug uptake, increased drug efﬂux, increased DNA
repair and MHL1 hypermethylation (3). In this study, we
identiﬁed HOIP, the catalytic E3 ubiquitin ligase component
of LUBAC, as an antiapoptotic factor attenuating the genotoxic
effect of genotoxic agents including cisplatin. We provide
evidence that HOIP depletion in several cancer cell lines can
potentiate cellular genotoxicity of cisplatin due to enhanced
apoptotic cell death response.
We show that two subunits of LUBAC, HOIP and SHAR-
PIN, are required to suppress cisplatin-induced apoptosis,
whereas we have no evidence that the subunit HOIL-1L
participates in the cisplatin response. Studies in vitro have
demonstrated that HOIP on its own has only weak E3
ubiquitin ligase activity, but that its catalytic activity is
strongly enhanced in the presence of either SHARPIN or
HOIL-1L, assembling a HOIP/SHARPIN or HOIP/HOIL-1L
complex respectively (40, 41). It is debatable whether these
subcomplexes coexist in vivo; however, genetic evidence
supports the idea that these LUBAC subcomplexes have
separable functions (22). SHARPIN-deﬁcient mice exhibit
chronic proliferative dermatitis (cpdm), a pathology not
observed in HOIL-1L–deﬁcient mice. Moreover, these stud-
ies show that SHAPRIN-deﬁcient MEFs have far higher levels
of TNF-a–induced FADD and caspase-8–dependent apopto-
tic cell death than cells from HOIL-1L–deﬁcient mice (24).
TNF-a–induced apoptosis is triggered by the formation of
a TRADD–TRAF2–RIP1–FADD–caspase-8 death-promoting
Figure 5. JNK activity is elevated
and essential for apoptotic cell
death in HOIP-depleted cells. A,
siRNA-transfected HEK293 cells
were treated with 25 mmol/L
cisplatin for the indicated times.
Cell lysates were analyzed by
immunoblotting. B, siCON- or
siHOIP-transfected HEK293 cells
were pretreated with 3 mmol/L JNK
inhibitor or 10 mmol/L ATM inhibitor
before vehicle only () or 5 mmol/L
cisplatin treatment (þ) as indicated.
JNK kinases were
immunoprecipitated from cell
lysates, and kinase activity was
measured using an in vitro kinase
assay. Activity is presented as
mU/mg cell lysate; , P ¼ 0.0396
(Student t test). C, siCON- or
siHOIP-transfected HEK293 cells
were pretreated with vehicle only
() or 3 mmol/L JNK inhibitor (þ)
before treatment with 5 mmol/L
cisplatin for the indicated times.
Cell lysates were analyzed by
immunoblotting. D, cell viability of
siCON- or siHOIP-transfected cells
pretreated with JNK inhibitor in
response to cisplatin was
measured by MTS cell proliferation
assay. E, as in C, except
that U2OS cells were used. Data
in B and D are represented as
mean  SEM from three
independent experiments.
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complex (TNFR1 complex II), whereas in response to geno-
toxic stress, an analogous ripoptosome complex, consisting
of RIP1–FADD–capase-8, is formed (42). Moreover, CUL3
RING ligase-mediated polyubiquitylation of caspase-8 sta-
bilizes and promotes caspase-8 activity (43). It is tempting to
speculate that a HOIP/SHARPIN ligase complex regulates
cisplatin-induced apoptosis via ripoptosome assembly and
activity. Indeed, this idea is supported by data indicating
that the ripoptosome component RIP1 is modiﬁed with
linear ubiquitin chains (23, 44). Whether the ripoptosome
components are direct targets for HOIP/SHARPIN-mediated
linear ubiquitylation following genotoxic stress will be the
subject of future investigations.
Besides an essential function for ATM in promoting the
apoptotic cell death response in response to cisplatin, we found
that basal and cisplatin-induced JNK kinase activity is signif-
icantly upregulated in HOIP-depleted cells. It has been shown
that sustained activation of JNK in ovarian cancer cells, in
response to cisplatin, leads to activation of the AP-1 transcrip-
tion factor and AP-1–induced FAS-L expression leading, in
turn, to Fas receptor–triggered apoptosis (15). Moreover, JNK
activation has previously been linked to the degradation of the
antiapoptotic factor c-FLIPL, suggesting that JNK hyperactiva-
tion would lead to an enhanced ripoptosome/caspase-8 activ-
ity (45). The importance of the JNK/FAS apoptosis pathway
is further demonstrated by the observation that several
Figure 6. HOIP depletion sensitizes a range of cancer cell lines to cisplatin-induced apoptotic cell death. HCT116 (A), HeLa (B), PC3 (C), ZR.75.1 (D),
MDA-MB-231 (E), or PEA1 (F) cells were transfected with mock siRNA (siCON) or siRNA targeting HOIP (siHOIP) and treated with 5 mmol/L cisplatin for the
indicated time before cell lysates were analyzed by immunoblotting with the antibodies indicated (top). Cell viability of siCON- or siHOIP-transfected cells in
response to the indicated concentration range of cisplatin was measured by MTS cell proliferation assays (bottom). Data shown are represented as mean
SEM from three independent experiments.
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independently derived cisplatin-resistant cancer cell lines
exhibit attenuated JNK activation (46).
The design of the RNAi approach applied in this study
allowed us to screen directly for targets whose downregula-
tion might either sensitize cancer cells for cisplatin or might
reverse cisplatin resistance in tumors. In all cancer cells
tested, siRNA depletion of HOIP reduced their viability and
enhanced apoptotic cell death following cisplatin exposure.
Enhanced cisplatin-induced apoptosis was also observed in
HOIPC879S/C879S MEFs that express catalytically inactive
HOIP. We, therefore, propose that HOIP E3 ligase activity
plays a critical role in limiting apoptotic cell death upon
cisplatin exposure. Indeed, our data show that HOIP-deplet-
ed cells exhibit enhanced apoptosis in response to treatment
with a wide range of genotoxins, as well as nongenotoxic
cellular stress inducers. This suggests that a HOIP-depen-
dent antiapoptotic mechanism is likely to be conserved in
the response to cellular stress in general. Hence, blocking or
easing the antiapoptotic function of HOIP will render cancer
cells more susceptible to apoptosis, and low levels of geno-
toxic stress will trigger apoptotic cell death.
Although it is clear that HOIP depletion renders cells hyper-
sensitive to cisplatin treatment, based on our current knowl-
edge it is not clear what, if any, contribution HOIP has to drug
resistance. Some evidence that HOIP overexpression may
contribute to cisplatin resistance in cancer comes from
large-scale gene–drug association studies (https://www.onco-
mine.com; ref. 47). Expression proﬁle data from a panel of
several hundred cancer cell lines derived from tumors classi-
ﬁed as cisplatin resistant or cisplatin sensitive have revealed
that cisplatin-resistant cancer cell lines (n ¼ 335) show a
signiﬁcantly higher expression of HOIP (P¼ 0.011) and SHAR-
PIN (P¼ 0.016) when comparedwith cisplatin-sensitive cancer
cell lines (n ¼ 29; Supplementary Fig. S4). Oncomine analysis
also revealed that both HOIP and SHARPIN are overexpressed
in serous ovarian carcinomas patient samples compared with
normal tissue (Supplementary Fig. S5). These data suggest that
HOIP/SHARPIN expression is altered in cancer cell lines, and
that an elevation of HOIP and HOIP's antiapoptotic function
may promote cisplatin resistance.
Enhancing or reestablishing the apoptotic cell death
program in tumor cells is a promising strategy for cancer
therapy. On the basis of our ﬁndings, we propose that small-
molecule inhibitory drugs targeting HOIP E3 ligase activity,
used in combination with cisplatin chemotherapy, might
potentiate caspase-8–mediated death in cancer cells. This
concept is supported by recent studies that describe Smac
mimetics, i.e., small molecules that mimic the antagonistic
activity of Smac toward inhibitor of apoptosis proteins (IAP),
as efﬁcient potentiators of cancer cell apoptosis. They
stimulate IAP auto-ubiquitylation and proteasomal degra-
dation, leading to TNF-a signaling, which, in turn, induces
ripoptosome activation and caspase-8–dependent cell death
in multiple cancer cell lines (48–50). We predict that HOIP
inhibitors, although acting through mechanisms different
from those of the Smac mimetics, would signiﬁcantly upre-
gulate cisplatin-induced caspase-8 activity. HOIP depletion
or deﬁciency does not kill transformed cells and hence HOIP
inhibitors are unlikely to be toxic when used alone. However,
HOIP plays a critical role in the innate immune response and
Figure 7. HOIP depletion sensitizes cisplatin-resistant ovarian cancer cell lines. A and B (left), A2780CisS and A2780CisR cells were transfected with
siCON or siHOIP as indicated and cell viability assessed byMTS cell proliferation assays. A and B (right), A2780CisS and A2780CisR cells were transfectedwith
siCON or siHOIP and treated with 5 mmol/L cisplatin for the indicated time. Cell lysates were analyzed by immunoblotting. C–F, cell lines were transfected
with siCON or siHOIP as indicated and cell viability assessed by MTS cell proliferation assays. Data shown are presented as mean  SEM from three
independent experiments.
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the application of HOIP inhibitors bear the potential risk of
stimulating inﬂammatory and/or auto-inﬂammatory side
effects (22). An in-depth analysis of the impact of HOIP
inhibition is needed to fully understand how HOIP can best
be exploited as an anticancer drug target. This study, how-
ever, provides the rationale for the development of HOIP
inhibitors to increase not only the efﬁcacy of ﬁrst-line
cisplatin chemotherapy but also to achieve a better clinical
outcome of cisplatin-based chemotherapy in drug-resistant
cancer.
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